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Abstract 
This thesis characterises the gut hormone oxyntomodulin, and explores the role of the 
hormone in the regulation of food intake, energy expenditure and body weight. 
Oxyntomodulin is a 37 amino acid enteroglucagon peptide which is secreted from the 
endocrine cells of the small intestine in proportion to nutrient ingestion levels. Acute 
administration of oxyntomodulin has been shown to reduce food intake in rodents and 
humans. In addition, repeated infusion of oxyntomodulin resulted in reduction in body 
weight and adipose tissue in both rodents and humans. It is thought that many of 
oxyntomodulin actions are mediated via the glucagon-like peptide-1 (GLP-1) receptor. 
However, the glucagon (GCG) receptor or an unknown receptor may be partly 
responsible for mediating its actions. Oxyntomodulin is rapidly degraded by proteases, 
resulting in the peptide having a half-life of twelve minutes in man. 
I have characterised oxyntomodulin, measuring its binding affinity for and bioactivity at 
the GLP-1 and GCG receptor, its effect on acute food intake in rodents and ability to 
stimulate insulin release. To investigate the short half-life of oxyntomodulin I 
investigated its susceptibility to degradation by proteases known to be important in the 
regulation of related peptides. I demonstrated that oxyntomodulin is a weak 
insulinotropic agent and is a substrate for the proteases dipeptidyl peptidase-IV (DPP 
IV) and neprilysin. 
Oxyntomodulin is rapidly degraded by proteases, making investigation of its putative 
actions on energy expenditure difficult. To overcome this problem I used peptide 
analogues of oxyntomodulin to further investigate the structure function relationship of 
the molecule. Using information gained about its structure and functions, I designed an 
analogue of oxyntomodulin (6421) with an increased potency and longevity of food 
intake inhibition. The effect of chronic administration of 6421 on body weight changes 
and food intake was investigated in rodents and its effect on energy expenditure 
measured. I demonstrated that administration of the oxyntomodulin analogue 6421 
caused a decreases in food intake and an increase in basal metabolic in rat. These two 
actions may be mediated by stimulation of the thyroid axis at the level of the 
hypothalamus and pituitary and/or by an increase in a-melanocortin stimulating 
hormone release in the hypothalamus. 
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Chapter 1 
Introduction 
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1.1 Food intake and the maintenance of body weight 
The balance between food intake and energy expenditure must be tightly regulated in 
order that a healthy body weight is achieved. The mechanism by which this process is 
regulated is termed energy homeostasis. If in the long term insufficient intake of food 
(hypophagia) occurs, most commonly seen when there is a fall in the availability of 
food or in the case of severe illness such as cancer (De Wys and Walters, 1975), the 
body is pushed into a catabolic state. This process results in weight loss as the bodies 
energy stores are utilised. Conversely, when food intake outweighs energy expenditure 
(hyperphagia), excess energy is stored, predominantly as adipose tissue and body 
weight increases. 
In most adults energy balance is tightly regulated and therefore body weight remains 
constant despite a huge variation in daily food intake and energy expended. A complex 
regulatory system comprising afferent signals and efferent effectors exist to balance 
energy intake and energy expenditure. Afferent signals include peripheral signals of 
energy storage which mainly originate from adipose tissue and signals of satiety which 
principally arise from the gut. The central nervous system (CNS) integrates humoral 
and neuronal signals arising from the periphery and inputs from the higher areas of the 
brain. The major CNS areas regulating energy homeostasis are the hypothalamus and 
brainstem. In addition to the homeostatic control of energy balance, feeding is 
powerfully influenced by the senses of taste and smell, and by the neural circuifry 
mediating pleasure and reward. 
Despite the bodies complex systems to maintain energy homeostasis, levels of obesity 
has reached epidemic proportions (World Health Organisation, 2000). Obesity is the 
result of an interaction between environmental factors and genes which optimise energy 
conservation and that were favoured for millions of years of relative famine (Ravussin 
and Bogardus, 2000). Evolutionary pressures have resulted in a drive to overeat when 
excess food is available. The environment in which these systems evolved is vastly 
different to those found today, where highly palatable food is widely available and low 
requirement for physical activity promotes the common forms of obesity. 
It was recently suggested that obesity will soon overtake smoking as the main 
preventable cause of morbidity and early mortality in America (Mokdad et al., 2004). 
In the UK it was estimated that obesity accounted for 18 million days of sickness 
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absence and 30,000 premature deaths in 1998. Furthermore, treating obesity costs the 
National Health Service (NHS) at least billion a year. The wider costs to the 
economy in lower productivity and lost output could be a further £2 billion each year 
(National Audit Office "Tackling Obesity in England" Session 2000 - 2001, 15 
February, 2001). 
As current behavioural and pharmacological approaches to manage weight are largely 
ineffective, it is necessary to develop effective anti-obesity treatments with minimal side 
effects. Furthering our understanding of the physiological systems regulating energy 
homeostasis is fundamental for this process to occur. 
1.2 The Hypothalamus 
A role for the hypothalamus in the integration of endocrine, autonomic and 
somatomotor systems is becoming increasingly apparent. In mammals, the 
hypothalamus has been shown to regulate many systems, including ingestive 
behaviours, thermoregulatory responses, the abdominal viscera, aggressive and 
defensive behaviours and sexual and maternal behaviours. 
The hypothalamus is a brain area which occupies the ventral half of the diencephalon on 
both sides of the third ventricle and lies immediately above the pituitary gland. The 
hypothalamus has extensive connections with the major ascending and descending fibre 
systems and these allow it to sense and influence activity in all major parts of the brain 
and spinal cord. The mammalian hypothalamus consists of more than forty distinct 
nuclei and areas, and many of the nuclei can be ftirther divided into subnuclei. 
Anatomically the hypothalamus has been divided into three distinct longitudinal zones, 
the periventricular, medial and lateral zones (Crosby and Woodbume, 1949) (figure 
1.1). 
1.2.1 The periventricular zone 
The periventricular zone contains nuclei that project to the neurohypophysis and the 
median eminence, and is primarily involved in regulating the secretion of pituitary 
hormones. This zone includes the preoptic nucleus anteriorly, the arcuate nucleus 
(ARC) posteriorly and the paraventricular nucleus (PVN) and the suprachiasmatic 
nuclei (SCN) centrally. 
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1.2.2 The medial zone 
The medial zone consists of several well-defined nuclei including the medial preoptic 
nucleus anteriorly, the dorsomedial (DMN) and ventromedial (VMN) nuclei centrally 
(dorsally and ventrally respectively), and the mammilary bodies posteriorly. It receives 
major inputs from the forebrain, particularly from the limbic system (hippocampus and 
amygdala) and projects to the periventricular and lateral zones as well as to most limbic 
and brainstem structures. It is involved in the initiation of motivated behaviours, such 
as copulation, aggression and appetite. 
1.2.3 The lateral zone 
The lateral zone contains neurones that are distributed among the fibres of the medial 
forebrain bundle. This is the least well defined zone, with few functional groups 
existing. Many anatomists view the lateral zone as the anterior continuation of the 
brainstem reticular formation and may be involved in general arousal and priming and 
preparation for motivated behaviours associated with hunger, thirst, reproduction and 
aggression. Recent evidence supports the production of orexigenic signals within the 
lateral hypothalamic area (LHA) an area of the lateral zone. Examples of these signals 
include, melanin-concentrating hormone (MCH) and orexin A (Broberger et al., 1998; 
Skofitsch et al., 1985), suggesting that the zone has an important role in the appetite 
regulating circuitry. 
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Figure 1.1 Organisation of the hypothalamus. A highly schematic 
representation of the hypothalamus showing a simplified view of its zones, regions, 
areas (a) and nuclei (n). Adapted from Paxinos and Watson (1998). 
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1.2.4 Arcuate Nucleus (ARC) 
The ARC is situated at the base of the hypothalamus on either side of the third ventricle 
and above the median eminence. The ARC also has extensive reciprocal coimections 
with other hypothalamic regions, including the PVN, DMN, VMH and LHA (Baker and 
Herkenham, 1995; Kalra et al., 1999). The ARC is in an ideal position to integrate 
signals for energy homeostasis due to the incomplete nature of the blood-brain barrier at 
its location (Hawkins et al., 2006). Therefore, neurones in the ARC are in contact with 
the blood supply and can act as a "sensor", receiving and integrating endocrine 
information about the supply of and demand for energy in the body. 
Neurones within the ARC are known to be sensitive to a wide array of hormones and 
nutrients including leptin, insulin, ghrelin, glucose and gonadal steroids (Cone et al., 
2001). The ARC houses a number of cell populations, some of which contain 
neuropeptides strongly implicated in the control of energy balance including NPY and 
a-melanocyte-stimulating hormone (a-MSH) (Baskin et al., 1995; Chronwall et al., 
1985). 
1.2.5 Paraventricular nucleus (PVN) 
The PVN lies adjacent to the superior part of the third ventricle in the anterior 
hypothalamus. There are several lines of evidence that suggest that the PVN 
participates in the control of ingestive behaviour (Gold et al., 1977). Ablation of the 
PVN causes hyperphagia and excessive weight gain (Aravich and Sclafani, 1983; 
Leibowitz et al., 1981). Microinjection of virtually all known orexigenic signals into 
the PVN stimulates feeding, whilst microinjection of anorexigenic compounds such as 
leptin (Yokosuka et al., 1998) corticotrophin-releasing hormone (CRH) (Krahn et al., 
1988) and glucagon-like peptide-1 (GLP-1) attenuates refeeding following a fast. 
1.2.6 The Dorsomedial Hypothalamic Nucleus (DMH) 
The DMH receives afferents from the brainstem and from most parts of the 
hypothalamus, including the VMH, LHA, suprachiasmatic nucleus and the medial 
preoptic nucleus (MPO). The DMH also contains high concentration of NPY 
immunoreactivity and nerve fibres. Inhibition of feeding by leptin enhanced neuronal c-
fos (an early gene marker of neuronal activation) in the DMH suggesting a role for this 
region in appetite regulation (Elmquist et al., 1997). 
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1.2.7 Lateral hypothalamus (LHA) 
The LHA contains sparsely distributed neuronal subpopulations and is the site of 
passage for the medial forebrain bundle and other fibres connecting the forebrain and 
midbrain structures with several hypothalamic sites. Lesion studies completed by Nand 
and Brobeck (1951) showed discreet lesions in the LHA caused appetite suppression, 
resulting in the area becoming know as the "feeding centre" (Nand and Brobeck, 1951). 
Whilst these early findings offered an over-simplified view, later findings that 
orexigenic signals, the orexins and MCH are produced in the LHA have meant the area 
is still thought to have an integral role in the appetite regulatory circuit. 
1.3 Role of the vagal nerve and brainstem in control of food intake 
The control of food intake and satiety is via integration of neural and humoral 
information by the CNS. The vagal nerve is involved in relaying information to and 
from most of the viscera of the thorax and abdomen in addition to structures of the head 
and neck. The main area of termination of vagal afferents is the nucleus of the solitary 
tract (NTS) located in the brainstem (Harding and Leek, 1971; Kalia and Mesulam, 
1980). Other vagal afferents fibres project to caudal brainstem nuclei such as the area 
postrema (AP) and the dorsal motor nucleus of the vagal nerve (Jeanningros, 1982). 
Afferent vagal nerve fibres have been shown to relay information fiom the 
gastrointestinal (GI) tract and the vagus has been shown to innervate the entire GI tract 
as far as the colon (Jeanningros, 1982). Evidence for the control of food intake by the 
GI tract has come from experiments where lesions of the AP and NTS have resulted in a 
reduction in food intake, which subsequently led to weight loss as the animal was 
unable to compensate by eating more (Kaplan et al., 1993). 
The brainstem responds to circulating humoral regulators signals from the vagus nerve 
and via the area postrema (AP). The AP is accessible to the peripheral circulation 
because it lacks an effective blood-brain barrier (Edwards and Ritter, 1982). It has been 
proposed that the hypothalamus responds to information regarding the metabolic state 
of the individual, while the brainstem is responsible for meal initiation and termination 
(Grill and Kaplan, 2002). The hypothalamus and brainstem are linked via projections 
from the neurones in the nucleus of the solitary tract (NTS) located in the brainstem, to 
the PVN and LHA. There are also projections of serotoninergic neurones of the Raphe 
nuclei in the brainstem to the ARC. Recent work suggests that the gut hormones 
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ghrelin and GLP-1 may mediate their effects on food intake at least in large part via the 
brainstem (Faulconbridge et al , 2003; Grill et al , 2004; Takahashi, 2003). 
It is evident that the control of feeding is not the role of any one system. Rather, it is 
the result of the integrative operation of various brain regions, psychological factors, 
neuronal and hormonal mechanisms, the GI tract and metabolic and nutrient factors. 
Over the past decade it has become apparent that the hypothalamus is central to this 
control, and that communication between the brainstem and the hypothalamus is 
important. However, the means for this communication is still unclear. 
1.4 Peptides involved in the regulation of food intake and body 
weight 
Within the hypothalamus, there is a distinct circuitry involved in the regulation of 
appetite and food intake. Changes in peripheral signals are sensed by the neurones 
within the hypothalamus, which then synthesise and release orexigenic and anorectic 
peptides. Below are examples of some of these peptides (table 1.1). 
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Orexigenic peptides Anorectic peptides 
• Agouti-related peptide (AgRP) • a-melanocyte-stimulating hormone 
• Endocannabinoids (aMSH) 
• Galanin • Cholecystokinin (CCK) 
• Ghrelin • Cocaine and amphetamine-
• Melanin-concentrating hormone regulated transcript (CART) 
(MCH) • Glucagon 
• Neuropeptide Y (NPY) • Glucagon-like peptides 1 & 2 
• Noradrenalin (GLP-1, GLP-2) 
• Insulin 
• Leptin 
• Neuromedin U 
• Oxyntomodulin 
• Pancreatic polypeptide (PP) 
• Peptide YY3.36 (PYY3.36) 
• Somatostatin 
• Serotonin 
• Thyrotrophin-releasing hormone 
(TRH) 
Table 1.1 Examples of peptide hormones implicated in the stimulation and 
inhibition of food intake. 
1.4.1 Neuropeptide Y (NPY) 
NPY is a 36 amino acid peptide that is widely and abundantly expressed within the 
nervous system (Allen et al , 1983). Together with peptide YY (PYY) and pancreatic 
polypeptide (PP), NPY makes up the PP-fold family of peptides, characterised by a 
common hairpin-like three-dimensional structure called the PP-fold (Nygaard et al., 
2006). 
Plasma NPY peptide levels are increased in response to fasting and are normalised by 
refeeding (Kalra et al., 1991). Repeated third ventricle injections of NPY cause 
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hyperphagia, decreased thermogenesis and obesity (Stanley et al., 1986). Metabolic 
changes induced by NPY favour energy storage as adipose tissue. ICV and PVN 
administration of NPY results in an increase in lipoprotein lipase activity, promoting fat 
deposition and increase in the amount of white adipose tissue (WAT) (Billington et al., 
1991). Central administration of NPY causes an inhibition of the thyroid axis resulting 
in reduced energy expenditure (Fekete et al., 2002). Intracerebroventricular (ICV) 
injection of NPY receptor antagonists or antiserum decreases food intake in rats 
(Darnels et al., 1995; Kanatani et al., 1996; Matthews et al., 1997), further illustrating 
the potential importance of NPY in the CNS regulation of appetite. 
1.4.2 Melanocortin and agouti protein 
The melanocortins are a family of peptides that include a-melanocyte stimulating 
hormone (a-MSH) and adrenocorticotrophic hormone (ACTH). Tissue specific post-
translational cleavage of the precursor molecule, pro-opiomelanocortin (POMC) gives 
rise to these proteins. Li the pituitary, where there are high levels of POMC expression 
post-translational processing gives rise to ACTH. This acts via the melanocortin-2 
receptor (MC2R) to stimulate adrenal steroidogenesis (Hall and Koritz, 1966; Weber et 
al., 1993). POMC expressed in the ARC and the NTS is processed to produce a-MSH. 
Alpha-MSH inhibits feeding and reduces body weight by acting as an agonist at the 
melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) (Hillebrand et al., 
2002). MC4R is thought to be the most important with respect to the control of energy 
homeostasis, as the MC4R knockout mouse has a hyperphagic and obese phenotype 
(Huszar et al., 1997). MC4R agonists, for example a-MSH administered ICV cause 
anorexia (Hughes et al., 1988; Tsujii and Bray, 1989), whereas antagonists increase 
food intake (Lu et al., 1994). Examples of endogenous antagonists are agouti protein 
and the related peptide, agouti-related peptide (AgRP), which bind with high affinity to 
both hypothalamic MC3 and MC4 receptors. Overexpression of agouti protein leads to 
hyperphagia and obesity in mice (Zemel et al., 1998). 
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1.4.3 Leptin 
The adipocyte hormone leptin is the protein of the obese (ob) gene, and leptin 
concentrations in plasma correlate directly to body fat mass (Considine et al., 1996; 
Rosenbaum et al., 1996). Peripheral and central administration of leptin to rodents 
causes a reduction in food intake and body weight (Halaas et al., 1995; Calapai et al., 
1998). Leptin acts on neurones in the ARC to stimulate anorexigenic neurones and to 
inhibit orexigenic neurones. It is thought to signal the levels of body fat stores to the 
CNS in an environment of nutritional plenty (thus conversely, low circulating leptin acts 
as a signal of starvation) (Ahima et al., 1996). Three genetic models exist, which allow 
further investigation of the role of leptin: the oh/oh mouse, which is leptin deficient 
(Bray and York, 1979) and the db/db mouse and fa/fa (Zucker) rat, both of which have 
dysfunctional leptin receptors (Chen et al., 1996; Ogawa et al., 1995). These animals 
are hyperphagic and obese as are humans with mutations in the ob gene (Montague et 
aL, 1997). 
1.4.4 Insulin 
Insulin, produced by the pancreatic beta cells, is the major regulator of peripheral 
glucose homeostasis modulating such processes as glucose uptake, gluconeogenesis and 
glycogen metabolism. In classical insulin target tissues such as skeletal muscle, adipose 
tissue and the liver, insulin acts via a receptor tyrosine kinase signal transduction 
cascade to mediate these effects upon metabolism. However insulin may also function 
as a signal of adiposity. Insulin circulates at levels proportional to fat mass (Woods and 
Porte, Jr., 1983) and reaches the CNS by receptor-mediated transport across the blood-
brain barrier (Woods et al., 2000). Insulin receptors are abundant in the mediobasal 
hypothalamus including the ARC (Werther et al., 1987) and ICV administration of 
insulin reduces food intake and causes weight loss in rodents (Chavez et al., 1995; 
Foster et al., 1991). Experimental evidence from murine gene-targeting strategies 
support a role for central insulin action in the regulation of adiposity and reproductive 
fimction (Bruning et al., 2000). 
1.4.5 Ghrelin 
Ghrelin is a novel 28 amino acid peptide and was originally purified from rat stomach 
(Kojima et al., 1999). It has been shown that acute and chronic peripheral 
administration to rats causes hyperphagia and obesity (Wren et al., 2000; Wren et al., 
2001b). Furthermore, in humans it has been shown that intravenous administration can 
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significantly increase caloric intake in a free-choice meal (Cheung et al., 1997; Wren 
et al., 2001a). Several lines of evidence suggest that ghrelin, when released from the 
gut, might act directly on the hypothalamic ARC to regulate feeding circuits, rather than 
acting via vagal innervation (Nakazato et al., 2001). 
1.4.6 Peptide YY (PYY) 
PYY is a 36-amino-acid peptide which is a member of the PP-fold family of peptides 
(Nygaard et al., 2006). PYY is secreted from the endocrine L cells of the large and 
small bowl, and is found at highest concentrations in the terminal ileum, colon and 
rectum (Adrian et al., 1985). The form mainly stored and circulating is PYY(3-36), 
which acts via the NPY Y2 receptor (Batterham et al., 2002). When PYY(3-36) is 
administered peripherally to both rodent and humans there is marked inhibition of food 
intake (Batterham et al., 2002). The observation that PYY(3-36) increases c-Fos 
expression within the ARC and the abundance of Y2 receptor in the ARC suggests that 
circulating PYY(3-36) inhibits appetite by acting directly on the ARC via the Y2 
receptor (Batterham et al., 2002). 
1.5 The hypothalamic-pituitary-thyroid (HPT) axis 
The PVN contains TRH-expressing neurones which have an important role in the 
regulation of energy homeostasis through their hypophysiotropic actions on anterior 
pituitary thyrotrophs to regulate circulating levels of thyroid hormones and via direct 
effects on the CNS (Lechan and Fekete, 2006). Hypophysiotropic TRH neurones are 
located in the parvocellular subdivision of the PVN and receive direct projections from 
a-MSH/CART neurones (Fekete et al., 2000) and NPY/AgRP neurones (Legradi and 
Lechan, 1999) in the ARC. These ARC neurones are able to influence the HPT axis in 
response to prevailing metabolic state (Lechan and Fekete, 2004). Other regions of the 
brain may also serve as metabolic sensors for hypophsiotropic TRH neurons including 
the DMH, which has direct projections to the PVN (Lechan and Fekete, 2006). 
Axons from hypophsiotropic TRH neurons in the PVN project to the median eminence, 
allowing access of TRH to the fenestrated capillaries of the portal system for transport 
to the anterior pituitary where TRH regulates the release of thyroid-stimulating hormone 
(TSH). TSH then stimulates the release of the thyroid hormones, thyroxine (T4) and 
3,3',5 tri-iodothyronine (T3), from the thyroid gland into the peripheral circulation. The 
HPT axis demonstrates negative feedback, in that thyroid hormones inhibit 
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hypophsiotropic TRH neurons and anterior pituitary thyrotrophs in order to maintain a 
'normal' set-point for circulating levels of plasma thyroid hormone (Lechan and Fekete, 
2006). The thyroid hormones are iodinated derivatives of tyrosine which play a critical 
role in differentiation, growth and metabolism. Under normal conditions T4 is the main 
product of the thyroid gland, although small amounts of T3 and inactivate reverse-Tg are 
secreted. T3 is the biologically active hormone which is derived from the metabolism of 
T4 in peripheral tissues by deiodinase activity (Bianco and Larsen, 2005). Circulating 
thyroid hormones bind reversibly to plasma proteins, and it is only the free hormone 
that is able to enter cells to bind to the nuclear receptor. The nuclear receptors mediate 
most of the physiological functions of the thyroid hormones and have much greater 
affinity for T3 (Yen, 2001). 
Thyroid hormones are required for normal ftinction of nearly all tissues and are 
particularly important in the regulation of obligatory (basal homeostatic fiinctions) and 
adaptive (thermogenesis) energy expenditure (Silva, 1995). The basal metabolic rate 
can be reduced by up to 30% in the absence of thyroid hormone, whereas 
hyperthyroidism increases metabolic rate (Silva, 2003). Thyroid hormones may also 
influence activity related energy expenditure, as an infusion of T3 has been shown to 
increase spontaneous physical activity in rodents (Levine et al., 2003). 
1.6 Proglucagon-derived products and exendin-4 
1.6.1 The proglucagon gene 
The structure of the mammalian proglucagon gene was first described in 1983 (Bell et 
al., 1983) and in 1986 the processing of the pre-hormone, pre-proglucagon to its 
constituent peptides was established (Mojsov et al., 1986). The proglucagon gene 
product undergoes tissue-specific post-translational processing in the intestine, pancreas 
and CNS (Drucker, 2005; Tang-Christensen et al., 2001) (figure 1.2). Cleavage of 
pancreatic proglucagon by prohormone convertase 2 in the islet a-cells gives rise 
primarily to 29 amino acid glucagon and the unprocessed major proglucagon fragment 
(MPGF) (Patzelt and Schiltz, 1984; Rouille et al., 1994; Webb et al., 2004). 
Prohormone convertase 1 and 3 are essential for cleavage of proglucagon into glicentin 
(enteroglucagon), oxyntomodulin, glucagon-like-peptide-1 (GLP-1) and glucagon-like 
peptide-2 (GLP-2) in enteroendocrine L-cells of the small intestine and in the NTS 
(Dhanvantari et al., 1996). The amino acid sequences of the proglucagon-derived 
products are shovm in figure 1.3. 
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peptide GRPP Glucagon •^•>0 GLP-1 SP-2 GLP-2 
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KRKRR 
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Post-translational processing PANCREAS 
GRPP Glucagon 
Glicentin 
(Enteroglucagon) Giicentin-related 
Glucagon 
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SP-2 
GLP-2 
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Oxyntomodulin 
GLP-1 (7-36) NH; 
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30 
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Major Proglucagon fragment 
Figure 1.2 A diagrammatic representation of the tissue-specific processing of 
preproglucagon in the pancreas and the CNS/intestine. GLP-1 (glucagon-like 
peptide-1); GLP-2 (glucagon-like peptide-2); GRPP (glicentin-related pancreatic 
polypeptide); SP-1 (spacer peptide-1); SP-2 (spacer peptide-2). Adapted from 
(George et aL, 1985). 
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qlucaqon H S Q G T F T S D Y S K Y L D S R R A Q D F V Q W L M N T 
GLP-1 H A E G T F T S D V S S Y L E G Q A A K E F 1 A W L V K G R G 
GLP-2 H A D G S F S D E M N T 1 L D N L A A R D F I N W L 1 Q T K 1 T D 
oxyntomodulin H S Q G T F T S D Y S K Y L D S R R A Q D F V Q W L M N T K R N R N N 1 A 
exendin4 H G E G T F T S D L S K Q M E E E A V R L F 1 E W L K N G G P S S G A P P P S 
glicentin R S L Q D T E E K S R S F S A S Q A D P L S D P D Q M N E D K R H S Q G T F T S D Y S K Y L D S R R A Q D F V Q W L M N T K R N R N N 1 A 
spacer peptide 1 K R N R N N 1 A 
• Conserved amino acids in GLP-1, GLP-2, glucagon, exendin-4 and oxyntomodulin 
n Conserved amino acids in four out of the following peptides: GLP-1, GLP-2, glucagon, 
exendin-4 and oxyntomodulin 
Figure 1.3 The amino acid sequences of the human proglucagon-derived peptides and exendin-4 (single 
amino acid key, see appendix A) 
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1.6.2 Glucagon 
Glucagon is a 29 amino-acid peptide hormone released from the a-cells of the islets of 
Langerhans. The primary function of glucagon is to regulate hepatic glucose 
production. Glucagon is released in response to hypoglycemia and is the main counter-
regulatory hormone to insulin. The insulin-to-glucagon ratio determines control of 
hepatic glucose production through rates of gluconeogenesis and glycogenolysis. 
Circulating levels of glucagon are low in the post-prandial state and increase with 
fasting. The glucagon (GCG) receptor, a G-protein coupled receptor (GPCR) is a 
member of the GPCR B family, subfamily B1 (Myojo et al., 1997) and mediates the 
actions of glucagon (Jelinek et al., 1993). The GCG receptor is a 485 amino acid 
protein which shares 42% sequence homology for the GLP-1 receptor, another member 
of the secretin-glucagon receptor family. Activation of the GCG receptor by glucagon 
causes an increase in intracellular adenylyl cyclase activity and intracellular calcium 
release. Glucagon binding sites have been identified in liver, kidney, intestinal smooth 
muscle, islet (3-cells, adipose tissue, cerebral cortex (Hansen et al., 1995; Svoboda et al., 
1994) and GCG receptor mRNA has been detected in spleen, thymus and adrenal glands 
(Dunphy et al., 1998). The metabolic derangement which occurs in type 2 diabetes is 
due to a failure of post-prandial glucagon and/or insulin resistance (Unger and Orci, 
1975). 
1.6.3 Glucagon-Iike peptide-1 
GLP-1 and GLP-2 are predominant products of proglucagon processing in the intestine 
and the CNS (Mojsov et al., 1986; Tager et al., 1980) (figure 1.2). However, further 
proteolytic cleavage of GLP-1 results in the fragments: GLP-1 (1-37), GLP-l(l-36), 
GLP-1 (7-36) and GLP-1 (7-37) (Kreymann et al., 1988; Mojsov et al., 1987; Orskov et 
al., 1994). The N-terminal truncated peptides, GLP-1 (7-36) and GLP-l(7-37), are 
biologically active (Hoist et al., 1987; Kreymann et al., 1987). In the rat brain, the 
GLP-1 activity has been demonstrated to be in the form of GLP-l(7-36)amide (Shimizu 
et al., 1987). In humans, it has also been demonstrated that the circulating active form 
of GLP-1 is GLP-1 (7-36)amide (Orskov et al., 1994) and it is this form which shall be 
referred to as GLP-1 in this document. GLP-1 shares 50 % sequence homology with 
glucagon and contains two helical regions at amino acid positions 7-14 and 18-29 
(Thornton and Gorenstein, 1994). GLP-1 acts via the GLP-1 receptor a member of the 
GPCR glucagon-secretin family, and signals through Gg leading to activation of 
adenylyl cyclise and increased levels of cyclic AMP. GLP-1 receptors are expressed in 
41 
the hypothalamus and brainstem (Goke et al., 1995a; Shimizu et al., 1987; Uttenthal et 
al., 1992), pituitary gland (Goke et al., 1995b), lung (Richter et al., 1990), pancreatic 
islets (Thorens, 1992) and kidney (Bullock et al., 1996). Fasting and refeeding 
modulate GLP-1 receptor expression in the hypothalamus and brainstem (Zhou et al., 
2003), with expression being lower in fed than fasted rats. 
GLP-1 is secreted from the L-cells of the gut in response to nutrient ingestion, the 
greatest increase being in response to a mixed meal (Herrmann et al., 2002). GLP-1 
physiologically stimulates glucose-dependent insulin secretion and insulin biosynthesis 
and inhibits glucagon secretion, gastric emptying and food intake (Drucker, 2001). 
GLP-1 also functions as a neurotransmitter, a population of neurones expressing 
preproglucagon mRNA has been found in the NTS of the brainstem (Larsen et al., 
1997). GLP-1 immunoreactive fibres have been demonstrated in forebrain areas 
including the hypothalamic DMN and PVN (Larsen et al., 1997), in the same regions or 
close to where GLP-1 receptors are present (Shughrue et al., 1996). 
One of the main functions of GLP-1 is thought to be as an incretin hormone. GLP-1 is 
one of the most important incretin hormones (Kreymann et al., 1987) and has been 
found to potentiate all steps of insulin biosynthesis (MacDonald et al., 2002). GLP-1 
receptor knockout mice exhibited fasting glucose hyperglycemia and reduced glucose-
stimulated insulin secretion, demonstrating the importance of GLP-ls incretin action 
(Scrocchi et al., 1996). 
GLP-1 is also a signal of energy homeostasis. Circulating GLP-1 levels are inversely 
correlated with body-mass (Hoist et al., 1983; Naslund et al., 1999; Verdich et al., 
2001a) and GLP-1 inhibits food intake when administered centrally and peripherally. 
Administration of GLP-1 into the ICV and directly into the PVN inhibits food intake in 
rats (Turton et al., 1996). Repeated daily ICV injections of GLP-1 over a six-day period 
reduces body weight in rats (Meeran et al., 1999). Intraperitoneal injection of GLP-1 to 
mice was found to inhibit refeeding in fasted mice (Neary et al., 2005; Rodriquez de et 
al., 2000). Conversely antagonism of the GLP-1 receptor by ICV administration of 
exendin9-39 increased daily food intake and resulted in body weight gain (Meeran et 
al., 1999). It is thought that the anorectic effect of GLP-1 probably occurs via 
hypothalamic and brainstem centres, as well as delayed gastric emptying (Flint et al., 
2001; Turton et al., 1996; Yamamoto et al., 2003). The anorectic effects of GLP-1 are 
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abolished following vagotomy or transaction of the brainstem-hypothalamic pathway in 
rodents, suggesting the vagal-brainstem pathway is vital for the anorectic action of 
GLP-1 in the brain (Abbott et al., 2005). GLP-1 administered intravenously or into the 
cerebral ventricles increase energy expenditure (measured by whole-body oxygen 
consumption and core temperature) in anaesthetised rodents, an effect which may also 
be mediated by the brainstem and sympathetic system (Osaka et al., 2005). No 
alteration in feeding behaviour was observed in GLP-1 receptor knockout mice 
(Scrocchi et al., 1996), suggesting that physiologically GLP-1 may not be important in 
regulating food intake. However developmental compensatory mechanisms in the 
knockout model can not be ruled out. 
The role for GLP-1 in physiological control of human appetite is not clear. Peripheral 
administration does inhibit food intake in normal individuals (Gutzwiller et al., 1999), 
in diabetics (Gutzwiller et al., 1999; Toft-Nielsen et al., 1999) and in non-diabetic obese 
men (Naslund et al., 1999). However, when infusions achieve levels comparable to 
those seen in the physiological state after meals, the effect on appetite and food intake is 
small (Flint et al., 2001; Verdich et al., 2001a). A recent meta-analysis of these studies 
has concluded that there is a reduction of 11.7% in energy intake following a single 
infusion of GLP-1 (Verdich et al., 2001a). GLP-1 secretion is reduced in obese subjects 
and weight loss normalises the levels (Verdich et al., 2001b). The anorectic effects of 
GLP-1 are however preserved in obesity. Prandial subcutaneous GLP-1 given for five 
days to obese, but otherwise healthy human subjects, results in a reduction of calorie 
intake of 15% and weight loss of 0.5kg (Naslund et al., 1999). A reduced secretion of 
GLP-1 could therefore contribute to the pathogenesis of obesity. 
GLP-1 has been reported to cause hypoglycemia in non-diabetic subjects (Edwards et 
al., 1998) which could limit its usefulness as an obesity therapy. However, the key 
limiting factor of the peptides usefulness as a treatment for diabetes or obesity is the 
peptides short half-life of one to two minutes in circulation (Deacon et al., 1995; Orskov 
et al., 1993). GLP-1 is rapidly broken down by the protease dipeptidyl peptidase IV 
(DPP IV) which removes the two N-terminal amino acids of bioactive GLP-1, 
converting it to GLP-1 (9-36) amide rendering it inactive (Hansen et al., 1999; Kieffer 
et al., 1995). Therefore, the development of GLP-1 based therapeutic approaches has 
focused on degradation-resistant, long-acting receptor agonists. 
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Both LY548806 an analogue of GLP-1 which is 25 times more resistant to DPP IV 
breakdown than native GLP-1 and CJC-1131 a GLP-1 analogue that consists of a DPP-
IV-resistant form of GLP-1 joined to a reactive chemical linker group that allows GLP-
1 to form a covalent and irreversible bond with serum albumin following subcutaneous 
injection have been shown to be longer acting than GLP-1 at reducing blood glucose 
levels (Baggio et al., 2004a; Kim et al., 2003). Studies of another GLP-1 analogue 
Liraglutide, a fatty acyl-derived DPP-IV-resistant form shows improved glycemic 
control in humans with type 2 diabetes (Madsbad et al., 2004) and is in late stage trials 
as a therapeutic agent. An alternative approach to extending the half-life of GLP-1 is 
inhibition of the enzyme DPP IV. This approach has been shown to be of success in 
treating type 2 diabetes (Ahren et al., 2002). Sitagliptin, a DPP IV inhibitor has been 
approved for treatment of type 2 diabetes in the United States while Vildagliptin another 
DPP IV inhibitor is close to being approved. Perhaps the most successful incretin 
mimetic to date and the leading novel treatment of type 2 diabetes is exendin-4 (also 
known as Exenatide and Byetta). 
1.6.4 Exendin peptides 
Exendin-3 and exendin-4 are 39 amino acid peptides, differing only at residues 2 and 3. 
Both peptides isolated from the salivary gland of the venomous lizards, namely 
Heloderma horridum and Heloderma suspectum respectively (Eng et al., 1990; Eng et 
al., 1992; Malhotra et al., 1992). Although they are products of non-mammalian genes 
and appear to be expressed only in the salivary gland (Chen and Drucker, 1997), they 
share over 50 % amino acid sequence homology with mammalian GLP-1 (figure 1.3). 
Both peptides have very high affinity for the GLP-1 receptor, where they act as highly 
potent agonists (Goke et al., 1993; Thorens et al., 1993). Exendin-4 displays similar 
properties to GLP-1 and regulates gastric emptying, insulin secretion, food intake and 
glucagon secretion (Goke et al., 1993; Navarro et al., 1996; Schepp et al., 1994). 
Furthermore, exendin-4 lowers blood glucose in both normal rodents and in rodents 
with experimental diabetes (Greig et al., 1999; Young et al., 1999) and humans with 
type 2 diabetes (Kolterman et al., 2003). Exendin-4 is much more efficacious than 
native GLP-1, largely due to its resistance to DPP-IV-mediated inactivation. Exendin-4 
(Exenatide) has recently been approved as a treatment for type 2 diabetes. As well as its 
incretin like properties is also effective at promoting weight loss in diabetic humans. 
Over a 28 day period, patients with type 2 diabetes treated twice daily with 10 pgof 
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exendin-4 demonstrated a weight loss of 1.8 ± 0 . 3 kg (Poon et al., 2005) and 2.8 ± 0.5 
kg over 30 weeks (Buse et al., 2004). 
1.6.5 Glucagon-like peptide-2 
GLP-2 is a 33 amino acid peptide product of proglucagon, which share sequence and 
structural similarities with glucagon and GLP-1. GLP-2 is secreted from intestinal L-
cells in a nutrient dependent manner and its actions are mediated by the GLP-2 receptor 
(Munroe et al., 1999). The actions of GLP-2 include inhibition of gastrointestinal 
motility and gastric acid secretion, stimulation of nutrient absorption, reduction of 
intestinal epithelial permeability and alterations in mucosal growth in response to 
nutrient availability (Drucker et al., 1996). Although central administration of GLP-2 
has been found to inhibit food intake in rodents (Tang-Christensen et al., 2000), GLP-2 
does not act as a satiety factor in normal human subjects (Schmidt et al., 2003). Like 
GLP-1, DPP IV is known to be a key factor in determining the circulating half-life of 
GLP-2 (Drucker et al., 1997). 
1.6.6 Glicentin 
Compared to many of the proglucagon derived peptides, relatively little information is 
knovm about the biological actions of glicentin, a 69 amino acid peptide. When 
administer at high does to rodents it has been shown to reduce pancreatic (Ohneda et al., 
1995), gastric (Kirkegaard et al., 1982) and ileal (Hirotani et al., 2000) secretion. It has 
also been shown to regulate gut motility (Shibata et al., 2001) and stimulate gut growth 
(Myojo et al., 1997). To date no separate receptor for glicentin has been identified and 
likely that some of these actions are attributable to activation of either glucagon, GLP-1 
or GLP-2 receptors. 
1.6.7 Oxyntomodulin 
In 1982 a bioactive form of enteroglucagon, the term applied to the region of 
proglucagon comprising of oxyntomodulin and glicentin was isolated from porcine 
jejuno-ileum (Bataille et al., 1982). The isolated enteroglucagon had similar biological 
effects to those of glucagon in the liver, interacting with hepatic glucagon-receptors and 
activating adrenylate cyclase (Bataille et al., 1973; Bataille et al., 1974). This putative 
peptide was called oxyntomodulin, as the peptide was highly active at the gastric 
oxyntic gland (Bataille et al., 1981a). Characterisation of the peptide sequence showed 
the amino acids were identical to that of residues 33-69 of glicentin (Hoist, 1982), 
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contain the full sequence of glucagon with an octapeptide tail (figure 1.2 and 1.3) 
(Bataille et al , 1981b). 
Clear understanding of the physiology of oxyntomodulin is complicated by difficulties 
in accurate measurement of plasma levels. There is cross-reactivity between the 
proglucagon-derived gene products due to sequence homology (figure 1.3). 
Oxyntomodulin-Iike immunoreactivity (OLI) is the term used to measure levels by 
radioimmunoassay, incorporating a subtraction assay to account for cross-reactivity 
with pancreatic glucagon (Hoist, 1997). 
The main products of post-translational processing of the proglucagon prohormone in 
the brain and intestine are GLP-1, GLP-2 and glicentin. The glicentin is then further 
cleaved to form oxyntomodulin and GRPP (Hoist, 1997). Brain regions containing 
oxyntomodulin (or the parent peptide glicentin) include the medulla oblongata, 
olfactory bulbs, cerebellum and cortex, and the hypothalamus (Blache et al., 1998). 
Significant amounts of oxyntomodulin have been found in human distal intestine 
(Baldissera et al., 1988). In rodents, the gastrointestinal tissue concentration of 
oxyntomodulin gradually increases from the duodenum and ileum, thereafter decreasing 
in caecum and colon (Kervran et al., 1987). Oxyntomodulin is released from the 
intestinal L-cells 5-10 minute after meal ingestion in proportion to calorie intake 
(Ghatei et al., 1983; Le et al., 1992), peaking at around 30 minutes (Anini et al., 1999). 
In common with other intestinal hormones, circulating levels of OLI demonstrate a 
diurnal variation, independent of food intake, with highest levels in the evening and 
lowest in the early morning (Le et al., 1992). 
Oxyntomodulin has a short half-life in circulation, reported to be 12 ± 1 minute in 
humans (Schjoldager et al., 1988) and 6.4 ± 0.5 minutes in rat (Kervran et al., 1990). 
While originally thought to be resistant to the protease DPP IV which cleaves other 
peptides in the family (Mentlein et al., 1993), it is now thought that breakdown of 
oxyntomodulin may be regulated by DPP IV as well as other endopeptidases (Zhu et al., 
2003). Renal clearance is also responsible for the short circulating half-life (Kervran et 
al., 1990). It was found that oxyntomodulin is a potent inhibitor of pentagastrin and 
liquid meal-stimulated gastric acid secretion in the gastric mucosa of rodents and 
humans (Dubrasquet et al., 1982; Jarrousse et al., 1985; Schjoldager et al., 1988; 
Schjoldager et al., 1989). Furthermore, oxyntomodulin was demonstrated to delay the 
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rate of gastric emptying (Schjoldager et al., 1989) with the time for 50% emptying of 
the stomach increasing from approximately 17 minutes to 35 minutes in response to an 
infusion of oxyntomodulin in healthy human volunteers. Fragments of the 
oxyntomodulin molecule remain effective at inhibition of stimulated gastric acid 
secretion, albeit with a requirement for a greater dose to compensate for the more rapid 
breakdown (Carles-Boimet et al., 1996; Jarrousse et al., 1985; Jarrousse et al., 1993). 
There is some in vitro evidence that oxyntomodulin, like GLP-1, promotes insulin 
release (Baldissera et al., 1988; Jarrousse et al., 1984). 
The administration of oxyntomodulin acutely reduces food intake in rodents, without 
altering behavioural patterns (Dakin et al., 2001; Dakin et al., 2004). Dark phase and 
fast-induced feeding are decreased following an injection of oxyntomodulin into the 
peritoneum or after administration into the cerebral ventricles, PVN or ARC (Dakin et 
al., 2001; Dakin et al., 2004). Chronic central administration and twice-daily peripheral 
injections of oxyntomodulin resulted in reduced body weight gain and adiposity (Dakin 
et al., 2002; Dakin et al., 2004). Dose-responses of oxyntomodulin in rodents were 
similar to those for GLP-1 for inhibiting food intake (Dakin et al., 2004). An infusion 
of oxyntomodulin to normal-weight human subjects reduced hunger and decreased 
calorie intake by 19.3%, an effect which persisted for up to twelve hours post-infusion 
(Cohen et al., 2003). Chronic administration of oxyntomodulin to overweight humans 
three times a day for 4 weeks resulted in weight loss and a reduction of energy intake at 
a study meal in the treatment group at the begiiming of the study and the end of the 
study (Wynne et al., 2005). 
Peripheral administration of oxyntomodulin activates c-Fos in the ARC, PVN, area 
postrema and NTS (Baggio et al., 2004b; Dakin et al., 2004; Horvath, 2005), and the 
anorectic effect of peripheral oxyntomodulin may be mediated by an increase in 
hypothalamic a-MSH (Dakin et al., 2002). Peripheral administration of oxyntomodulin 
has also been found to reduce circulating ghrelin by 20% in rodents (Dakin et al., 2002) 
and 44% in humans (Cohen et al., 2003) which may contribute to the anorectic actions. 
Many hormones involved in body weight homeostasis have effects on energy 
expenditure as well as food intake. Whether this is the case for oxyntomodulin is at 
present unresolved. Animals injected peripherally or ICV with oxyntomodulin lose 
more weight than pair-fed animals, suggestive of an increase in energy expenditure, 
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postulated to be mediated by the thyroid axis (Dakin et al., 2002; Dakin et al., 2004). 
However, analysis of energy expenditure in mice did not confirm an acute effect of ICV 
oxyntomodulin on metabolic rate (Baggio et al., 2004b). The data for oxyntomodulin 
contrasts with that seen with a single injection of exendin-4, which when given IP or 
ICV reduces metabolic rate in mice, consistent with similar data for GLP-1 (Baggio et 
al., 2004b). However a study of energy expenditure in humans following repeated 
subcutaneous administration of oxyntomodulin showed an increase in activity-specific 
energy expenditure, although no change in basal metabolic rate was observed (Wynne et 
aL,2006). 
As yet, the existence of a pharmacologically unique oxyntomodulin receptor has not 
been clearly demonstrated. Although oxyntomodulin shares much sequence similarity 
with glucagon, the peptide binds to the GCG receptor in liver membranes with 
approximately 2-10% affinity of glucagon (Baldissera et al., 1988; Bataille et al., 1982). 
It has been suggested that the effects of both GLP-1 and oxyntomodulin on energy 
homeostasis are mediated by the GLP-1 receptor. Oxyntomodulin can bind the GLP-1 
receptor but with an affinity several orders of magnitude lower for oxyntomodulin than 
for GLP-1 (Dakin et al., 2001; Fehmaim et al., 1994; Schmidtler et al., 1994). The 
weakness of oxyntomodulin in vitro binding to the GLP-1 receptor argues against 
physiological function in vivo, although it is possible that the GLP-1 receptor could 
mediate effects of oxyntomodulin via a paracrine effect with higher local tissue 
concentrations. Evidence to suggest that the GLP-1 receptor mediates the actions of 
oxyntomodulin include the blockade of the anorectic effects of oxyntomodulin by 
exendin(9-39) (which is an antagonist at the GLP-1 receptor) (Dakin et al., 2004) and of 
the effects on acid secretion from an enriched parietal cell preparation (Schepp et al., 
1996). Persuasive evidence also comes from the lack of effect of oxyntomodulin on 
food intake in GLP-1 receptor knockout mice (Baggio et al., 2004b). 
However there is also evidence for actions of oxyntomodulin that are not mediated via 
the GLP-1 receptor. The specificity of exending.sg used in blockade experiments is not 
absolute (Turton et al., 1996) and furthermore, although exending.sg can block the 
appetite effects of centrally administered oxyntomodulin and GLP-1, the antagonist 
administered into the ARC is able to abolish the effect of peripherally-administered 
oxyntomodulin but not peripheral GLP-1. In addition, in one study the peripheral 
administration of oxyntomodulin resulted in increased c-Fos in the ARC but not in the 
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brainstem and this pattern of neuronal activation differs from the brainstem pattern seen 
with GLP-1 (Dakin et al., 2004). There could be distinct receptors mediating the 
physiological effects GLP-1 and oxyntomodulin (Dakin et al., 2001) or both hormones 
may act via the same receptor while still leading to differentiated effects via, for 
example, differences in receptor milieu or downstream signalling (Baggio et al., 2004b). 
In support of an alternative receptor, a recent study suggests that oxyntomodulin 
elevates murine heart rate via a GLP-1 receptor-independent mechanism (Sowden et al., 
2007). The differential effects of GLP-1 and oxyntomodulin may therefore be due to 
the presence of separate receptors. Alternatively, difference in peptide breakdown, 
tissue penetration, or context-dependent alterations in receptor signalling (such as 
receptor-activity-modifying proteins which regulate the affinity of calcitonin receptors 
(Bom et al., 2002)) may result in the observed differences between these two 
proglucagon products. 
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1.7 Aims of investigations 
1) To investigate a range of effects and properties of oxyntomodulin, GLP-1 and 
the related peptide exendin-4 to determine whether they demonstrate any 
differences in properties that might imply different modes of action; 
2) To investigate oxyntomodulin's susceptibility to DPP IV-mediated breakdown 
and to identify DPP IV resistant modifications; 
3) To investigate the effects of rational changes to the domain structure of 
oxyntomodulin on receptor binding, resistance to proteolytic degradation and 
food intake; 
4) To design an analogue of oxyntomodulin that is more potent and causes longer 
lasting inhibition of food intake than native oxyntomodulin and study the effect 
of chronic administration of this analogue on food intake and body weight 
change in rodents; 
5) Investigate the effect of a long lasting analogue of oxyntomodulin on energy 
expenditure in rat and the mechanism by which it mediates its effects. 
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Chapter 2 
Materials and Methods 
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2.1 Peptides 
Human oxyntomodulin, human GLP-1 and exendin-4 were purchased from Bachem, 
Ltd. Oxyntomodulin analogues were custom synthesised by Advanced Biotechnology 
Centre or BIOMOL International LP. 
All peptide used in the studies described in this thesis are the human sequence, unless 
otherwise stated and all sequence information is of the human form unless otherwise 
stated. In humans, it has been demonstrated that the circulating active form of GLP-1 is 
GLP-1 (7-3 6)amide (Orskov et al., 1994) and it is this form which shall be referred to as 
GLP-1 in this document. 
When requesting custom synthesis of peptides, a purity of >80% was requested. When 
it became apparent that this was not been achieved, supplier of peptides was changed 
from ABC, Imperial College to BIOMOL International LP. However, due to the time 
and cost of resynthesising peptides it was not possible to resynthesise all impure 
peptides. Therefore, results from studies where low purity of peptide (also likely to 
contain low peptide content) had been identified were carefiilly analysed, taking into 
account the likely reduced peptide affinity to receptor and peptide bioactivity caused by 
impurities such as salt or incorrectly synthesised peptide. Where possible conclusions 
drawn from experiments using low purity peptides were confirmed by experiments 
using a peptide of greater purity, albeit in a more complex analogue background. 
2.1.1 Custom synthesis of peptides 
Custom peptide synthesis by Advanced Biotechnology Centre and BIOMOL 
International LP was completed as described below using an automated 
fluorenylmethoxycarbonyl solid phase peptide synthesis (Fmoc SPPS) methodology. 
Details of the method used are described below. 
2.1.1.1 Peptide synthesis 
Advanced Biotechnology Centre used the following protocol. Peptides were 
synthesised by Fmoc SPPS with each amino acid added sequentially to the growing 
peptide chain from the C-to the N-terminus applying 0.45M 2-( 1 H-benzotriazol-1 -yl)-
1,1,3,3 -tetramethy lur onium hexafiuorophosphate (HBTU)/1 -hydroxybenzotriazole 
hydrate (HOBt) in dimethylformamide (DMF) and N,N-diisopropylethylamine as 
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coupling reagents. Removal of the N-Fmoc protecting group was carried out with 20% 
piperidine in N-methylpyrrolidone followed by sequential washes. 
BIOMOL used the following protocol, peptides were synthesised on TentaGel® resins, 
appropriately derivatised with one of a number of cleavable linkers, using an Fmoc/t-
butyl-based solid-phase synthesis strategy. Temporary N"-amino group protection is 
afforded by the Fmoc-group, with t-butyl ethers being utilised for protection of tyrosine, 
serine, and threonine hydroxyl side chains, whilst t-butyl esters protect the side chains 
of aspartic and glutamic acid residues. Histidine and lysine side chains were protected 
as their IST- and N®- tertbutyoxycarbonyl (Boc) derivatives respectively, cysteine as its 
S-trityl derivative, and arginine guanidine moiety as its Pbf derivative. Where N®-
acylation of lysine was required, orthogonal protection was afforded by the 
incorporation of l-(4,4-dimethyl-2,6-dioxocyclohexylidene)3-methyl-butyl lysine 
(Lys(ivDde)), which was deprotected on solid phase using 2% hydrazine in DMF. 
Acylation was carried out using diisopropylcarbodiimide (DIC)/l-hydroxybenzotriazole 
hydrate (HOBt). 
2.1.1.2 Peptide cleavage 
Advanced Biotechnology Centre used the following protocol. Peptides were cleaved 
from the resin with simultaneous deprotection using 82% trifluoroacetic acid (TFA) at 
room temperature for 3 hours in the presence of 5% thioanisole, 5% water, 2% 
ethanedithiol and 6% (w/v) phenol. In the case of cysteine-containing peptides, the 
cleavage mixture was filtered and precipitated in ice-cold diethyl ether. The remaining 
resin was washed once with TFA, fihered, and combined with the previous fractions. 
The precipitates were stored at 4°C overnight and collected by filtration, washed with 
ice-cold diethyl ether, and allowed to dry at room temperature. For non-cysteine 
containing peptides the cleavage mixture was filtered, the resin washed with TFA then 
dichloromethane, and the filtrates combined and concentrated under vacuum to oil. The 
peptide was precipitated in ice-cold diethyl ether, collected by filtration and allowed to 
dry at room temperature. The crude peptides were dissolved in TFA/AcN 
(acetonitrile)/water and lyophilized overnight. 
BIOMOL International LP used the following protocol. Upon completion of the 
synthesis peptides were cleaved from the solid support, with removal of side chain 
protecting groups, by treatment with aqueous trifluoroacetic acid (TFA) (95%) 
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containing triisobutylsilane (TIS) (5%) as a scavenger. TFA and scavengers were 
removed by evaporation and trituration. 
2.1.1.3 Purification of peptides and quality control 
Both Advanced Biotechnology Centre and BIOMOL International LP purified peptides 
by reverse phase preparative high performance liquid chromatography (HPLC) followed 
by lyophilisation. The purified product was subsequently analysed by reverse phase 
HPLC and by matrix-assisted laser desorption ionization mass spectroscopy (MALDI-
2.2 Animal studies 
2.2.1 Animals 
All animal procedures undertaken were approved by the British Home Office under the 
UK Animal (Scientific Procedures) Act 1986 (Project Licence 70/5516). 
Adult male C57/BL6J mice (Harlan) weighing 20-25 g were maintained in individual 
cages under controlled temperature (21-23°C) and lights (12:12 hour light-dark cycle 
lights on at 0700). Animals were allowed ad libitum access to water and ad libitum 
access to RMl diet (Special Diet Services) unless otherwise stated. To minimise any 
non-specific stress effects animals were regularly handled and acclimatised to intra-
peritoneal (IP) or subcutaneous (SC) injections. 
Diet induced obese mice were generated by feeding group-housed C57/BL6J mice 
(8/cage) high fat diet (% energy content: fat 60, protein 20, carbohydrate 20) (Research 
Diets Inc.) for 16 weeks. All other conditions were the same as those described above. 
Adult male Wistar rats (Harlan) weighing 200-300 g were maintained in individual 
cages under controlled temperature (21-23°C) and lights (12:12 hour light-dark 
schedule, lights on at 0700). Animals were allowed ad libitum access to water and ad 
libitum access to RMl diet (Special Diet Services) unless otherwise stated. To 
minimise any non-specific stress effects animals were regularly handled and 
acclimatised to SC injections. 
Feeding studies were planned and executed to minimise stress to animals. For all acute 
feeding studies, studies were completed on days where technicians were not operating 
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in the same room, cages had not been changed on the proceeding day and noise was 
minimised. For chronic studies where housing had to be changed part-way through the 
study period cage housing material from the old cage was added to the new cage. 
2.2.2 Acute feeding studies using mice (IP administration of compound) 
Experiments were carried out during the early light phase (0800-1000), in mice which 
had been fasted from 1600 the preceding day, unless otherwise stated. Fasted mice 
were used as the agents tested were expected to have anorectic effects, and the higher 
food intake of mice after a fast is more likely to successfully demonstrate such effects. 
Specific experimental details are noted for each study, but in each case the following 
was observed. For mice feeding studies, a maximal volume of 0.1 ml was injected IP, 
their body weight was recorded at zero hours and mice returned to their home cage with 
a known amount of food following peptide administration. Food was reweighed at 
regular intervals post-injection; food was removed from the hopper, a visual inspection 
of the cage made to check for any food spillage/hoarding and food weighed using 
balances accurate to 0.01 g. Mouse body weight was measured 24 hour post-injection. 
All mice feeding studies were completed in conditions where external stressors were 
minimised. Feeding studies for Chapters 5 and 6 were completed in a different animal 
house to those of other chapters, as larger cohorts of mice were required. All housing 
conditions were kept the same, mice were purchased from the same supplier and the 
same equipment including balances were used for all studies. 
2.2.3 Acute feeding studies using rats (IP and SC administration of compounds) 
Experiments were carried out during the early light phase (0800-1000), in rats which 
had undergone a 24 hour fast, unless otherwise stated. Specific experimental details are 
noted for each study, but in each case the following was observed. For rat feeding 
studies, a maximal volume of 1 ml was injected IP and a maximal volume of 0.2 ml was 
injected SC. Rat body weights were recorded at zero hours and rats returned to their 
home cage with a known amount of food. Food was reweighed at regular intervals 
post-injection; food was removed from the hopper, a visual inspection of the cage made 
to check for any food spillage/hoarding and food weighed using balances accurate to 
0.0Ig. Rat body weight was measured 24 hour post-injection. 
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2.2.4 Subcutaneous implantation of Alzet Osmotic Minipumps 
Alzet® Osmotic Minipumps (Durect Corporation) are an established method of chronic 
delivery and have previously been used for administration of appetite-regulation 
peptides, including PYY (Pittner, et al, 2004) and ghrelin (Tschop et al, 2000). These 
implantable pumps have the advantage of continuous administration without the need 
for connectors or frequent handling. Prior to implantation, the peptide is injected into a 
flexible central reservoir within the pump. This reservoir is separated by an 
impermeable membrane from an outer chamber with high salt concentration. Once 
implanted into the animal, fluid enters via a semi-permeable cellulose outer membrane 
due to the high osmotic pressure of the salt. This mechanically compresses the central 
reservoir and results in delivery of the treatment agent at a fixed rate (dependent on 
outer membrane permeability) via a stainless steel flow moderator. The pumps utilised 
in the experiments were model 2001 (length 300 mm, circumference 0.7 mm, weight 
1.1 g, release rate 1 |il/hour) and models 1007D (length 150 mm, circumference 0.6 
mm, weight 0.4 g, release rate 1 |al/hour). On the morning of surgery, pumps were 
loaded with either oxyntomodulin or analogue 6421 reconstituted in saline (5%) and 
water (95%) or vehicle (saline (5%) and water (95%)). Osmotic pumps were implanted 
subcutaneously below the scapulae in mice, and subcutaneously into the flank in rats, 
anesthetised with inhaled isoflurane (Abbott Laboratories Limited) and the incision was 
closed with two surgical staples. Intra-operative antibiotic (Enrofloxacin 5 mg/kg 
intramuscularly (ICE Healthcare)) was administered. Delivery of pump content is 
confirmed by measuring residual volume of reservoir at the end of the study and 
comparing it to the theoretical volume which can be calculated. 
2.2.5 Metabolic cages: The Comprehensive Laboratory Animal Monitoring 
System 
Open circuit Comprehensive Lab Animal Monitoring System (CLAMS) was used for 
the investigation of energy homeostasis. CLAMS is an automated cage system that 
allows simultaneous and continuous measurement of food intake, activity and metabolic 
parameters including CO2 production and O2 consumption (figure 2.1 and 2.2). 
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A 
ZTOT BEAMS 
XAMB BEAMS 
FEEDER 
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Figure 2.1 The setup of a CLAMS cage, a) A simplified drawing of a CLAMS 
cage showing the positioning of the feeder and the X and Z infra-red beams, b) a 
photograph of a rat CLAMS cage. 
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Food intake is measured by placing food in feeders attached to the end of each cage. 
Each feeder is in contact with a balance directly linked to the computer. Activity is 
measured by the total number of infra-red photo-beams broken per sampling period. 
Two types of activity are monitored: X ambulatory (XAMB) and Z total (ZTOT) (figure 
2.1a). XAMB beams, located along the side of the cage, measures the number of 
consecutive beams broken from the horizontal movement of the animal, whereas ZTOT 
beams, located above and parallel to the XAMB beams, detect the rearing movement of 
the animal. 
CO2 production and O2 consumption is measured by indirect calorimetry. Room air is 
pumped into each cage at a fixed flow rate, referred to as "source air". Air is then 
sampled from each cage sequentially at regular intervals to determine the CO2 and O2 
composition. After every 8 cages, air is sampled from an empty reference chamber and 
the difference between the reference measurement and each chamber effluent is 
calculated. To eliminate the effect of any changes in water content, all samples are 
passed through a drier before assessment of O2 and CO2 content. Prior to a cage run, 
the O2 and CO2 sensors are calibrated with a specialised calibration gas (20.5% O2, 
0.5% CO2, 79.0% N2). Between sample measurements, a settle time is allotted for any 
residual gases to clear from the sample tube before measuring the next sample. During 
the calibration process a CO2 zero is required. Room air is therefore passed through 
soda lime which removes any CO2 content before reaching O2 and CO2 sensors (figure 
2.:%. 
VCO2 and VO2 readings can also be used to give an indication of the type of fiiel being 
utilised. Different fiiels require different quantities of O2 in order to be oxidized, 
therefore, the volumes of O2 consumed and CO2 produced vary depending on the type 
of fuel. In a carbohydrate, one molecule of CO2 is produced for every O2 molecule 
oxidized. However, to oxidize a fat a higher proportion of O2 is required. For example, 
23 O2 molecules are required to oxidize the saturated fatty acid palmitic acid 
CH3(CH2)i4COOH), whereas only 16 CO2 molecules are produced. Therefore, the ratio 
of CO2 produced to O2 consumed gives an indication of the type of fiael being utilised 
and is termed as respiratory quotient (RQ) or respiratory exchange ratio (RER). 
Oxidation of a carbohydrate gives a RER of 1.0, whereas the oxidation of a fat produces 
an RER of approximately 0.7. 
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Figure 2.2 A simplified representation of the CLAMS set-up. Calorimetry 
circuitry is in black, food intake and activity circuitry in red and the computer 
software in blue. Food and activity data is recorded directly by the computer. For 
calorimetry measurements, sample air is passed through a drier prior to 
assessment of O2 and CO2 content. 
A 24 chamber CLAMS (Columbus Instruments, Columbus, OH, USA) was used for the 
investigation of energy homeostasis. Rats were individually housed in plexiglass 
chambers, through which air was passed at a flow rate of 2.5 1/min. Exhaust air from 
each air-tight chamber was sampled for 1 minute at 30 minute intervals. Sample air was 
sequentially passed through O2 and CO2 sensor (Columbus Instruments) for 
determination of O2 and CO2 content. For each animal, O2 consumption and CO2 
production values were normalised with respect to body weight and corrected to an 
effective mass value (Blaxter, 1989). These values were used to calculate 
respiratory exchange RER and energy expenditure. The ambulatory activity of each 
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rodent was assessed simultaneously using the optical beam technique (Opto M3, 
Columbus, OH, USA). Cumulative consecutive photo-beam breaks across the XAMB 
and single photo-beam breaks across the (ZTOT) were recorded over each 30 minute 
interval. 
2.3 Production of hGLP-1 receptor and hGCG receptor 
overexpressing cell lines 
2.3.1 Production of competent bacteria 
Gram negative bacteria such as E. coli have a cell wall which prevents entry of 
exogenous DNA. To allow entry of plasmids into the bacteria, they have to be rendered 
competent to take up DNA. There are several ways of achieving this, including 
electroporation and treatment with cations. The method of choice is treatment with 
cations, which is reliable and relatively easy. There have been several adaptations to the 
original method (Hanahan, 1983) including the ions used, their concentration and 
incubation times. 
Materials 
LB (appendix B) 
Tetracycline (Sigma) 10 mg/ml in absolute ethanol 
TFB I (appendix B) 
TFB II (appendix B) 
XL 1-Blue E.coli (Stratagene Ltd.) 
Method 
One hundred millilitres of LB supplemented with 5 pg/ml tetracycline (LBtet) was 
inoculated with a colony of XL 1-Blue and incubated overnight, with vigorous shaking, 
at 37°C. One millilitre of this culture was inoculated into 100 ml of fresh LBtet 
(prewarmed to 37°C) and incubated at 37°C, with vigorous shaking, until the bacteria 
were in log phase growth (OD550 = 0.4-0.5). The bacteria were recovered by 
centrifugation at 800g for 15 minutes. The bacteria were resuspended in 40 ml ice cold 
TFB I and incubated on ice for 10 minutes. The bacteria were recovered as above and 
resuspended in 4 ml TFB II and incubated on ice for 15 minutes. Following incubation 
50|al aliquots of cell suspension were frozen in a dry ice/ethanol bath and stored at -
70°C. 
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2.3.2 Transformation of competent bacteria 
Although treating bacteria with cations renders them competent to take up DNA, to 
obtain efficient transformations requires several additional steps. The initial step, 
incubation on ice, is believed to allow attachment of the plasmid to the bacterial cell 
membrane. The heat shock step is believed to allow efficient transport of the plasmid 
into the bacteria. The subsequent incubation allows expression of the resistance genes 
before exposure to the antibiotic. 
Materials 
LB 
LB (amp) plates (appendix B) 
Competent bacteria (section 2.4.1) 
pCMV6-XL5-GCG receptor (Origene) (appendix D) 
pCMV6-XL5-GLP-l receptor (Origene) (appendix D) 
Method 
A 50 nl aliquot of frozen competent bacteria was thawed on ice, 10 ng of plasmid (5 ^1) 
added and the mixture incubated on ice for 20 minutes. The reaction was then 
incubated at 42°C for two minutes followed by incubation on ice for two minutes. Two 
hundred microlitres LB was added and the reaction incubated at 37°C for 30 minutes. 
Simultaneously, agar plates (supplemented with ampicillin) were dried and the 
transformed bacteria added to the plate. The bacteria were spread over the surface of 
the agar, the plates inverted and incubated at 37°C overnight. 
2.3.3 Small scale preparation of plasmid 
Initially, plasmids were isolated on a small scale culture to allow several clones to be 
analysed simultaneously (Sambrook and Russell, 2000). To isolate plasmids from 
bacteria it is necessary to disrupt the cell wall to release the plasmid and at the same 
time remove contaminating proteins, genomic DNA and RNA. The method used 
involves disruption of the cell wall by treatment with alkaline SDS followed by 
precipitation of bacterial debris with sodium acetate. This step also removes most of the 
genomic DNA, since in bacteria this is anchored to the cell wall. The RNA is removed 
at a later stage by either treatment with RNase A or alkali. 
Materials 
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L B (amp) 
Alkaline SDS (appendix B) 
3 M Sodium acetate pH 4.6 (appendix B) 
Phenol/chloroform/isoamyl Alcohol (25:24:1) (VWR International) 
GTE (appendix B) 
25 mM Tris-HCl pH 8.0 
lOmMEDTA 
50 mM Glucose 
Propan-2-ol 
0.3 M sodium chloride 
Absolute ethanol 
Method 
Two millilitres LB supplemented with 0.05 mg/ml ampicillin (LB (amp)) were inoculated 
with a single bacteria colony and incubated overnight at 37°C with vigorous shaking. 
One and a half millilitres of the culture was centrifuged for two minutes at 12300g to 
pellet the bacteria. The supernatant was discarded and the pellet resuspended in 100 pi 
GTE. Two hundred microlitres alkaline SDS were added and the sample incubated on 
ice for 5 minutes followed by the addition of 150 pi 3 M sodium acetate and a further 5 
minute incubation on ice. The precipitated bacterial debris was removed by 
centrifugation for 5 minutes at 12300g at room temperature and 350 pi supernatant was 
transferred to a clean tube. An equal volume of phenol/chloroform/isoamyl alcohol was 
added and the sample mixed. The phases were separated by centrifugation for 3 
minutes at 12300g and the aqueous phase transferred to a fresh tube. The DNA was 
precipitated by the addition of 0.6 volumes of propan-2-ol and incubated at room 
temperature for 10 minutes. DNA was dissolved in 100 pi 0.3 M sodium chloride and 
250 pi ice cold absolute ethanol was added and the solution incubated at -20°C for at 
least 1 hour. The DNA was recovered by centrifugation at 12300g at room temperature 
and dissolved in 10 pi GDW. 
2,3.4 Restriction endonuclease digestion of plasmid DNA 
In order to select which clones contained the correct plasmid DNA was digested with 
restriction endonuclease enzymes analysed by gel electrophoresis. Clones containing 
the correct size inserts were chosen for large scale preparation. 
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Materials 
Plasmid DNA 
Restriction endonucleases: EcoR I and Xho I (New England Biolabs) 
lOx Restriction buffer (as supplied) 
lOxBSA 
Method 
In separate reactions the products of small sale preparation of plasmid was diluted in 
autoclaved GDW, BSA and restriction buffer added to give a final concentration of Ix 
BSA and Ix restriction buffer. Restriction endonucleases were added to five times 
excess; the volume of enzyme added was kept below 10% of the final volume. The 
reaction was incubated for a minimum of 1 hour at 37°C. 
2.3.5 Electrophoresis of DNA fragments 
After restriction digestion, the DNA was size fractionated by electrophoresis on an 
agarose gel to confirm if an insert was present. 
Materials 
Agarose, type II-A medium EEO (Sigma) 
5Ox TAE (appendix B) 
2 M Tris-Acetate pH 8.5 
0.5 M EDTA pH 8.0 
Ethidium bromide (lOmg/ml) (Sigma) 
DNA marker (1KB ladder, Invitrogen) 
Gel loading buffer (appendix B) 
Method 
A 0.7% (w/v) agarose gel was prepared by dissolving the agarose in Ix TAE using a 
microwave oven. The gel was cooled to 45°C and ethidium bromide added to a final 
concentration of 0.5 pig/ml. Three microliters of loading buffer were added to 10 p] of 
restriction enzyme digest, 1 p,l of DNA marker was added to 9 [0.1 GDW and treated the 
same way. The samples were loaded onto the gel and electrophoresed at 1.5V/cm. The 
DNA was visualised by illumination with UV light (300 nm). 
63 
2.3.6 Large scale plasmid purification 
This is essentially a scaling up of the previous method (section 2.3.3) but was followed 
by a caesium chloride gradient to further purify the plasmid. 
Materials 
LB 
MP 1 (appendix B) 
25 mM Tris-HCI pH 8.0 
10 mM EDTA 
15% Sucrose 
0.3 M Sodium chloride 
Lysozyme (Sigma) 
Alkaline SDS 
3 M Potassium acetate pH 4.6 (appendix B) 
DNase free RNase A (Sigma) 
Phenol/chloroform/isoamyl alcohol (25:24:1) 
IxTE 
Method 
Following small scale preparation of the plasmid the size of the insert was confirmed by 
restriction digest (2.3.4). A large scale preparation of the plasmid was carried out prior 
to purification using a caesium chloride gradient. A small quantity of bacteria 
containing the plasmid with the correct size was inoculated into 500 ml LB(amp) and 
incubated at 37°C overnight with vigorous shaking. The bacteria were recovered by 
centrifugation for 8 minutes at 3000g (HS-4 rota in RC-5B super speed centrifuge, Du 
Pont) at 4°C. The pellet was resuspended in 25 ml MPl supplemented with 2 mg/ml of 
lysozyme and the samples incubated at room temperature for 5 minutes. Fifty millilitres 
of alkaline SDS were added, the sample mixed until clear and incubated on ice for 5 
minutes. Then 37.5 ml of 3 M potassium acetate were added, the samples mixed and 
the bacterial debris removed by centrifugation for 15 minutes 9000g (HS-4 rota in RC-
5B super speed centrifuge) at 4°C. The supernatant was transferred to a clean tube and 
0.6 volumes of propan-2-ol added and samples incubated on ice for 15 minutes. As 
before the DNA was recovered by centrifugation (9000g, 4°C). The pellet was 
dissolved in 10 ml Ix TE, RNase A added to a concentration of 0.1 mg/ml and the 
reaction incubated at 37°C for 30 minutes. Addition of an equal volume of 
phenol/chloroform/isoamyl alcohol terminated the reaction, the mixture mixed and 
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phases separated by centrifUgation for 20 minutes at lOOOOg and 4°C. The aqueous 
phase was transferred to a new microtube and 0.1 volumes 2 M sodium acetate, pH 5.2 
and one volume propan-2-ol added, and the reaction incubated at -20°C for at least 1 
hour. 
2.3.7 Caesium chloride gradient purification 
The technique was used to purify large quantities of plasmid. The purification method 
depends on the decrease in density of nucleic acids when they bind ethidium bromide. 
Ethidium bromide binds by intercalation into the DNA, causing the DNA helix to 
partially unwind. Binding occurs to a higher degree in linear genomic DNA or nicked 
plasmid DNA than the closed circular supercoiled plasmid DNA, so the different states 
of DNA form separate bands in the caesium gradient (Sambrook and Russell, 2000). 
Materials 
TES (appendix B) 
50 mM Tris-HCl, pH 8.0 
50 mM Sodium chloride 
5 mM EDTA 
Caesium chloride (Sigma) 
Ethidium bromide (lOmg/ml) 
Propan-2-ol, caesium chloride saturated (appendix B) 
Ix TE (appendix B) 
Mineral oil 
Method 
The DNA obtained from section 2.3.6 was recovered by centrifugation for 20 minutes at 
24000g (HB4 rotor in RC5B super speed centrifuge, Du Pont) and 4°C and dissolved in 
7.85 ml TES. Eight grams of caesium chloride were dissolved in the DNA solution, 
150 pi ethidium bromide added and the solution mixed. The sample was loaded into 
polyallomer tube (Ultracrimp, Du Pont), overlayed with mineral oil, the tube sealed and 
centrifuged for 16 hours at 20°C and 185500g (A1256 rotor, OTD-55B centrifuge, Du 
Pont). After centrifugation, the DNA bands were visualised by UV illumination and the 
band containing the closed circular DNA removed using a 20G needle and a 2 ml 
syringe. The ethidium bromide was removed from the plasmid by repeated extraction 
with an equal volume of caesium chloride saturated propan-2-ol, until both phases were 
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colourless. The DNA was precipitated by addition of two volumes of GDW and six 
volumes of room temperature absolute ethanol. The DNA was recovered by 
centrifugation for 15 minutes at room temperature and 24000g, the supernatant removed 
and the pellet dissolved in 0.4 ml GDW. The DNA was ethanol precipitated, recovered 
by centrifugation for 10 minutes at 12300g, dissolved in 1 ml GDW and quantified 
spectrophotometrically (section 2.3.8). 
2.3.8 Quantification of DNA by a spectrophotometer 
The DNA was diluted 1:100 in GDW and 1 ml placed into a quartz cuvette. The 
absorbance was read at 260 and 280 nm, to check for contamination of DNA by RNA 
and protein (UV0160 spectrophotometer, Kyoto, Japan). DNA samples which were 
considered clean enough for further use were those with an optical density of 1.8-2.0 
(optical density = 260 nm/280 nm) The concentration of DNA was calculated using the 
following formula: concentration (ng/ml) = (Aieox dilution factor x 50)/1000. 
2.3.9 Polyethylenimine (PEI) mediated in vitro gene transfer 
In order to create a readily available source of the human GLP-1 and GCG receptors the 
plasmids containing the DNA constructs of the receptors were transfected into HEK 
293T cells. PEI is a cationic polymer in which every third atom is an amine nitrogen 
residue. In the presence of 5% glucose, PEI and DNA interact to form stable complexes 
which are taken up by pinocytosis across the cellular plasma membrane. 
2.3.9.1 Maintenance of cells 
Materials 
HEK 293T cells (LGC Promochem) 
Dulbecco's modified medium (DMEM) without sodium pyruvate containing 
4.5g/l Glucose (Invitrogen) 
Foetal bovine serum (FBS) (Invitrogen) 
lOOx Antibiotic (Invitrogen) 
lOOIU/ml Penicillin 
100 pg/ml Streptomycin 
Non-enzyme cell dissociation buffer (Sigma) 
Method 
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HEK 293T cells were cultured in DMEM supplemented with 10% FBS and 1% 
antibiotic. Medium was changed every 2-3 days and the cells sub-cultured when 70% 
confluent using a non-enzymatic cell dissociation buffer. Briefly, the medium was 
aspirated from the flask and 2 ml/50 cm^ flask surface area of room temperature cell 
dissociation buffer added. Cells were incubated at room temperature until they 
detached from the flask. Five millilitres fresh medium added to the flask and cells 
recovered by centrifugation for 5 minutes at lOOg. The cells were resuspended in fresh 
medium and transferred to a new flask at a dilution of 1:5. 
2.3.9.2 Transfection of cells 
Materials 
0.1 M 25 kD PEI (Aldrich Chemical Company) (appendix B) 
sterile water 
10% Glucose 
Plasmid DNA 
Method 
Twenty four hours prior to transfection, cells at passage number 8 were sub-cultured 
and plated at a density of 20000 cells/60 mm plate (Invitrogen) in standard media. 
Transfections were carried out when the cells were 40% confluent. 
PEI/DNA complexes were made with PEI (average Mw ~ 25000) according to the 
method described by (Abdallah et al., 1996). A 0.1 M stock solution of 25 kD PEI pH 
7.0 was prepared and filtered through a 0.2 ^m filter prior to use. The plasmid DNA 
was prepared such that each plate was transfected with 6 \ig DNA in 5% (w/v) glucose 
(the 10% glucose solution was also sterilised by passage through a 0.2 fim filter). The 
cells were cotransfected with pCMV6-XL5-GCG receptor or pCMV6-XL5-GLP-l 
receptor (see section 2.3.7) and pcDNA3.1+ ((plasmid containing neomycin resistance 
gene) (Invitrogen)) and 9 nitrogen equivalents of PEI. The amount of PEI required was 
calculated according to the ratio of PEI amine nitrogen equivalents to DNA phosphate 
where 1 |am of 0.1 M PEI = 100 nmol amine nitrogen and 10 |xg DNA = 30 nmol DNA 
phosphate. Thus for 9 nitrogen equivalents 45 pg DNA (135 nmol DNA phosphate) 
requires 810 nmol amine nitrogen i.e. 8.1 |j.1 of 0.1 M PEI. 
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Four plates were transfected with each receptor plasmid, and pcDNAS.l and two plates 
with receptor plasmid only (controls). PEI solution was slowly added to the DNA 
solution and glucose, vortexed for 30 seconds and allowed to stand at room temperature 
for 10 minutes before use. The PEI/DNA/glucose mix was added slowly to the cells 
and incubated for 3 hours at 37°C, 5% CO2, after which the media was removed and 
replaced with standard media (DMEM supplemented with 10% FBS and 1% antibiotic 
and cells maintained as described in 2.3.9.1). Forty eight hours later, media was 
supplemented with 800 jig/ml Geneticin, and media replaced every 48 hours with fresh 
Geneticin until all control cells were dead, usually 10 days after the start of treatment. 
Remaining cells from each plate were then transferred to T-10 flask (1 plate to 1 flask), 
and then maintained as described in 2.3.9.1. 
Selection of mixed clones (population of cells in each flask) were completed by 
measuring change in cAMP levels following treatment with 10 nM oxyntomodulin 
(2.5.1). Mixed clones with the largest change in cAMP levels following administration 
of oxyntomodulin were selected for use in receptor binding and bioactivity studies. 
2.4 Receptor binding studies 
Cell membrane suspensions were prepared from various tissues and cell types. The 
binding studies detailed below tested the specific binding of peptides to the receptors on 
these membranes. 
2.4.1 Preparation of membranes from rat and mouse tissues 
Membranes were prepared by the method of homogenisation and differential 
centrifugation as described previously (Bhogal et al., 1993; Kim et al., 2003). Tissues 
were collected from rats and mice which were maintained in conditions as described in 
section 2.2.1, except they were either singularly housed or in groups of 5 (rats) or ten 
(mice). Rats were killed by decapitation in the early light phase, tissues dissected, snap 
frozen in liquid nitrogen and stored at -70°C. Tissues from a minimum of 20 rats were 
required for a membrane preparation of each tissue. Mice were killed by cervical 
dislocation in the early light phase, tissues dissected, snap frozen in liquid nitrogen and 
stored at -70°C. Tissues from a minimum of 40 mice were required for a membrane 
preparation of each tissue. 
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Tissues were homogenised (Ultra-Turrax T25, IKA Labortechnik) in ice cold 
homogenisation buffer (50 mM HEPES buffer pH 7.4 containing 0.25 M sucrose, 10 
Hg/ml soybean trypsin inhibitor (Sigma), 0.5 p,g/ml pepstatin (Sigma), 0.5 ^ig/ml 
antipain (Sigma), 0.5 p,g/ml leupeptin (Sigma), 0.1 mg/ml benzamidine (Sigma) and 
1ml lOOKIU/ml aprotinin (Trasyol, Bayer)) at 4°C. 
The homogenates were centrifuged at lOOOg (Beckman J2-21, rotor JS-13.1) for 15 
minutes at 4°C, and supematants were then centrifuged at lOOOOOg (Sorvall 
Ultracentrifuge OTD55B, rotor A-841, DuPont, Cambridgeshire, UK) for 60 minutes at 
4°C. Pellets were removed and resuspended in 10 volumes of the above buffer without 
sucrose using hand-held glass/Teflon homogenisers (Jencons), and re-centrifuged at 
lOOOOOg for 60 minutes at 4°C as before. Finally, pellets were resuspended to a final 
protein concentration of 2-3mg/ml and stored at -70°C. Protein concentration was 
measured by biuret assay (section 2.4.3). 
2.4.2 Preparation of membranes from cells 
Membrane preparations were made from the following cell lines; HEK 293T, HEK 
293T overexpressing rGLP-1 receptor, HEK 293T overexpressing hGLP-1 receptor, and 
CHO cells overexpressing rGLP-1 receptor. Cell membranes preparations were made 
from all cell lines between passage numbers 15-35. 
2.4.2.1 Maintenance of cells 
All cell lines except RINm5F cells were maintained as described in section 2.3.9.1. 
RINm5F cells were cultured as described in section 2.3.9.1 except cells cultured in 
RPMI medium 1640 containing 5.5 mg/1 glucose (Invitrogen) supplemented with 10% 
FCS (Invitrogen) and 1% antibiotic (section 2.3.9.1). 
2.4.2.2 Receptor purification 
The culture medium was removed and the cells detached from the flasks using cell ice 
cold 0.02 M phosphate buffered saline (PBS) (Sigma) and scrapping, a minimum of 30 
T 175cm^ flasks used for a membrane preparation. Cells were centrifuged at 200g for 5 
minutes (Sigma Laboratory Centrifuges 3, K18, rotor No. 19777-H), the supematants 
discarded and the pellets put onto ice. Pellets resuspended in 20 ml of ice-cold 
homogenisation buffer (as for tissue membrane preparation, section2.4.1) and cells 
homogenised for 1 minute with an Ultra Turrax homogeniser (IKA Labortechnik). 
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Homogenates were further centrifuged for 30 minutes at 4°C lOOOOOg (Sorvall OTD 
55B ultra-centrifuge, DuPont). Supematants were discarded and pellets resuspended in 
homogenisation buffer without sucrose using a hand-held/Teflon homogeniser 
(Jencons). Finally, pellets were resuspended to a final protein concentration of 1-2 
mg/ml and stored at -70°C. Protein concentration was measured by biuret assay (section 
2.4.3). 
2.4.3 Biuret Assay 
Protein concentrations of membranes were assessed by the biuret method. A stock 
solution of 10 mg/ml BSA (Sigma) was used to construct a standard curve (0, 1 , 2 , 3 , 4 
and 5 mg) of protein/500 p.! with distilled water. Typically 50-200 p,l of membrane 
suspension was assayed, volumes adjusted to 500 [il with distilled water and 3 ml biuret 
reagent (appendix B) was added to all tubes. The tubes were then incubated at 100°C 
for 2 minute. Samples were left at room temperature for 30 minutes before the 
absorbance at A540 nm was measured in a spectrophotometer (UV-160, Shimadzu). 
The absorbance values of the sample of membrane were converted to mg of protein by 
linear regression using the standard curve. 
2.4.4 lodination of peptides 
Radioiodination of peptides attaches atoms to the peptide, enabling them to be used 
as tracers for displacement assays. lodination technique used was dependent on the 
physical properties of the peptides being iodinated. 
2.4.4.1 The Bolton-Hunter method 
The Bolton and Hunter method (Bolton and Hunter, 1973) was used to iodinate exendin-4. 
Thirty seven MBq (200 |j,l) of Bolton and Hunter (BH) reagent (Amersham-Pharmacia 
Biotech) was dried under a gentle stream of nitrogen over approximately 1 hour. Exendin-
4 30 p,g was dissolved in 50 jil of 0.14 M sodium borate buffer pH 8.3 and added to the dry 
BH reagent. The reaction was allowed to proceed for 2 hours at room temperature and 
then stopped by addition of 1 ml of 10% (vol/vol) AcN (Rathbum Chemicals Ltd.)/water 
plus 0.05% (vol/vol) TFA (Rathbum Chemicals Ltd.). Reaction products were purified by 
reverse phase HPLC using a NovaPak Cig column (Millipore). The column was 
equilibrated for 10 minutes with 15% (vol/vol) AcN solution in water containing 0.05% 
(vol/vol) TFA, at a flow rate of Iml/min before addition of the iodinated reaction mixture. 
The AcN concentration was maintained at 20% for the first 10 minutes and then increased 
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to 45% AcN over the following 90 minutes. Fractions were collected every 1.5 minutes 
into tubes containing 1 ml 20 mM HEPES (pH 11) and 0.3% (vol/vol) BSA (MP 
Biomedicals). The specific activity (SA) of the iodinated peptide was estabhshed by RIA. 
2.4.4.2 The direct iodogen method 
The direct iodination method used was as previously described (Owji et al., 1995) and 
used to iodinate glucagon. 15 p-g of peptide in 10 jxl of 0.2 M phosphate buffer pH 7.2 
was reacted with 37 MBq of Na (Amersham-Pharmacia Biotech) and 23 nM (10 p,g) of 
1,3,4,6,-tetrachloro-3a, 6a-diphenylglycoluril (lodogen reagent, Pierce Chemical Co) for 4 
minutes at 22°C. The '^^I-peptide was purified by reverse phase high performance liquid 
chromatography (as above) using an AcN/ H2O /0.05% TFA gradient. 
2.4.5 GLP-1 receptor binding studies 
For binding studies to the GLP-1 receptor iodinated exendin-4 was used as it has been 
shown to bind specifically to the GLP-1 receptor and is more stable than either GLP-1 
or oxyntomodulin therefore reducing variability in the assay. Cell membranes (200 ng) 
from either animal tissue (lung) or from GLP-1 receptor overexpressing cell lines (CHO 
overexpressing rGLP-1 receptor and HEK 293T cells overexpressing hGLP-1 receptor) 
were used for these studies. Cell membrane was incubated for 90 minute at room 
temperature in silanized polypropylene tubes (Sigma) with ^^^I-exendin-4 (500 BqilOO 
pM) in binding buffer (25 mM HEPES pH 7.4, 2 mM MgCli, 0.05% Tween 20 (Sigma), 
1% BSA (MP Biomedicals), 4 mM phenylmethanesulphonylfluoride (PMSF) (Sigma), 
0.5 mM diprotin A (Sigma), 0.5 mM phosphoramidon (Sigma)) in a final assay volume 
of 0.5 ml. The receptor-^^^I-exendin-4 complex was separated from free tracer by 
centrifugation at 15600g (Sigma Laboratory Centrifuges 3, K18) for 3 minutes. The 
supernatant was removed and discarded and the pellet resuspended and washed with 
500 1^1 fresh buffer and re-centrifugation. After centrifugation and removal of 
supernatant the bound label was measured using a y-counter (NE 1600, NE Technology 
Ltd.). Specific binding was calculated as the difference between the amount of 
exendin-4 peptide bound in the absence (total) and presence (non-specific) of unlabelled 
peptide. For competition binding curves, membranes were incubated as above in the 
presence of increasing concentrations of unlabelled peptide and results expressed as % 
specific binding. All curves were performed with points in triplicate and each curve 
repeated with different membrane preparations unless stated. IC50 values were 
calculated using Prism (Version 4) (GraphPad Software Inc.) 
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2.4.6 GCG receptor binding studies 
Receptor binding assays were completed as described in section 2.4.5, except 
glucagon used as the label and cell membranes from rat liver or HEK 293T cells 
overexpressing hGCG receptor was the source of receptor. 
2.5 cAMP release assay 
Secondary messengers such as 3', 5' cyclic adenosine monophosphate (cAMP) are 
modulated by binding of active molecules to G protein-coupled receptors (GPCRs) and 
as such can be quantified to measure bioactivity of test compounds. This was utilised to 
measure bioactivity of both native peptides and custom designed peptides against a 
series of GPCRs. 
3', 5' Cyclic adenosine monophosphate from whole cell preparations was measured 
using the adenylyl cyclase activation flashplate assay (PerkinElmer). Seventy percent 
confluent clone 5 cells passage number 20-30 (CHL cells stably transfected with rat 
GLP-1 receptor (Widmann et al., 2005) (kind gift from Professor Bernard Thorens), or 
70% confluent HEK 293T cells stably transfected with hGCG receptor, passage number 
15-25 (maintained as described in section 2.3.9.1), were harvested using non-enzymatic 
cell dissociation buffer (Sigma). Cells were washed by centrifugation at 200g and 
resuspended in stimulation buffer (PerkinElmer) at a concentration of 5 x lO'^  cells/ml 
and 50 1^1 of cell suspension added to reach reaction well, except those of the standard 
curve. Peptides to be tested were diluted to the desired concentrations (see specific 
experiments) in 0.02 M PBS (Sigma), and added to wells, with each concentration 
tested in duplicate. Total volume for all wells was adjusted to 100 |^ 1 using PBS. After 
30 minutes incubation at room temperature 100 p-l detection mix containing 0.74 KBq 
cAMP tracer was added to each well. Plate was sealed and incubated for a further 
two hours at room temperature, and then counted using a 96-well microplate 
scintillation counter (Wallace microbeta Trilux, PerkinElmer). cAMP concentration 
was calculated using a non-linear plot generated by Prism (Version 4) and results 
quantified from the standard curve. 
2.6 Insulin release 
2.6.1 Insulin release from RINmSF cells 
RINm5F cells were maintained as described in section 2.4.2.1. Forty eight hours prior 
to the study 70-80% confluent cells were harvested using non-enzymatic cell 
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dissociation buffer (Sigma) and plated at 50000 cells/ml on 24 well plate (Invitrogen) (1 
ml/well) in standard media. On day of study cells were transferred to serum free 
glucose free RPMI media (Invitrogen) and incubated for 2 hours at 37°C. After 2 hours 
cells were treated with peptides at increasing concentration (specific experimental 
details noted by each experiment), dissolved in RPMI media (5.5 nM glucose, serum 
free), with each concentration tested in triplicate. For a positive control, cells were 
treated with 1 M potassium chloride. Cells were incubated with test compounds for 1 
hour before the media was removed and stored at -20°C until assayed. 
2.6.2 Insulin release in vivo 
Mice were housed in groups of 5 and handled daily and acclimatised to IP injections 
prior to the studies. For each study, the mice were fasted from 16:00 the day before. 
On the morning of the study they were injected IP with peptide together with 1.5 mg/g 
glucose solution (0.025 M) and killed by CO2 inhalation 8 minutes after injection and 
blood was collected by cardiac puncture using a heparinized syringe into a microfuge 
tube containing 0.06 mg aprotinin (Trasylol, Bayer). The samples were centriftiged at 
15600g (Sigma Laboratory Centrifiiges 3, K18) for 10 minutes, plasma collected and 
stored at -20°C until assayed. 
2.6.3 Insulin radioimmunoassay (RIA) 
The insulin RIA was used to measure levels of insulin in cell culture media. All details 
are outlined in appendix C. 
2.6.4 Quantification of insulin secretion by ELISA assay 
Plasma insulin was measured using a commercially-available ultra-sensitive insulin 
assay (Crystal Chem Inc., IL, USA). The principle of the assay is sample is added to 
antibody-coated microplate, binding any insulin in the sample. Anti-mouse insulin 
enzyme conjugate is then added which binds to the attached insulin. An enzyme 
substrate for the conjugated enzyme is added, resulting in a colour change. 
Measurement of absorbance provides a quantitative read out of insulin in the sample 
added. 
For the experiment 5 pi of mouse plasma (or mouse insulin standard) was added to the 
wells containing 95 ^1 of sample diluent solution, with each sample been tested in 
duplicate. Plate was then incubated for 2 hours at 4°C, before being washed 5 times 
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with 300 |j,l wash buffer. To all wells 100 |j,l of anti-mouse-insulin enzyme conjugate 
was added, and the plate incubated for 30 minutes at room temperature. Then 100 |al 
enzyme substrate was added and after 10 minutes the absorbance at 450 nm (subtracting 
wave length: 630 nm) (Labsystems and Life Sciences International Ltd). The plasma 
insulin concentration was then calculated from the standard curve. 
2.7 Proteolytic degradation of peptides 
2.7.1 Dipeptidyl-peptidase IV hydrolyses 
Digest buffer (100 mM TRIS-HCl, pH8) containing 2 nmol of peptide and 10 mU of 
porcine kidney DPP IV (Sigma) was incubated at 37°C. The reaction was terminated at 
different time points (15-240 minutes) by addition of 10 jj,g diprotin A. The reactions 
were subsequently analysed using reverse phase HPLC. Samples were centrifuged at 
12500xg for 5 minutes at room temperature prior to HPLC analysis (Jasco HPLC 
system, (solvent delivery system PU-2080 plus, autosampler AS-2057 plus, degasser 
DG2080-53, dynamic mixer 2080-32 UV detector uv-2075 using a Phenomenex 
Gemini Cig (5-^m particles) 250 mm x 4.6 mm column). The samples were applied to a 
Ci8 column and eluted using a linear AcN/water gradient acidified with 0.05% TFA. 
The gradient characteristics were 27-31% AcN over forty minutes. The eluted peptides 
were detected spectrophotometrically at a wavelength of 214 nm. Percentage 
degradation of peptide was calculated by comparing area under peaks of reactions with 
and without enzyme. For the method to be valid the same volume of sample with and 
without enzyme has to be injected on to the column for analysis. Absorbance is 
measured at 214 nm as this is the point where the peptide bond absorbs, minimising any 
change in absorbance caused by quantity of any one amino acid. 
2.7.1.1 Matrix-assisted laser desorption/ionization-Time of flight analysis (MALDI-
ToF) of DPP IV proteolytic breakdown products 
MALDI-ToF mass spectrometry analysis of digests was performed by Advanced 
Biotechnology Centre (Imperial College, London, UK). Digests were performed as 
described in section 2.7.1, except 5 nmol of peptide was digested by 25 mU of DPP IV 
in a reaction volume of 340 |j,l for 240 minutes. Half of the digest was analysed by 
HPLC (section 2.7.1) and the remaining half sent to Advanced Biotechnology Centre 
for analysis. Theoretical masses were calculated for peptide breakdown products and 
compared to masses identified by MALDI-ToF mass spectrometry. 
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2.7.2 Neutral endopeptidase (neprilysin) protease assay 
The neprilysin protease assay was carried out as the DPP IV assay protocol above, but 
in a different digest buffer (50 mM TRIS-HCl, 50 mM NaCl pH 7.5), with 200 ng of 
recombinant human neprilysin-2 (R&D Systems). The incubated samples were run and 
analysed as above, but with a 15-60% acetonitrile plus 0.05% TFA/water plus 0.05% 
TFA gradient over 30 minutes. Degradation products were monitored by their 
absorbance at 214 nm. Percentage degradation of peptide was calculated by comparing 
area under peaks of reactions with and without enzyme. For the method to be valid the 
same volume of sample with and without enzyme has to be injected on to the column 
for analysis. Absorbance is measured at 214 nm as this is the point where the peptide 
bond absorbs, minimising any change in absorbance caused by quantity of any one 
amino acid. 
2.8 Static incubation of explants 
2.8.1 Static incubation of hypothalamic explants 
To investigate the effect of peptides on release of hypothalamic a-MSH and TRH a 
static incubation system was used (Stanley et al., 1999). Male Wistar rats (Harlan) were 
killed by decapitation (between 09:00 and 10:00 hours) and the whole brain was 
immediately removed and mounted ventral surface uppermost. The mounted brain was 
placed in cooed (2-4°C) oxygenated, chamber of artificial cerebrospinal fluid (aCSF) 
(appendix B) within a vibrating microtome (Motorised Advanced Vibroslice, model 
MA752, Campden Instruments). A 1.7 mm slice was taken from the basal 
hypothalamus blocked lateral to the Circle of Willis, which encompassed the MPO, 
PVN, DMH, LHA and ARC. The hypothalami was initially incubated in a water bath at 
25°C in tubes containing 1 ml aCSF saturated with 95% 0% and 5% CO2. When all 
hypothalamic explants have been placed in the incubation tubes, a two hour 
equilibration period was commenced: the water bath temperature was increased to 37°C 
and the aCSF was changed at the start of the period and after 1 hour. Following 
equilibration, each explant was incubated for a further 45 minute in 600 ^1 aCSF (basal 
period) before being challenged with a 45 minute test period of peptide. The viability 
of the tissue was confirmed by a final 45 minute period of potassium stimulation in 
which the explants were exposed to aCSF containing 56 mM KCl (replacing the sodium 
sahs with potassium to retain isotonicity. At the end of each experimental period, the 
aCSF was removed and stored at -20°C until measurement of peptide release by RIA. 
Viable explants (>80%) were defined as hypothalami which released a greater amount 
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of neuropeptide following potassium stimulation. Non-viable explants were excluded 
from data analysis. 
2.8.2 Static incubation of anterior pituitary segments 
The direct effect of peptide hormones on TSH release from the pituitary was determined 
using ex-vivo anterior pituitary segments. This method was a modification of that 
previously described (Buckingham and Hodges, 1977). Male Wistar rats were killed by 
decapitation (between 09:00 and 10:00 hours) and anterior pituitary glands were 
immediately harvested and divided into 4 pieces of approximately equal size. The 
segments were randomly placed (one segment per well) in the wells of a 48-well plate 
(Nunc International) and incubated in 500 |il of aCSF. The anterior pituitary quadrants 
were maintained for two hours at 37°C in a humidified environment saturated with 95% 
O2 and 5% CO2, with the aCSF changed at 1 and 2 hours. The segments were then 
incubated for a further 4 hours in either aCSF alone (control) or with peptide. At the 
end of this period, the aCSF was removed and stored at -20°C until measurement of 
TSH by RIA. 
2.8.3 Hormone measurements 
Measurements of hormone release were carried out by RIA. All details are outlined in 
appendix C. 
2.9 Statistical analysis 
All data are expressed as the mean value ± S.E.M. Interval food intake and peptide 
hormone levels were compared by one-way ANOVA followed by post-hoc Bonferroni 
correction. A method used to study longitudinal data which consists of repeated 
measures of an individual or cluster of individuals taken over time. These repeated 
measures from any one individual or cluster are correlated with each other and are 
therefore no longer independent. Generalized Estimation Equations (GEE) use the data 
to estimate the correlation between a single individual or cluster's response and provide 
a correct estimate of each effect's variance. Continuous data was analysed using a 
Generalised Estimating Equation (GEE) and if significantly different finther analysed 
by a non-parametric two-sample Wilcoxon rank-sum (Mann-Whitney) test comparing 
the control group to the treatment group. The following programmes were used for 
statistical analysis: Prism (Version 4) and Strata (StrataCorp). In all cases, values of 
p<0.05 were considered statistically significant. 
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Chapter 3 
Characterisation of oxyntomodulin 
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3.1 Introduction 
Oxyntomodulin was first isolated in 1982 (Bataille et al., 1982). It is one of several 
active peptides derived from the mammalian proglucagon gene for which a specific 
receptor has yet to be identified, the other peptides being glicentin and miniglucagon 
(Drucker, 2001) (see section 1.6.1). Oxyntomodulin is classed as an enteroglucagon. 
The enteroglucagons were first identified by the similarity of their biological effects to 
those of glucagon in the liver, interacting with hepatic glucagon-receptors and activating 
adenylyl cyclase (Bataille et al., 1974). The oxyntomodulin peptide sequence is the 
same as glucagon (1-29) with an octapeptide (Lys-Arg-Asn-Lys-Asn-Asn-Ile-Ala) 
extension at the C-terminal (figure 1.2). Oxyntomodulin is most highly expressed in the 
gut and brain (Hoist, 1997). Oxyntomodulin shares sequence homology with other 
proglucagon derived products such as GLP-1, GLP-2 and glucagon, as well as the 
reptilian peptide exendin-4 (figure 1.3). 
Investigation into the physiological functions of oxyntomodulin has revealed that it can 
exert numerous effects, such as regulation of food intake, gastric emptying and gastric 
secretion. 
3.1.1 Oxyntomodulin receptor interaction 
Oxyntomodulin has weak affinity for both the glucagon receptor and the GLP-1 
receptor. Both receptors are G protein-coupled receptors (GPCR) and are members of 
the secretin-glucagon receptor family, subfamily B1 of family B (Josefsson, 1999; 
Harmar, 2001). The members of subfamily B1 are expressed in the gastrointestinal tract 
and/or brain, and signal through Gs leading to activation of adenylyl cyclase and 
increased levels of cyclic adenosine monophosphate (cAMP). Feeding studies 
conducted in the GLP-1 receptor knockout mouse model showed oxyntomodulin, GLP-
1 and exendin-4 had no effect on food intake, suggesting that the GLP-1 receptor is 
necessary for mediating the anorectic effects of these peptides (Baggio et al., 2004b). 
This data supports the current, generally accepted, belief that the actions of 
oxyntomodulin on food intake are mediated via the GLP-1 receptor. However, some 
actions of oxyntomodulin, such as its ability to directly elevate intrinsic heart rate in the 
mouse, occur via a GLP-1 receptor independent mechanism and are mediated by an 
unknown receptor (Sowden et al., 2007). 
78 
3.1.2 Oxyntomodulin affects food intake and bodyweight 
Oxyntomodulin is released by the intestinal L cells in response to food intake. 
Consequently, the effect of oxyntomodulin on food intake and body weight has been the 
focus of much investigation. 
Intraperitoneal (IP) administration of oxyntomodulin (30 nmol/kg) to fasted rats inhibits 
refeeding for 8 hour post-injection compared to saline controls (Dakin et al., 2004). 
Peripheral administration of oxyntomodulin to freely feeding rats at the onset of the 
dark phase, the start of the rat's natural feeding period also inhibited food intake. IP 
administration of oxyntomodulin (30 nmol/kg) at the start of the dark phase 
significantly inhibited food intake compared to saline controls until 2 hours post-
injection (Dakin et al., 2004). Intracerebroventricular (ICV) administration of 
oxyntomodulin (3 nmol) significantly reduced refeeding compared to saline controls 
until 4 hours post-injection in fasted rats (Dakin et al., 2001). Intraparaventricular 
nucleus injection of oxyntomodulin (1 rrniol) also inhibited refeeding in fasted rats, 
cumulative food intake was lower than that of saline controls until 8 hours post-
injection (Dakin et al., 2001). It has also been demonstrated that ICV administration of 
oxyntomodulin (3 nmol) significantly reduced food intake compared with that of saline-
treated animals until 1 hour post-injection in freely feeding rats at the onset of the dark 
phase (Dakin et al., 2001). 
In addition to acute studies, the effects of chronic administration of oxyntomodulin have 
been investigated in rodents. Daily ICV injections of oxyntomodulin (1 nmol) for 7 
days resulted in reduced food intake and reduced weight gain in rats (Dakin et al., 
2002). In the same study, the pair-fed group (animals treated with saline but restricted 
to the median food intake of the oxyntomodulin treated group) gained significantly 
more weight than the oxyntomodulin treated rats. This suggests that the decrease in 
weight gain induced by oxyntomodulin cannot be fully explained by the decrease in 
food intake, but may be due in part to oxyntomodulin increasing energy expenditure. 
Chronic IP administration of oxyntomodulin also resulted in a reduction of weight gain 
and adiposity (Dakin et al., 2004). 
The effect of oxyntomodulin on appetite and food intake in humans has been studied. 
Intravenous infusion of oxyntomodulin (3.0 pmol/kg/min) for 90 minute to 13 healthy 
humans, with BMI values of 20.4-27.1 kg/m^, decreased calorie intake at a buffet meal 
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by 19.3% (Cohen et al., 2003). The cumulative reduction of calorie intake persisted up 
to 12 hours post-infusion and subjective feelings of hunger and buffet meal duration 
were significantly reduced after the infusion of oxyntomodulin. There was no 
significant difference in either nausea or the perceived palatability of the meal between 
the groups (Cohen et al., 2003). A subsequent study investigated the effect of SC 
preprandial administration of oxyntomodulin 3 times daily for a period of 4 weeks to 
volunteers with a mean BMI of 33.7 ± 0.9 kg/m^ (Wynne et al., 2005). Administration 
of oxyntomodulin resulted in a 2.4 ± 0.4% reduction in body weight compared with 0.5 
± 0.6% reduction in the control group. This represented a significant weight loss of 2.3 
± 0.4 kg in the treatment group compared with 0.5 ± 0.5 kg in the control group. The 
efficacy of oxyntomodulin to reduce food intake at test meals did not diminish 
throughout the four week study. There was no change in the subjective palatability of 
the food following oxyntomodulin treatment (Wynne et al., 2005). 
3.1.3 Oxyntomodulin and insulin secretion 
GLP-1 receptor agonists such as GLP-1 and exendin-4 are some of the most potent 
insulinotropic hormones known. It has been speculated that oxyntomodulin, also a 
GLP-1 receptor agonist, may have some action in promoting insulin release. 
Oxyntomodulin can stimulate insulin release in vitro when infused into isolated pig and 
rat pancreas (Baldissera et al., 1988; Jarrousse et al., 1984). Yet, to date there is no 
reported effect of oxyntomodulin on increasing plasma insulin levels in rodents in vivo. 
Human studies investigating the effects of acute administration of oxyntomodulin 
showed a small but significant rise in plasma insulin levels (Schjoldager et al., 1988; 
Wynne et al., 2005) post-injection. However, both studies failed to show 
oxyntomodulin acting as an incretin. In the study by Scholdager et al (1988) variation 
in food intake eliminated the possibility of showing an incretin effect and in the study 
by Wynne et al (2005) no change in insulin levels were detected after food intake, 
suggesting that oxyntomodulin does not have insulinotropic effects (Wynne et al., 
2005y 
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3.2 Aims 
Aims to: 
1) Characterise the affinity of oxyntomoduHn and related peptides to the GLP-1 
receptor and GCG receptor using receptor binding assays; 
2) Characterise the in vitro bioactivity of oxyntomodulin and related peptides at the 
GLP-1 receptor and the GCG receptor; 
3) Investigate and compare the effects of oxyntomodulin and related peptides on 
acute food intake in fasted mice; 
4) Investigate and compare the incretin-like behaviour of oxyntomodulin and 
related peptides in vitro and in vivo. 
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3.3 Materials and methods 
3.3.1 Peptides 
Table 3.1 summarises the peptides used in the experiments described in this chapter. 
3.3.2 Receptor binding of oxyntomodulin, GLP-1 and exendin-4 to the GLP-1 
receptor 
Measurement of analogue affinity to the GLP-1 receptor was completed using the 
protocol outlined in section 2.4.5. Cell membrane was purified from rat lung (2.4.1), rat 
hypothalamus (2.4.1), CHO cells overexpressing rGLP-1 receptor (2.4.2) and HEK 
293T cells overexpressing hGLP-1 receptor (2.4.2) and provided the source of GLP-1 
receptor. ^^^I-exendin-4 was used as the competing radiolabelled peptide. Binding 
affinities were calculated from a minimum of 3 separate experiments in which each 
concentration of unlabelled peptide was tested in triplicate. Values are shown as mean 
±SEM. 
Displacement assays were completed using GLP-1 receptor purified from several 
different tissues and cell lines to examine: species variation, differences between 
centrally and peripherally expressed receptor and differences between overexpressed 
cloned receptor (used in bioassay) and endogenously expressed receptor. 
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Peptide Residue number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 
oxyntomodulin H S Q G T F T S D Y S K Y L D S R R A Q D F V Q W L M N T K R N R N N 1 A 
glp-1 H A E G T F T S D V S S Y L E G Q A A K E F 1 A W L V K G R G Nh 2 
exendin-4 H G E G T F T s D L s K Q M E E E A V R L F 1 E w L K N G G P S s G A P P P S 
glucagon H S Q G T F T s D Y s K Y L D S R R A Q D F V Q w L M N T 
porcine oxyntomodulin H S Q G T F T s D Y s K Y L D S R R A Q D F V Q w L M N T K R N K N N 1 A 
eel oxyntomodulin H s Q G T F T N D Y s K Y L E T R R A Q D F V Q w L M N S K R S G G P T 
I I Amino acids different to those in the corresponding position of human oxyntomoduHn 
Table 3.1 Sequence information of the peptides used in chapter 3 (sequence information given is of the 
human peptide unless otherwise stated). 
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3.3.3 Receptor binding of glucagon, oxyntomodulin, GLP-1 and exendin-4 to the 
glucagon receptor 
Measurement of analogue affinity to the rat GCG receptor was completed using the 
protocol outlined in section 2.4.6. Cell membrane purified from either rat liver (2.4.1) 
or HEK 293T cells overexpressing hGCG receptor (2.4.2) provided the source of GCG 
receptor. ^^^I-glucagon was used as the competing radiolabelled peptide. Binding 
affinities were calculated from a minimum of 3 separate experiments in which each 
concentration of unlabelled peptide was tested in triplicate. Values are shown as mean 
±SEM. 
Displacement assays were completed using GCG receptor purified from a cell line 
overexpressing hGCG and rat liver to examine: species variation, and differences 
between overexpressed cloned receptor (used in bioassay) and endogenously expressed 
receptor. 
3.3.4 Receptor binding of homologues of oxyntomodulin to the rat GLP-1 
receptor 
Measurement of analogue affinity to the rat GLP-1 receptor was completed using the 
protocol outlined in section 2.4.5. Cell membrane was purified from rat lung and 
provided the source of GLP-1 receptor (2.4.1). '^^I-exendin-4 was used as the 
competing radiolabelled peptide. Binding affinities were calculated from a minimum of 
3 separate experiments in which each concentration of unlabelled peptide was tested in 
triplicate. Values are shown as mean ± SEM. 
Oxyntomodulin is present in most mammalian species and is conserved between 
humans, rat and mice. However, porcine and eel oxyntomodulin have amino acid 
sequence variations compared to the human oxyntomodulin peptide. Investigation of 
the effect of these sequence changes on affinity to the rat GLP-1 receptor was tested. 
3.3.5 In vitro bioactivity studies of oxyntomodulin, GLP-1, glucagon and exendin-4 
at the GLP-1 receptor 
The ability of oxyntomodulin, GLP-1, glucagon and exendin-4 to stimulate cAMP 
production was investigated using the protocol described in section 2.5.1. HEK 293T 
cells overxpressing the human GLP-1 receptor were used for the experiments. EC50 
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values were calculated from a minimum of 3 separate experiments in which each 
peptide concentration was tested in duplicate. 
3.3.6 In vitro bioactivity studies of oxyntomodulin, GLP-1, glucagon and exendin-4 
at the GCG receptor 
The ability of oxyntomodulin, GLP-1, glucagon and exendin-4 to stimulate cAMP 
production was investigated using the protocol described in section 2.5.1. HEK 293T 
cells overexpressing the hGCG receptor were used for the experiments. EC50 values 
were calculated from a minimum of 3 separate experiments in which each peptide 
concentration was tested in duplicate. 
3.3.7 Feeding studies using fasted mice 
The effects of oxyntomodulin analogues on food intake were investigated in fasted 
mice, as described in section 2.2.2. Peptides were administered via IP injection and 
food intake measured at 1, 2, 4, 8 and 24 hours post-injection, unless otherwise stated. 
Statistical analysis of results was completed as outlined in section 2.9. 
3.3.7.1 Effect of oxyntomodulin on food intake in fasted mice 
The study was designed to characterise the effect of oxyntomodulin on food intake in 
fasted mice. Peptide used in this study was human oxyntomodulin (800, 1400, 2200, 
3800 nmol/kg) (n=8-9 for all groups). 
3.3.7.2 Effect of human and porcine oxyntomodulin on food intake in fasted mice 
Previously, results showed that human and porcine oxyntomodulin both bound to the 
GLP-1 receptor with similar affinity. This study was designed to examine whether the 
ability of the peptides to reduce food intake reflected their affinity for the GLP-1 
receptor reflected their. Peptides used for this study were human oxyntomodulin (2700 
nmol/kg) and porcine oxyntomodulin (2700 nmol/kg) (n=8-9 for all groups). The dose 
of human oxyntomodulin used was chosen as it had previously been shown to 
significantly reduce food intake in the 0-1 hour interval compared to saline controls. 
3.3.7.3 Effect of glucagon and oxyntomodulin on food intake in fasted mice 
The study was designed to compare the effect of oxyntomodulin and glucagon on food 
intake in fasted mice. The peptides used for this study were oxyntomodulin (1000 and 
2700 nmol/kg) and glucagon (1000 and 2700 nmol/kg) (n=9-10 for all groups). A dose 
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of oxyntomodulin which had previously caused a non-significant decrease in food 
intake and one which caused a significant reduction in food intake were chosen to try 
and show any putative differences in peptide activity. 
3.3.7.4 Effect of GLP-1 on food intake in fasted mice 
The study was designed to characterise the effect of GLP-1 on food intake in fasted 
mice. Peptide used for this study were GLP-1 (30, 100, 300 and 900 nmol/kg) (n=8-9 
for all groups). 
3.3.7.5 Effect of exendin-4 on food intake in fasted mice 
The study was designed to characterise the effect of exendin-4 on food intake in fasted 
mice. Peptides used for this study were exendin-4 (0.3, 1, 3, and 10 nmol/kg) and 
oxyntomodulin (1400 nmol/kg) for comparison (n=8-10 for all groups). 
3.3.8 Incretin behaviour of oxyntomodulin and related peptides 
3.3.8.1 In vitro investigation of the in cretin-like behaviour of oxyntomodulin and 
related peptides 
Experiments were completed as described in section 2.6.1. Briefly, RINmSF cells were 
maintained in RPMI medium (5.5 mg/1 glucose) supplemented with 10% PCS. Cells 
were serum and glucose starved 2 hours prior to study and then the medium replaced 
with RPMI containing 5.5 mg/1 glucose, protease inhibitors (10% concentration of those 
used in section 2.4.1) and oxyntomodulin or other peptides at a range of concentrations 
between 0-1000 nM. Cells were incubated for 1 hour with peptide after which time the 
media was removed. The insulin concentration in the media was measured by RIA 
(section 2.6.3). 
3.3.8.2 In vivo investigation of the incretin-like behaviour of oxyntomodulin and 
related peptides 
Experiments were completed as described in section 2.6.2. Briefly, fasted mice 
received an IP injection of peptide or saline together with 1.5 mg/g (0.025 M) glucose 
solution. Eight minutes after injections, mice were killed by CO2 inhalation and blood 
collected by cardiac puncture. Plasma was separated by centrifugation and stored at -
20 C until insulin levels were measured using an insulin ELISA (section 2.6.4). 
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3.4 Results 
3.4.1 Binding affinities of oxyntomodulin, GLP-1, exendin-4 and glucagon to the 
GLP-1 receptor 
3.4.1.1 Binding to membrane preparation of rat lung 
Binding assays were completed as described in section 2.4.5 and 3.3.1. Assays using 
^^^I-exendin-4 routinely showed greater than 70% specific binding to membranes 
prepared from rat lungs (76.6 ± 1.4%, n=6). The binding affinities of oxyntomodulin, 
GLP-1 and exendin-4 to rat lung membrane are shown graphically in figure 3.1, and 
summarised in table 3.2. Oxyntomodulin bound to cell membrane preparation of lung 
tissue with an affinity approximately 2 orders of magnitude lower than that of GLP-1 
(oxyntomodulin IC50 29.1 nM, GLP-1 IC50 0.30 nM). Exendin-4 bound with a similar 
affinity to that of GLP-1 (exendin-4 IC50 0.31 nM) while glucagon did not displace 
exendin-4 from lung membrane. 
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Figure 3.1 
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Binding affinity of oxyntomodulin, GLP-1 and exendin-4 to the 
rGLP-1 receptor. Rat lung cell membrane was the source of GLP-1 receptor and 
^^^I-exendin-4 was used as the competing peptide. I C 5 0 value calculated as mean ± 
SEM of 3 separate experiments. 
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3.4.1.2 Binding to membrane preparation of CHO cells overexpressing rat GLP-1 
receptor 
Binding assays with exendin-4 routinely showed greater than 90% specific binding 
to a cell membrane preparation of the cloned rGLP-1 receptor (CHO cells expressing 
rGLP-1 receptor: 91.2 ± 1.9%, n=3). The binding affinities of oxyntomodulin, GLP-1 
and exendin-4 at the rGLP-1 receptor are shown graphically in figure 3.2, and 
summarised in table 3.2. Oxyntomodulin bound to the cloned rGLP-1 receptor 
overexpressed in CHO cells with over 100-fold lower affinity than GLP-1 and exendin-
4 (oxyntomodulin IC50 95.8 nM, GLP-1 IC50 0.24 nM and exendin-4 IC50 0.53 nM). No 
binding of ^^^I-exendin-4 was detected to a membrane preparation of untransfected 
CHO cells (data not shown). 
13 -12 -11 -10 -9 -8 -7 
log [peptide] M 
Figure 3.2 Binding affinity of oxyntomodulin, GLP-1 and exendin-4 to the 
rGLP-1 receptor. Cell membrane of CHO cells overexpressing cloned rGLP-1 
receptor was the source of GLP-1 receptor and ^^^I-exendin-4 was used as the 
competing peptide. I C 5 0 value calculated as mean ± SEM of 3 separate 
experiments. 
3.4.1.3 Binding to membrane preparation of rat hypothalamus 
Binding assays with ^^^I-exendin-4 routinely showed greater than 50% specific binding 
to a cell membrane preparation of rat hypothalamus (53.4 + 3.1%, «=3). The binding 
affinities of oxyntomodulin and related peptides at the hypothalamic membrane are 
shown graphically in figure 3.3, and summarised in table 3.2. Oxyntomodulin bound to 
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the rat hypothalamic membrane with over 25-fold lower affinity than GLP-1 and 
exendin-4, while glucagon did not displace ^^^I-exendin-4 from rat hypothalamus 
membrane (oxyntomodulin IC50 7.8 nM, GLP-1 IC50 0.25 nM and exendin-4 IC50 0.31 
nM). 
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Figure 3.3 Binding affinity of oxyntomodulin, GLP-1 and exendin-4 to the 
rGLP-1 receptor. Rat hypothalamus cell membrane was the source of GLP-1 
receptor and ^^^I-exendin-4 was used as the competing peptide. I C 5 0 value 
calculated as mean ± SEM of 3 separate experiments. 
3.4.1.4 Binding to membrane preparation of HEK 293T cells overexpressing 
human GLP-1 receptor 
Binding studies with ^^^I-exendin-4 routinely showed greater than 65% specific binding 
to cell membrane prepared from HEK 293T cells overexpressing human GLP-1 receptor 
(67.7 ± 2.0%, n=6). The binding affinities of oxyntomodulin, GLP-1 and exendin-4 at 
the human GLP-1 receptor are shown graphically in figure 3.4, and summarised in table 
3.2. Oxyntomodulin bound to cell membrane preparations from HEK 293T cells 
overexpressing hGLP-1 receptor with approximately 200-fold lower affinity than GLP-
1 or exendin-4 (oxyntomodulin IC50 53.4 nM, GLP-1 IC50 0.25 nM and exendin-4 IC50 
0.26 nM). Glucagon did not displace '^^I-exendin-4 from the membrane preparation of 
CHO cells expressing the hGLP-1 receptor and '^^I-exendin-4 did not bind to 
untransfected HEK cells (data not shown). 
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Figure 3.4 Binding affinity of oxyntomodulin, GLP-1 and exendin-4 to the 
rGLP-1 receptor. Cell membrane of HEK 293T cells overexpressing cloned 
hGLP-1 receptor was the source of GLP-1 receptor and ^^^I-exendin-4 was used as 
the competing peptide. I C 5 0 value calculated as mean ± SEM of 3 separate 
experiments. 
oxyntomodulin 29.1 ±4.4 95.8 ±10.8 7.8 ±1.6 53.4 ± 1.6 
glucagon >10000 >10000 >10000 >10000 
GLP-1 0.30 ±0.04 0.24 ±0.05 0.25 ± 0.07 0.25 ±0.01 
exendin-4 0.31 ±0.05 0.53 ± 0.02 0.31 ±0.14 0.26 ± 0.05 
Table 3.2 Binding affinity to the GLP-1 receptor of oxyntomodulin glucagon, 
GLP-1 and exendin-4. Cell membrane preparations from rat tissue and 
overexpressing cell lines used as the source of GLP-1 receptor and ^^^I-exendin-4 
was used as the competing peptide. I C 5 0 value calculated as a mean of a minimum 
of 3 separate experiments. Values shown are mean ± SEM. 
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3.4.2 Binding affinities of oxyntomodulin, GLP-1, exendin-4 and glucagon to the 
GCG receptor 
3.4.2.1 Binding to membrane preparation of rat liver membrane 
Binding studies with ^^^I-glucagon routinely showed greater than 90% specific binding 
to membranes prepared from rat liver tissue (94.8 ± 0.8%, n=4). The binding affinities 
of oxyntomodulin and glucagon to liver cell membrane are shown graphically in figure 
3.5, and summarised in table 3.3. The affinity of oxyntomodulin to liver cell 
membranes was an order of magnitude lower than glucagon. GLP-1 and exendin-4 did 
not displace ^^^I-glucagon. 
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Figure 3.5 Binding affinity of oxyntomodulin and glucagon to the rGCG 
receptor. Rat liver cell membrane was the source of GCG receptor and 
glucagon was used as the competing peptide. I C 5 0 value calculated as mean ± SEM 
of 3 separate experiments. 
3.4.2.2 Binding to membrane preparation of HEK 293T cells overexpressing 
hGCG receptor 
Binding studies with ^^^I-glucagon routinely showed greater than 90% specific binding 
to cell membrane prepared from HEK 293T cells overexpressing hGCG receptor (94.7 
± 0.9% n=3). The binding affinities of oxyntomodulin and glucagon are shown 
graphically in figure 3.6, and summarised in table 3.3. Oxyntomodulin bound to cell 
membranes prepared from HEK 293T cells overexpressing hGCG receptor with 
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approximately 5-fold lower affinity than glucagon. GLP-l and exendin-4 did not 
displace ^^^I-glucagon. 
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Figure 3.6 Binding affinity of oxyntomodulin and glucagon to the hGCG 
receptor. Cell membrane of HEK 293T cells overexpressing the hGCG receptor 
was the source of GCG receptor and ^^^I-glucagon was used as the competing 
peptide. I C 5 0 value calculated as mean ± SEM of 3 separate experiments. 
oxyntomodulin 20.0 ±4.5 5.84 ±0.58 
glucagon 1.1 ±0.15 1.1 ±0.13 
GLP-l >10000 >10000 
Exendin-4 >10000 >10000 
Table 3.3 Binding affinity to the GCG receptor of oxyntomodulin glucagon, 
GLP-l and exendin-4. Cell membrane preparations from rat tissue and an 
overexpressing cell line used as the source of GCG receptor and ^^^I-glucagon was 
used as the competing peptide. I C 5 0 value calculated as a mean of a minimum of 3 
separate experiments. Values shown are mean ± SEM. 
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3.4.3 Binding affinities of homologues of oxyntomodulin to rat GLP-1 receptor 
Oxyntomodulin has been characterised in several species and binding affinity of some 
of these homologues to the rGLP-1 receptor was tested. Binding assays with 
exendin-4 routinely showed greater than 70% specific binding (76.6 ± 1.4 %, n=6). 
There was no detectable difference between the binding of human and porcine 
oxyntomodulin to the rat GLP-1 receptor, while eel oxyntomodulin bound with 
approximately 20-fold lower affinity. The binding affinities for human, porcine and eel 
oxyntomodulin to the rGLP-1 receptor against '^^I-exendin-4 are summarised in table 
3.4. 
Human 29.1 ±4.4 
Porcine 29.7 + 2.8 
Eel 553 + 14.2 
Table 3.4 Binding affinity to the GLP-1 receptor of human, porcine and eel 
oxyntomodulin. Rat lung cell membrane was used as the source of GLP-1 receptor 
and ^^^I-exendin-4 was used as the competing peptide. I C 5 0 value calculated as a 
mean of a minimum of 3 separate experiments. Values shown are mean ± SEM. 
3.4.4 Bioactivity of oxyntomodulin, GLP-1, exendin-4 and glucagon at the GLP-1 
receptor 
3.4.4.1 Bioactivity at the rat GLP-1 receptor 
The ability of oxyntomodulin, GLP-1 and exendin-4 to stimulate cAMP accumulation 
in CHO cells overexpressing the rGLP-1 receptor was investigated. The bioactivity of 
oxyntomodulin was approximately 100-fold less than GLP-1 and exendin-4 
(oxyntomodulin EC50 1.8 ± 0.2nM, GLP-1 E C 5 0 0.018 ± 0.005 nM and exendin-4 EC50 
0.016 ± 0.04 nM) (figure 3.7). Glucagon did not stimulate cAMP production in this cell 
line. 
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Figure 3.7 Stimulation of cAMP production by oxyntomodulin, GLP-1 and 
exendin-4 in CHO cells overexpressing rGLP-1 receptor. EC50 values calculated as 
mean ± SEM of 3 separate experiments. 
3.4.4.2 Bioactivity at the human GLP-1 receptor 
The bioactivity of oxyntomodulin, GLP-1 and exendin-4 at HEK 293T cells 
overexpressing the human GLP-1 receptor was measured. Oxyntomodulin was 
approximately 120-fold weaker than GLP-1 and 80-fold weaker than exendin-4 at 
stimulating cAMP production (oxyntomodulin EC50 6.7 ± 1.0, GLP-1 EC50 0.049 ± 
0.011 and exendin-4 EC50 0.081 ± 0.021) (figure 3.8). Glucagon caused no increase in 
cAMP production, compared to basal levels and there was no change in cAMP levels 
when untransfected cells were treated with oxyntomodulin, GLP-1 or exendin-4 (data 
not shown). 
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Figure 3.8 Stimulation of cAMP production by oxyntomodulin, GLP-1 and 
exendin-4 in HEK 293T cells overexpressing hGLP-1 receptor. ECgo values 
calculated as mean ± SEM of 3 separate experiments. 
3.4.5 Bioactivity of oxyntomodulin at the hGCG receptor 
The human cDNA clones of the GCG receptor stably transfected into HEK 293T cells 
and the ability of oxyntomodulin and glucagon to evoke a cAMP response was 
measured. Both oxyntomodulin and glucagon caused an increase in cAMP production 
in cells expressing the GCG receptor, glucagon was approximately 50-fold more potent 
at stimulating cAMP release (oxyntomodulin EC50: 3.2 ± 0.5 nM, glucagon EC50 0.06 ± 
0.02 nM) (figure 3.9). There was no change in cAMP levels when untransfected cells 
were treated with either glucagon or oxyntomodulin. Treatment of cells expressing the 
hGCG receptor with exendin-4 and GLP-1 did not stimulate cAMP production (data not 
shown). 
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Figure 3.9 Stimulation of cAMP production by oxyntomodulin and glucagon in 
HEK293T cells overexpressing hGCG receptor. E C 5 0 value calculated as mean ± 
SEM of 3 separate experiments. 
3.4.6 Peripheral administration of oxyntomodulin to mice 
3.4.6.1 Effect of human oxyntomodulin on acute food intake in fasted mice 
Administration of all doses of oxyntomodulin, except 800 nmol/kg, resulted in a 
significant reduction of food intake compared to saline controls at the 0-1 hour interval 
(0-1 hour food intake: saline 1.23 ± 0.05 g, oxm (800 nmol/kg) 1.22 ± 0.05 g, oxm 
(1400 nmol/kg) 0.95 ± 0.07 g, oxm (2200 nmol/kg) 0.77 ± 0.12 g, oxm (3800 nmol/kg) 
0.35 ± 0.04 g) (figure. 3.10). At the 1-2 hour interval, none of the doses of 
oxyntomodulin tested reduced food intake significantly compared to saline controls (1-2 
hour food intake; saline 0.73 ± 0.05 g, oxm (800 nmol/kg) 0.68 ± 0.08 g, oxm (1400 
nmol/kg) 0.85 ± 0.10 g, oxm (2200 nmol/kg) 0.87 ± 0.11 g, oxm (3800 nmol/kg) 0.95 ± 
0.06 g) (figure. 3.10). Food intake was not significantly different to that of saline 
controls at any other time point (data not shown). 
96 
1.50-
1.25-
I 1004 
I 0.75-i 
T3 
o 0.50-1 
0.25-
0.00-
X 
X 
X X 
T 
IZZl Saline 
• 800 " 
[=11400 
I: f I ??nn 
H 3 8 0 0 J 
OXM 
nmol/kg 
0 - 1 hr 1 - 2 hr 
Figure 3.10 Dose response of the effect of oxyntomodulin on food intake in fasted 
mice. Oxyntomodulin was administered at 800,1400,2200 and 3800 nmol/kg (n=8-
9). *p<0.05, **p<0.01, ***p<0.001 compared to saline. 
3.4.6.2 Effect of human and porcine oxyntomodulin on effect of food intake in 
fasted mice 
Administration of human oxyntomodulin (2700 nmol/kg) and porcine oxyntomodulin 
(2700 nmol/kg) resulted in an acute reduction of food intake compared to saline controls 
(0-1 hour food intake: saline 0.81 ± 0.03 g, human oxyntomodulin (2700 nmol/kg) 0.46 
± 0.06 g, porcine oxyntomodulin (2700 nmol/kg) 0.39 ± 0.04 g) (figure 3.11). There 
was no significant difference in food intake between human and porcine oxyntomodulin 
groups at any time point measured. 
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Figure 3.11 Comparison of anorectic effects of human and porcine 
oxyntomodulin. Human and porcine oxyntomodulin were administered at 2700 
nmol/kg (n=8-9). **p<0.01 compared to saline. 
3.4.7 Effect of glucagon, GLP-1 and exendin-4 on food intake in fasted mice 
3.4.7.1 Effect of glucagon on food intake in fasted mice 
Administration of neither oxyntomodulin (1000 nmol/kg) nor glucagon (1000 nmol/kg) 
resulted in a significant difference in food intake compared to saline controls (figure 
3.12). Oxyntomodulin (2700 nmol/kg) and glucagon (2700 nmol/kg) significantly 
inhibited food intake at 0-1 hour post-administration compared to saline controls (food 
intake 0-1 hour; saline 1.01 ± 0.06 g, oxyntomodulin (2700 nmol/kg) 0.40 ± 0.03 g, 
glucagon (2700 nmol/kg) 0.76 ± 0.06 g) (figure 3.12). At the 0-1 hour interval, 
administration of oxyntomodulin (2700 nmol/kg) resulted in a significantly greater 
reduction in food intake than administration of glucagon (2700 nmol/kg). No 
significant differences were observed between treatment groups of between treatment 
groups and saline controls at any interval measured after 0-1 hour. 
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Figure 3.12 Comparison of anorectic effects of oxyntomodulin and glucagon. 
Peptides used in study were oxyntomodulin (1000 and 2700 nmol/kg) and glucagon 
(1000 and 2700 nmol/kg) (n=9-10). *p <0.05, **p <0.01 vs. saline treated controls, 
''p<0.05 2700 nmol/kg oxm vs. 2700 nmol/kg glucagon. 
3.4.7.2 Effect of GLP-1 on acute food intake in fasted mice 
All doses of GLP-1 (30, 100, 300 and 900 nmol/kg) resulted in a reduction in food 
intake compared to saline controls at the 0-1 hour interval (0-1 hour food intake: saline 
0.85 ± 0.05 g, GLPP-1 (30 nmol/kg) 0.72 ± 0.07 g, GLP-1 (100 nmol/kg) 0.45 ± 0.03 g, 
GLP-1 (300 nmol/kg) 0.28 ± 0.05 g, GLP-1 (900 nmol/kg) 0.20 ± 0.04 g) (figure 3.13). 
By the 1-2 hour interval only GLP-1 (900 nmol/kg) resulted in a significantly reduction 
of food intake compared to saline controls (1-2 hour food intake: saline 0.37 ± 0.06 g, 
GLP-l (30 nmol/kg), 0.43 ± 0.08 g, GLP-1 (100 mnol/kg) 0.33 ± 0.04 g, GLP-1 (300 
nmol/kg) 0.44 ± 0.04 g, GLP-1 (900 nmol/kg) 1 0.23 ± 0.05 g). Food intake of 
treatment groups was not significantly different to saline controls at any interval after 1 -
2 hour. 
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Figure 3.13 Dose response of the anorectic effect of GLP-1 on food intake in 
fasted mice. GLP-1 was administered at 30, 100, 300 and 900 nmol/kg (n=8-9). 
***p<0.001 compared to saline. 
3.4.7.3 Effect of exendin-4 on acute food intake in fasted mice 
As previously demonstrated, oxyntomodulin (1400 nmol/kg) significantly reduced food 
intake in the 0-1 hour interval only, compared to saline controls (0-1 hour food intake: 
saline 0.94 ± 0.03 g, oxyntomodulin (1400 nmol/kg) 0.64 ± 0.08 g). Administration of 
exendin-4 (1, 3 and 10 nmol/kg) caused a significant reduction in food intake compared 
to saline controls up to the 1-2 hour interval (1-2 hour food intake: saline 0.46 ± 0.08 g, 
exendin-4 (1 nmol/kg) 0.10 ± 0.04 g, exendin-4 (3 nmol/kg) 0.05 ± 0.01, exendin-4 (10 
nmol/kg) 0.04 ± 0.02 g) (figure 3.15). Groups treated with exendin-4 (3 and 10 
nmol/kg) continued to have a significantly reduced food intake compared to saline 
controls at the 2-4 hour interval (2-4 hour food intake: saline 0.52 ± 0.09 g, exendin-4 
(3 nmol/kg) 0.17 ± 0.05 g, exendin-4 (10 nmol/kg) 0.08 ± 0.04 g). By the 4-8 hour 
interval only exendin-4 (10 nmol/kg) resulted in a significant reduction in food intake 
compared to saline controls (4-8 hour food intake; saline 1.24 ± 0.11 g, exendin-4 (10 
nmol/kg) 0.76 ±0.17 g). 
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Figure 3.14 Dose response of the effect of exendin-4 on food intake in fasted 
mice, Exendin-4 was administered at 0.3, 1, 3 and 10 nmol/kg and oxyntomodulin 
at 1400 nmol/kg, (n=8-10). *p <0.05, **p <0,01, ***p <0,01 compared to saline, 
3,4.8 Incretin-like behaviour of oxyntomodulin and related peptides 
Oxyntomodulin has been reported to have incretin-like behaviour. To investigate this, 
insulin release was measured following treatment of cells and mice with 
oxyntomodulin. 
3.4.8.1 In vitro investigation of incretin like behaviour of oxyntomodulin and 
related peptides 
Incubation of RINmSF cells with either oxyntomodulin, GLP-1 or exendin-4 resulted in 
a dose dependent increase of insulin secretion (figure 3.15). The minimal dose of 
oxyntomodulin to stimulate significantly greater secretion of insulin than basal levels 
was 30 nM (basal 1.09 ± 0.14 ng/ml, oxm (30 nM) 2.15 ± 0.27 ng/ml, oxm (100 nM) 
3.18 ± 0.34 ng/ml, oxm (300 nM) 2.95 ± 0.31 ng/ml and oxm(1000 nM) 3.55 ± 0.08 
ng/ml) (figure 3.15a). The minimal dose of GLP-1 to stimulate significantly greater 
secretion of insulin than basal levels was 1 nM (basal, 1.06 ± 0.06 ng/ml, GLP-1 (1.0 
nM) 2.56 ± 0.15 ng/ml GLP-1 (10 nM) 3.09 ± 0.53 ng/ml, GLP-1 (30 nM) 3.97 ± 0.41 
ng/ml, GLP-1 (100 nM) 3.84 ± 0.53 ng/ml, GLP-1 (1000 nM) 3.94 ± 0.27 ng/ml) 
(figure 3.15b). The minimal dose of exendin-4 to stimulate significantly greater 
secretion of insulin than basal levels was 10 nM (basal 1.12 ± 0.09 ng/ml, exendin-4 (10 
nM) 2.06 ± 0.34 ng/ml, exendin-4 (30 nM) 3.24 ± 0.46 ng/ml, exendin-4 (100 nM) 3.36 
± 0.63 ng/ml and exendin-4 (1000 nM) 2.75 ± 0.44 ng/ml) (figure 3.15c), 
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Figure 3.15 Effect of a) oxyntomodulin, b) GLP-1 and c) exendin-4 on secretion of 
insulin from RINmSF. 1 x 10^  cells incubated with peptide for 60 minutes and 
insulin levels of media measured. Value calculated as mean ± SEM of a minimum 
of 4 separate experiments (n=4-5). *p <0.05, **p <0.01 vs. untreated controls. 
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3.4.8.2 In vivo investigation of incretin-like behaviour of oxyntomodulin and 
related peptides 
The effect of peripheral administration of either oxyntomodulin, GLP-1 or exendin-4 in 
combination with peripheral administration of glucose on plasma insulin in mice was 
examined. Administration of oxyntomodulin, GLP-1 and exendin-4 with glucose 
resulted in a dose-dependent increase of plasma insulin levels (figure 3.16). 
In vivo investigations of oxyntomodulin's incretin-like behaviour showed doses of 
oxyntomodulin above 20 nmol/kg resulted in a significant increase in mouse plasma 
insulin levels, compared to the glucose-only group (plasma insulin levels: saline 0.59 ± 
0.10 ng/ml, glucose 1.31 ± 0.27 ng/ml; oxm (10 nmol/kg) 2.75 ± 0.60 ng/ml, oxm (20 
nmol/kg) 6.12 ± 1.22 ng/ml, oxm (40 nmol/kg) 8.10 ± 0.72 nmol/kg) (figure 3.16a). In 
a subsequent experiment, all doses of oxyntomodulin tested (higher doses than in 
previous study, designed to establish maximal effect) resulted in a significant increase 
of plasma insulin levels compared to the glucose-only group (plasma insulin levels: 
saline 0.54 ± 0.03 ng/ml, glucose 1.23 ± 0.06 nmol/kg, oxm (40 nmol/kg) 5.84 ± 1.27 
ng/ml, oxm (200 nmol/kg) 5.69 ± 1.41 ng/ml and oxm (1000 nmol/kg) 6.06 ± 1.14 
nmol/kg) (figure 3.16b). Administration of GLP-1 (10,20 and 40 nmol/kg) resulted in a 
significantly higher plasma insulin level than the glucose only group (figure 3.16c) 
whilst administration of exendin-4 at 10 nmol/kg or higher elevated plasma insulin 
levels significantly higher than the glucose-only group (figure 3.16d). 
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Figure 3.16 Effects on plasma insulin of IP administration of glucose 1.5mg/g 
(0.025M) with a) oxyntomodulin ,b) oxyntomodulin, c) GLP-1, d) exendin-4. Mice 
were killed 8 minutes after injection and blood taken by cardiac puncture for 
measurement of plasma insulin (n=6-10). Value calculated as mean ± SEM of a 
minimum of 4 separate experiments. *p<0.05, **p<0.01, vs. glucose alone. 
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3.5 Discussion 
The experiments described at the start of this chapter were designed to establish the 
affinity of oxyntomodulin, GLP-1, exendin-4 and glucagon for the GLP-1 receptor. 
Results from displacement assays using rat lung cell membranes as the source of GLP-1 
receptor demonstrated that oxyntomodulin bound with an approximately 100-fold lower 
affinity than either GLP-1 or exendin-4. The use of rat lung as a source of GLP-1 
receptor was preferable for displacement assays as it is both readily available and 
convenient to prepare. However, establishing that a similar pattern of affinity existed 
for oxyntomodulin, GLP-1 and exendin-4 binding to GLP-1 receptor isolated from 
several different sources was important to allow interpretation of data from a variety of 
experimental settings, for example, correlating data produced from feeding studies 
conducted in mice to receptor affinity data produced where rat tissues was the source of 
GLP-1 receptor. Previous experimental data from the group reported oxyntomodulin, 
GLP-1 and exendin-4 bound to the GLP-1 receptor prepared from mouse lung with 
similar affinity as those I observed at the rat lung membrane (oxyntomodulin IC50 37.1 
nM, GLP-1 IC50 0.34 nM and exendin-4 0.36 nM, personal communication). Results 
from binding studies using cell membrane prepared from a cell line overexpressing the 
human GLP-1 were also in close agreement with those from studies using rat lung. 
Taken together, the results suggesting inter-species variation of the GLP-1 receptor is 
minimal. 
The receptor affinity data I obtained from assays using rat lung was inconsistent with 
previously published investigating binding to rat hypothalamic membranes (Dakin et 
al., 2001). To investigate if the differences were caused by the source of membrane or 
the competing ligand used (I used ^^^I-exendin-4, Dakin et al (2001) used ^^^I-GLP), I 
completed a series of displacement assays using rat hypothalamic membrane. The 
results of these studies were consistent with the data of Dakin et al (2001). At the 
hypothalamus, affinity of oxyntomodulin to the GLP-1 receptor was approximately 3-
fold higher than at the lung, whilst GLP-1 and exendin-4 bound with similar affinity to 
both membrane preparations. Changes in levels of receptor expression could have 
differential effects on the affinity of ligands for the GLP-1 receptor. It is also possible 
that oxyntomodulin interacts with a different receptor in the lung to which exendin-4 
does not bind. This would result in a falsely low affinity for the lung receptor. The 
most obvious candidate for this is the glucagon receptor; however it has been reported 
that glucagon mRNA is not expressed in lung tissue and the glucagon receptor itself 
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could not be detected (Iwanij, Vincent, 1990; Svoboda et al., 1994). Reported findings 
from other GPCRs may provide a possible explanation for this variation. Receptor 
activity modifying proteins (RAMPS) add a further level of receptor regulation to the 
calcitonin receptor-like receptor system, affecting the selectivity of the receptors for 
their cognate ligands (Hilairet et al., 2001), and RAMPS may be involoved in regulation 
of other receptors. Alternatively, accessory proteins such as caveolin-1, a peptide 
known to play a role in regulating cellular trafficking and function of the GLP-1 
recepotr could be involved (Syme et al., 2006). 
Cell lines overexpressing the receptors of interest were made, allowing in vitro 
assessment of ligand class to be determined and the bioactivity of the peptide to be 
measured. Non-physiological systems such as cell lines overexpressing receptors are 
unlikely to represent a true likeness of the physiological system. Overexpression of 
receptors often results in the receptor being present at higher densities than 
physiologically normal, resuhing in possible loss of membrane integrity. Proteins 
which may be associated with the GLP-1 or GCG receptor may be absent, and the 
systems required for any post-transcriptional modification of the receptor may be 
incomplete. A further consideration in the use of cell lines overexpressing receptors is 
receptors may not be correctly coupled to the secondary messenger system, which could 
result in artificially low EC50 values. Taking these factors into consideration, it was 
necessary to confirm the validity of the overexpressing cell line system. Receptor 
binding data using membrane prepared from HEK 293T cells overexpressing the hGLP-
1 receptor and from CHO cells overexpressing the rGLP-1 receptor were consistent with 
the results obtained from studies using membrane prepared from rat lung, with affinity 
of oxyntomodulin two orders of magnitude lower than GLP-1 and exendin-4. Absolute 
EC50 values from both hGLP-1 receptor cell lines varied, but difference between 
peptides were consistent, suggesting values are reliable. 
Variation was observed in the binding affinity of oxyntomodulin to the human and rat 
GCG receptor. Oxyntomodulin bound with approximately 20-fold lower affinity than 
glucagon at the rGCG receptor and 6-fold lower affinity than glucagon at the hGCG 
receptor. The human and rGCG receptor share 81% protein homology, while human 
and rat glucagon are identical, suggesting that it is unlikely that species variation could 
explain the observed difference. An alternative explanation is the differences in the 
source of purified receptor. Rat GCG receptor was purified from liver cells and human 
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GCG receptor was purified from HEK 293T cells overexpressing the hOCG receptor. 
Specific I exendin-4 binding to the liver membrane preparation was observed 
(although this was insufficient for an IC50 value to be calculated (data not shown)), yet 
no binding of I exendin to the overexpressed hGCG receptor was observed. This 
difference indicates the presence of other receptors in the liver preparation to which 
oxyntomodulin binds. Literature suggests that the GLP-1 receptor is expressed at low 
levels in rat liver (Villanueva-Penacarrillo et al., 1995), and is therefore a possible 
receptor to which oxyntomodulin may bind. If there were an extra population of 
receptors to which oxyntomodulin bound, there would be an increase in the quantity of 
peptide required to inhibit binding of a fixed amount of ^^^I-glucagon, assuming 
glucagon did not also bind to this receptor. 
The ability of oxyntomodulin to bind to both the GLP-1 and GCG receptor is a unique 
difference between itself and exendin-4, GLP-1 and glucagon which have affinity to 
only one of the receptors. At present, results from transgenic models suggest the 
anorectic effects of oxyntomodulin are mediated via the GLP-1 receptor (Baggio et al., 
2004b). However, the experiments by Baggio et al (2004b) could not rule out the 
possibility that an unknown receptor might be partly responsible for mediating the 
actions of oxyntomodulin on food intake. Indeed, recent research has identified actions 
of oxyntomodulin which are independent of the GLP-1 receptor. For example, 
oxyntomodulin has been shown to regulate the heart rate of mice, an effect maintained 
in the GLP-1 receptor deficient mouse (Sowden et al., 2007). 
Novel ligands cannot be fully characterised by displacement assays alone as the assay 
cannot distinguish different ligand classes. To determine if the peptide is an agonist, 
antagonist or partial agonist, further analysis is required such as measuring changes in 
levels of secondary messenger. Oxyntomodulin, exendin-4 and GLP-1 all signal via the 
Gs coupled GLP-1 receptor, thus activation of the receptor increases adenylyl cyclase 
activity resulting in increased levels of intracellular cAMP. The EC50 values of 
oxyntomodulin and related peptides calculated from changes in cAMP show some 
similarity to that observed with receptor affinity. However the EC50 for oxyntomodulin 
was approximately 140-fold higher than that for GLP-1 at the rat GLP-1 receptor whilst 
its IC50 was almost 400-fold higher. There are a number of potential explanations for 
this. Oxyntomodulin could be a more potent agonist at the receptor than GLP-1. This 
would result in a greater degree of receptor activation when oxyntomodulin is bound 
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rather than GLP-1. However the most likely explanation is the phenomenon of 'spare 
receptors . In many biological systems many more receptors are expressed than are 
required to obtain the maximal biological response (Feuerstein et al , 1994). This 
results in greater sensitivity to ligand binding than would be expected from competition 
binding data especially for low affinity ligands (Clark and Medzihradsky, 1986; Patri et 
al, 2008). The high degree of homology between human and rat GLP-1 receptor is 
highlighted by the similar trend of EC50 values obtained in overexpressing GLP-1 
receptor cell lines of each species. 
Feeding studies completed in this chapter demonstrated that peripheral administration of 
oxyntomodulin resulted in a transient reduction of food intake. An equivalent reduction 
in food intake at the 0-1 hour interval was achieved with doses of GLP-1 and exendin-4 
several fold. From the receptor affinity and bioactivity data of oxyntomodulin, it was 
not surprising that a higher dose of oxyntomodulin was required to inhibit food intake 
than the required dose of GLP-1 and exendin-4. The transient nature of food intake 
inhibition caused by oxyntomodulin and GLP-1 is likely to reflect the peptide's short 
half-life. The greater half-life of exendin-4 compared to GLP-1 is also a possible reason 
why a higher dose of GLP-1 was required to inhibit food intake in the 0-1 hour despite 
having similar bioactivity in the in vitro assay and similar affinity for the GLP-1 
receptor. Other factors such as ability of the peptide to cross the blood brain barrier 
could also influence the dose of peptide required to reduce food intake. 
Administration of drugs can modify behaviour by indirect mechanisms, for instance 
causing nausea will reduce food intake. It is possible that the actions of oxyntomodulin, 
GLP-1 and exendin-4 on food intake may be a result of such behavioural changes. 
Behavioural studies investigating the effects of oxyntomodulin, GLP-1 and exendin-4 
have been completed by other members of the group, and the results are shown in 
appendix E (personal communication, unpublished data). Results from the 
observational studies demonstrate administration of peptides (at a sufficient does to 
inhibit food intake by 30-40%) caused no significant changes in mouse behaviour 
compared to saline other than percentage of time spent feeding (figure 9.5.1). The 
behaviours measured included drinking, sleeping and rearing were unchanged. Using a 
different behavioural study design, an indirect measurement of nausea was measured 
using conditioned taste avoidance. Results of these studies demonstrated that doses of 
oxyntomodulin and GLP-1 which reliably reduce food intake by 40% did not indicate 
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activation of nausea like behaviour (figure 9.5.2a). When exendin-4 was tested at doses 
3 times higher than the lowest dose found to inhibit food intake, exendin-4 did not 
trigger a response indicating nausea (figure 9.5.2b). Based on these results, conditioned 
taste avoidance behaviour and fluid intake was not measured when investigating the 
actions of oxyntomodulin analogues. 
Evidence from my in vitro investigations using RINm5F cells demonstrates that 
oxyntomodulin has an insulinotropic action. Oxyntomodulin caused a significant 
increase in insulin secretion from RINm5F cells. Oxyntomodulin is a weaker 
insulinotropic agent than either GLP-1 or exendin-4, as a higher concentration of 
peptide was required to cause the same change of insulin release. Furthermore, I have 
provided evidence that oxyntomodulin can, in vivo, stimulate insulin release in mice. IP 
administration of oxyntomodulin with glucose causes a dose dependent increase in 
insulin release. A higher dose of oxyntomodulin was required to cause maximal release 
of insulin than that required with either GLP-1 or exendin-4. 
Oxyntomodulin, GLP-1 and exendin-4 have many common functional properties such 
as their ability to inhibit food intake, stimulate insulin release, bind to and activate the 
GLP-1 receptor and regulate gastric emptying. Oxyntomodulin is distinguished from 
GLP-1 and exendin-4 by its ability to bind to the GCG receptor. Oxyntomodulin also 
has several functions which are thought to be mediated via GLP-1 receptor independent 
mechanisms such as development of the eye (Vessey et al., 2005), control of intrinsic 
heart rate (Sowden et al., 2007) and gastric acid secretion (Carles-Bonnet et al., 1996). 
Perhaps the most contentious property of oxyntomodulin is its effect on energy 
expenditure. Several groups have reported contrasting data; oxyntomodulin treated rats 
having reduced body weight and adiposity compared to rats pair-fed to oxyntomodulin 
treatment group (Dakin et al., 2002), oxyntomodulin having no effect on energy 
expenditure in mice (Baggio et al., 2004b) and oxyntomodulin increasing activity-
related energy expenditure in humans (Wynne et al., 2005). As demonstrated in feeding 
studies described in this chapter oxyntomodulin has relatively low potency at reducing 
food intake compared to GLP-1 and exendin-4, and is short acting compared to 
exendin-4. Both of these characteristics hamper investigations of the effect of 
oxyntomodulin on energy expenditure. It would therefore be useful for the further 
characterisation of oxyntomodulin to develop an analogue with a greater half-life, 
allowing investigation of the peptides effect on energy expenditure. 
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Chapter 4 
The role of dipeptidyl-peptidase 4 
in the inactivation of 
oxyntomodulin and N-terminal 
modification of oxyntomodulin 
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4.1 Introduction 
4.1.1 Short peptide bioactive half life 
Many of the peptides derived from proglucagon have a short circulating half life, 
including GLP-1 (2 minute in rodents), GLP-2 (7 minute in man), glucagon (5-6 minute 
in man) and oxyntomodulin (12 minute in man) (Alford et al., 1976; Hartmann et al., 
2000; Kieffer et al., 1995; Schjoldager et al., 1988). Renal filtration and protease 
degradation are key mechanisms by which short peptides are inactivated (Griffiths and 
McDermott, 1983; Kenny and Stephenson, 1988; Ruiz-Grande et al., 1990; Tavares et 
al., 2000). Serine proteases (Frohman et al., 1989), aminopeptidase (Bongers et al., 
1992), carboxypeptidases (Krivoy and Kroeger, 1964) and metallo-proteinases (Hupe-
Sodmann et al., 1997) are classes of proteases shown to regulate the activity of 
hormones and neuropeptides. One of the best characterised aminopeptidases is 
dipeptidyl-peptidase 4 (DPP IV), which is known to play an important role in regulating 
the activity of gut hormones including GLP-1 and PYY. 
4.1.2 Dipeptidyl-peptidase 4 
DPP IV, also known as CD 26, EC 3.4.14.5, or adenosine deaminase binding protein, is 
a membrane-associated peptidase of 766 amino acids that was first identified in rat liver 
homogenates and in enzyme preparations of acylase I (Hopsu-Havu and Glenner, 1966). 
DPP rV has a dual role; as a binding protein to components of the extracellular matrix 
such as collagen, perhaps functioning as a cell adhesion molecule (Loster et al., 1995), 
and as a regulatory protease (Mentlein, 1999). DPP IV is highly expressed in 
endothelial cells, differentiated epithelial cells and lymphocytes (De Meester et al., 
1999). The enzyme DPP IV has also been detected in plasma (Durinx et al., 2000; 
Iwaki-Egawa et al., 1998; Ohkubo et al., 1994) and in cerebrospinal fluid (Mitro and 
Lojda, 1988). Thus DPP IV is expressed in regions exposed to circulating hormones 
and neuropeptides and found in fiuids which contain these factors. 
4.1.2.1 DPP IV and peptide inactivation 
The role of DPP IV in the inactivation of bioactive peptides was recognised twenty 
years ago (Heymann and Mentlein, 1978; Kato et al., 1978). Nearly all natural and 
synthetic bioactive peptides studied comprised of less than 80 amino acids and with an 
N-terminal sequence of X-Pro or X-Ala (where 'X' = any amino acid except proline) 
have been shown to be good substrates for DPP IV mediated degradation (Bongers et 
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al., 1992; De Meester et al., 1999; Lambeir et al., 2002). In addition to the classical 
substrates, DPP IV has been shown to cause a slow release of dipeptides composed of 
X-Ser or X-Gly from substrates such as macrophage-derived chemokine (Proost et al., 
1999). Many peptides are rendered inactive after cleavage by DPP IV; examples 
include GLP-1, GLP-2, neuropeptide Y and glucose-dependent insulinotropic peptide 
(GIP) (De Meester et al., 1999; Mentlein, 1999). However, cleavage of PYY(l-36) to 
PYY(3-36) results in a peptide with a higher affinity for the Y2 receptor and hence 
PYY(3-36) exerts a stronger anorectic effect than PYY(l-36) (Mentlein, 1999). The 
ability of DPP IV to enhance and inactivate peptide action enables this enzyme to play 
an important role in the regulation of physiological processes. 
4.1.2.2 DPPIV breakdown of GLP-1, glucagon and oxyntomodulin 
X-Pro or X-Ala, the classic DPP IV target sequences, were the first identified DPP IV 
sensitive sites. Perhaps one of the best characterised DPP IV substrates containing such 
a sequence is GLP-1, with His-Ala at positions 1 and 2. GLP-1 is rapidly degraded by 
DPP rV from GLP-1 (7-36) to GLP(9-36), and it is thought that DPP IV degradation is 
the primary mechanism of GLP-1 inactivation, contributing to the peptides short half-
life of less than 2 minute in man (Deacon, et al., 1995). As well as the classic DPP IV 
substrates, other N-terminal sequences can also be cleaved by DPP IV. A wide range of 
N-terminal sequences, including X-Ser, X-Gly, X-Leu and X-Val, are recognised target 
sites of DPP IV (Bongers et al., 1992; Martin et al., 1993). The identification of X-Ser 
as a DPP IV target site widened the list of proteins susceptible to DPP IV proteolysis to 
include glucagon and oxyntomodulin. Incubation of glucagon with purified porcine 
DPP IV yielded sequential production of glucagon(3-29) and glucagon(5-29), and 
incubation of glucagon with human plasma yielded glucagon(3-29) (Pospisilik et al., 
2001). A further study identified oxyntomodulin as a target of DPP IV in vitro (Zhu et 
al., 2003). Physiological levels of oxyntomodulin may therefore be regulated by DPP 
IV. 
4.1.2.3 DPP IV inhibitors and DPP IV resistant peptides 
The microbial peptides diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) are 
substrates that are slowly hydrolysed by DPP IV and are competitive inhibitors of DPP 
IV at micromolar concentrations (Rahfeld et al., 1991). Inhibitors of DPP IV provide 
useful tools for investigation of the behaviour of DPP IV and of its substrates. Specific 
DPP IV inhibitors which act at low concentrations, such as Vildagliptin (LAF 237) and 
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Sitagliptin, are currently being assessed in late-stage clinical trials for potential clinical 
applications (Ristic et al., 2005; Aschner et al., 2006; Rosenstock et al., 2007). 
Administration of DPP IV inhibitors have been shown to increase the ratio of 
active/total GLP-1 making a physiological insulin secretion possible in people with type 
2 diabetes (Herman et al., 2006). However, the expected decrease in body weight 
resulting from elevated GLP-1 levels was not observed in patients treated with 
Vildagliptin for four weeks (Ahren et al., 2002). This may be a consequence of having 
lower DPP IV activity, reducing the conversion of PYYl-36 to PYY3-36 (Jackson et 
al,2007). 
Exendin-4 is naturally resistant to DPP IV mediated degradation, a factor thought to 
contribute to the longer duration of its anorexigenic and incretin actions compared to 
those of the structurally and functionally related GLP-1. The greater resistance of 
exendin-4 to in vivo degradation by DPP IV is thought to stem from the Gly residue at 
position 2 rather than the Ala found at the same position in GLP-1. The same 
substitution has been shown to significantly increase the resistance of GIP to DPP IV 
mediated degradation (Gault et al., 2003). Factors other than N-terminal sequence have 
been reported to influence a peptides susceptibility to DPP IV mediated degradation. 
Two forms of adenylate cyclase activating polypeptide, one 28 residues long, the 
second a C-terminally extended 38 residue form, were tested for their affinity for DPP 
IV and their turnover rate by the enzyme. The C-terminal extended form bound with 
higher affinity and was degraded at a faster rate than the short form (Lambier, et al., 
2001a). Other papers report contrasting findings reporting that substrate recognition by 
DPP IV does not extend much further than residue 3 (Lambier et al, 2001b). 
The half-life of a peptide can be increased by preventing its degradation by DPP IV 
(Madsbad et al., 2004). This can be achieved by several strategies. DPP IV-resistant 
analogues of GLP-1 have been produced by substituting amino acid residue 2 (Ala) with 
other amino acids bearing short side chains, e.g. Gly, Ser or Thr (Deacon et al., 1995). 
An alternative option is to use small molecule DPP IV inhibitors, although these may 
have unpredictable side effects. Acetylation of the N-terminus has also proved effective 
in protecting GLP-1 from DPP IV degradation, resulting in a longer duration of 
bioactivity than the native hormone (O'Harte et al., 2002; Liu et al, 2004). 
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4.2 Aims 
1) To confirm that oxyntomodulin is an in vitro substrate for DPPIV degradation 
and to identify breakdown products; 
2) To investigate the importance of DPPIV mediated inactivation of 
oxyntomodulin in vivo by studying the effect of co-administration of a DPPIV 
inhibitor and oxyntomodulin on food intake in fasted mice; 
3) To design a range of oxyntomodulin analogues with modification of residues 1, 
2 and 3 of the N-terminal and characterise their, 
a. resistance to DPPIV 
b. affinity to the GLP-1 receptor 
c. in vitro bioactivity at the GLP-1 receptor 
d. in vivo effect on acute food intake in fasted mice. 
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4.3 Materials and methods 
4.3.1 Custom designed analogues of oxyntomodulin 
Oxyntomodulin analogues with sequence changes at position 2 and 3 were designed to 
characterise the peptides sensitivity to DPP IV mediated degradation (table 4.1). 
Analogues were designed by substituting amino acids of position 2 and 3 from GLP-1 
and exendin-4, or by replacing amino acid by its charge, e.g. acidic for acidic. The 
effect of these modifications on GLP-1 receptor binding affinity, resistance to 
breakdown by DPP IV and anorectic actions were examined. As substitutions of 
position 2 and 3 reduced sensitivity to DPP IV degradation but not block it, further 
analogues with modifications of position 1 were designed. Changes at position 1 
included DHisl-oxm (D isomer of His), DesHisl-oxm (His at position one removed) 
and acetylHisl-oxm (modified His residue at position 1). Having established that DHis 
isomer at position 1 blocked DPP IV mediated breakdown of oxyntomodulin, further 
analogues were designed incorporated modification of positions 2 to establish if a N-
terminally modified analogues would improve the bioactivity of oxyntomodulin and 
duration of food intake inhibition sufficiently to be used in studies investigation 
oxyntomodulin's mechanism of energy expenditure. 
All peptides were manufactured using the protocols described in section 2.1. 
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Peptide Residue number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 
oxyntomodufin H S Q G T F T S D Y S K Y L D S R R A Q D F V Q W L M N T K R N R N N 1 A 
qlp-1 H A E G T F T S D V S S Y L E G Q A A K E F 1 A W L V K G R G 
exendin4 H G E G T F T s D L s K Q M E E E A V R L F 1 E w L K N G G P S S G A P P P S 
Aia2-oxm H A Q G T F T s D Y s K Y L D S R R A Q D F V Q w L M N T K R N R N N 1 A 
Glv2-oxm H G Q G T F T s D Y s K Y L D S R R A Q D F V Q w L M N T K R N R N N 1 A 
Glu3-oxm H S E G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
Asp3-oxm H S D G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
Ala2-Asp3-oxm H A D G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
Ala2-Glu3-oxm H A E G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
DesHisI -oxm S Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
DHisI -oxm dH S Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
AcetylHisI -oxm aH S Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
DHisI Ala2 oxm dH A Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
DHisI-Val2-oxm dH V Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
DHisI-Glv2-oxm dH G Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
DHisI Ala2 Glu3 oxm dH A E G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
DHisI Ser2 Glu3 oxm dH S E G T F T s D Y s K Y L D 3 R R A Q D F V Q w L M N T K R N R N N 1 A 
DHisI -Aia2-Asp3-oxm dH A D G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N 1 A 
I I Amino acids different to those in the corresponding position of human oxyntomodulin 
dH = DHis stereoisomer of His aH= Acetylated form of His 
Tabel 4.1 Peptides used in the experiments described in chapter 4 
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4.3.2 Quantification of DPP IV mediated degradation of oxyntomodulin and 
oxyntomodulin analogues 
Resistance to DPP IV mediated degradation was calculated using the protocol described 
in section 2.7.1. Reaction samples of 2 nmol or 5 nmol of peptide were incubated with 
or without 10 mU or 25 mU DPP IV respectively at 37°C for 120 minute in a total 
volume of 130 |a,l (or 325 pi for the 5 nmol peptide/25 mU experiment) before analysis 
by reverse phase HPLC. A gradient of 2-30% acetonitrile/water (both containing 0.05% 
TFA) 0-10 minute, and 30-48% acetonitrile/water (both containing 0.05% TFA) 10-40 
minute was used unless otherwise stated and absorbance measured at a wavelength of 
214 nm (Jasco HPLC system, solvent delivery system PU-2080 plus, autosampler AS-
2057 plus, degasser DG2080-53, dynamic mixer 2080-32 UV detector uv-2075 using a 
Phenomenex Gemini Cig (5-)am particles) 250 mm x 4.6 mm column). Percentage 
degradation was calculated by comparing area under peak in reactions with and without 
enzyme. Percentage degradation values were calculated from a minimum of 2 
experiments. Chromatograms shown are representative examples. 
4.3.3 Matrix-assisted laser desorption/ionization-time of flight (MALDI-ToF) 
mass spectrometry analysis of new peak observed in HPLC analysis 
A sample of an oxyntomodulin DPP IV digest (4.3.2) was sent to Advanced 
Biotechnology Centre, Imperial College, for MALDI-ToF mass spectrometry analysis. 
4.3.4 DPP IV mediated breakdown of oxyntomodulin to oxm(3-37) 
DPP IV mediated degradation of oxyntomodulin (15 nmol) was completed as described 
in section 4.3.2, with the ratio of enzyme to peptide maintained at 10 mU DPP IV for 
every 2 nmol oxyntomodulin. Reactions were incubated for 0, 30, 120 and 240 minute, 
and terminated by addition of 1.0 jj,g diprotin A (an inhibitor of DPP IV). Reverse 
phase HPLC analysis of 4 nmol of these reactions was also completed as described in 
section 4.3.2. 
4.3.5 Receptor binding studies to the GLP-1 receptor 
Measurement of analogue affinity to the rat GLP-1 receptor was completed using the 
protocol outlined in section 2.4.5. Cell membrane was purified from rat lung and 
provided the source of GLP-1 receptor (2.4.1). '^^I-exendin-4 was used as the 
competing radiolabelled peptide. Binding affinities were calculated from a minimum of 
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3 separate experiments in which each concentration of unlabelled peptide was tested in 
triplicate. Values are shown as mean ± SEM. 
4.3.6 In vitro bioactivity studies of analogues and peptide fragments 
The protocol described in section 2.5.1 was used to investigate the ability of 
oxyntomodulin analogues with position 1 modifications to stimulate cAMP production. 
DPP IV breakdown products of endogenous oxyntomodulin were also tested. CHO 
cells overexpressing the rGLP-1 receptor were used for the experiments. E C 5 0 values 
were calculated from 3 experiments and, within each experiment peptide, concentrations 
were tested in duplicate. 
4.3.7 Feeding studies using fasted mice 
The effects of oxyntomodulin analogues on food intake were investigated in fasted 
mice, as described in section 2.2.2. Peptides were administered via IP injection and 
food intake measured at 1, 2, 4, 8 and 24 hours post-injection, unless otherwise stated. 
Statistical analysis of results was completed as outlined in section 2.9. 
4.3.7.1 Co-administration of oxyntomodulin and valine pyrrolidide to fasted mice 
The effect on food intake of co-administration of oxyntomodulin and valine pyrrolidide 
(VP), a DPP IV inhibitor, was investigated using fasted mice. The feeding study was 
completed as described in section 2.2.2, with the following modifications. All mice 
received 2 injections, the first an IP injection of saline or oxyntomodulin (2700 
nmol/kg), the second a SC injection of saline or VP (22 mmol/kg) (kind gift from 
Novartis). In total there were 4 groups of mice which received a combination of the IP 
and SC injections (n=12 for all groups). 
4.3.7.2 Effect of position 1 modifications of oxyntomodulin on food intake in fasted 
mice 
Analogues of oxyntomodulin with modifications at position 1 were tested for their 
anorectic effect. Peptides used for this study were oxyntomodulin (2700 nmol/kg), 
DHisl-oxm (2700 nmol/kg) and DesHisl-oxm (2700 nmol/kg) (n=10 for all groups). 
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4.3.7.3 Effect of position 1 and 2 modifications of oxyntomodulin on food intake in 
fasted mice 
The study was designed to investigate anorectic effects of analogues with modifications 
at positions 1 and 2. Peptides used in this study were DHisl-Ala2-oxm (2700 nmol/kg) 
and oxyntomodulin (2700 nmol/kg) (n=10 for all groups). 
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4.4 Results 
4.4.1 In vitro analysis of DPP IV breakdown of oxyntomodulin 
Resistance of oxyntomodulin to DPP IV mediated degradation was tested by incubation 
of 2 nmol of peptide with 10 mU human DPP IV at 37°C for 120 minute. The reaction 
was terminated by the addition of 1.0 jag diprotin A. Reverse phase HPLC was used to 
identify loss of parent compound and the presence of a novel peaks (figure 4.1). A 
sample of the reaction containing DPP IV was analysed using MALDI-ToF mass 
spectrometry to identify the molecular weight of the material forming the new peak. 
MALDI-ToF mass spectrometry analysis identified 2 main peaks, with masses of 4453 
(4454-1 and 4228 (4229-1 H^) (figure 4.2). The peak at 4453 mass units 
corresponds to native oxyntomodulin (theoretical mass of 4450) and the peak at 4228 
mass units corresponds to oxm(3-37) (theoretical mass: 4224). 
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Figure 4.1 In vitro degradation of oxyntomodulin by DPP IV. Oxyntomodulin 
(2 nmol) was incubated for 120 minute with 10 mil DPP IV at 37 C. Digests were 
analysed by reverse phase HPLC using a 27 - 31% water/acetonitrile gradient 
over 40 minute. 
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Figure 4.2 MALDI-ToF mass spectrometry analysis of oxyntomodulin 
following 120 minute incubation with 10 mU DPP IV. 
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4.4.2 Effect of co-administration of a DPP IV inhibitor and oxyntomodulin on 
acute food intake in fasted mice 
To demonstrate specific breakdown of oxyntomodulin in an in vivo setting is a complex 
experiment. Deacon et al attempted to demonstrate glucagon breakdown in the 
anesthetised pig and concluded that both glucagon and oxyntomodulin are likely to be 
degraded by DPP IV (Deacon et al., 2003). In a simpler experimental design setting, 
the effect of oxyntomodulin on food intake was shown to be enhanced by co-
administration of VP, a DPP IV inhibitor. 
Administration of oxyntomodulin (2700 mnol/kg) significantly reduced food intake for 
the first hour post-administration compared to saline. As previously observed, food 
intake of mice treated with oxyntomodulin returned to levels of the control group 
thereafter. Administration of VP (22 nmol/kg) did not effect food in any interval 
measured. Co-administration of VP (22 nmol/kg) and oxyntomodulin (2700 nmol/kg) 
resulted in a significant enhancement of food intake inhibition compared to 
oxyntomodulin alone in the 0-1 hour interval only, (figure 4.3). 
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Figure 4.3 Figure 4.3 Effect of co-administration of valine pyrrolidide (VP) 
and oxyntomodulin on food intake in fasted mice, a) 0-1 hour, b) 1-2 hour interval 
(n=12). ***p<0.001 compared to saline or comparison between groups indicated. 
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4.4.3 Rate of oxyntomodulin break down and characterisation of oxm(3-37) 
Oxyntomodulin was digested by DPP IV to provide a source of oxm(3-37) which could 
be used to investigate the affinity and bioactivity of the truncated peptide at the rGLP-1 
receptor. Under standard conditions (10 mU DPP IV with 2 nmol peptide, incubation at 
37°C), maximal degradation of oxyntomodulin was observed after 4 hours (figure 4.4). 
Analysis of digest samples by reverse phase HPLC demonstrated a time dependent 
relationship for degradation of oxyntomodulin to oxm(3-37) (30 minute 40%, 120 
minute 83%, 240 minute 98% loss of native peptide) (figure 4.4). Chromatogram of the 
sample incubated for 240 minute shows a shoulder to the oxm(3-37) peak. The 
shoulder may represent a further breakdown species, oxm(5-37). The digestion of 
oxyntomodulin in standard conditions provided a marker to which resistance of 
oxyntomodulin analogues to DPP IV mediated degradation could be compared. 
oxm(1-37) 
oxm(3-37) ISOOOOn 
125000-
-27.5 
100000 
75000- -25.0 > 
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25000 
-22.5 
•0 min 
31 
Time (min) 
30 min 120 min •240 min 
Figure 4.4 Time course of DPP IV mediated degradation of oxyntomodulin. 
Oxyntomodulin (2 nmol) was incubated with peptide with 10 mU DPP IV for 0, 30, 
120 and 240 minuteute at 37°C. Digests were analysed by reverse phase HPLC 
using a 27-31% water/acetonitrile gradient over 40 minute. 
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Samples from figure 4.4 were also analysed for their affinity for the GLP-1 receptor and 
for their bioactivity. As the percentage oxm(3-37) increased, affinity at the GLP-1 
receptor was reduced (digest sample: 0 minute IC50: 31 ±2.6 nM, 30 minute IC50: 134 
± 8.7 nM, 120 minute IC50: 232 ± 17.1 nM, 240 minute IC50: 221 ± 19 nM) (figure 
4.5a). cAMP release from CHO cells overexpressing rGLP-1 receptor was greatest for 
samples containing a higher percentage of oxm(l-37) (digest sample: 0 minute EC50 2.8 
nM; 30 minute EC50 16.8 ± 2.5 nM; 120 minute EC50 117 ± 23nM, 240 minute EC50147 
± 21 nM) (figure 4.5b). 
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Figure 4.5 Time course of DPP IV mediated conversion of oxyntomodulin to 
oxm(3-37). a) Affinity of oxyntomodulin and oxm(3-37) to the rGLP-1 receptor 
and b) bioactivity of oxyntomodulin and oxm(3-37) at the rGLP-1 receptor. ND = 
not determined. Rat lung cell membrane was the source of GLP-1 receptor and 
^^^I-exendin-4 used as the competing peptide for receptor binding assays. I C 5 0 
value calculated as mean ± SEM of 3 separate experiments. CHO cells 
overexpressing rGLP-1 receptor used for bioactivity assay. E C 5 0 value calculated 
as mean ± SEM of 3 separate experiments. 
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4.4.4 N-terminal modifications of oxyntomodulin and their effects on DPP IV 
resistance 
4.4.4.1 Affinity to the rGLP-1 receptor and resistance to DPP IV mediated 
degradation of oxyntomodulin, GLP-1, exendin-4 and analogues of oxyntomodulin 
with changes to amino acids 2 and 3 
Affinities of oxyntomodulin, GLP-1 and exendin-4 for the GLP-1 receptor were as 
previously reported (table 3.2). Substitution of Ser2 of oxyntomodulin with Ala2 
caused no change in affinity to the rGLP-1 receptor (table 4.2, figure 4.6), while 
substitution of Ser2 for Gly2 resulted in an approximately 12-fold decrease in affinity to 
the receptor (table 4.2, figure 4.6). Substitution of Glu for Gin at position 3 reduced 
affinity to the GLP-1 receptor by 3-fold, whilst substitution for Asp at position 3 did not 
alter the analogues affinity to the GLP-1 receptor (table 4.2 figure 4.7). 
Peptides with combinations of these substitutions at positions 2 and 3 were produced 
and tested for their affinity to the GLP-1 receptor. Analogue Ala2-Asp3-oxm bound to 
the GLP-1 receptor with 2-fold greater affinity than oxyntomodulin, while affinity of 
the peptide Ala2-Glu3-oxm to the GLP-1 receptor was 2-fold lower than the native 
peptide (table 4.2, figure 4.8). 
GLP-1 was more sensitive than either oxyntomodulin or exendin-4 to DPP FV mediated 
degradation (% degradation after 30 minute in standard conditions: GLP-1 100%, 
oxyntomodulin 40%, exendin-4 0%) (table 4.2). Increasing the incubation period from 
30 minute to 120 minute resulted in a greater amount of oxyntomodulin being degraded, 
whilst exendin-4 remained resistant to DPP IV mediated degradation (oxyntomodulin 
82%, exendin-4 0%). Modifying position 2 of oxyntomodulin by substituting Ser for 
Ala increased the extent of peptide degradation after incubation with DPP IV 
(oxyntomodulin 40%, Ala2-oxm 94%). A modest improvement of resistance to DPP IV 
mediated breakdown was observed when Gly replaced Ser at position 2 (oxyntomodulin 
40%, Gly2-oxm 19% degradation) (table 4.2). Modification of position 3 was sufficient 
to alter the peptides sensitivity to DPP IV mediated degradation. Replacing Gin with 
either Asp or Glu at position 3 resulted in reduced breakdown after 30 minute 
incubation with 10 mU DPP IV (oxyntomodulin 40%, Glu3-oxm 8%, Asp3-oxm 20%) 
(table 4.2). Combinations of amino acid substitutions at position 2 and 3 created 
peptides with increased sensitivity to DPP IV mediated breakdown compared to 
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oxyntomodulin after 30 minute incubation with 10 mU of DPP IV (oxyntomodulin 40% 
Ala2-Asp3-oxm 53%, Ala2-Glu3-oxm 57%) (table 4.2). 
100-
75-
O) 
c 
••5 
c 
m 
u 
E 504 
u 
o 
a (/) 
^ 254 
0 
i 
Ala2-oxm IC50: 28.1 nM 
Gly2-oxm IC50: 367 nM 
1 1— 
13 -12 -11 
—I— 
-10 
T —r-
- 6 -9 -8 -7 
log [peptide] M 
Figure 4.6 Binding affinity of analogues of oxyntomodulin with amino acid 
substitutions at position 2 to the rGLP-1 receptor. Rat lung cell membrane was 
the source of GLP-1 receptor and ^^^I-exendin-4 used as the competing peptide. 
I C 5 0 value calculated as mean ± SEM of 3 separate experiments. 
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Figure 4.7 Binding affinity of analogues of oxyntomodulin with amino acid 
substitutions at position 3 to the rGLP-1 receptor. Rat lung cell membrane was 
the source of GLP-1 receptor and ^^^I-exendin-4 used as the competing peptide. 
I C 5 0 value calculated as mean ± SEM of 3 separate experiments. 
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Figure 4.8 Binding affinity of analogues of oxyntomodulin with amino acid 
substitutions at position 2 and 3 to the rGLP-1 receptor. Rat lung cell membrane 
was the source of GLP-1 receptor and ^^^I-exendin-4 used as the competing 
peptide, I C 5 0 value calculated as mean ± SEM of 3 separate experiments. 
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Native sequence 
oxm (Hisl-Ser2-Gln3...) 29.1 ±4.4 40 82 
GLP-1 (Hisl-Ala2-Glu3...) 0.3 ± 0.21 100 100 
Ex-4 (Hisl-Gly2-Glu3...) 0.3 ±0.18 0 0 
Position 2 changes 
Ala2-oxm 28.1 ±3.6 94 94 
Gly2-oxm 367±21 19 51 
Position 3 changes 
Glu3-oxm 93.3 ± 11.1 8 38 
Asp3-oxm 30.0 ±2.8 20 56 
Position 2 and 3 changes 
Ala2-Asp3-oxm 15.6 ±1.6 53 77 
Ala2-Glu3-oxm 61.3 ±4.5 57 69 
Table 4.2 The binding affinity for the rGLP-1 receptor and susceptibility to 
DPP IV mediated degradation of oxyntomodulin, GLP-1, exendin-4 and analogues 
of oxyntomodulin with N-terminal modifications. I C 5 0 value calculated as a mean 
of a minimum of 3 separate experiments. Values shown are mean ± SEM. 
Percentage degradation was calculated by comparing area under peak of ± DPP 
IV samples analysed by HPLC. 
4.4.4.2 Position 1 modifications of oxyntomodulin to improve DPP IV resistance 
Tnmcation of oxyntomodulin by 2 amino acids at the N-terminus caused a reduction in 
affinity to, and bioactivity at, the GLP-1 receptor. Literature suggests that modification 
of the N-terminal amino acid of peptides that are sensitive to DPP IV mediated 
degradation can help protect the peptide from such proteolysis. Therefore, analogues of 
oxyntomodulin with modifications to the N-terminal amino acid (His) were produced. 
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Modifications included substitution of L isomer His to D isomer (DHis), acetylation of 
the N-terminal His amino acid (acetylHis) and removal of Hisl (DesHis). These 
modifications of position 1 resulted in complete resistance to DPP IV mediated 
degradation of the peptide (table 4.3, figure 4.9-4.11). 
Position 1 modifications screened for DPP IV resistance were tested for their affinity to 
the rGLP-1 receptor (table 4.3). Receptor binding data suggests that all modifications 
resulted in a large reduction in binding affinity compared to oxyntomodulin, with 
binding of DesHis 1-oxm and acetylHis 1-oxm reduced so greatly that an I C 5 0 value 
could not be determined. Bioactivity of the analogues modified at position 1 was tested 
by measuring their ability to stimulate cAMP production in cells overexpressing the 
rGLP-1 receptor. Peptides DesHis 1-oxm and acetylHis 1-oxm failed to stimulate cAMP 
production above basal levels, indicating that the peptides were not bioactive at the 
GLP-1 receptor (data not shown), whilst peptide DHis 1-oxm was approximately 10-fold 
less bioactive than native sequence oxyntomodulin (figure 4.12). 
oxyntomodulin 29.1 ±4.4 40 82 
DesHisl-oxm >10000 0 0 
DHisl-oxm 1064 ±272 0 0 
acetylHis 1-oxm >10000 0 0 
Table 4.3 The binding affinity for the rGLP-1 receptor and susceptibility to 
DPP IV mediated degradation of oxyntomodulin, DesHisl-oxm, DHisl-oxm and 
acetylHis 1-oxm. I C 5 0 value calculated as a mean of a minimum of 3 separate 
experiments. Values shown are mean ± SEM. Percentage degradation was 
calculated by comparing area under peak of ± DPP IV samples analysed by HPLC. 
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Figure 4.10 In vitro breakdown of DesHisl-oxm by DPP IV. DesHisl-oxm (2 
nmol) incubated for 120 minute with 10 mU DPP IV at 37°C. Digests were 
analysed by reverse phase HPLC using a 0-47% water/acetonitrile gradient over 
47 minute. 
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Figure 4.11 In vitro breakdown of aeetylHisl-oxm by DPP IV. AcetylHisl-oxm 
(2 nmol) incubated for 120 minute with 10 mU DPP IV at 37°C. Digests were 
analysed by reverse phase HPLC using a 27-31% water/acetonitrile gradient over 
40 minute. 
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Figure 4.12 cAMP production by oxyntomodulin and DHisl-oxm in CHO cells 
overexpressing rGLP-1 receptor. E C 5 0 values calculated from a minimum of 2 
separate experiments. 
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4.4.4.3 Further investigation of N-terminal modifications of oxyntomodulin 
Substitution of DHis for His at position 1 of oxyntomodulin caused a 30-fold reduction 
in affinity to the rGLP-1 receptor compared to oxyntomodulin. However, DHisl-oxm 
was resistant to DPP IV mediated degradation and was bioactive. Further DHisl-oxm 
analogues with additional substitutions at positions 2 and 3 were designed and 
produced. 
Replacement of Hisl with DHisl in all N-terminal analogues reduced binding, 
irrespective of the identity of amino acids at positions 2 and 3 (table 4.4, figures 4.13 
and 4.14). The DHisl analogue with highest affinity to the GLP-1 receptor was DHisl-
Ala2-Asp3-oxm, which bound to the GLP-1 receptor with approximately 12-fold lower 
affinity than oxyntomodulin, but 3-fold higher affinity than DHisl-oxm. Other amino 
acid substitutions were tested, but none showed any improvement in binding affinity 
(table 4.4). 
All oxyntomodulhi analogues screened with a DHisl modification at position 1 showed 
fall protection from DPP IV mediated degradation (table 4.4). 
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Position 1 and 2 changes 
DHisl-Ala2-oxm 544± 103 3 0 
DHisl-Val2-oxm >10000 2 0 
DHisl-Gly2-oxm 3540 ±785 0 0 
Position 1,2 and 3 changes 
DHisl- Ala2-Glu3-oxm 624±89 0 0 
DHis 1-Ser2-Glu3-oxm 972±138 3 0 
DHis 1 - Ala2-Asp3 -oxm 380±65 0 0 
Table 4.4 The binding af finity for the rGLP-1 receptor and susceptibility to 
DPP IV mediated degradation of oxyntomodulin analogues with modifications of 
the N-terminal. I C 5 0 value calculated as a mean of a minimum of 3 separate 
experiments. Values shown are mean ± SEM. Percentage degradation was 
calculated by comparing area under peak of ± DPP IV samples analysed by HPLC. 
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Figure 4.13 Binding affinity of analogues of oxyntomodulin with modifications of 
amino acids at positions 1 and 2 to the rGLP-1 receptor. Rat lung cell membrane 
was the source of GLP-1 receptor and ^^^I-exendin-4 used as the competing 
peptide. I C 5 0 value calculated as mean ± SEM of 3 separate experiments. 
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Figure 4.14 Binding affinity of analogues of oxyntomodulin with amino acid 
modifications at positions 1, 2 and 3 to the rGLP-1 receptor. Rat lung cell 
membrane was the source of GLP-1 receptor and ^^'I-exendin-4 used as the 
competing peptide. I C 5 0 value calculated as mean ± SEM of 3 separate 
experiments. 
4.4.5 Oxyntomodulin analogues: effect on food intake 
4.4.5.1 Effect of position 1 modifications of oxyntomodulin on food intake in fasted 
mice 
Administration of oxyntomodulin (2700 nmol/kg) and DHisl-oxm (2700 nmol/kg) 
resulted in a significant reduction in food intake compared to the saline control group in 
the 0-1 hour interval only (figure 4.15a). As expected, administration of DesHisl-oxm 
(2700 nmol/kg) did not effect food intake at any time point, compared to saline controls 
(figure 4.15a). At both the 0-1 hour and 1-2 hour interval, there was a non-significant 
trend of a greater reduction in food intake by DHisl-oxm (2700 nmol/kg), in 
comparison to oxyntomodulin (2700 nmol/kg) and when analysed cumulatively there 
was a significant difference in 0-2 hour food intake between the groups (figure 4.15b). 
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Figure 4.15 Effect of analogues of oxyntomodulin with modifications at position 
1 on a) interval, and b) cumulative food intake in fasted mice. Oxyntomodulin and 
analogues DesHisl-oxm and DHisl-oxm were administered at 2700 nmol/kg 
(n=10). *p<0.05, ***p<0.001 compared to saline, ^p<0.05 compared between 
groups indicated. 
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4.4.5.2 Effect of position 1 and 2 modifications of oxyntomodulin on food intake in 
fasted mice 
As previously demonstrated, oxyntomodulin (2700 nmol/kg) significantly reduced food 
intake in the first hour compared to saline controls. Administration of DHisl-oxm 
(2700 nmol/kg), Ala2-oxm (2700 nmol/kg) and DHisl-Ala2-oxm (2700 nmol/kg) 
resulted in significantly reduced food intake compared to the saline control group in the 
first hour post-injection (figure 4.16). At the 1-2 hour interval DHisl-Ala2-oxm 
significantly inhibited food intake compared to saline controls and compared to 
oxyntomodulin (figure 4.16). 
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Figure 4.16 Effect of oxyntomodulin analogues with N-terminal modifications on 
food intake in fasted mice. Oxyntomodulin and analogues DHisl-oxm, Ala2-oxm 
and DHisl-Ala2-oxm were administered at 2700 nmol/kg (n=10). *p<0.05, 
**p<0.01, ***p<0.001 compared to saline or groups indicated. 
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4.5 Discussion 
Previously, Zhu et al identified oxyntomodulin as an in vitro substrate for DPP IV 
degradation (Zhu, et al., 2003). To confirm this finding and to identify the degradation 
products, oxyntomodulin was incubated with DPP IV and the sample analysed by 
MALDI-ToF mass spectrometry. Analysis indicated that oxm(3-37) was the only 
observed degradation product of the digest incubated for 120 minute. However, in the 
digest sample incubated for 240 minute, the chromatogram provided evidence of a 
second breakdown product which may represent oxm(5-37). This would align with 
established data on DPP IV mediated breakdown of glucagon, which is first degraded to 
glucagon(3-29) and sequentially to glucagon(5-29) by purified porcine DPP IV 
(Pospisilik, et al., 2001). Mass analysis of the observed peak would be required to 
confirm if the second species was produced by DPP IV mediated degradation indeed 
oxm(5-37). 
However, DPP IV does not necessarily play the same role in the inactivation of 
oxyntomodulin in vivo as it does in vitro. To study the role of DPP IV in regulating 
oxyntomodulin in vivo, oxyntomodulin and a DPP IV inhibitor VP, were co-
administered to mice and food intake was measured. Results of the study demonstrated 
a greater reduction in food intake after co-administration of oxyntomodulin and VP 
compared to oxyntomodulin alone, suggesting that DPP IV is involved in the 
inactivation of oxyntomodulin in vivo. 
A series of oxyntomodulin analogues with modifications to the N-terminal sequence 
were designed and produced. Oxyntomodulin was modified with the aim of reducing 
susceptibility to DPP IV mediated degradation whilst maintaining affinity for the GLP-1 
receptor. 
Initially, I had to establish the relative sensitivities of oxyntomodulin, GLP-1 and 
exendin-4 to DPP IV mediated degradation. Oxyntomodulin was found to be more 
resistant than GLP-1 to DPP IV mediated proteolysis. Following incubation for thirty 
minute with DPP IV, GLP-1 was completely degraded, whilst 60% of the 
oxyntomodulin remained intact. This suggests that although the sequence Hisl-Ser2 
can act as a recognition sequence and substrate for DPP IV, it does so less efficiently 
than Hisl-Ala2, as contained in GLP-1. 
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Previously it was thought that amino acids at positions 1 and 2 determined the 
susceptibility of a peptide to DPP IV degradation. It has now been recognised that the 
amino acid at position 3 and other unknown sequence elements can determine a 
peptide's resistance to DPP IV mediated degradation (Lambeir et al., 2001a; Lambeir et 
al., 2001b). Proteolysis experiments using exendin-4, GLP-1 and analogues of 
oxyntomodulin with sequence modifications taken from exendin-4 and GLP-1, 
highlight the importance of factors other than the first two amino acids in determining a 
peptide's susceptibility to DPP IV mediated breakdown. Analogue Hisl-Ala2-oxm, the 
sequence of GLP-1, was more resistant to proteolysis than GLP-1, whilst Hisl-Gly2-
oxm, containing the initial dipeptide sequence of exendin-4, was more sensitive to DPP 
IV mediated degradation than exendin-4. To investigate the importance of the amino 
acid at the third position of the molecule in determining sensitivity to DPP IV mediated 
degradation, analogues of oxyntomodulin were made with the amino acid at position 3 
switched to that of GLP-1 and exendin-4 (Glu). Substitution of Glu for Gin at position 
3 in the oxyntomodulin sequence increased resistance to DPP IV mediated degradation, 
reducing degradation from 82% after 120 minute incubation with DPP FV to 38%. The 
greater resistance of Hisl-Ala2-Glu3-oxm than its glutamine containing counterpart to 
DPP IV mediated degradation further demonstrates the influence of position 3. My 
results also suggest that factors other than the first three amino acids influence the 
susceptibility of these peptides to DPP IV mediated degradation. For example, 
conversion of the first three amino acids of oxyntomodulin to those of GLP-1 does not 
result in the same sensitivity to DPP IV mediated degradation as that observed for the 
endogenous GLP-1 sequence. My results strongly agree with the reported finding that 
residues remote from the cleavage site can modulate DPP IV substrate selectivity 
(Lambier et al., 2001a). 
Although subtle changes to the oxyntomodulin sequence were able to moderately alter 
susceptibility to DPP IV mediated degradation, it seemed unlikely that these relatively 
minor changes would result in sufficient protection from degradation to increase the 
bioactivity of oxyntomodulin. Therefore, further modifications were investigated. The 
substitution of DHis for LHis at position 1 of oxyntomodulin results in complete 
resistance to DPP IV mediated degradation. This is true for all the analogues I tested 
containing DHis at the first position. Similarly, DesHisl-oxm and acetylHisl-oxm were 
completely resistant to DPP IV mediated degradation. My results suggest that, whilst 
the second and third amino acids in the peptide can be varied and still act as substrates 
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for DPP IV, there may be an absolute requirement for His in the first position of the 
sequence. However, without testing analogues of oxyntomodulin with different 
residues at position 1 this can not be confirmed. It would also be of interest to test 
further analogues of oxyntomodulin with different residues at position 1 to determine 
the importance of His 1 in the peptides bioactivity and affinity for the GLP-1 receptor. 
For DPP IV resistant analogues to be effective in vivo, they would have to retain their 
ability to bind to the GLP-1 receptor. The affinity of successful analogues for the GLP-
1 receptor was therefore analysed in receptor binding assays. The initial assays 
compared the ability of oxyntomodulin, GLP-1 and exendin-4 to displace ^^^I-labelled 
exendin-4 fi:om rat lung membrane, a well characterised assay for the GLP-1 receptor. 
This demonstrated that both GLP-1 and exendin-4 had an I C 5 0 of approximately 0.3 nM, 
whilst that of oxyntomodulin was 100-fold greater with an I C 5 0 of 29.1 nM. The vast 
majority of changes to the sequence of oxyntomodulin resulted in a deterioration in 
receptor binding, the only exception being Ala2-Asp3-oxm which had an I C 5 0 of 15.0 
nM. This is a surprising since the binding affinity of both Ala2-oxm (28.1 nM) and 
Asp3-oxm (30 nM) were very similar to that of native sequence oxyntomodulin. These 
results suggest that predicting I C 5 0 values for analogues is very difficult and that there 
are multiple sequence motifs involved in regulating the binding of oxyntomodulin to the 
GLP-1 receptor. However, it does appear that an amino acid in position 1 is critical for 
binding to the GLP-1 receptor as oxm(2-37) had no detectable affinity to the GLP-1 
receptor ( I C 5 0 for DesHisl-oxm >10000 nM). These results must be treated with 
caution as the DesHisl-oxm tested had low purity, which is likely to have contributed to 
the deterioration of receptor binding affinity. A new synthesis of DesHisl-oxm would 
therefore be required to confirm this result. Modifying His 1 to the D isomer caused a 
reduction in affinity of the peptide for the GLP-1 receptor, but retained peptide 
bioactivity. A number of modifications to DHisl-oxm were made in an attempt to 
improve affinity for the GLP-1 receptor. Interestingly, the only modifications that 
increased the affinity of this analogue were those in which Ala was substituted for ser at 
position 2, yielding DHis 1 -Ala2-oxm, with an I C 5 0 of 544 nM, and DHis 1 -Ala2-Asp3 -
oxm with an I C 5 0 approximately one third that of DHisl-oxm at 380 nM. Similar 
improvements in binding affinity are seen when the same substitutions are made with L-
His at position 1, suggesting that some substitutions can have effects independent of 
other sequence alterations. 
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Three of the DPP IV resistant analogues, DHisl-oxm, DesHisl-oxm and DHisl-Ala2-
oxm were tested in vivo. Ala2-oxm was used as a DPP IV sensitive comparison with a 
higher affinity for the GLP-1 receptor. The results on food intake were surprising. 
DesHisl-oxm had no effect on food intake. This was expected as it has negligible 
binding affinity for the GLP-1 receptor. However, although DHisl-oxm has a 36-fold 
lower affinity for GLP-1 receptor than native oxyntomodulin, its anorectic effects were 
similar to those of oxyntomodulin. DHisl-Ala2-oxm was more effective than 
oxyntomodulin at reducing food intake, although its I C 5 0 value was 18-fold higher. 
Perhaps most intriguingly of all, Ala2-oxm, which had a 2-fold greater affinity for the 
GLP-1 receptor, reduced food intake to a lesser degree than an equimolar dose of 
oxyntomodulin. Together, these results suggest that in vivo efficacy is more strongly 
influenced by susceptibility to degradation than by affinity at the receptor. Indeed, one 
of the observed differences between GLP-1 and exendin-4 is that exendin-4 is more 
resistance to DPP IV mediated degradation, which may contribute to the prolonged 
ability of exendin-4 to inhibit food intake as shown in Chapter 3. These experiments 
demonstrate that, when designing other analogues, testing them in vivo is vital. 
Furthermore, the efficacy of a peptide at reducing food intake cannot be directly 
inferred from affinity for the GLP-1 receptor alone; resistance to degradation must also 
be considered. 
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Chapter 5 
Investigation of the properties of 
structural domains of 
oxyntomodulin using 
oxyntomodulin analogues 
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5.1 Introduction 
Many GPCR ligands have potential therapeutic applications, but their clinical use is 
limited by their short duration of action and need for repeated administration. The 
bioefficacy of these ligands can be increased by increasing their efficacy at activating 
the pertinent receptor and by extending their biological half-life. Design of such ligands 
can be facilitated by determining the structure-function relationships of the ligand-
receptor complex. To understand how ligands cause a specific biological activity via a 
receptor it is important to determine how the ligand and receptor interact. Determining 
the functional and structural properties of a peptide ligand associated with receptor 
binding and activation can give insight into these interactions and may permit the design 
of peptide analogues with enhanced receptor binding and activation properties. 
Similarly, determining the elements of the peptide structure important in breakdown in 
vivo can assist the rationale design of analogues with extended biological half-lives. 
Research into the structure-function relationships of the hormones insulin and GLP-1 
(Garber, 2005) has resulted in modified versions of these peptides which may prove 
useful in the treatment of diabetes. 
5.1.1 Investigation of receptor peptide function 
A number of well established strategies are used to help delineate peptide-receptor 
interactions. Several of these utilise peptide analogues. Sequential truncation from 
either end of the molecule can be used to determine the minimal structural requirements 
for bioactivity. Critical residues in the primary sequence can be identified by alanine 
scanning (Adelhorst 1994; Xiao et al., 2001). Once structure-function relationship has 
been established, agonists can be developed with improved selectivity and affinity for a 
specific receptor, enhanced signal transduction or physiological activity effects, greater 
resistance to proteolytic degradation, and improved bioavailability (Hruby, 2002). 
Structure-conformation studies of glucagon and glucagon analogues have identified 
sequence features of glucagon important for receptor binding and activation (Hruby, 
1982). Theses studies have aided the development of glucagon antagonists (Ahn et al., 
2001). Similar strategies have been successfully pursued with other peptides including 
somatostatin and GIF (Hinke et al., 2004; Pawlikowski and Melen-Mucha, 2004). 
As previously described, chronic SC administration of GLP-1 lowers plasma glucose in 
patients with type 2 diabetes (Todd et al., 1997). Unfortunately, GLP-1 is rapidly 
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inactivated in vivo preventing it being used as a therapy (Nauck and Meier, 2005). 
GLP-1 analogues such as Liraglutide and CJC-1131 (Agerso et al., 2002; Kim et al , 
2003) have a longer duration of biological action than GLP-1 and are currently in late 
stage clinical trials assessing their efficacy as anti-diabetic agents. 
5.1.2 Structure and properties of oxyntomodulin 
To date, the three-dimensional structure of oxyntomodulin has not been characterised by 
either nuclear magnetic resonance (NMR) or X-ray crystallography. However, the 
three-dimensional shapes of the structurally related peptides GLP-1, exendin-4 and 
glucagon have been characterised (Chang et al., 2002; Neidigh et al., 2001; Sasaki et al., 
1975) and may therefore provide clues as to the structure of oxyntomodulin. 
Cleavage of GLP-1 by DPP IV produces GLP-1 (9-36), which has reduced binding 
affinity for the GLP-1 receptor. In addition, at high concentrations it acts as an 
antagonist at this receptor (Knudsen and Pridal, 1996; Wettergren et al., 1998). These 
data suggest that the N-terminus of GLP-1 is important both for binding and activation 
of the GLP-1 receptor. Evidence suggests that the N-terminal of exendin-4 is also 
important receptor activation; the N-terminally truncated peptide, exendin (9-39) is a 
high affinity GLP-1 receptor antagonist (Montrose-Rafizadeh et al., 1997). This data 
suggests that the N-terminal of oxyntomodulin is likely to be important to the peptide's 
activity at the GLP-1 receptor. 
GLP-1, exendin-4 and glucagon have no defined structure in aqueous solution, but in 
the presence of micelles adopt an alpha-helical structure in the mid-section, with 
flexible regions at the N- and C-terminals (Al-Sabah and Doimelly, 2004; Neidigh et al., 
2001; Thornton and Gorenstein, 1994). Several amino acids in the helical region of 
GLP-1 and exendin-4 are conserved. These amino acids are all thought to be found on 
the side of the idealised helix which faces the receptor. Conservation of these amino 
acids suggest a common important function and they are thought to be important for 
receptor binding (Lopez de and Donnelly, 2002; Al-Sabah and Donnelly, 2003). 
Several of these amino acids are also found in oxyntomodulin, suggesting that it may 
form a similar a- helix. GLP-1 mutational analysis suggests that residues 1 ,4 ,6 and 7 
in the N-terminal and 9, 13, 15, 22, 23 and 26 in the mid-section are critical for receptor 
binding (Adelhorst et al., 1994; Gallwitz et al., 1994). Conversely, residues 8, 11, 12 
and 16 appear not to be important as alanine substitutions in these positions do not 
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affect GLP-1 receptor binding or activation (Xiao et al., 2001). If some or all of the 
actions of oxyntomodulin are mediated via the GLP-1 receptor, the residues 
corresponding to those demonstrated to be critical to receptor binding in the GLP-1 
molecule are likely to be important in maintaining the secondary structure of 
oxyntomodulin and thus receptor binding. 
The C-terminus of GLP-1 has also been shown to influence peptide-receptor 
interactions and peptide activity, although it appears to be less critical than the N-
terminus. It has been hypothesised that the C-terminus, in particular amino acids at 
positions 28 and 29, are involved in specific receptor recognition (Adelhorst et al., 
1994). Exendin-4 contains an additional 9 amino acid sequence at the C-terminus. This 
sequence is thought to fold back on itself to form a Trp-cage motif, greatly enhancing 
the peptide's affinity for the GLP-1 receptor (Al-Sabah and Donnelly, 2003). 
Oxyntomodulin differs from glucagon by an additional sequence of 8 amino acids at the 
carboxy-terminal. The differences in the physiological properties of glucagon and 
oxyntomodulin may help to illuminate the role of this octapeptide sequence in receptor 
binding and peptide degradation. 
5.1.3 Neprilysin and proglucagon derived peptide breakdown 
Peptidases other than DPP-IV have also been shown to breakdown preproglucagon 
derived peptides (Hupe-Sodmann et al., 1997). Neutral endopeptidase 24.11 (NEP) is a 
membrane-bound zinc metallopeptidase that cleaves peptides at the amino-terminal side 
of aromatic or hydrophobic amino acids. In vitro studies have identified six potential 
NEP cleavage sites in GLP-1, with hydrolysis putatively occurring between Glu27-
Phe28, Trp31-Leu32, Aspl5-Vall6, Serl8-Tyrl9, Tyrl9-Leu20 and Phe28-Ile29 
(Hupe-Sodmann et al., 1995) (table 5.1). Of the 6 amino acids dictating these NEP 
cleavage sites in GLP-1, 4 are conserved in oxyntomodulin, and the other 2 are replaced 
with alternative potential NEP substrates (table 5.1). In vivo studies have also 
demonstrated that GLP-1 and glucagon are broken down by NEP (Plamboeck et al., 
2005; Trebbien et al., 2004). In contrast, exendin-4 lacks many of the NEP substrate 
sites (Hupe-Sodmann et al., 1995), which may contribute to the slow metabolic 
clearance rate of exendin-4 in humans (Edwards et al., 2001). Given the sequence 
similarities between glucagon and GLP-1, it seems likely that NEP also plays a role in 
the breakdown of oxyntomodulin. However, this has not been previously investigated. 
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Peptide \es due number 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 
oxyntomodulin H S Q G T F T S D Y S K Y L D S R R A Q D F V Q W L M N T K R N R N N 1 A 
qlp-1 H A E G T F T S D V s S Y L E G Q A A K E F 1 A W L V K G R G 
Table 5.1 Identified in vitro NEP cleavage sites of GLP-1 and conserved sites in oxyntomodulin 
I Identified NEP cleavage point in GLP-1 
5.2 Aims 
To investigate: 
1) The properties of the structural domains of oxyntomodulin using peptide 
analogues; 
2) The role of NEP in oxyntomodulin inactivation. 
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5.3 Materials and methods 
5.3.1 Custom designed analogues of oxyntomodulin 
Truncated forms of oxyntomodulin were first designed to establish the characteristics of 
different regions of the molecule. The effect of these truncations on GLP-1 receptor 
binding affinity and anorectic actions were examined. Peptide analogues of 
oxyntomodulin were subsequently designed to incorporate alternative sequence inserts 
of varying length from the sequences of exendin-4 or GLP-1 (table 5.2). The functional 
significance of different regions of oxyntomodulin was further investigated using these 
chimeric peptides by examining their effects on oxyntomodulin's affinity for the GLP-1 
receptor, resistance to NEP mediated degradation and anorectic actions. Having 
established that exendin-4 inserts improve the ability of oxyntomodulin analogues to 
reduce food intake, increase resistance to NEP mediated breakdown and increase 
affinity to the GLP-1 receptor, further analogues were designed to further elucidate 
which specific sections of the insert were responsible for these changes. 
All peptides were manufactured using the protocols described in section 2.1. 
5.3.2 Receptor binding studies to the GLP-1 receptor 
Measurement of analogue affinity to the rat GLP-1 receptor was completed using the 
protocol outlined in section 2.4.5. Cell membrane was purified from rat lung and 
provided the source of GLP-1 receptor (2.4.1). ^^^I-exendin-4 was used as the 
competing radiolabelled peptide. Binding affinities were calculated from a minimum of 
3 separate experiments in which each concentration of unlabelled peptide was tested in 
triplicate. Values are shown as mean ± SEM. 
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Peptide Residue iiuml)er 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 
oxvntomodtilin H S Q G T F T S D Y S K Y L D S R R A Q D F V Q W L M N T K R N R N N 1 A 
qlp-1 H A E G T F T S D V S S Y L E G Q A A K E F 1 A w L V K G R G 
exendin4 H G E G T F T s D L s K Q M E E E A V R L F 1 E w L K N G G P S S G A P P P S 
oxiii(qlp15-31) H S Q G T F T s D Y s K Y L E G Q A A K E F 1 A w L V K G R G 
oxm(qlp27-31) H S Q G T F T s D Y s K Y L D S R R A Q D F V Q w L V K G R G 
oxin(ex14-39) H S Q G T F T s D Y s K Y M E E E A V R L F 1 E w L K N G G P S S G A P P P S 
oxni(ex27-39) H S Q G T F T s D Y s K Y L D S R R A Q D F V Q w L K N G G P S S G A P P P s 
oxm1-15 H S Q G T F T s D Y s K Y L D 
oxin19-37 A Q D F V Q w L M N T K R N R N N 1 A 
oxm30-37 K R N R N N 1 A 
oxm(ex15-18) H S Q G T F T s D Y s K Y L E E E A A Q D F V Q w L M N T K R N R N N 1 A 
oxiii(ex15-21) H S Q G T F T s D Y s K Y L E E E A V R L F V Q w L M N T K R N R N N 1 A 
oxm(ex15-23) H S Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L M N T K R N R N N 1 A 
0X111(8x15-24) H s Q G T F T s D Y s K Y L E E E A V R L F 1 E w L M N T K R N R N N 1 A 
oxm(ex16-24) H s Q G T F T s D Y s K Y L D E E A V R L F 1 E w L M N T K R N R N N 1 A 
oxm(ex27-30) H s Q G T F T s D Y s K Y L D S R R A Q D F V Q w L K N G G R N R N N 1 A 
oxni(ex27-31) H s Q G T F T s D Y s K Y L D S R R A Q D F V Q w L K N G G P N R N N 1 A 
oxiii(ex27-33) H s Q G T F T s D Y s K Y L D s R R A Q D F V Q w L K N G G P S S N N 1 A 
oxiii(ex29-32) H s Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N G G P S R N N 1 A 
oxiti(ex29-33) H s Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N G G P S S N N 1 A 
oxiii(ex30-33) H s Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T G P S S N N 1 A 
0X111(6x15-24,27-33) H s Q G T F T s D Y s K Y L E E E A V R L F 1 E w L K N G G P s S N N 1 A 
I I Amino acid residues in GLP-1 different to those found in oxytomodulin 
I I Amino acid residues in exendin-4 different to those found in oxytomodulin 
Table 5.2 Summary of peptides used in chapter 5 
O 
5.3.3 Quantification of susceptibility to NEP mediated degradation 
Resistance to NEP mediated degradation was calculated using the protocol described in 
section 2.7.2. Reaction samples of 2 nmol or 5 nmol of peptide were incubated with or 
without 200 ng or 500 ng NEP respectively at 37°C for 120 minutes in a total volume of 
130 pi (or 325 p.1 for the 5 nmol peptide/500 ng NEP experiments) before analysis by 
reverse phase HPLC. A gradient of 2-15% acetonitrile/water (both containing 0.05% 
TFA) 0-5 minutes, and 15-50 % acetonitrile/water (both containing 0.05% TFA) 5-40 
minutes was used unless otherwise stated, and absorbance measured at a wavelength of 
214 nm (Jasco HPLC system, solvent delivery system PU-2080 plus, autosampler AS-
2057 plus, degasser DG2080-53, dynamic mixer 2080-32 UV detector uv-2075 using a 
Phenomenex Gemini Cig (5-nm particles) 250 mm x 4.6 mm column). Percentage 
degradation was calculated by comparing area under peak in reactions with and without 
enzyme. Percentage degradation values were calculated from a minimum of 2 
experiments. Chromatograms shown are representative examples. 
5.3.4 Feeding studies using fasted mice 
The effects of oxyntomodulin analogues on food intake were investigated in fasted 
mice, as described in section 2.2.2. Peptides were administered via IP injection and 
food intake measured at 1, 2, 4, 8 and 24 hr post-injection, unless otherwise stated. 
Statistical analysis of results was completed as outlined in section 2.9. 
5.3.4.1 The effect of chimeric peptides on food intake 
Chimeric peptides of oxyntomodulin with GLP-1 or exendin-4 sequence inserts were 
produced and their effect on food intake measured. Peptides used for this study were 
oxyntomodulin (2700 imiol/kg), oxm(glp 15-31) (2700 nmol/kg), oxm(glp27-31) (2700 
nmol/kg), oxm(exl4-39) (2700 nmol/kg) and oxm(ex27-39) (2700 nmol/kg) (n=7-8 for 
all groups). 
Initial studies using chimeric peptides showed substituting sections of oxyntomodulin 
with sections of GLP-1 did not improve the anorectic effects of the peptide. However, 
substituting sections of oxyntomodulin with sections of exendin-4 did increase the 
ability of the peptides to inhibit refeeding in fasted mice. To further investigate 
oxyntomodulin/exendin-4 chimeric peptides, their ability to reduce food intake was 
compared to exendin-4. Peptides used for this study were exendin-4 (100 nmol/kg), 
oxm(ex27-39) (100 nmol/kg) and oxm(exl4-39) (100 nmol/kg) (n=7-8 for all groups). 
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Peptides were tested at a lower dose than in the previous studies to permit investigation 
of potential differences in their duration of action. 
5.3.4.2 Effect of oxyntomodulin analogues with amino acid sequence inserts taken 
from exendin-4 on food intake 
This study was designed to compare the anorectic effects of chimeric oxyntomodulin 
analogues containing short, medium and long mid-section exendin-4 inserts with those 
of oxyntomodulin. Peptides used in this study were oxyntomodulin (2700 nmol/kg), 
oxm(exl5-18) (2700 nmol/kg), oxm(exl5-21) (2700 nmol/kg) and oxm(exl5-24) (2700 
nmol/kg) (n=7-8 for all groups). 
5.3.4.3 Dose response studies of effective mid-section insert analogues 
Study 5.3.4.2 demonstrated that peptides oxm(exl5-21) and oxm(exl5-24) significantly 
reducing food intake in fasted mice up to and including the 8-24 hour interval. Dose 
response studies were completed for both these peptides to investigate putative 
differences in their ability to reduce food intake. Peptides used in these studies were 
oxyntomodulin (1400 nmol/kg), oxm(exl5-21) (3, 10, 30 and 100 nmol/kg) and 
oxm(ex 15-24) (1,3, 10 and 30 nmol/kg) (n=7-8 for all groups). 
5.3.4.4 Refined mid-section insert analogues 
Previously, administration of oxm(ex 15-24) resulted in the most potent and longest 
duration of food intake inhibition compared to other exendin-4 mid-section analogues. 
Peptides used for this study were oxm(ex15-24) (30 nmol/kg) and oxm(ex 16-24) (30 
nmol/kg) (n=7-8 for all groups). 
5.3.4.5 Further mid-section insert variants 
This study was designed to further investigate the length of exendin-4 sequence insert in 
the mid-section of oxyntomodulin required to optimally improve its anorectic effects. 
Peptides used for this study were oxm(exl5-24) (30 nmol/kg) and oxm(exl5-23) (30 
nmol/kg) (n=8-9 for all groups). 
5.3.4.6 C-terminal insert analogues 
Receptor affinity binding studies demonstrated that analogue oxm(ex27-33) had greater 
affinity to the human GLP-1 receptor than oxyntomodulin and oxm(ex30-33). In this 
study the ability of these peptides to inhibit food intake was tested. Peptides used for 
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this study were oxyntomodulin (2700 nmol/kg), oxm(ex27-33) (2700 nmol/kg) and 
oxm(ex30-33) (2700 nmol/kg) (n=9-10 for all groups). 
5.3.4.7 Investigation of length of C-terminal inserts required for improved 
anorectic effects 
This study was designed to investigate the length of exendin-4 sequence insert in the C-
terminal of oxyntomodulin required to optimally improve its anorectic effects. Peptides 
used for this study were oxm(ex27-31) (300 nmol/kg), oxm(ex27-30) (300 nmol/kg) 
and oxm(ex27-33) (300 nmol/kg) (n=9-10 for all groups). 
5.3.4.8 Further investigation of C-terminal insert analogues 
This study was designed to further investigate whether the sequence insert of 27-33 of 
exendin-4 was the optimal length substitution at the C-terminal of oxyntomodulin to 
improve its anorectic effects. Peptides used for this study were oxm(ex27-33) (300 
nmol/kg) and oxm(ex29-32) (300 nmol/kg) (n=9-10 for all groups). 
5.3.4.9 Further investigation of C-terminal insert analogues 
This study was designed to further investigate whether the sequence insert of 27-33 of 
exendin-4 was the optimal length to substitution at the C-terminal of oxyntomodulin to 
improve its anorectic effects. Peptides used for this study were oxm(ex27-33) (300 
nmol/kg) and oxm(ex29-33) (300 nmol/kg) (n=9-10 for all groups). 
5.3.4.10 Dose response of best C-terminal insert analogue 
The study was designed to identify the lowest dose of oxm(ex27-33) required to cause a 
significant reduction in food intake compared to saline controls. Previously, feeding 
studies had identified that a sequence insert comprised of amino acids 27-33 of exendin-
4 was the optimal insert length at the C-terminus of oxyntomodulin to improve its 
anorectic effects. Peptides used for this study were oxyntomodulin (1400 nmol/kg, the 
minimal dose to reliably cause a significant reduction in food intake compared to saline 
controls) and oxm(ex27-33) (3, 10, 30, and 100 nmol/kg) (n=7-8 for all groups). 
5.3.4.11 Effect of oxyntomodulin analogue with combined substitutions of 
mid-section and C-terminus sequences on food intake 
The study was designed to compare the anorectic effects of a oxyntomodulin analogue 
containing the optimal mid-section and C-terminal exendin-4 inserts with those of an 
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analogue containing only a mid-section exendin-4 insert and with exendin-4. Peptides 
used for this study were exendin-4 (100 nmol/kg), oxm(exl5-24) (100 nmol/kg) and 
oxm(exl 5-24,27-33) (100 nmol/kg) (n=8-9 for all groups). 
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5.4 Results 
5.4.1 Chimeric peptides 
5.4.1.1 Affinity of truncated and chimeric peptides for the GLP-1 receptor 
The truncated forms of oxyntomodulin investigated (oxml-15, oxml9-37 and oxmSO-
37) showed little or no specific binding to the GLP-1 receptor (data not shown). 
Chimeric peptides of oxm/GLP-1 and oxm/exendin-4 bound with greater affinity than 
oxyntomodulin to the GLP-1 receptor. All chimeric peptides tested bound to the GLP-1 
receptor with at least 15-fold greater affinity than native oxyntomodulin. Oxm/exendin-
4 chimeric peptides bound with greater affinity than chimeric peptides with the 
corresponding sequence of GLP-1. The results are shown in figures 5.1, 5.2 and table 
5.3. 
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Figure 5.1 Binding affinity of oxm/GLP-1 chimeric peptides to the rGLP-1 
receptor. Rat lung cell membrane was the source of GLP-1 receptor and * ^ I-
exendin-4 used as the competing peptide. IC50 value calculated as mean ± SEM of 
3 separate experiments. 
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Figure 5.2 Binding affinity of oxm/exendin-4 chimeric peptides to the rGLP-1 
receptor. Rat lung cell membrane was the source of GLP-1 receptor and 
exendin-4 used as the competing peptide. I C 5 0 value calculated as mean ± SEM of 
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oxyntomodulin 29.1 ±4.4 72 
GLP-1 0.30 ±0.04 81 
exendin-4 0.31 ±0.05 0 
oxml-15 >10000 NT 
oxm 19-37 >10000 NT 
oxm30-37 >10000 NT 
oxm(glp 15-31) 0.51 ±0.11 96 
oxm(glp27-31) 1.95 ±0.31 74 
oxm(exl4-39) 0.16 ±0.01 6 
oxm(ex27-39) 0.29 ± 0.02 6 
Table 5.3 The binding affinity for the rGLP-1 receptor and susceptibility to 
NEP mediated degradation of oxyntomodulin, truncated oxyntomodulin peptides 
and oxm/GLP-1, oxm/exendin-4 chimeric peptides. I C 5 0 value calculated as a 
mean of a minimum of 3 separate experiments. Values shown are mean ± SEM. 
Percentage degradation was calculated by comparing area under peak of ± NEP 
samples analysed by HPLC. NT = not tested. 
5.4.1.2 In vitro susceptibility to NEP mediated degradation of native and chimeric 
peptides 
Both oxyntomoduUn and GLP-1 were susceptible to NEP mediated degradation, with 
72% and 82% of the respective peptides, being degraded after 2 hours incubation with 
the enzyme (figure 5.3 and 5.4). Exendin-4 was resistant to NEP mediated degradation, 
with no change in peak size observed following incubation for 2 hours with 200 ng NEP 
(figure 5.5). As the truncated forms oxyntomodulin investigated (oxml-15, oxm 19-37 
and oxm30-37) showed little or no specific binding to the GLP-1 receptor their 
susceptibility to NEP degradation was not examined. Chimeric peptides with GLP-1 
inserts were more susceptible to NEP mediated degradation than native oxyntomodulin, 
with oxm(glpl5-31) showing 96% breakdown (figure 5.6) and oxm(glp27-31) showing 
74% breakdown after 2 hours incubation with the enzyme (figure 5.7). Oxm/exendin-4 
chimeric peptides were more resistant than native oxyntomodulin to NEP mediated 
degradation, with both oxm(exl4-39) and oxm(ex27-39) showing only 6% breakdown 
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after 2 hours incubation with the enzyme (figures 5.8 and 5.9). Results are summarised 
in table 5.3. 
3 < 
=L 
250000-
200000 
150000 -
100000-
50000 -
1 
rSO 
- 4 0 
- 3 0 
- 2 0 
- 1 0 
10 
—I— 
15 
> 
o 
20 25 
Time (min) 
oxm oxm & neprilysin 
Figure 5.3 In vitro degradation of oxyntomodulin by NEP. Oxyntomoduiin (5 
nmol) was incubated for 120 minutes with 500 ng NEP at 3TC. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.4 In vitro degradation of GLP-1 by NEP. GLP-1 (5 nmol) was 
incubated for 120 minutes with 500 ng NEP at 37°C. Digests were analysed by 
reverse phase HPLC using a 15-50% water/acetonitrile gradient over 35 minutes. 
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Figure 5.5 In vitro degradation of exendin-4 by NEP. Exendin-4 (2 nmol) was 
incubated for 120 minutes with 200 ng NEP at 2>TC. Digests were analysed by 
reverse phase HPLC using a 15-50% water/acetonitrile gradient over 35 minutes. 
—r-
10 
30 
200000-1 
150000-
3 
< 100000 
50000-
j . - -A— 
—f— 
5 10 15 20 25 30 
Time (min) 
oxm(glp15-31) oxm(glp15-31) & neprilysin 
Figure 5.6 In vitro degradation of oxm(glp 15-31) by NEP. Oxm(glp 15-31) (5 
nmol) was incubated for 120 minutes with 500 ng NEP at 37''C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.7 In vitro degradation of oxm(glp27-31) by NEP. Oxni(glp27-31) (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.8 In vitro degradation of oxm(exl4-39) by NEP. Oxm(exl4-39) (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.9 In vitro degradation of oxm(ex27-39) by NEP. Oxm(ex27-39) (5 
nmol) was incubated for 120 minutes with 500 ng NEP at 2>TC. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
5.4.1.3 The effect of truncated and chimeric peptides on food intake in fasted mice 
The truncated forms oxyntomodulin investigated (oxml-15, oxm 19-37 and oxm30-37) 
had no anorectic effects in fasted mice at doses between 1000 and 2800 nmol/kg (results 
not shown). 
Studv A: GLP-1 and Exendin-4 chimeric peptides 
Oxyntomodulin 2700 nmol/kg reduced food intake significantly in the first hour (as 
previously demonstrated). Oxm/GLP-1 chimeric peptides also reduced food intake, 
with oxm(glp 15-31) causing a greater reduction in food intake than oxm(glp27-31). 
However, inserting the GLP-1 tail did not create a more potent or long lasting peptide 
than oxyntomodulin itself, and in 0-1 hour interval oxm(glp27-31) caused a 
significantly smaller reduction in food intake than oxyntomodulin. Replacing the native 
oxyntomodulin sequence with corresponding exendin-4 sequences increased the 
duration of the anorectic effects. Longer exendin-4 sequence inserts were associated 
with longer lasting anorectic effects. Oxm(exl4-39) significantly reduced food intake 
up to and including the 4-8 hour interval, while oxm(ex27-39) reduced food intake up to 
the 2-4 hour interval (figure 5.10). Both oxm(exl4-39) and oxm(ex27-39) caused a 
significantly greater reduction in food intake than oxyntomodulin in the 1-2 hour 
interval and oxm(exl4-39) also caused a greater reduction in the 2-4 and 4-8 hour 
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interval than oxyntomodulin. No significant differences between any groups were 
present in the 8-24 hour interval (data not shown). 
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Figure 5.10 Effects of chimeric peptides on interval food intake in fasted mice. 
Oxyntomodulin, oxm(glpl5-31), oxm(glp27-31), oxm(exl4-39) and oxm(27-39) 
were all administered at 2700 nmol/kg (n=7-8). *p<0.05, **p<0.01, ***p<0.001 
compared to saline or comparison between groups indicated. 
Study B: Further investigation of oxvntomodulin/exendin-4 chimeric peptides 
Exendin-4 and oxm(exl4-39) at 1000 nmol/kg significantly reduced food intake 
compared to saline controls at all intervals measured up to and including the 4-8 hour 
interval (figure 5.11). There were no significant differences between the effects of 
exendin-4 and oxm(exl4-39) at any interval measured. Oxm(ex27-39) caused a 
significantly greater reduction in food intake compared to saline controls in the 0-1 hour 
interval only (figure 5.11). 
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Figure 5.11 Effects of oxyntomodulin/exendin-4 chimeric peptides on food intake 
in fasted mice. Exendin-4, oxm(ex27-39) and oxm(exl4-39) were all administered 
at 1000 nmol/kg (n=7-8). *p<0.05, **p<0.01, ***p<0.001 compared to saline. 
5.4.2 Oxyntomodulin analogues with mid-section exendin-4 sequence inserts 
5.4.2.1 Effect of substitution of amino acid sequences from the mid-section of 
oxyntomodulin on binding affinity at the GLP-1 receptor 
The introduction of mid-section of exendin-4 sequence inserts into the oxyntomodulin 
molecule altered the affinity of these analogues for the GLP-1 receptor. Substitution of 
oxyntomodulin amino acids 15-18 with those from the corresponding exendin-4 
sequence caused a reduction in affinity to the GLP-1 receptor (oxyntomodulin 29.1 ± 
4.4 nM, oxm(ex 18-21) 59 ± 16 nM) (figure 5.12), but longer exendin-4 sequence inserts 
increased affinity for the GLP-1 receptor (figure 5.12 and 5.13). Oxyntomodulin with 
positions 15-23 substituted with those of exendin-4 had the greatest affinity for the 
GLP-1 receptor of all the mid-section analogues tested (2.2 ± 0.5 nM). The results are 
summarised in table 5.4. 
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Figure 5.12 Binding affinity of analogues of oxyntomodulin with mid-section 
exendin-4 sequence inserts to the rGLP-1 receptor. Rat lung cell membrane was 
the source of GLP-1 receptor and ^^^I-exendin-4 used as the competing peptide. 
I C 5 0 value calculated as mean ± SEM of 3 separate experiments. 
1 0 0 -
D) 
C 
c 
CO 
o 
i+Z 
g 
a 
CO 
75-
50-
25-
0-
• oxm(ex 15-23) IC50: 2.2 nM 
A oxm{ex15-24) 10%: 4.6 nM 
T oxm(ex 16-24) IC50: 4.3 nM 
1 1 r -
-14 -13 •12 -11 -10 -9 -8 
log [peptide] M 
Figure 5.13 Binding affinity of analogues of oxyntomodulin with mid-section 
exendin-4 sequence inserts to the rGLP-1 receptor. Rat lung cell membrane was 
the source of GLP-1 receptor and ^^^I-exendin-4 used as the competing peptide. 
ICso value calculated as mean ± SEM of 3 separate experiments. 
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oxm(exl5-18) 58.6 ±8.2 42 
oxm(ex 15-21) 4.0 ±0.6 39 
oxm(exl5-23) 2.2 ±0.5 0 
oxm(ex 15-24) 4.6 ± 1.0 6 
oxm(ex 16-24) 4.3 ± 0.6 2 
Table 5.4 The binding affinity for the rGLP-1 receptor and susceptibility to 
NEP mediated degradation of oxyntomodulin analogues with mid-section exendin-
4 sequence inserts. I C 5 0 value calculated from a minimum of 3 separate 
experiments. Values shown are mean ± SEM. Percentage degradation was 
calculated by comparing area under peak of ± NEP samples analysed by HPLC. 
5.4.2.2 Susceptibility of oxyntomodulin analogues with mid-section sequence 
modifications to NEP mediated degradation 
Analogues with mid-section exendin-4 sequence inserts had reduced susceptibility to 
NEP mediated degradation. Analogues which contained substituted amino acids at 
positions 23 and 24 were the least susceptible to NEP mediated degradation (table 5.4). 
Shorter mid-section exendin-4 inserts were less susceptible to NEP mediated 
degradation than native oxyntomodulin, with oxm(exl5-18) showing 42% breakdown 
and oxm(exl5-21) showing 39% breakdown compared with 72% breakdown of native 
oxyntomodulin after 2 hours incubation with the enzyme. Representative 
chromatograms shown in figures 5.14-5.17, results summarised in table 5.4. 
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Figure 5.14 In vitro degradation of oxm(exl5-18) by NEP. Oxm(exl5-18) (5 
nmol/kg) was incubated for 120 minutes with 500 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.15 In vitro degradation of oxm(exl5-21) by NEP. Oxm(exl5-21) (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 2>TC. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.16 In vitro degradation of oxm(exl5-23) by NEP. Oxm(exl5-23) (5 
nmol/kg) was incubated for 120 minutes with 500 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.17 In vitro degradation of oxm(exl5-24) by NEP. Oxm(exl5-24) (2 
nmol/kg) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.18 In vitro degradation of oxm(exl6-24) by NEP. Oxin(exl6-24) (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
5.4.2.3 Effect of oxyntomodulin analogues with exendin-4 sequence inserts on food 
intake in fasted mice. 
Studv A: Mid-section insert analogues 
Oxyntomodulin 2700 nmol/kg reduced food intake significantly in the first hour (as 
previously demonstrated). All analogues of oxyntomodulin tested caused a significant 
reduced food intake up to and including the 1-2 hour interval compared to saline. In the 
0-1 hour interval oxm(exl5-24) was significantly more potent than oxyntomodulin at 
reducing food intake. Analogues oxm(ex 15-21) and oxm(ex 15-24) significantly 
reduced food intake compared to saline up to and including the 4-8 hour interval. In the 
8-24 hour interval only oxm(exl5-24) caused a significant reduction in food intake 
compared to saline. The results are shown in figure 5.19. 
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Figure 5.19 Effects of oxyntomodulin analogues with mid-section exendin-4 
sequence inserts on food intake in fasted mice. Oxyntomodulin and analogues 
oxm(exl5-18), oxm(exl5-21) and oxm(exl5-24) were all administered at 2700 
nmol/kg (n=8-9). *p<0.05, **p<0.01, ***p<0.001 compared to saline or indicated 
groups. 
Study B: Dose response studies of effective mid-section insert analogues 
The lowest dose of oxm(exl5-21) and oxm(exl5-24) tested able to significantly reduce 
food intake in the 0-1 hour interval was 10 nmol/kg for both peptides. A dose of 10 
nmol/kg oxm(exl5-24) caused a significantly greater reduction in food intake than 1400 
nmol/kg oxyntomodulin in the 0-1 hour interval. The lowest dose of oxm(exl5-21) to 
cause a significantly greater reduction in food intake than 1400 nmol/kg oxyntomodulin 
in the 0-1 hour interval was 30 nmol/kg. Higher doses of both peptides; 100 nmol/kg 
oxm(exl5-21), 30 nmol/kg oxm(ex 15-24) had a sustained effect on food intake, 
resulting in reduced food intake in the 2-4 hour interval (later intervals not measured) 
(figure 5.20). 
169 
a) 
1.00n 
0.75H 
3 
0) 
S 0.50H 
0.25-
0 .00 -
* * 
*** I 
# # # 
* * * 
1 
0-1 
# # # 
* * * 
I ' T ' I T 
1 - 2 
interval (hours) 
I Saline 
I oxm 1400 nmol/kg 
3 
oxm(ex15-21) 
nmol/kg 
b) 
1.00-
0.75-
3 
0) 
5 0 . 5 0 -
c 
I 
0.25 
0.00 
I 
0-1 1-2 
interval (hours) 
I Saline 
I oxm 1400 nmol/kg 
r 
3 oxm(ex15-24) 
nmol/kg 
30 
2-4 
Figure 5.20 Dose response of the effects of analogues oxm(exl5-21) and 
oxm(exl5-24) on food intake in fasted mice. Oxm(exl5-21) was administered at 3, 
10, 30 and 100 nmol/kg. Oxm(exl5-24) was administered at 1, 3, 10 and 30 
nmol/kg (n=7-8). 
compared to oxyntomodulin 
**p<0.01, ***p<0.001 compared to saline, *^p<0.01, ^^p<0.001 
Study C: Refined mid-section insert analogues 
Administration of 30 nmol/kg oxm(exl5-24) and oxm(exl6-24) significantly reduced 
food intake compared to saline in the 0-1 and 1-2 hour interval (figure 5.21) The 
anorectic effects of oxm(ex 15-24) lasted significantly longer than those of oxm(exl6-
170 
24) and caused a significantly greater inhibition of food intake in the 2-4 hour interval 
(figure 5.21). 
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Figure 5.21 Effects of oxyntomodulin analogues with mid-section exendin-4 
sequence inserts on food intake in fasted mice. Analogues oxm(exl5-24) and 
oxm(exl6-24) were administered at 30 nmol/kg (n=8-9). *p<0.05, **p<0.01, 
***p<0.001 compared to saline or between groups shown. 
Studv D: Further mid-section insert variants 
Analogues oxm(ex 15-24) and oxm(exl5-23) at 30 nmol/kg significantly reduced food 
intake compared to saline in the first hour post-injection. Both analogues significantly 
reduced food intake up to and including the 2-4 hour interval and no significant 
differences between the actions of the two analogues were observed at any time point 
during this study (figure 5.22). 
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Figure 5.22 Effects of oxyntomodulin analogues with mid-section exendin-4 
sequence inserts on food intake in fasted mice. Analogues oxm(exl5-24) and 
oxm(exl5-23) were administered at 30 nmol/kg (n=8-9). **p<0.01, ***p<0.001 
compared to saline. 
5.4.3 Oxyntomodulin analogues with C-terminal exendin-4 sequence inserts 
5.4.3.1 Effect of substitution of short amino acid sequences from the C-terminal 
section of oxyntomodulin on receptor binding 
Substituting C-terminal oxyntomodulin amino acids with exendin-4 sequence inserts 
altered affinity to the rGLP-1 receptor. Substituting amino acids at positions 27-30, 27-
33, 29-32 and 29-33 improved affinity to the GLP-1 receptor, but substituting amino 
acids 27-31 or 30-33 caused a reduction in affinity to the receptor. Results are shown in 
table 5.5 and figures 5.23-5.25. 
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Figure 5.23 Binding affinity of analogues of oxyntomodulin with exendin-4 
sequence inserts to the rGLP-1 receptor. Rat lung cell membrane was the source 
of GLP-1 receptor and ^^^I-exendin-4 used as the competing peptide. IC50 value 
calculated as mean ± SEM of 3 separate experiments. 
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Figure 5.24 Binding affinity of analogues of oxyntomodulin with exendin-4 
sequence inserts to the rGLP-1 receptor. Rat lung cell membrane was the source 
of GLP-1 receptor and ^^^I-exendin-4 used as the competing peptide. I C 5 0 value 
calculated as mean ± SEM of 3 separate experiments. 
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Figure 5.25 Binding affinity of analogues of oxyntomodulin with exendin-4 
sequence inserts to the rGLP-1 receptor. Rat lung cell membrane was the source 
of GLP-1 receptor and ^^^I-exendin-4 used as the competing peptide. I C 5 0 value 
calculated as mean ± SEM of 3 separate experiments. 
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oxm(ex27-30) 10.3 ±2.1 12 
oxm(ex27-31) 125 ± 16.3 0 
oxm(ex27-33) 9.6 ±1.1 1 
oxm(ex29-32) 10.4 ± 1.8 51 
oxm(ex29-33) 4.8 ±0.6 4 
oxm(ex30-33) 199 ± 14.2 6 
Table 5.5 The binding affinity for the rGLP-1 receptor and susceptibility to 
NEP mediated degradation of oxyntomodulin analogues with C-terminal exendin-4 
sequence inserts. I C 5 0 value calculated from a minimum of 3 separate experiments. 
Values shown are mean ± SEM. Percentage degradation was calculated by 
comparing area under peak of ± NEP samples analysed by HPLC. 
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5.4.3.2 Effect of substitution of the C-terminal sequence of oxyntomodulin with 
exendin-4 sequence inserts on susceptibility to NEP mediated degradation 
Substitution of the C-terminal sequence of oxyntomodulin with exendin-4 sequence 
inserts improved the peptides resistance to NEP mediated degradation. All inserts other 
than 29-32 offered almost complete protection from NEP mediated breakdown, results 
are shown in table 5.5 and figures 5.26-5.31. 
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Figure 5.26 In vitro degradation of oxm(ex27-30) by NEP. 0xm(ex27-30) (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
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Figure 5.27 In vitro degradation of oxm(ex27-31) by NEP. Oxm(ex27-31) (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.28 In vitro degradation of oxm(ex27-33) by NEP. Oxm(ex27-33) (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.29 In vitro degradation of oxm(ex29-32) by NEP. Oxm(ex29-32) (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.30 In vitro degradation of oxm(ex29-33) by NEP. Oxm(ex29-33) (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 5.31 In vitro degradation of oxin(ex30-33) by NEP. Oxm(ex30-33) (5 
nmol) was incubated for 120 minutes with 500 ng NEP at 2>TC. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
5.4.3.3 Effect of substitution of the C-terminal sequence of oxyntomodulin with 
exendin-4 sequence inserts on food intake in fasted mice 
Study A: C-terminal insert analogues 
Oxyntomodulin 2700 nmol/kg reduced food intake significantly in the first hour (as 
previously demonstrated). All analogues tested significantly reduced food intake 
compared to saline controls in the 0-1 hour interval. Analogue oxm(ex27-33) caused a 
significantly greater reduction in food intake than that observed in mice treated with the 
same dose of oxyntomodulin at this time point. Analogue oxm(ex27-33) significantly 
reduced food intake compared to saline, and this anorectic effect was significantly 
greater than that of oxyntomodulin, up to and including the 4-8 hour interval (figure 
5.32). 
178 
1.25n 
1.00-
O) 
% 0.75H 
(0 
•a 0.50-
o 
o 
0.25-
0.00- CL a 
*** A 
I 
*** X 
0-1 4-8 1-2 2-4 
interval (hours) 
I Saline i ^ H o x m C ] o x m ( e x 3 0 - 3 3 ) I I oxm(ex27-33) 
peptide dose 2700 nmol/kg 
Figure 5.32 Effect of oxyntomodulin analogues with C-terminal exendin-4 inserts 
on food intake in fasted mice. Oxyntomodulin and analogues oxm(ex30-33) and 
oxm(ex27-33) were administered at 2700 nmol/kg (n=9-10). **p<0.01, ***p<0.001 
compared to saline or comparison between groups indicated. 
Study B: Investigation of length of C-terminal inserts required for improved anorectic 
effects 
Analogue oxm(ex27-31) did not significantly influence food intake compared to saline 
at any measured interval. Analogue oxm(ex27-30) only significantly reduced food 
intake compared to saline in the 0-1 hour interval. Of the analogues tested, oxm(ex27-
33) was most potent at inhibiting food intake and had longest duration of action, 
significantly reducing food intake at the 0-1 and 1-2 hour interval compared to saline 
controls. The results are shown in figure 5.33. 
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Figure 5.33 Effect of oxyntomodulin analogues with C-terminal exendin-4 inserts 
on food intake in fasted mice. Analogues oxm(ex27-31), oxm(ex27-30) and 
oxm(ex27-33) were administered at 300 nmol/kg (n=9-10). **p<0.01, ***p<0.001 
compared to saline or comparison between groups indicated. 
Study C: Further investigation of C-terminal insert analogues 
As previously shown, 300 nmol/kg oxm(ex27-33) significantly reduced food intake 
compared to saline in the 0-1 and 1-2 hour interval. Analogue oxm(ex29-32) was as 
potent as oxm(ex27-33) in the first hour at reducing food intake, but its anorectic effects 
were not sustained past the first hour. The results are shown in figure 5.34. 
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Figure 5,34 Effect of oxyntomodulin analogues with C-terminal exendin-4 inserts 
on food intake in fasted mice. Analogues oxni(ex27-33) and oxm(ex29-32) were 
administered at 300 nmol/kg (n=9-10). **p<0.01, ***p<0.001 compared to saline. 
Study D: Further investigation of C-terminal insert analogues 
As previously shown, 300 nmol/kg oxm(ex27-33) significantly reduced food intake 
compared to saline in the 0-1 and 1-2 hour intervals. Analogue oxm(ex29-33) 
significantly reduced food intake compared to saline in the first hour only. The results 
are shown in figure 5.35. 
181 
u> 
1.00n 
0.75-
0 
5 0.504 
1 
S 0.25-
0.00. 
•kick 
*** 
T T T T 
0-1 
T 
I 
T 
2-4 1 - 2 
interval (hours) 
Saline l l oxm(ex27-33) ^^•oxm{ex29-33) 
peptide dose 300 nmol/kg 
Figure 5.35 Effect of oxyntomodulin analogues with C-terminal exendin-4 inserts 
on food intake in fasted mice. Analogues oxm(ex27-33) and oxm(ex29-33) were 
administered at 300 nmol/kg (n=9-10). *p<0.05, **p<0.01, ***p<0.001 compared 
to saline. 
Study E: Dose response effect of oxm(ex27-33) on food intake 
Oxyntomodulin (1400 nmol/kg) and 100 nmol/kg oxm(ex27-33) significantly reduced 
food intake compared to saline in the 0-1 hour interval only. Lower doses of oxm(ex27-
33) failed to significantly inhibit food intake (figure 5.36). 
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Figure 5.36 Dose response of the effect of analogue oxm(ex27-33) on food intake 
in fasted mice. Oxm(ex27-33) was administered at 3,10, 30 and 100 nmol/kg (n=8-
9). Oxyntomodulin (1400 nmol/kg) was tested for comparison. ***p<0.001 
compared to saline. 
5.4.4 Combination of mid-section and C-terminus sequence substitutions 
Analogue oxm(exl5-24,27-33), which combines the mid-section and C-terminal 
exendin-4 sequence inserts established in the previous experiments to cause the longest 
increase in duration of action and potency, was tested for GLP-1 receptor affinity, 
resistance to NEP mediated degradation and its anorectic actions in fasted mice. 
5.4.4 1 Affinity for the GLP-1 receptor of oxm(exl5-24,27-33), 
Oxm(exl5-24,27-33) bound to the rGLP-1 receptor with an IC50 value of 0.57 nM, 
(figure 5.37). The results are compared to the binding affinities of analogues with 
single region inserts and exendin-4 in table 5.6. 
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Figure 5.37 Binding affinity of oxni(exl5-24,27-33) to the rGLP-1 receptor. Rat 
- | 
-4 
lung cell membrane was the source of GLP-1 receptor and ^^^I-exendin-4 used as 
the competing peptide. I C 5 0 value calculated as mean ± SEM of 3 separate 
experiments. 
exendin-4 0.31 ±0.05 0 
oxm(ex 15-24) 4.6 ± 1 6 
oxm(ex27-33) 12 
oxm(ex 15-24,27-33) 0.57 ±0.12 0 
Table 5.6 Binding affinity to the rGLP-1 receptor and susceptibility to NEP 
mediated degradation of oxyntomodulin analogues with individual or combined 
mid-section and C-terminal inserts. I C 5 0 value calculated from a minimum of 3 
separate experiments, values shown are mean ± SEM. Percentage degradation was 
calculated by comparing area under peak of ± NEP samples analysed by HPLC. 
5.3.4 2 Effect of combined substitutions of mid-section and C-terminus sequences 
of oxyntomodulin with exendin-4 sequence inserts on susceptibility to NEP 
mediated degradation 
In standard conditions as described above, oxm(exl5-24,27-33) was not degraded by 
NEP following 2 hours incubation. Representative chromatogram shown in figure 5.38, 
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and results are compared to the sensitivity to NEP mediated degradation of analogues 
with single region inserts and exendin-4 in table 5.6. 
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Figure 5.38 In vitro degradation of oxm(exl5-24,27-33) by NEP. Oxm(exl5-
24,27-33) (2 nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. 
Digests were analysed by reverse phase HPLC using a 15-50% water/acetonitrile 
gradient over 35 minutes. 
5.4.4 3 Effect of oxyntomodulin analogue with combined substitutions of mid-
section and C-terminus sequences on food intake in fasted mice 
Study A: Combination of mid-section and C-terminal 
Exendin-4 significantly reduced food intake compared to saline at all intervals measured 
up to and including the 4-8 hour interval (as previously shown). At all intervals tested 
both oxm (ex 15-24) and oxm(ex15-24,27-33) significantly reduced food intake 
compared to saline. No significant difference was observed between the level of food 
intake inhibition caused by exendin-4 and oxm(exl 5-24,27-33). However in the 8-24 
hour interval, oxm(exl5-24,27-33) caused a significantly greater reduction in food 
intake than oxm(exl5-24) (figure 5.39). 
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Figure 5.39 Effect of oxyntomodulin analogues with exendin-4 inserts on food 
intake in fasted mice. Exendin-4 and analogues oxm(exl5-24) and oxm(exl5-
24,27-33) were administered at 100 nmol/kg (n=8-9). *p<0.05, **p<0.01, 
***p<0.001 compared to saline or groups indicated. 
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5.5 Discussion 
The studies described in this chapter aimed to identify the sequence elements of 
oxyntomodulin which determine its affinity for the GLP-1 receptor, bioactivity and 
susceptibility to breakdown by NEP. Truncated oxyntomodulin peptides and analogues 
of oxyntomodulin with amino acid substitutions were utilised to identify important 
sequence elements. Initial studies demonstrated that truncated forms of oxyntomodulin 
with either the amino or carboxy terminus removed had greatly reduced affinity for the 
GLP-1 receptor and did not inhibit refeeding when administered to fasted mice. The 
importance of the N-terminus of oxyntomodulin for receptor affinity and bioactivity 
was previously demonstrated in Chapter 4. The breakdown product of oxyntomodulin 
following incubation with DPP IV, oxm(3-37), was shown to have weak affinity for, 
and no bioactivity at, the GLP-1 receptor. GLP-1 also requires a complete N-terminus 
to maintain its affinity for the GLP-1 receptor, though exendin-4 maintains its affinity to 
the receptor after N-terminal truncation. 
Previously it has been reported that the terminal octapeptide of oxyntomodulin is able to 
stimulate gastric acid secretion, and that it is this sequence which alters the affinity of 
oxyntomodulin from preferentially binding to the GCG receptor to binding to the GLP-
1 receptor. The octapeptide alone had no affinity to the GLP-1 receptor and when 
administered to mice had no affect on food intake, suggesting that any biological 
actions of this peptide are mediated by a receptor other than the GLP-1 receptor. 
Chimeric peptides substituting GLP-1 or exendin-4 sequence inserts at strategic points 
in the oxyntomodulin molecule were used to further explore the structure/function 
relationships of oxyntomodulin. GLP-1 and exendin-4 were selected as both peptides 
are well characterised, structurally related to oxyntomodulin and potent agonists of the 
GLP-1 receptor. However, GLP-1 and exendin-4 differ in their plasma half life; GLP-1 
is rapidly degraded with a half-life of less than 2 minute in man (Deacon et al., 1995), 
whilst metabolic clearance of exendin-4 in humans is similar to the glomerular filtration 
rate with its half-life measured in hours rather than minutes in man (Edwards et al., 
2001). All chimeric oxm/GLP-1 and oxm/xendin-4 analogues bound with at least a 15-
fold greater affinity to the GLP-1 receptor than native oxyntomodulin, with 
oxm/.exendin-4 peptides binding with a higher affinity than oxm/GLP-1 analogues. 
Both oxm/GLP-1 peptides tested ((oxm(glpl5-31), oxm(glp27-23)) reduced food intake 
compared to saline. However, oxm(glp27-23) was less potent than native 
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oxyntomodulin. In contrast, both of the oxm/exendin-4 chimeric peptides caused a 
greater inhibition of food intake than oxyntomodulin in the first hour, and the duration 
of action of their anorectic effect was extended beyond that of oxyntomodulin. The 
improved affinity of chimeric peptides to the GLP-1 receptor suggests that the mid-
section and C-terminus of peptides are important for their binding to the GLP-1 
receptor. 
Exendin-4 was completely resistant to NEP mediated proteolysis, while more than 80 
and 70% of native GLP-1 and native oxyntomodulin were respectively broken down by 
NEP under the same conditions in vitro. Oxm/GLP-1 chimeric peptides were highly 
susceptible to NEP mediated degradation, but oxm/exendin-4 peptides were almost 
completely resistant. The duration of the anorectic effects of these analogues appears to 
inversely correlate with their susceptibility to NEP mediated degradation, hi addition to 
NEP resistance, exendin-4 has a 9-amino acid sequence at the C-terminal which 
improves receptor binding affinity and results in increased biological activity (Doyle et 
al., 2003). Thus the potency of the oxm/exendin-4 chimeric peptides may be due to a 
combination of factors including an improved a-helical structure and altered C-terminus 
increasing their affinity for the GLP-1 receptor and fewer sites susceptible to 
endopeptidase degradation extending their biological half-life. 
Having demonstrated that amino acid sequences from exendin-4 can be inserted into 
oxyntomodulin without compromising biological activity, further analogues were 
designed and produced with shorter inserts of exendin-4 sequences to explore the roles 
of specific sections of oxyntomodulin. The choice of amino acids to be replaced was 
partly determined by results of preceding experiments, but also informed by previously 
published studies on GLP-1 structure-activity. Previous studies of GLP-1 identified the 
N-terminal as important for receptor affinity, the C-terminal as important for biological 
activity and the mid-section, a hinge region, as comprising an a-helix linking the two 
domains (Adlehorst K., et al., 1994). 
Investigation of the mid-section of oxyntomodulin, in particular positions 15-24, 
identified this linking region as critical in determining the ability of the peptide to 
reduce food intake. The amino acids 15-24 of exendin-4 form part of an a-helical 
structure, and inserting this sequence into oxyntomodulin resulted in an improved 
potency and increased duration of anorectic action. The length of sequence insert in this 
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region of the molecule was crucial to the properties of the analogue. Short inserts of up 
to four amino acids in the mid-section reduced the peptide's affinity to the GLP-1 
receptor. Longer inserts of seven or more amino acids increased affinity to the GLP-1 
receptor by 5-12 fold. Inserting different lengths of an a-helix domain may change the 
orientation of the existing helix which could improve or hindering the peptide binding 
to the receptor, and this may be responsible for the contrasting binding affinities of 
analogues with mid-section exendin-4 inserts. Circular dichroism would be a useful 
technique to further analyse this and to explore the secondary structure changes caused 
by sequence modifications. 
Investigation of the mid-section of oxyntomodulin identified it as a region susceptible to 
endopeptidase degradation. Analogues with the longest lasting anorectic effects were 
those with greatly reduced susceptibility to NEP mediated breakdown. Interestingly, 
although oxm(exl5-18) bound with half the affinity of oxyntomodulin to the GLP-1 
receptor, its potency was similar to that of oxyntomodulin at reducing food intake in the 
first hour, and it continued to inhibit food intake in the 1-2 hour interval. This was one 
of several observations suggesting that resistance to endopeptidase breakdown may be 
more critical than binding affinity in determining efficacy of a peptide at reducing food 
intake, and in particular its duration of action. Another example of the importance of 
resistance to endopeptidase degradation was highlighted by the feeding studies 
investigating the dose response effects of oxm(exl5-21) and oxm(ex 15-24). Both 
peptides bound with similar affinity to the GLP-1 receptor, but differed in their 
resistance to NEP mediated breakdown. Six times more oxm(exl5-21) than oxm(15-
24) was broken down by NEP in vitro. Though both peptides had a similar effect on 
food intake in the 0-1 hour interval, both requiring 10 nmol/kg to cause a significant 
reduction in food intake, at later intervals the dose of oxm(exl5-21) required to 
maintain the reduction in food intake was three times higher than that of oxm(ex 15-24). 
Analysis of the sequence changes introduced by the exendin-4 inserts suggests peptide 
secondary structure or 3-dimensional shape is critical in determining the peptide's 
resistance to NEP mediated breakdown. Sites which are potentially subject to NEP 
proteolysis include nonpolar and polar uncharged amino acids. Analogues oxm(exl5-
21) and oxm(exl5-23) differ by a single amino acid (both oxyntomodulin and exendin-4 
have Phe at position 22), but oxm(exl5-23) is significantly more resistant to 
degradation by NEP in vitro. The amino acid substitution responsible is that of Val for 
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the endogenous He. Both of these residues are potential target sites for NEP mediated 
degradation. Thus, as this sequence change did not alter the number of potential NEP 
target sites, other factors such as the overall conformation of the molecule appear likely 
to influence susceptibility to NEP mediated degradation. Analogues containing an 
insert of exendin-4 sequence of sufficient length for two helical turns greatly improved 
binding affinity and resistance to NEP mediated degradation compared to 
oxyntomodulin. These factors suggest that the secondary shape of the molecule 
determined by the mid-section is critical to the bioactivity of the peptide. 
Studies with chimeric peptides identified that the same level of resistance to NEP 
mediated degradation was achieved by substituting an exendin-4 sequence insert for 
residues 27-39 as with substituting residues 14-39, indicating that the more limited 
carboxy terminus changes may be sufficient to protect oxyntomodulin from NEP 
mediated degradation. However, the C-terminus sequence of exendin-4 and 
oxyntomodulin differ significantly, so it may be premature to conclude that only the 
equivalent oxyntomodulin residues require protection from NEP breakdown. To 
investigate the role of the C-terminus of oxyntomodulin, peptide analogues with smaller 
number of amino acid changes were produced. As with previous analogues, inserts of 
exendin-4 were used and the sequence inserted is thought to form part of a second a-
helix in exendin-4. 
Substituting as few as 4 amino acids, oxm(ex30-33) in the C-terminus was sufficient to 
offer the same level of resistance from NEP mediated degradation as inserting amino 
acids 27-39 from exendin-4. Predicting sequence changes likely to offer protection 
from NEP mediated breakdown was not possible as substituting target sites to sites not 
recognised by NEP did not reduce the susceptibility of the peptide to breakdown. For 
example, replacing the amino acids Lys-Arg-Asn-Arg to Gly-Pro-Ser-Ser (positions 30-
33) would be predicted to result in a peptide more susceptible to NEP mediated 
breakdown, but actually resulted in peptide seemingly significantly less susceptible to 
such breakdown. This result again suggests that factors other than sequence alone are 
responsible for determining peptide susceptibility to NEP mediated degradation. 
Evidence that secondary or tertiary shape is at least partially responsible for these 
changes in susceptibility to NEP breakdown is provided by the observation that 
changing the sequence of the carboxy terminus offers protection from degradation to a 
mid-section shown to be sensitive to enzyme mediated breakdown. Methods such as 
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circular dichroism and nuclear magnetic resonance would be required to further 
elucidate the secondary and tertiary structure of oxyntomodulin and its analogues. 
Modifications of the C-terminal region affected the affinity of the peptide for the GLP-1 
receptor and its ability to inhibit refeeding in fasted mice, in addition to altering its 
susceptibility to NEP mediated degradation. As previously demonstrated by 
experiments investigating the effects of changes to the mid-section of oxyntomodulin, 
experiments examining the effects of changes to the C-terminal region suggest that 
resistance to NEP mediated degradation is more important than affinity for the GLP-1 
receptor in determining the ability of the peptide to inhibit food intake. Analogue 
oxm(ex30-33) bound with 6-fold lower affinity than oxyntomodulin, but was as potent 
as oxyntomodulin at reducing food intake in the first hour, perhaps due to its 
significantly greater protection from endopeptidase breakdown. Oxm(ex29-33) bound 
to the GLP-1 receptor with similar affinity to oxm(27-33) and caused a similar degree 
of food intake inhibition in the first hour. However, it did not reduce food intake in the 
1-2 hour interval where as oxm(ex27-33), a peptide more resistant to NEP, continued to 
inhibit food intake in the 1-2 hour interval. The C-terminus of oxyntomodulin appears 
critical for the functions biological activity. Small changes result in large differences in 
the characteristics of the peptide. This was highlighted by experiments demonstrating 
that altering residues 27-31 and 30-33 reduced affinity for the GLP-1 receptor by over 
4-fold, while sequence inserts one amino acid longer improved binding afffinity 3-fold. 
The studies described above suggest that both the C-terminus and the mid-section of 
oxyntomodulin are important for the peptide's affinity to the GLP-1 receptor and 
resistance to breakdown by endopeptidases. They also suggest that susceptibility to 
NEP mediated degradation rather than affinity to the GLP-1 receptor is the primary 
factor determining the potency and duration of the anorectic effects of oxyntomodulin 
analogues. The analogue studies also suggest that susceptibility to NEP mediated 
degradation and affinity to the GLP-1 receptor is dependent on the three-dimensional 
shape of the molecule rather than on specific sequences. Thus an oxyntomodulin 
analogue containing both the optimal mid-section and C-terminus inserts had improved 
binding affinity and a longer anorectic effect than would have been predicted from the 
effects of the single inserts. 
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Chapter 6 
Modifications of oxyntomodulin to 
increase peptide half-life 
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6.1 Introduction 
In Chapter 5, I described experiments investigating the structnre-function relationships 
of the oxyntomodulin molecule and the effects of substituting parts of the molecule with 
exendin-4 sequence inserts. In this chapter a further series of peptides were designed 
and tested to investigate whether the efficacy of the analogue oxm(ex15-24,27-33) at 
reducing food intake could be improved. Further analogues were designed primarily to 
try and increase the duration of food intake inhibition. The therapeutic profile, speed 
and potency of action, was considered as a secondary aim. Changes to the N-terminal, 
mid-section and C-terminal were tested, as well as increasing the size of the molecule 
by extending the amino acid sequence and by the addition of non-peptide side chains. 
6.1.1 Peptide modifications to enhance longevity 
Larger peptides are generally less susceptible than short-chain peptides to degradation 
by endopeptidases (Hupe-Sodmarm et al., 1995). Increasing the length of a peptide 
chain is therefore a possible strategy for prolonging the actions of a peptide. However, 
addition of extra amino acids to a peptide can result in changes to the peptide structure, 
altering its interaction with receptors and its biological properties. Alanine screening is 
a technique used to investigate the effect of single amino acid changes on peptide 
function. Alanine is a small hydrophobic amino acid with a neutral charge and thus 
causes minimal change to the secondary structure of a peptide. It has been hypothesised 
that the same properties which make alanine a good substitute also make it suitable for 
elongating a peptide (Adelhorst et al., 2004). 
The addition of acyl side chains can also increase the half-life of a peptide in vivo 
(Chang et al., 2003). This effect is thought to be due to two mechanisms. Firstly, 
acylation promotes binding of the molecule to albumin, the principal extracellular 
protein. Albumin has a relative mass of approx 67 kDa and at least eight fatty-acid-
binding sites and binds reversibly to endogenous fatty acids, as well as several 
pharmacological agents. The binding of a peptide to albumin restricts access to its N-
terminal, preventing degradation by amino terminal peptidases such as DPP IV and 
reducing the clearance rate by renal filtration (Knudsen et al., 2000). Secondly, albumin 
is abundant in the extracellular subcutaneous space, a possible site of peptide 
administration, and slow clearance from this site would help ensure a slower onset of 
drug absorption and perhaps processing (Garber, 2005). Adding fatty acid side chains 
to proteins to promote their binding to albumin is an approach that has been 
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successfully applied to insulin (Kurtzhals et a l , 1995; Kurtzhals et a l , 1997; Markussen 
et al., 1996) and to proglucagon-derived peptides. For example, a fatty acylated human 
GLP-1 analogue, Liraglutide [Lys^^(N®-Y(N"-hexadecanoyl-Glu)),Arg^'^]GLP 1(7-37) has 
been produced which differs from GLP-1 by an amino acid substitution at position 34 
(lysine changed to arginine) and is covalently coupled to an acyl side-chain. Liraglutide 
has a comparable potency to GLP-1, but its plasma half-life is significantly increased to 
14 hours in pigs and 10-12 hours in humans, as compared to less than 2 minute for 
GLP-1 (Chang et al., 2003; Deacon et al, 1995; Juhl et al., 2002; Knudsen et al., 2000). 
Other reported strategies for prolonging the biological activity of a peptide include 
directly coupling the peptide to large molecules such as albumin or polyethylene glycol 
(PEG). Covalent binding to albumin has shown some therapeutic promise for GLP-1. 
For example, the compound CJC-1131 has a reactive chemical linker at the carboxy-
terminal end of the molecule (Cys 34 residue) which permits covalent coupling to 
albumin following administration in vivo. The covalent binding to albumin increases 
the half-life of this peptide to approximately 2 weeks in humans, corresponding to the 
circulating half-life of albumin itself (Leger et al., 2004). Additionally, CJC-1131 has 
been made more resistant to DPP IV degradation by replacing the Ala found at position 
2 with DAla. Albugon, a human GLP-1-albumin recombinant protein, retains the 
ability to activate the GLP-1 receptor (albeit with a reduced EC50) and has the biological 
properties of the parent peptide except for an increased circulating half-life (Baggio et 
al., 2004a; Kim et al., 2003). Other methods of conferring resistance to degradation 
include conjugation to biotin (Chaturvedi et al., 1984) or PEG (Lee et al., 2005). The 
latter has the potential to enhance the pharmacological profile while retaining the 
biological profile (Lee et al., 2005), depending on the site and degree of PEGylation. 
6.2 Aims 
The aims of this chapter were to use the information gained from Chapters 3, 4 and 5 to 
design an analogue of oxyntomodulin which maintains similar physiological properties 
of oxyntomodulin but causes a more potent and longer lasting inhibition of food intake. 
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6.3 Materials and Methods 
6.3.1 Custom designed analogues of oxyntomodulin 
In Chapters 4 and 5, peptides analogues were designed to investigate the functional 
significance of different regions of oxyntomodulin. Using results from these chapters, a 
further series of oxyntomodulin analogues were deigned with the objective of producing 
an analogue which inhibited food intake for an extended period of time. In the first 
instance N-terminal modifications, which prevented DPP IV mediated breakdown, were 
combined with sequence changes of the mid-section and C-terminal which had 
improved the analogues affinity for the GLP-1 receptor, increased resistance to NEP 
mediated breakdown and increased duration of food intake inhibition (table 6.2.a). The 
effect of these changes on GLP-1 receptor binding affinity, resistance to breakdown by 
DPP IV and NEP and anorectic actions were examined. Peptide analogues of 
oxyntomodulin were subsequently designed to investigate if altering the putative helical 
region of the mid-section by incorporating amino acids from the a-helix domain of 
latrotoxin (the venom of Latrodectus spiders) increased analogues duration of food 
intake inhibition. Having designed analogues with improved receptor binding affinity 
to the GLP-1 receptor, increased resistance to DPP IV for NEP mediated breakdown 
and increased duration of food intake inhibition a further series of analogues were 
designed to investigate if strategies such as acylation, PEGylation or coupling to 
albumin extended the analogues duration of action (table 6.2b). 
All peptides were manufactured using the protocols described in section 2.1. 
6.3.2 Receptor binding studies to the GLP-1 receptor 
Measurement of analogue affinity to the rat GLP-1 receptor was completed using the 
protocol outlined in section 2.4.5. Cell membrane was purified from rat lung and 
provided the source of GLP-1 receptor (2.4.1). ^^^I-exendin-4 was used as the 
competing radiolabelled peptide. Binding affinities were calculated from a minimum of 
3 separate experiments in which each concentration of unlabelled peptide was tested in 
triplicate. Values are shown as mean ± SEM. 
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N Terminal | Mid-section {liin(|e le^ion) | C-Terminal 
Peptide Residue niiinl>er 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 
oxin H S Q G T F T S D Y S K Y L D S R R A Q D F V Q W L M N T K R N R N N 1 A 
exeniiin4 H G E G T F T s D L s K Q M E E E A V R L F 1 E W L K N G G P S S G A P P P S 
Ala2^p3-oxm H A D G T F T s D Y s K Y L D S R R A Q D F V Q w L M N T K R N R N N 1 A 
oxin(ex15-21) H S Q G T F T s D Y s K Y L E E E A V R L F V Q w L M N T K R N R N N 1 A 
oxin(ex15-24) H S Q G T F T s D Y s K Y L E E E A V R L F 1 E w L M N T K R N R N N 1 A 
DHis1-Ala2-oxm(ex15.23,27-33) dH A, Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S S N N 1 A 
DHisI J\Ia2-oxm(ex15-24,27-33) dH A Q G T F T s D Y s K Y L E E E A V R L F 1 E w L K N G G P S S N N 1 A 
DHis1J\Ia2-oxm(ex15^3,2733)-Ala38,39 dH A Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S S N N 1 A A A 
Ala2-Asp3-oxni(ex15-24.27-33)JVIa383 H A D G T F T s D Y s K Y L E E E A V R L F 1 E w L K N G G P S S N N 1 A A A 
DHis1-Ala2-61113-0X01(6x1554,27 33)JMa383 dH A E G T F T s D Y s K Y L E E E A V R L F 1 E w L K N G G P S S N N 1 A A A 
DHis1-Ser2-Asp3.oxm(ex15-24,2733)-Ala3839 dH S D G T F T s D Y s K Y L E E E A V R L F 1 E w L K N G G P S S N N 1 A A A 
oxin-Glu15-Gln16(ex17-21) H S Q G T F T s D Y s K Y L E Q E A V R L F V Q w L M N T K R N R N N 1 A 
DHis1-Ala2-Glii15-Glii16.Glu17-Leii18-Val19-Arij20(ex21-
23,27-32)-Lvs33-Lvs38 (6100) dH A Q G T F T s D Y s K Y L E Q E L V R L F 1 Q w L K N G G P S K N N 1 A K 
DHis1-Ala2-oxin(ex15-17)-Leii18(ex19^,27^)JMa3839 
(6103) dH A Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S S N N 1 A A A 
oxin(8x15-19)-Lvs20(ex21-24) H S Q G T F T s D Y s K Y L E E E A V K L F 1 E w L M N T K R N R N N 1 A 
DHis1-Ala2-Glii15-Glii16-Glii17-Leii18-Val19^ry20-
Tvr21 (6x22-23,27.32)-Lvs33-Lvs38 (6101) dH A Q G T F T s D Y s K Y L E Q E L V R Y F 1 Q w L K N G G P S K N N 1 A K 
oxin-Lvs33 H S Q G T F T s D Y s K Y L D S R R A Q D F V Q w L M N T K R N K N N 1 A 
DHis1.Ala2-oxm(ex15-23,27J2).Lys33JMa3839 (6104) dH A Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S K N N 1 A A A 
I I Unique amino acid changes 
I I Position of exendin-4 residues that differ to those found in oxyntomodulin, and position of exendin-4 residues in analogues 
dH = DHis stereoisomer of histadine 
Table 6.1 a Table of N-terminal and mid-section modified analogues investigated in chapter 6. 
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N-T$fmii)al | Mid-section (liiiuie leqion) I 
Peptide Residue niimbet 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
oxm-Lvs38 H S Q G T F T S D Y S K Y L D S R R A Q D F V 0 W L M N T K R N R N N 1 A K 
oxm-Ala38 # H S Q G T F T S D Y S K Y L D S R R A Q D F V Q w L M N T K R N R N N 1 A A 
oxm-Ala383 H s Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N A A A 
0 X m-Aia38 3 - t vs lO H s Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N A A A K 
oxiTi^la3842 H s Q G T F T s D Y s K Y L D s R R A Q D F V Q w L M N T K R N R N N A A A A A A 
DHisI Ala2-oxmi6x15-23,2733)-AI^39-Lvs40 dH A Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S S N N A A A K 
DHis1J^la2-oxm(ex15^^732)-Lvs33JMa38,39-Lvs40 dH A Q G T F T s D Y s K Y L E E E A V R L F i Q w L K N G G P S K N N A A A K 
DHisI JMa2-oxm(ex15^^7;32)-Lys33-Ala38,39-Glii40,41- dH A Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S K N N A A A E E K 
lauroyi dH A Q G T F T s D Y s K Y L E E E A V R L F i Q w L K N G G P S K N N A A A K-C12 
DHb1JMa2-oxm(ex15-23^7-32)-Lys33^la383-Glw40,41-
Lvs42-octanovl (6404) dH A Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S K N N A A A E E K-C8 
DHisI-At^-«xm(ex15^,2733)J^la383-Lys40,41-Lys42-
laurovl(84D6) dH A Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S S N N A A A K K K-C12 
DHisI JVia2-oxm(ex15^^7-33) JMa383-Lys40^1 -Lys42. 
Mall) (5946) dH A Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S S N N A A A K K K-Malb 
DHk1VMa24»xm(ex15^^732)4.yg33JM@38;39^lu40;41. 
Lvs42.PEG ($405) dH A Q G T F T s D Y s K Y L E E E A V R L F 1 Q w L K N G G P S K N N i A A A E E K-PEG 
DHis1-oxm-Glii15,16,17-Leu18-Val19-Lys20-Tyr21-Plie22-
lle23-4>xm(ex27^21-Lvs33 (6407) dH S Q G T F T s D Y s K Y L E E E L V K Y F 1 Q w L K N G G P S K N N 1 A 
DHtslTAIa2-oxin-Glii15-Glii16-Glii174-eii18-\/al19-Lys20-
Tyr21-Phe224le23-oxm(ex27^2)-Lys33 (6421) dH A Q G T F T s D Y s K Y L E Q E L V K Y F 1 Q w L K N G G P S K N N 1 A 
I I Unique amino acid changes 
I I Position of exendin-4 residues in analogues 
dH = DHis stereoisomer of histadine 
K-C8 = Lysine with octanoyl fatty acid side chain K-C12 = Lysine with palmitoyl fatty acid side chain 
KPEG = Site of PEGylation K=Malb = Site of conjugation to mouse albumin 
# = Acylated versions of this peptide not included in summary table 
Table 6.1 b Table of analogues with C-terminal, fatty acid, albumin or PEG modifications used in chapter 6, 
6.3.3 Quantification of susceptibility to DPP IV mediated degradation 
Resistance to DPP IV mediated degradation was calculated using the protocol described 
in section 2.7.1. Reaction samples of 2 nmol or 5 nmol of peptide were incubated with 
or without 10 mU or 25 mU DPP IV respectively at 37°C for 120 minutes in a total 
volume of 130 p,l (or 325 |j.l for the 5 nmol peptide/25 mU experiment) before analysis 
by reverse phase HPLC. A gradient of 2-30% acetonitrile/water (both containing 0.05% 
TFA) 0-10 minutes, and 30-48% acetonitrile/water (both containing 0.05% TFA) 10-40 
minutes was used unless otherwise stated and absorbance measured at a wavelength of 
214 nm (Jasco HPLC system, solvent delivery system PU-2080 plus, autosampler AS-
2057 plus, degasser DG2080-53, dynamic mixer 2080-32 UV detector uv-2075 using a 
Phenomenex Gemini Cig (5-|am particles) 250 mm x 4.6 mm column). Percentage 
degradation was calculated by comparing area under peak in reactions with and without 
enzyme. Percentage degradation values were calculated from a minimum of 2 
experiments. Chromatograms shown are representative examples. 
6.3.4 Quantification of susceptibility to neutral endopeptidase 24.11 (NEP) 
mediated degradation 
Resistance to NEP mediated degradation was calculated using the protocol described in 
section 2.7.2. Reaction samples of 2 nmol or 5 nmol of peptide were incubated with or 
without 200 ng or 500 ng NEP respectively at 37°C for 120 minutes in a total volume of 
130 |j,l (or 325 ^1 for the 5 nmol peptide/5OOng NEP experiments) before analysis by 
reverse phase HPLC. A gradient of 2-15% acetonitrile/water (both containing 0.05% 
TFA) 0-5 minutes, and 15-50 % acetonitrile/water (both containing 0.05% TFA) 5-40 
minutes was used unless otherwise stated, and absorbance measured at a wavelength of 
214 imi (Jasco HPLC system, solvent delivery system PU-2080 plus, autosampler AS-
2057 plus, degasser DG2080-53, dynamic mixer 2080-32 UV detector uv-2075 using a 
Phenomenex Gemini Cig (5-|im particles) 250 mm x 4.6 mm column). Percentage 
degradation was calculated by comparing area under peak in reactions with and without 
enzyme. Percentage degradation values were calculated from a minimum of 2 
experiments. Chromatograms shown are representative examples. 
6.3.5 Feeding studies using fasted mice 
The effects of oxyntomodulin analogues on food intake were investigated in fasted 
mice, as described in section 2.2.2. Peptides were administered via IP injection and 
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food intake measured at 1, 2, 4, 8 and 24 hour post-injection, unless otherwise stated. 
Statistical analysis of results was completed as outlined in section 2.9. 
6.3.5.1 Screening N-terminal modifications 
The anorectic effects of several different N-terminal modifications of the analogue 
oxm(exl5-24,27-33)-Ala38,39 were compared. Peptides used for this study were 
DHisl-Ala2-oxm(exl5-24,27-33)-Ala38,39 (7 nmol/kg), DHisl-Ala2-Glu3-oxm(exl5-
24,27-33)-Ala38,39 (7 nmol/kg), DHisl-Ser2-Asp3-oxm(exl5-24,27-33)-Ala38,39 (7 
nmol/kg) and Ala2-Asp3-oxm(ex15-24,27-33)-Ala38,39 (n=7-8 for all groups). 
6.3.5.2 Effect on food intake inhibition of a long lasting analogue with and without 
a DPP IV resistant modiflcation 
This study was designed to investigate the importance of resistance to DPP IV mediated 
degradation on analogues anorectic effects. Analogue DHis 1 -Ala2-oxm(exl 5-24,27-
33) (100 nmol/kg), shown to be resistant to in vitro DPP IV mediated degradation and 
oxm(exl5-24,27-33) (100 nmol/kg), shown to be degraded by DPP IV in an in vitro 
assay were used in this study (n=9-10 for all groups). 
6.3.5.3 Effects of DHisl-Ala2-oxm(exl5-24,27-33), oxyntomodulin and exendin-4 
on food intake in fasted mice 
This study was designed to compare the anorectic effects of DHisl-Ala2-oxm(exl5-
24,27-33) to those of oxyntomodulin and exendin-4. Peptides used for this study were 
DHis 1 -Ala2-oxm(ex15-24,27-33) (0.1, 0.3 and 0.9 nmol/kg), oxyntomodulin (1400 
nmol/kg) and exendin-4 (0.6 nmol/kg). Oxyntomodulin and exendin-4 were tested at 
the minimal doses to reliably cause a significant reduction in food intake compared to 
saline controls (n=8-9 for all groups). 
6.3.5.4 Investigation of modification at position 16 
The study was designed to investigate the anorectic effects of modification of position 
16. Peptides used for this study were oxm(exl5-21) (30 nmol/kg) and oxm-Glul5-
Glnl6(ex 17-21) (30 nmol/kg) (n=9-10 for all groups). 
6.3.5.5 Investigation of modification at position 18 
The study was designed to investigate the anorectic effects of modification of position 
18. Peptides used for this study were DHis 1 -Ala2-oxm(ex 15-23,27-33)-Ala38,39 (6 
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nmol/kg) and DHisl-Ala2-oxni(exl5-17)-Leul8(exl9-23,27-33)-Ala38,39 (6103) (2 
and 6 nmol/kg) (n=8-9 for all groups). 
6.3.5.6 Investigation of modification at position 20 
The study was designed to investigate the anorectic effects of modification of position 
20. Peptides used for this study were oxm(exl5-24) (100 nmol/kg) and oxm(exl5-19)-
Lys20-(ex21-24) (100 nmol/kg) (n=8-9 for all groups). 
6.3.5.7 Investigation of modification at position 21 
The study was designed to investigate the anorectic effects of modification of position 
21. Peptides used for this study were DHis 1 -Ala2-Glul 5-Glnl 6-Glul 7-Leul 8-Vall 9-
Arg20(ex21-23,27-32)-Lys33-Lys38 (6100) (2 nmol/kg) and DHisl-Ala2-Glul5-
Glnl 6-Glul 7-Leul 8-Val 19-Arg20-Tyr21 (ex22-23,27-32)-Lys33-Lys3 8 (6101) (2 
nmol/kg) (n=8-9 for all groups). 
6.3.5.8 Investigation of modification at position 33 
The study was designed to investigate the anorectic effects of modification of position 
33. Peptides used for this study were oxyntomodulin (1400 nmol/kg) and oxm-Lys33 
(1400 nmol/kg) (n= 9-10 for all groups). 
6.3.5.9 Investigation of modification at position 33 in a complex analogue of 
oxyntomodulin 
The study was designed to investigate the anorectic effects of modification of position 
33 in a complex analogue of oxyntomodulin. Peptides used for this study were DHisl-
Ala2-oxm(exl5-23,27-33)-Ala38,39 (3 nmol/kg) and DHisl-Ala2-oxm(exl5-23,27-32)-
Lys33-Ala38,39 (6104) (3 nmol/kg) (n=8-9 for all groups). 
6.3.5.10 Effect of C-terminally extended analogues of oxyntomodulin on food 
intake in fasted mice 
C-terminally extended analogues of oxyntomodulin were produced and their effect on 
food intake measured. Previously, in vitro studies showed C-terminally extended 
analogues to be more resistant than oxyntomodulin to NEP mediated degradation, and 
this study compared the anorectic effects of theses analogues to those of 
oxyntomodulin. Peptides used for this study were oxm-Ala38 (1400 nmol/kg), oxm-
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Ala38,39 (1400 nmol/kg), oxm-Ala38-42 (1400 nmol/kg) and oxyntomodulin (1400 
nmol/kg) (n=7-8 for all groups). 
6.3.5.11 Effect of DHisl-Ala2-oxm(exl5-24,27-33)-Ala38,39 on food intake in 
fasted mice 
Previously, a C-terminal extension of oxyntomodulin was shown to increase the 
anorectic effect of the peptide. This study was designed to investigate the anorectic 
effect of a C-terminally extended analogue of oxyntomodulin. The peptides used for 
this study were DHisl-Ala2-oxm(exl5-24,27-33) (2 nmol/kg) and DHisl-Ala2-
oxm(exl5-24,27-33)-Ala38,39 (0.5, 1.0 and 2.0 rmiol/kg) (n=8-9 for all groups). 
6.3.5.12 Investigation of Lys38 extension and addition of a fatty acid side 
chain 
This study was designed to investigate if the predicted increased duration of food intake 
inhibition resulting from addition of a fatty acid side chain, compensated for the 
observed reduction in binding affinity caused by addition of a fatty acid side chain. 
Peptides used for this study were oxyntomodulin (1400 nmol/kg), oxm-Lys38 (1400 
nmol/kg), oxm-Lys38 [octanoyl] (1400 nmol/kg), oxm-Lys38[lauroyl] (1400 rmiol/kg), 
and oxm-Lys38[palmitoyl] (1400 rmiol/kg) (n=8-9 for all groups). 
6.3.5.13 Investigation of C-terminal extensions and addition of a fatty acid 
side chains 
This study was designed to investigate if addition of Lys at position 40 to oxm-Ala38,39 
modified the anorectic effect of the analogue. Peptides used for this study were oxm-
Ala38,39 (1400 nmol/kg) and oxm-Ala38,39-Lys40 (1400 nmol/kg) (n=8-9 for all 
groups). A follow up study was designed to investigate the anorectic effects of addition 
of a fatty acid group to oxm-Ala38,39-Lys40. Peptides used for this study were 
oxyntomodulin (1400 nmol/kg), oxm-Ala38,39-Lys40[lauroyl] (1400 nmol/kg) and 
oxm-Ala38,39-Lys40[palmitoyl] (1400 nmol/kg) (n=8-9 for all groups). 
6.3.5.14 Investigation of C-terminal extension for placement of a fatty acid 
side chain in a complex analogue 
This study was designed to investigate the anorectic effect of addition of the C-terminal 
extension Ala38,39-Lys40 to a modified analogue of oxyntomodulin. This study was 
required prior to testing acylated forms of the peptides, enabling clarification of the 
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cause for any change to the property of the peptide. Peptides used for this study were 
DHisl-AIa2-oxm(exl5-23,27-33) (5 nmol/kg), DHisl-Ala2-oxm(exl5-23,27-33)-
Ala38,39 (5 nmol/kg) and DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39-Lys40 (5 
nmol/kg) (n=8-9 for all groups). A follow up study was designed to test the anorectic 
effect of an alternative C-terminal extension, Lys33-Ala38,39-Lys40. This study was 
required prior to testing acylated forms of the peptides, enabling clarification of the 
cause for any change to the property of the peptide. Peptides used for this study were 
DHis 1 -Ala2-oxm(ex15-23,27-32)-Lys33-Ala38,39 (3nmol/kg), DHis 1 -Ala2-oxm(ex 15-
23,27-33)-Ala38,39-Lys40 (3rmiol/kg) and DHisl-Ala2-oxm(exl5-23,27-32)-Lys33-
Ala38,39-Lys40 (3nmol/kg) (n=8-9 for all groups). 
6.3.5.15 Investigation of addition of a lauroyl group to analogue DHisl-Ala2-
oxm(exl5-23,27-32)-Lys33-Ala38,39-Lys40 
This study was designed to investigate the anorectic effect of addition of an acyl group 
to a potent analogue with a prolonged duration of food intake. Peptides used for this 
study were DHis 1 -Ala2-oxm(ex15-23,27-32)-Lys33-Ala38,39-Lys40 (10 nmol/kg) and 
DHis 1 -Ala2-oxm(ex15-23,27-32)-Lys33-Ala38,39-Lys40[lauroyl] (10 nmol/kg) (n=8-9 
for all groups). 
6.3.5.16 Investigation of addition of a lauroyl group to analogue DHisl-Ala2-
oxm(exl5-23,27-32)-Ala38,39-Lys40 
This study was designed to investigate the anorectic effect of addition of an acyl group 
to a potent analogue with a prolonged duration of food intake inhibition. Peptides used 
for this study were DHis 1 -Ala2-oxm(ex 15-23,27-33)-Ala38,39-Lys40 (3 and 7 
nmol/kg) and DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39-Lys40[lauroyl] (3 and 7 
nmol/kg) (n=8-9 for all groups). 
6.3.5.17 Investigation of the effect of PEGylation of a potent oxyntomodulin 
analogue on food intake in fasted mice 
This study was designed to compare the anorectic effects of an acylated analogue to 
those of analogues with and without a PEG group. Proteins were coupled to a PEG 
group with an average Mw of 5000. Peptides used for this study were DHisl-Ala2-
oxm(exl5-23,27-32)-Lys33-Ala38,39-Glu40,41-Lys42 (6403) (6 nmol/kg), DHisl-
Ala2-oxm(exl5-23,27-32)-Lys33-Ala38,39-Glu40,41-Lys42[octanoyl] (6404) (6 
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nmol/kg) and DHisl-Ala2-oxm(exl5-23,27-32)-Lys33-Ala38,39-Glu40,41-
Lys42[PEG] (6 nmol/kg) (n=8-9 for all groups). 
6.3.5.18 Investigation of addition of albumin on peptide bioactivity 
This study was designed to compare the anorectic effects of an analogue with and 
without an albumin group. Native oxyntomodulin and an acylated form (6406) were 
used as comparators to help evaluate the effectiveness of this modification. Peptides 
used for this study were oxyntomodulin (1400 nmol/kg), 6406 (6 nmol/kg) and DHisl-
Ala2-oxm(exl5-23,27-33)-Ala38,39-Lys40,41,42[Malb] (5946) (10, 100 and 1000 
nmol/kg) (n=8-9 for all groups). 
6.3.5.19 Comparison of oxyntomodulin analogues 6421 and 6407 to 
oxyntomodulin and exendin-4 effects on food intake in fasted mice 
This study was designed to compare the anorectic effects of a series of analogues which 
combined the beneficial modifications to oxyntomodulin described in Chapter 5 and 6. 
Peptides used for this study were oxyntomodulin (1400 nmol/kg), exendin-4 (6 
nmol/kg), 6421 (see table 6.1b) (6 nmol/kg) and 6407 (see table 6.1b) (6 nmol/kg) (n=9-
10 for all groups). 
6.3.6 In vitro bioactivity of analogues 6421 and 6407 
The protocol described in section 2.5.1 was used to investigate the ability of 
oxyntomodulin analogues 6421 and 6407 to stimulate cAMP production. CHO cells 
overexpressing the rGLP-1 receptor were used for the experiments. EC50 values were 
calculated from 3 experiments and, within each experiment peptide, concentrations were 
tested in duplicate. 
203 
6.4 Results 
6.4.1 N-terminal modilOicatioiis 
Previously, N-terminal modifications of oxyntomodulin were examined to determine 
whether DPP IV mediated degradation was a cause of oxyntomodulin inactivation 
(Chapter 4). Results showed that oxyntomodulin was susceptible to DPP IV mediated 
breakdown. Co-administration of a DPP IV inhibitor or analogues of oxyntomodulin 
with DPP IV resistant N-terminal sequences increased oxyntomodulin's potency at 
reducing food intake. 
A series of N-terminal modified analogues of oxm(exl5-24,27-33)-Ala38,39 (see 
section 6.4.3 for details about C-terminus extension) were designed using the DPP IV 
resistant sequences described in Chapter 4. 
6.4.1.1 Binding affinities of N-terminally modified analogues to the GLP-1 receptor 
All N-terminal modifications of the parent peptide, oxm(exl 5-24,27-33)-Ala38,39 
resulted in minor changes (less than 2-fold) of their affinity for the rGLP-1 receptor. 
Results are shown in table 6.2 and figure 6.1. 
6.4.1.2 Susceptibility to DPP IV mediated degradation of N-terminally modified 
analogues 
As previously observed, substituting His for DHis at position 3 protects the peptide 
from DPP IV mediated degradation. All DHisl analogues screened showed full 
resistance to DPP IV mediated breakdown, whilst those analogues with His I were 
susceptible to DPP IV mediated breakdown (table 6.2). Combined mid-section and C-
terminus substitutions had no effect on DPP IV resistance (Ala2-Asp3-oxm(exl5-24,27-
33)-Ala38,39 showed 74% breakdown, Ala2-Asp3-oxm showed 77% breakdown). 
Representative chromatograms of the results are shown in figure 6.2-6.7 and results 
summarised in table 6.2. 
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a) 
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Figure 6.1 Binding affinity of oxm(exl5-24,27-33)-Ala38,39 and N-terminal 
modifications of this analogue to the rGLP-1 receptor. Rat lung cell membrane 
was the source of GLP-1 receptor and ^^^I-exendin-4 used as the competing 
peptide. I C 5 0 value calculated as mean ± SEM of 3 separate experiments. 
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oxm(exl 5-24,27-33)-Ala38,39 0.31 ±0.03 80 
DHis 1 -Ala2-oxm(exl 5-24,27-
33)-Ala38,39 
0.29 ± 0.04 2 
DHis 1 -Ala2-Glu3-oxm(ex 15-
24,27-33)-Ala38,39 
0.23 i 0.05 1 
DHis 1 -S er2-Asp3 -oxm(ex 15-
24,27-33)-Ala38,39 
0.30 ± 0.06 0 
Ala2-Asp3-oxm 15.6 ± 1.6 77 
Ala2-Asp3-oxm(exl 5-24,27-33)-
Ala38,39 
0.30 ±0.07 74 
Table 6.2 The binding affinity for the rGLP-1 receptor and susceptibility to 
DPP IV mediated degradation of oxm(exl5-24,27-33)-Ala38,39 and N-terminal 
modifications of this analogue. I C 5 0 value calculated from a minimum of 3 
separate experiments. Values shown are mean ± SEM. Percentage degradation 
was calculated by comparing area under peak of ± DPP IV samples analysed by 
HPLC. 
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Figure 6.2 In vitro degradation of oxm(exl5-24,27-33) by DPP IV. Oxm(exl5-
24,27-33)-Ala38,39 (2 nmol) was incubated for 120 minutes with 10 uM DPP IV at 
37°C. Digests were analysed by reverse phase HPLC using a 30-48% 
water/acetonitrile gradient over 40 minutes. 
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Figure 6.3 In vitro degradation of DHisl-AIa2-oxm(exl5-24,27-33)-Ala38,39 by 
DPP IV. DHisl-Ala2-oxm(exI5-24,27-33)-Ala38,39 (2 nmol) was incubated for 120 
minutes with 10 uM DPP IV at 37°C. Digests were analysed by reverse phase 
HPLC using a 30-48% water/acetonitrile gradient over 40 minutes. 
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Figure 6.4 In vitro degradation of DHisl-Ala2-Glu3-oxm(exl5-24,27-33)-
Ala38,39 by DPP IV. DHisl-Ala2-Glu3-oxm(exl5-24,27-33)-Ala38,39 (2 nmol) was 
incubated for 120 minutes with 10 mU DPP IV at 37^C. Digests were analysed by 
reverse phase HPLC using a 30-48% water/acetonitrile gradient over 40 minutes. 
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Figure 6.5 In vitro degradation of DHisl-Ser2-Asp3-oxni(exl5-24,27-33)-
Ala38,39 by DPP IV. DHisl-Ser2-Asp3-oxm(exl5-24,27-33)-Ala38,39 (5 nmol) was 
incubated for 120 minutes with 25 mU DPP IV at 37°C. Digests were analysed by 
reverse phase HPLC using a 30-48% water/acetonitrile gradient over 40 minutes. 
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Figure 6.6 In vitro degradation of Ala2-Asp3-oxm by DPP IV. Ala2-Asp3-oxm 
(2 nmol) was incubated for 120 minutes with 10 mU DPP IV at 37°C. Digests were 
analysed by reverse phase HPLC using a 27-33% water/acetonitrile gradient over 
40 minutes. 
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Figure 6.7 In vitro degradation of Ala2-Asp3-oxm(exl5-24,27-33)-Ala38,39 by 
DPP IV. Ala2-Asp3-oxm(exl5-24,27-33)-Ala38,39 (5 nmol) was incubated for 120 
minutes with 25 mU DPP IV at 37°C. Digests were analysed by reverse phase 
HPLC using a 30-48% water/acetonitrile gradient over 40 minutes, 
6.4.1.3 Effect of N terminally modiGed oxyntomodulin analogues on food intake 
Study A: Screening N terminal modifications 
All analogues except Ala2-Asp3-oxm(exl5-24,27-33)-Ala38,39 (7 nmol/kg), caused a 
significant reduction in food intake at the 0-1 hour interval (figure 6.8). In the 1-2 hour 
interval, all peptides reduced food intake significantly compared to saline, as was 
observed in the 2-4 hour interval. DHis 1 -Ala2-oxm(ex 15-24,27-33)-Ala38,39 and 
DHisl-Ala2-Glu3-oxm(exl5-24,27-33)-Ala38,39 demonstrated a trend of a greater 
reduction in food intake than other analogues tested at the 2-4 hour interval. At the 4-8 
hour interval, the LHis analogue Ala2-Asp3-oxm(ex 15-24,27-33)-Ala38,39 failed to 
reduce food intake significantly, whilst all the DHis analogues caused a significant 
reduction in food intake compared to saline (figure 6.8). In the 8-24 hour interval no 
analogue caused a significant reduction in food intake (data not shown). 
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Figure 6.8 Comparison of anorectic effects of a range of N-terminal modified 
analogues. Analogues DHisl-Ala2-oxm(exl5-24,27-33)-Ala38,39, DHisl-Ala2-
Gluu3-oxm(exl5-24,27-33)-Ala38,39, DHisl-Ser2-Asp3-oxm(exl5-24,27-33)-
Ala38,39 and Ala2-Asp3-oxm(exl5-14,27-33)-Ala38,39 were administered at 7 
nmol/kg (n=7-8). **p<0.01, ***p<0.001 compared to saline. 
Study B: Effect of a long lasting analogue on food intake with and without a DPP IV 
resistant modification 
At all intervals tested, oxm(exl5-24,27-33) (100 nmol/kg) and DHisl-Ala2-oxm(exl5-
24,27-33) (100 nmol/kg) significantly reduced food intake compared to saline (figure 
6.9). A non-significant trend of DHis 1 -Ala2-oxm(ex 15-24,27-33) causing a greater 
inhibition of food intake than oxm(ex 15-24,27-33) was observed at the 1-2 and 2-4 hour 
interval. At the 4-8 hour interval, DHis 1 -Ala2-oxm(exl 5-24,27-33) caused a 
significantly greater reduction in food intake than oxm(exl5-24,27-33) (figure 6.9). 
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Figure 6.9 Effects of oxyntomodulin analogues with and without DPP IV 
resistant N-terminal modifications on food intake in fasted mice. Oxm(exl5-24,27-
33) and DHisl-Ala2-oxm(exl5-24,27-33) were administered at 100 nmol/kg (n=9-
10). *p<0.05, ***p<0.001 compared to saline or comparison between groups 
indicated. 
Study C: Effect of DHisl-Ala2-oxm('exl5-24.27-33). oxvntomodulin and exendin-4 on 
food intake in fasted mice 
Oxyntomodulin (1400 nmol/kg) and exendin-4 (0.6 nmol/kg) reduced food intake 
significantly in the first hour (as previously demonstrated). 0.9 nmol/kg was the lowest 
dose of DHisl-Ala2-oxm(exl 5-24,27-33) tested to significant reduce food intake 
compared to saline controls, with greater inhibition of feeding observed in the 0-1 and 
1-2 hr intervals (figure 6.10). 
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Figure 6.10 Dose response of the effect of analogue DHisl-Ala2-oxm(exl5-24,27-
33) on food intake in fasted mice. DHisl-Ala2-oxm(exl5-24,27-33) was 
administered at 0.1, 0.3 and 0.9 nmol/kg. Oxyntomodulin (1400 nmol/kg) and 
exendin-4 (0.6 nmol/kg) was tested for comparison (n=8-9). *p<0.05, ***p<0.001 
compared to saline. 
6.4.2 Mid-section modiflcations of oxyntomodulin 
My previous results identified that amino acids at positions 15-24 of oxyntomodulin 
play a critical role in regulating the peptide's affinity to the GLP-1 receptor, 
susceptibility to NEP mediated degradation and peptide's bioactivity (Chapter 5). 
Further investigation of the mid-section was completed by producing a series of 
analogues with substituted amino acids in this region. Modifications which improved 
the profile of the peptide were at position 16, 18, 20, 21 and 24. 
6.4.2.1 Binding affinities of analogues with modified mid-sections to the GLP-1 
receptor 
Substitution of Glu for Gin at position 16 in analogue oxm(ex 15-21) resulted in a small 
reduction of analogue affinity for the GLP-1 receptor (table 6.3). Substitution of Arg 
for Leu at position 18 caused a 3-fold reduction in binding affinity of the analogue 
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DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39 (table 6.3). Substitution of Tyr for Lys at 
position 20 in analogue oxm(ex 15-24) resulted in a small reduction of analogue affinity 
for the GLP-1 receptor (table 6.3). Changing Leu21 to Tyr21 caused a small 
improvement in affinity to the GLP-1 receptor, as demonstrated by the following 
peptide: DHisl-Ala2-Glul5-Glnl6-Glul7-Leul8-Vall9-Arg20(ex21-23,27-32)-Lys33-
Lys38 (6100) and DHis 1 -Ala2-Glul5-Glnl6-Glul7-Leul8-Val 19-Arg20-Tyr21 (ex22-
23,27-32)-Lys33-Lys38 (6101). Results are summarised in table 6.3. 
oxm(exl5-21) 4.0 ±0.6 
oxm-Glu 15 -Gin 16(ex 17-21) 4.7 ± 0.3 
DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39 0.29 ± 0.07 
DHis l-Ala2-Leul8-oxm(exl 5-23,27-33)-Ala38,39 1.0±0.15 
oxm(ex 15-24) 4.6 ± 1.0 
oxm(ex 15-19)-Lys20-(ex21 -24) 2.7 ±0.4 
6100 0.66 ± 0.09 
6101 0.49 ± 0.07 
Table 6.3 The binding affinity for the rGLP-1 receptor of analogues with 
further modifications to the mid-section. I C 5 0 value calculated from a minimum of 
3 separate experiments. Values shown are mean ± SEM. 
6.4.2.2 Effect of analogues of oxyntomodulin with mid-section modifications on 
food intake in fasted mice 
Study A: Investigation of modification at position 16 
As previously shown, administration of oxm(exl5-21) (30 nmol/kg) resulted in a 
significant reduction of food intake in the 0-1 hour interval. Substitution of Glu 16 with 
Gin 16 reduced the peptides potency of inhibiting food intake in the first hour, resulting 
in a non-significant reduction of food intake compare to saline controls. However, the 
peptide containing Gin at position 16 caused a significant reduction in food intake 
compared to saline controls at the 1-2 and 2-4 hour interval, whilst oxm(exl5-21) did 
not (figure 6.11). 
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Figure 6.11 Effects of oxyntomodulin analogues with and without further 
modifications at position 16 on food intake in fasted mice. Analogues oxm(exl5-
21) and oxm-Glul5-Glnl6(exl7-21) were administered at 30 nmol/kg (n=9-10). 
**p<0.01, ***p<0.001 compared to saline. 
Study B: Investigation of modification at position 18 
Administration of the comparator peptides, DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39 
(6 nmol/kg) and DHisl-Ala2-oxm(exl5-17)-Leul8-(exl9-23,27-33)-Ala38,39 (6103) (6 
nmol/kg) resulted in a significant reduction in food intake compared to saline at all 
intervals measured. The reduction in food intake caused by DHisl-Ala2-oxm(exl5-
23,27-33)-Ala38,39 (6 nmol/kg) was significantly greater than that caused by 6103 (6 
nmol/kg) in the 0-1 hour interval (figure 6.12). At the 4-8 hour interval, the reduction in 
food intake resulting from administration of 6103 (6 nmol/kg) was significantly greater 
than that caused by DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39 (6 nmol/kg) (figure 
6.12). 
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Figure 6.12 Effects of oxyntomodulin analogues with and without further 
modifications at position 18 on food intake in fasted mice. Analogues DHisl-Ala2-
oxm(exl5-23,27-33)-Ala38,39 was administered at 6 nmol/kg and analogue 6103 
administered at 2 and 6 nmol/kg (n=8-9). **p<0.01, ***p<0.001 compared to 
saline. 
Study C: Investigation of modification at position 20 
Peptides oxni(15-24) (100 nmol/kg) and oxm(exl5-19)-Lys20-(ex21-24) (100 nmol/kg) 
significantly reduced food intake compared to saline at the 0-1, 1-2, 2-4 and 4-8 hour 
intervals. Oxm(exl5-19)-Lys20-(ex21-24) showed a non-significant trend of reducing 
food intake to a greater degree than oxm( 15-24) at the 2-4 and 4-8 hour intervals (figure 
6.13). Both peptides failed to significantly reduce food intake at the 8-24 hour interval 
(data not shovm). 
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Figure 6.13 Effects of oxyntomodulin analogues with and without further 
modifications at position 20 on food intake in fasted mice. Analogues oxm(exl5-
19) and oxm(exl5-19)Lys20(ex21-24) were administered at 100 nmol/kg (n=8-9). 
**p<0.01, ***p<0.001 compared to saline. 
Study D: Investigation of modification at position 21 
Peptides DHisl-Ala2-Glul5-Glnl6-Glul7-Leul8-Vall9-Arg20(ex21-23,27-32)-Lys33-
Lys38 (6100) (2 nmol/kg) and DHis 1 -Ala2-Glul5-Glnl6-Glul7-Leul8-Val 19-Arg20-
Tyr21(ex22-23,27-32)-Lys33-Lys38 (6101) (2 nmol/kg) significantly reduced food 
intake at the 0-1, 1-2 and 2-4 hour interval compared to saline controls. Both peptides 
failed to cause a significant reduction in food intake in the 4-8 hour interval compared 
to saline (figure 6.14). 
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Figure 6.14 Effects of oxyntomodulin analogues with and without further 
modiOcations at position 21 on food intake in fasted mice. Analogues 6100 and 
6101 were administered at 100 nmol/kg (n=8-9). *p<0.05, **p<0.01, ***p<0.001 
compared to saline. 
6.4.3 Further modiHcation of the C-terminal of oxyntomodulin analogues 
I had previously investigated the function of the C-terminus by substituting amino acids 
at position 27-33 with those of exendin-4 (Chapter 5). These changes improved the 
affinity of the peptide to the GLP-1 receptor, its resistance to NEP mediated degradation 
and its anorectic actions. Several further modifications to the C-terminal insert were 
tested. Only the substitution of Ser for Lys at position 33 of oxyntomodulin or Arg for 
Lys in analogues containing exendin-4 sequence improved the anorectic properties of 
the peptide. 
6.4.3.1 Affinity to GLP-1 receptor of oxyntomodulin analogues with modified 
position 33 
Replacing residue 33 with Lys in oxyntomodulin and analogue DHisl-Ala2-oxm(exl5-
23,27-33)-Ala38,39 did not affect peptide affinity for the GLP-1 receptor (table 6.4). 
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oxyntomodulin 29.1 ±4.4 
oxm-Lys33 31.2 ±3.7 
DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39 0.29 ± 0.07 
DHis 1 -Ala2-oxm(exl 5-23^7-32)-Lys33- 0.25 ± 0.06 
Ala38,39 (6104) 
Table 6.4 The binding affinity for the rGLP-1 receptor of analogues with 
further modifications to the C-terminus. IC50 value calculated from a minimum of 
3 separate experiments. Values shown are mean ± SEM. 
6.4.3.2 Effect of analogues of oxyntomodulin with C-terminal modifications on 
food intake in fasted mice 
Study A: Investigation of modification at position 33 
Oxyntomodulin (1400 nmol/kg) and analogue oxm-Lys33 significantly reduced food 
intake at the 0-1 hour compared to saline controls. Mice treated with analogue oxm-
Lys33 consumed significantly less food than those treated with oxyntomodulin in the 1-
2 hour interval. Mice treated with oxyntomodulin and oxm-Lys33 consumed 
significantly more food than saline controls in the 2-4 hour interval, and no significant 
difference was observed between peptides at this time point (figure 6.15). 
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Figure 6.15 Comparison of the anorectic effects of oxyntomodulin and oxm-
Lys33. Oxyntomodulin and oxm-Lys33 were administered at 1400 nmol/kg (n=9-
10). **p<0,01, ***p<0.001, compared to saline or groups indicated. 
Study B: Modification of position 33 in a potent analogue of oxyntomodulin 
At the 0-1, 1-2 and 2-4 hour interval, both DHisl-Ala2-oxm(exl 5-23,27-33)-Ala38,39 
(3 nmol/kg) and analogue 6104 (3 nmol/kg) (see table 6.1a) significantly reduced food 
intake compared to saline controls. Analogue 6104 caused a significantly greater 
reduction of food intake than saline and DHis 1 -Ala2-oxm(ex 15-23,27-33)-Ala38,39 at 
the 4-8 hour interval (figure 6.16). None of the treatment groups caused a significant 
reduction in food intake in the 8-24 hour interval compared to saline controls (data not 
shown). 
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Figure 6.16 Effects of oxyntomodulin analogues with and without further 
modifications at position 33 on food intake in fasted mice. Analogues DHisl-Ala2-
oxm(exl5-23,27-33)-Ala38,39 and analogue 6104 were administered at 3 nmol/kg 
(n=8-9). *p<0.05, **p<0.01, ***p<0.001 compared to saline or groups indicated. 
6.4.4 Length of peptide 
Peptide length is known to influence its susceptibility to proteolytic breakdown by 
enzymes such as NEP and their rate of renal filtration. Analogues were designed to 
examine if anorectic effects of peptides with a C-terminal extension was extended 
6.4.4.1 Effect of C-terminus extension to oxyntomodulin and oxyntomodulin 
analogues on affinity to the rat GLP-1 receptor 
Peptides with C-terminal extensions were tested to determine the effect of the extension 
on receptor affinity. Modifying the C-terminus altered the peptide's affinity to the 
GLP-1 receptor. A single Ala extension to oxyntomodulin resulted in a 6-fold decrease 
in affinity to the GLP-1 receptor, whilst addition of Ala-Ala resulted in a small increase 
in the affinity of the analogue for the GLP-1. A C-terminal extension of 5 Ala's to 
oxyntomodulin resulted in a small decrease in the peptide's affinity to the GLP-1 
receptor. Results are shown in figure 6.17, 6.18 and table 6.5. 
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Figure 6.18 Binding affinity of analogues of oxyntomodulin with and without a 
C-terminal extension, to the rGLP-1 receptor. Rat lung cell membrane was the 
source of GLP-1 receptor and ^^^I-exendin-4 used as the competing peptide. I C 5 0 
value calculated from 3 separate experiments. 
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oxyntomodulin 29.1 ±4.4 72 
oxm-Ala38 194 ±0.32 41 
oxm-Ala38,39 20.8 ±3.1 39 
oxm-Ala38-42 38.6 ±7.5 21 
DHis 1 - Ala2-oxm(ex 15-
24,27-33) 
0.61 ±0.10 8 
DHis 1 - Ala2-oxm(ex 15-
24,27-33)-Ala38,39 
0.29 ± 0.04 7 
Table 6.5 The binding affinity for the rGLP-1 receptor and susceptibility to 
NEP mediated degradation of analogues of oxyntomodulin with C-terminal 
extensions. I C 5 0 value calculated from a minimum of 3 separate experiments. 
Values shown are mean ± SEM. Percentage degradation was calculated by 
comparing area under peak of ± NEP samples analysed by HPLC. 
6.4.4.2 Resistance to NEP mediated degradation of C-terminal modified peptide 
As predicted, extending the length of the peptide resulted in resistance to NEP mediated 
degradation, with the longest extension showing the greatest level of resistance to NEP 
mediated degradation (table 6.5 figures 6.19-6.21). 
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Figure 6.19 In vitro breakdown of oxm-Ala38 by NEP. Oxm-Ala38 (5 nmol) was 
incubated for 120 minutes with 500 ng NEP at 37°C. Digests were analysed by 
reverse phase HPLC using a 15-50% water/acetonitrile gradient over 35 minutes. 
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Figure 6.20 In vitro breakdown of oxm-Ala38,39 by NEP. Oxm-Ala38,39 (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°(C Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
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Figure 6.21 In vitro breakdown of oxm-Ala38-42 by NEP. Oxm-Ala38-42 (2 
nmol) was incubated for 120 minutes with 200 ng NEP at 37°C. Digests were 
analysed by reverse phase HPLC using a 15-50% water/acetonitrile gradient over 
35 minutes. 
6.4.4.3 Effects of analogues with C-terminal extensions on food intake in fasted 
mice 
Study A: Effect of C-terminus extension of oxyntomodulin on food intake in fasted 
mice 
Oxyntomodulin, oxm-Ala38, oxm-Ala38,39 and oxm-Ala38-42) (all peptides 
administered at 1400 nmol/kg) significantly reduced food intake at the 0-1 hour interval 
compared to the saline control group. The reduction in food intake caused by oxm-
Ala38,39 was significantly greater than that achieved oxyntomodulin at the 0-1 hour 
interval. All peptides failed to reduce food intake at any interval measure after the 0-1 
hour interval (figure 6.22). 
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Figure 6.22 Effect of oxyntomodulin analogues with C-terminal extensions on 
food intake in fasted mice. Oxyntomodulin and analogues oxm-Ala38, oxm-
Ala38,39 and oxm-Ala38-42 were administered at 1400 nmol/kg (n=7-8). *p<0.05, 
**p<0.01, ***p<0.001 compared to saline. ''p^O.OS compared to oxyntomodulin. 
Study B: Effect of DHisl-Ala2-oxTn(exl5-24.27-33)-Ala38.39 on food intake in fasted 
mice 
As previously demonstrated, DHisl-Ala2-oxm(exl5-24,27-33) (Inmol/kg) was a potent 
inhibitor of food intake, reducing food intake in the 0-1 and 1-2 hour intervals. DHisl-
Ala2-oxm(exl5-24,27-33)-Ala38,39 (Inmol/kg) failed to significantly reduce food 
intake in the first hour. However, food intake of animals treated by DHisl-Ala2-
oxm(exl5-24,27-33)-Ala38,39 (1 nmol/kg) was significantly less than that consumed by 
saline controls at the 1-2 and 2-4 hour interval. In the 2-4 hour interval DHisl-Ala2-
oxm(exl5-24,27-33)-Ala38,39 (1 nmol/kg) showed a non-significant reduction in food 
intake compared to DHis 1 -Ala2-oxm(ex 15-24,27-33) (1 nmol/kg) (figure 6.23). 
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Figure 6.23 Dose response of the effect of analogue DHisl-Ala2-oxm(exl5-24,27-
33)-Ala38,39 on food intake in fasted mice. DHisl-Ala2-oxm(exl5-24,27-33)-
Ala38,39 was administered at 0.5, 1.0 and 2.0 nmol/kg. DHisl-AIa2-oxm(exl5-
24,27-33) (2 nmol/kg) was tested for comparison (n=8-9). *p<0.05, **p<0.01, 
***p<0.001 compared to saline. 
6.4.5 Addition of a fatty acid side chain 
Addition of a fatty acid group to a peptide is an established technique for increasing the 
half-life of a peptide by protecting it from proteolytic degradation and renal filtration. 
Placement of the fatty acid group is critical, as the large side chain can alter peptide-
receptor interactions. 
6.4.5.1 Placement of the fatty acid: effect on affinity to the GLP-1 receptor 
As I previously demonstrated, substitution of Arg for Lys at position 33 had no effect 
on peptide affinity to the GLP-1 receptor. Other neutral modifications were the addition 
of Ala38,39-Lys40 extension, which bound to the GLP-1 receptor with similar affinity 
as oxm-Ala38,39. My previous results showed that a single Ala extension reduced 
affinity to the GLP-1 receptor over 6-fold. A single Lys extension also caused a 
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decrease in receptor affinity, reducing the binding affinity 3-fold. Results are 
summarised in table 6.6. 
The addition of a palmitoyl group altered the peptide's ability to bind to the rGLP-1 
receptor. Oxm-Lys30[palmitoyl] and oxm-Lys33[palmitoyl] bound with an IC50 of 
greater than 10000 nM, affinity of oxm-Lys3 8 [palmitoyl] for the GLP-1 receptor was 
5-fold lower than that of the non-acylated peptide. Addition of a fatty acid group to 
oxm-Ala38,39-Lys40 did not alter the peptides affinity to the GLP-1 receptor. Addition 
of a palmitoyl group to DHisl-Ala2-oxm(exl5-23,27-32)-Lys33-Ala38,39-Lys40, an 
analogue with high receptor affinity for the GLP-1 receptor, did not affect the analogues 
receptor affinity. Results are summarised in table 6.6. 
6.4.5.2 Placement of the fatty acid: effect on peptide resistance to NEP mediated 
degradation 
The addition of a palmitoyl group to peptides susceptible to NEP mediated proteolysis 
resulted in a reduction in observed degradation. As previously seen, extending the 
peptide length also reduced the susceptibility of the peptide to NEP mediated 
degradation. The results for all peptides investigated are summarised in table 6.6. 
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oxyntomodulin 29.1 ±4.4 72 
oxm-Lys3 0 [palmitoyl] >10000 48 
oxm-Lys33 31.2 ±3.7 57 
oxm-Lys33 [palmitoyl] >10000 43 
oxm-Ala38 194 ±0.32 41 
oxm-Lys38 100 ± 14.8 48 
oxm-Ly s3 8 [palmitoyl] 515 ±30.2 39 
oxm-Ala38,39 20.8 ±3.1 39 
oxm-Ala38,39-Lys40 27.8 ± 4.6 40 
oxm-Ala38,39-Lys40 [palmitoyl] 26.7 ±3.2 18 
DHisl-Ala2-oxm(exl5-23,27-
32)-Lys33-Ala38,39 
0.22 ± 0.04 7 
DHis 1 -Ala2-oxm(ex15-23,27-
32)-Lys33-Ala38,39-Lys40 
0.25 ± 0.05 5 
DHis 1 - Ala2-oxm(ex15-23,27-
32)-Lys33-Ala38,39-
Lys40 [palmitoyl] 
0.21 ± 0.04 5 
Table 6.6 The binding affinity for the rGLP-1 receptor and susceptibility to 
NEP mediated degradation of analogues of oxyntomodulin with C-terminal 
extensions and addition of a fatty acid group. I C 5 0 value calculated from a 
minimum of 3 separate experiments. Values shown are mean ± SEM. Percentage 
degradation was calculated by comparing area under peak of ± NEP samples 
analysed by HPLC. 
6.4.5.3 Placement of the fatty acid and its effect on food intake in fasted mice 
Study A: Effect of addition Lvs38 extension and addition of a fatty acid side chain on 
Lys38 
At the 0-1 hr interval, oxni-Lys38 (1400 nmol/kg) and oxm-Lys38[lauroyl] (1400 
nmol/kg) inhibited food intake to the same degree as oxyntomodulin (1400 nmol/kg), 
with administration of peptides resulting in a significantly greater inhibition of food 
intake than saline controls. Addition of an octanoyl and palmitoyl group reduced the 
peptides ability to inhibit food intake, with analogues oxm-Lys3 8 [octanoyl] (1400 
228 
nmol/kg) and oxm-Lys38[palmitoyl] (1400 nmol/kg) failing to significantly inhibit food 
intake compared to saline controls at any interval (figure 6.24). 
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Figure 6.24 Effect of oxyntomodulin analogues with a Lys extension and addition 
of a fatty acid groups on food intake in fasted mice. Oxyntomodulin and analogues 
oxm-Lys38, oxm-Lys38[octanoyl], oxm-Lys38[lauroyl] and oxm-Lys38[palmitoyl] 
were administered at 1400 nmol/kg (n=8-9). *p<0.05 compared to saline. 
Study B and C: Effect of C-terminal extension and addition of fatty acid to 
oxyntomodulin 
Addition of Lys at position 40 (oxm-Ala38,39-Lys40) (1400 nmol/kg) caused a small, 
non-significant reduction in the peptide's ability to inhibit refeeding in the 0-1 hour 
interval compared to oxm-Ala38,39 (1400 nmol/kg) (figure 6.25a). 
Administration of oxm-Ala38,39-Lys40[palmitoyl] (1400 nmol/kg) and oxm-Ala38,39-
Lys40[lauioyl] (1400 nmol/kg) caused a significantly greater reduction of food intake 
than oxyntomodulin and saline controls at the 0-1 hr interval (figure 6.25b). At the 1-2 
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and 2-4 hour interval both the acylated peptides showed a significantly greater reduction 
in food intake compared to oxyntomodulin. However, only oxm-Ala38,39-
Lys40[palmitoyl] in the 1-2 hour interval showed a significant reduction in food intake 
compared to saline (figure 6.25b). 
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Figure 6.25 Effect of a) Lys40 addition to oxm-Ala38,39 b) addition of fatty acid 
chain to Lys40 of oxm-Ala38,39-Lys40, on food intake in fasted mice. All peptides 
were tested at 1400 nmol/kg and administered via IP injection (n=8-9). *p<0.05, 
**p<0.01, ***p<0.001 compared to saline, 
oxyntomodulin. 
p<0.05, ''*'p<0.01, compared to 
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Study D and E: Investigation of C-terminal extension for fatty acid placement in a 
complex analogue 
Administration of DHisl-Ala2-oxm(exl5-23,27-33) (5 nmol/kg), DHisl-Ala2-
oxm(exl5-23,27-33)-Ala38-39 (5 rmiol/kg) and DHisl-Ala2-oxm(exl5-23,27-33)-
Ala38,39-Lys40 (5 rmiol/kg) resulted in a significant reduction of food intake compared 
to saline in all intervals up to and including the 4-8 hour interval (figure 6.26a). 
No significant difference in food intake was observed betv^een DHisl-Ala2-oxm(exl5-
23,27-32)-Lys33-Ala38,39 (3 nmol/kg), DHis 1 -Ala2-oxm(ex 15-23,27-33)-Ala38,39-
Lys40 (3 nmol/kg) and DHisl-Ala2-oxm(exl5-23,27-32)-Lys33-Ala38,39-Lys40 (3 
nmol/kg) at any interval measured (figure 6.26b). All peptides caused a significant 
reduction in food intake compared to saline up to the 4-8 hour interval. 
Study F and G: Investigation of addition of laurovl group on different C-terminal 
extensions 
At all intervals measured up to the 8-24 hour, administration of DHisl-Ala2-oxm(exl5-
23,27-32)-Lys33-Ala38,39-Lys40 (10 nmol/kg) and DHisl-Ala2-oxm(exl5-23,27-32)-
Lys33-Ala38,39-Lys40[lauroyl] (10 nmol/kg) resulted in a significant reduction on food 
intake compared to saline. No significant difference was observed between DHisl-
Ala2-oxm(exl5-23,27-32)-Lys33-Ala38,39-Lys40 and DHisl-Ala2-oxm(ex15-23,27-
32)-Lys33-Ala38,39-Lys40[lauroyl] at any interval measured (figure 6.27a). 
DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39-Lys40 (3 nmol/kg) and DHisl-Ala2-
oxm(ex 15 -23,27-3 3)-Ala3 8,3 9-Lys40 [lauroyl] (3 nmol/kg) significantly reduced food 
intake compared to saline at the 0-1 and 1-2 hour interval. The same peptides at 7 
nmol/kg continued to reduce food intake up to and including the 4-8 hour interval. No 
significant difference was observed between the acylated and non-acylated peptide at 
either dose or any interval (figure 6.27b). 
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Figure 6.26 Effect of C-terminal extensions to DHisl-Ala2-oxm(exl5-23,27-33) 
on food intake in fasted mice, a) analogues DHisl-Ala2-oxm(exl5-23,27-33), 
DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39 and DHisl-Ala2-oxm(exl5-23,27-33)-
Ala38,39-Lys40 were administered at 5 nmol/kg (n=8-9), b) analogues DHisl-Ala2-
oxm(exl5-23,27-32)-Lys33-Ala38,39, DHisl-Ala2-oxm(exl5-23,27-33)-Ala38,39-
Lys40 and DHisl-Ala2-oxm(exl5-23,27-32)-Lys33-Ala38,39-Lys40 were 
administered at 3 nmol/kg (n=8-9). *p<0.05, **p<0.01, ***p<0.001 compared to 
saline. 
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Figure 6.27 Effect of addition of fatty acid group to C-terminal extended 
peptides a) DHisl-Ala2-oxni(exl5-23,27-32)-Lys33-Ala38,39-Lys40 (n=8-9), b) 
DHisl-Ala2-oxni(exl5-23,27-33)-Ala38,39-Lys40, on food intake in fasted mice 
(n=8-9). *p<0.05, **p<0.01, ***p<0.001 compared to saline. 
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6.4.6 Modifications of oxyntomodulin to enhance longevity in vivo 
Addition of an albumin or PEG group to peptides has been reported to increase the 
duration of action of peptide hormones, such as insulin. The same principle was applied 
to oxyntomodulin analogues. 
6.4.6.1 Effect of addition of PEG and mouse albumin to oxyntomodulin analogues 
on affinity to the GLP-1 receptor 
The comparator peptides 6403 and 6404 (table 6.1a and b) bound with similar affinity 
as other modified analogues to the GLP-1 receptor, whereas PEGylated analogue 6405 
(table 6.1.b) bound with a 20-foId lower affinity. Conjugation of a mouse albumin 
group (analogue 5946m table 6.1.b) also resulted in a large reduction in affinity to the 
GLP-1 receptor (results summarised in table 6.7). 
DHisl-Aia2-oxm(exl5-23^7-32)-Lys33-Ala38,39-
Glu40,41-Lys42 (6403) 
0.44 ± 0.03 
DHisl-Ala2-oxm(exl5-23,27-32)-Lys33-Ala38,39-
Glu40,41-Lys42[octanoyl] (6404) 
0.17 ±0.05 
DHisl -Ala2-oxm(exl 5-23^7-32)-Lys33-Ala38,39-
Glu40,41-Lys42pPEG] (6405) 
10.2 ±2.1 
DHis 1 -Ala2-oxm(exl 5-23,27-33)-Ala38,39-
Lys40,41,42[Malb] (5946) 
7.2 ±0.85 
DHisl-Ala2-oxm(exl5-23,27-32)-Lys33-Ala38,39-Lys40 0.25 ± 0.04 
Table 6.7 The binding affinity for the rGLP-1 receptor of analogues with C-
terminal extensions and addition of a fatty acid, albumin or PEG group. I C 5 0 value 
calculated from a minimum of 3 separate experiments. Values shown are mean ± 
SEM. 
6.4.6.2 Effect of addition of PEG group and albumin to oxyntomodulin analogue 
on food intake in fasted mice 
Study A: Effect of PEGvlation of a potent oxyntomodulin analogue on food intake in 
fasted mice 
DHisl-Ala2-oxm(exl5-23,27-32)-Lys33-Ala38,39-Glu40,41-Lys42 (6403) (6 nmol/kg) 
was used as a comparator, and caused a significant reduction in food intake compared to 
saline at all intervals up to and including 4-8 hour. The acylated form of the peptide 
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(6404) (6 nmol/kg) and PEGylated variant (6405) (6 nmol/kg) caused a significant 
reduction in food intake in the 0-1, 1-2 and 2-4 hour interval (figure 6.28). 
Study B: Investigation of addition of albumin on peptide bioactivitv 
Oxyntomodulin (1400 nmol/kg) and DHisl-Ala2-oxm(exl 5-23,27-33)-Ala3 8,39-
Lys42[lauroyl] (6406) (6 nmol/kg) were used as comparators. Oxyntomodulin caused a 
significant reduction in food intake in the 0-1 hour interval only, as previously 
observed. Analogue 6406 reduced food intake at all intervals measure up to and 
including the 4-8 hour interval. DHisl-Ala2-oxm(exl5-23,27,33)-Ala38,39-
Lys40,41,42[Malb] (5946) at 10 nmol/kg failed to reduce food intake in all intervals 
measured. The highest dose of analogue 5946 tested, 1000 nmol/kg, caused a 
significant reduction in food intake up to and including the 2-4 hour interval (figure 
6.29). 
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Figure 6.28 Effect of PEGylation of analogue on food intake in fasted mice. 
Analogue 6403, 6404 and 6405 were administered at 6 nmol/kg (n=8-9). *p<0.05, 
**p<0.01, ***p<0.001 compared to saline. 
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Figure 6.29 Dose response of the effect of addition of an albumin group on food 
intake in fasted mice. Analogue 5946 was administered at 10, 100 and 1000 
nmol/kg. Oxyntomodulin (1400 nmol/kg) and analogue 6406 (6 nmol/kg) were 
tested for comparison (n=8-9). *p<0.05, ***p<0.001 compared to saline. 
6.4.7 Combined modification 
The successful modifications described above were combined to make the following 
peptides, 6421 DHis 1 -Ala2-oxm-Glul 5-Glnl 6-Glul 7-Leul 8-Val 19-Lys20-Tyr21 -
Phe22-Ile23-oxm-(ex27-32)-Lys33 and 6407 DHisl-Ser2-oxm-Glul5-Glul6-Glul7-
Leul8-Vall9-Lys20-Tyr21-Phe22-Ile23-oxm-(ex27-32)-Lys33. 
6.4.7.1 Analogues of oxyntomodulin: affinity for and bioactivity at the GLP-1 
receptor 
Affinity to and bioactivity at the GLP-1 receptor was measured at both the human and 
rat GLP-1 receptor. Analogues 6421 and 6407 bound with an order of magnitude 
higher than native oxyntomodulin to both the human and rat receptor, but with lower 
affinity than exendin-4. Peptide bioactivity at the GLP-1 receptor was higher for 6421 
and 6407 than oxyntomodulin. Analogue 6421 bound with higher affinity to and was 
more bioactive than 6407 at both the human and rat GLP-1 receptor. Results are 
summarised in table 6.8. 
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• 
oxm 29.1 ±4.4 53.4 ± 1.6 1.8 ±0.2 6.7 ± 1.0 
exendin-4 0.31 ±0.05 0.26 ± 0.05 0.016 ± 0.004 0.081 ±0.021 
6421 0.98 ±0.11 6.1 ± 1.02 0.021 ± 0.005 0.74 ±0.15 
6407 1J^± &24 12.5 ±3.51 0.024 ± 0.004 1.2 ±0.24 
Table 6.8 Binding affinity and bioactivity of modified analogues of 
oxyntomodulin at the rat and human GLP-1 receptor. Binding studies were 
completed using either rat lung or cell membrane of cells overexpressing hGLP-1 
receptor as the source of receptor and ^^^I-exendin-4 as the competing peptide. 
cAMP production was measured in CHO cells overexpressing rGLP-1 receptor 
and HEK 293Tcells overexpressing hGLP-1 receptor. I C 5 0 and E C 5 0 values were 
calculated from a minimum of 3 separate experiments, errors shown are ± SEM. 
6.4.7.2 Susceptibility of analogues of oxyntomodulin to DPP IV and NEP mediated 
degradation 
Analogues 6421 and 6407 were completely resistant to DPP IV mediated breakdown, 
with 100% of parent peptide remaining following an in vitro test peptide (2 nmol) ± 1 0 
mU DPP IV incubated for 2 hours at 37°C (data not shown). Results of in vitro studies 
investigating the analogue's susceptibility to NEP mediated breakdown demonstrated 
that both peptides were almost completely resistant to breakdown at test conditions 
(6421 4% breakdown, 6407 7% breakdown (results not shown). 
6.4.7.3 Effect of oxyntomodulin, exendin-4 and analogues 6421 and 6407 on food 
intake in fasted mice 
Oxyntomodulin (1400 nmol/kg) significantly reduced food intake compared to saline 
controls at the 0-1 hour interval. Mice treated with analogues 6421 (6 nmol/kg), 6407 
(6 nmol/kg) or exendin-4 (6 nmol/kg) consumed significantly less food than mice 
treated with saline oxyntomodulin (1400 nmol/kg) at all intervals up to 8-24 hours. At 
0-1 hour the reduction in food caused by 6421 and 6407 was significantly less than the 
reduction caused by the same dose of exendin-4. In the 8-24 hour interval, 6421 was 
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the only peptide to cause a significant reduction in food intake compared to saline 
(figure 6.30). 
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Figure 6.30 Effect of oxyntomodulin analogues with combined modifications on 
food intake in fasted mice. Oxyntomodulin analogues 6421 and 6407 were 
administered at 6 nmol/kg. Oxyntomodulin (1400 nmol/kg) and exendin-4 (6 
nmol/kg) were tested for comparison (n=9-10). *p<0.05, **p<0.01, ***p<0.001 
compared to saline. **^p<0.01, *^^p<0.001 compared to exendin-4. 
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6.5 Discussion 
Experiments described in previous chapters demonstrated that small changes to the 
sequence of oxyntomodulin can have large effects on the affinity of the peptide to the 
GLP-1 receptor, its bioactivity and its resistance to protease degradation. Experiments 
described in this chapter were designed to examine the effect of further modifications to 
the structure of oxyntomodulin on bioactivity, with the aim of increasing the half-life of 
the peptide. 
The experiments described in Chapter four suggested that oxyntomodulin was 
susceptible to DPP IV mediated degradation, and the degree of susceptibility was 
largely, but not completely, determined by the sequence of amino acids at position 1, 2 
and 3. Analogues with sequence changes to the mid-section and C-terminus of the 
molecule were as readily broken down by DPP IV as native oxyntomodulin, confirming 
the importance of the N-terminus for determining susceptibility to DPP IV mediated 
breakdown. The importance of protection from DPP IV mediated degradation was 
highlighted by the improved longevity of the anorectic effects of N-terminally modified 
versions of oxm(exl 5-24,27-33). Substitution of DHis for LHis at position 1 did not 
improve the biological properties of oxyntomodulin as it reduced affinity to the GLP-1 
receptor by over 30-fold. However, such modifications to analogues with changes to 
the mid-section and C-terminus of the molecule were well tolerated and caused no loss 
of affinity to the GLP-1 receptor. This observation is in agreement with the finding that 
N-terminally truncated form of exendin-4, exendin(9-39) maintaining high affinity to 
the GLP-1 receptor (Turton, et al, 1996). Together these observations indicate that 
some or all of the exendin-4 residues at 15-24 and 27-33 are in determining the peptides 
affinity for the GLP-1 receptor in affinity. 
The results of experiments described in Chapter 5 showed substitution of amino acids 
from the known a-helical segment of exendin-4 into the mid-section of oxyntomodulin 
increased the affinity of the peptide for the GLP-1 receptor and increased the bioactivity 
of the peptide. Changes to the exendin-4 insert were then tested in an attempt to 
determine the optimal changes to improve the bioactivity of oxyntomodulin. Many of 
the sequence changes tested were taken from the a-helix domain of latrotoxin (the 
venom of Latrodectus spiders). Changes were considered useful if they either increased 
potency or duration of the anorectic actions of the peptide. The comparator peptides 
used in these studies contained inserts of exendin-4 and had previously been shown to 
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be more resistant than oxyntomodulin to NEP mediated breakdown. Resistance to NEP 
mediated breakdown was therefore not examined for every novel peptide. 
An unexpected characteristic of some of the amino acid changes made was an apparent 
delay to the onset of the peptide's maximal effect of inhibition of food intake. 
Substitution of Gin for Glu at position 16 and Leu for Arg at position 18 reduced the 
peptide's effect on food intake inhibition in the first hour, but extended the duration of 
the anorectic effects of the peptide. The tested amino acid substitutions at position 16 
and 18 caused only small changes in peptide's affinity to the GLP-1 receptor suggesting 
that factors other than receptor affinity caused these changes in bioactivity profile. 
Possible reasons for the delayed onset of action include a slower rate of peptide 
absorption, reduced potency or a longer half-life. The drive to eat in fasted mice is 
much higher in the first hour of refeeding than in the second, when they are relatively 
more satiated. Therefore, peptides with a relatively low potency might fail to inhibit 
food intake in the first hour but, may have sufficiently potent anorectic effects to reduce 
food intake in these mice once their hunger has been partially satiated if they are still 
bioactive at this time point. Indeed, a slower onset of action could be a useful 
characteristic of the peptide if it was to be used as a therapeutic agent, as it may reduce 
nausea, a common side effect of administration of exendin-4 to humans. Other 
substitutions to the mid-section considered useful were those which showed improved 
longevity of their anorectic effects or improved affinity to the GLP-1 receptor. 
Substituting Lys for Ser at position 33 increased the duration of action of both 
oxyntomodulin and a more potent analogue of oxyntomodulin. Combining specific C-
terminal sequence changes with specific mid-section changes resulted in analogues over 
200 times more potent at inhibiting food intake than native sequence oxyntomodulin 
and with anorectic effects that lasted for up to 8 hours longer. The peptides bound to 
both the human and rat GLP-1 receptor with an affinity several orders of magnitude 
higher affinity than oxyntomodulin. They were also completely protected from in vitro 
DPP IV mediated degradation and had greatly reduced susceptibility to in vitro NEP 
mediated degradation compared to oxyntomodulin. 
Increasing the length of native oxyntomodulin by addition of extra amino acids at the C-
terminal resulted in a small improvement in the duration of the anorectic effects of the 
peptide. This improvement may be a consequence of larger peptides being more 
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resistant to proteolytic degradation and/or a reduced rate of renal filtration (Hupe-
Sodmann et al , 1995; Knudsen et al , 2000). Analogues with longer amino acid 
extensions were more resistant to NEP mediated degradation and had longer acting 
anorectic effects. Addition of C-terminal extensions to analogues resistant to NEP 
mediated degradation did not enhance the duration of their anorectic effects. This 
suggests that the improvements in the biological properties of these extended versions 
of oxyntomodulin are primarily due to their resistance to NEP mediated degradation 
rather than reduced renal filtration. It also suggests that amino acid extensions would 
not be a useful strategy for improving the duration of the anorectic effects of analogues 
already resistant to NEP mediated degradation. 
The addition of acyl groups, coupling to large proteins or coupling to a PEG group, 
have previously been shown to extend the half-life of a peptide (Baggio et al., 2004a; 
Lee et al., 2005; Nauck et al., 2006), but were largely ineffective at increasing the 
duration of the anorectic actions of oxyntomodulin. Addition of acyl groups to C-
terminally extended oxyntomodulin did further increase the duration of peptide action. 
However, this effect was dependent upon placement of the side chain. It seems 
probable that stearic hindrance of receptor binding occurred if the side chain was too 
close to the peptide binding site. As observed with C-terminal extensions, addition of 
acyl groups improved the resistance of native oxyntomodulin to NEP mediated 
degradation and duration of its anorectic effects. However, no improvements in 
bioactivity were observed when acyl groups were added to analogues of oxyntomodulin 
which were already resistant to NEP mediated degradation. These results suggest that 
increased resistance to proteolytic degradation is the likely cause of the observed 
increased bioactivity of oxyntomodulin analogues coupled to acyl groups. Addition of 
mouse albumin or a PEG group reduced the affinity of peptide to the GLP-1 receptor 
which likely explains the modest effects of these analogues food intake. 
Thus while it is possible to modify the biological activity of oxyntomodulin by the 
addition of large side chains or molecules, these changes did not confer additional 
bioactivity on the analogues which already had primary structures modified to greatly 
improve their bioactivity. Given the complications such groups cause to the analogue 
synthesis process, I did not further investigate these types of modification. 
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Chapter 7 
The effect of oxyntomodulin 
analogue 6421 on energy 
homeostasis in rodents 
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7.1 Introduction 
Peripheral signals of appetite from the gastrointestinal tract acutely regulate food intake. 
These signals have also been shown to control longer-term body weight homeostasis. 
For example, rodent studies have demonstrated that repeated administration of ghrelin 
increases body weight gain and adiposity (Wren et al , 2001a), whereas chronic 
administration of PYY (3-36) (Batterham et al., 2002), exendin-4 (Mack et al., 2006) 
and oxyntomodulin (Dakin et al., 2004) cause a reduction in bodyweight gain and 
adiposity. 
The weight loss which occurs following repeated IP oxyntomodulin injection is 
postulated to be due to an increase in energy expenditure as well as a decrease in energy 
intake. This is demonstrated by the fact that oxyntomodulin treated rats lose more body 
weight than rats saline treated rats and those pair-fed to the oxyntomodulin group 
(Dakin et al., 2002). Whilst oxyntomodulin has been reported to increase activity-
related energy expenditure by 143+/-109 kcal/day or 26.2+/-9.9% in man (Wynne et al., 
2005), no change in energy expenditure of rodents treated with oxyntomodulin was 
observed when measured directly (Baggio et al., 2004b). It is important to characterise 
the mechanism of action by which oxyntomodulin reduces body weight in rodents in 
order to elucidate its possible role as an anti-obesity therapy in humans. 
The central satiety action of oxyntomodulin is thought to occur via the brainstem. 
Peripheral administration of oxyntomodulin has been shown to induce c-Fos (a marker 
of neuronal activity) in the ARC (Dakin et al., 2004; Horvath, 2005), PVN, area 
postrema and NTS (Baggio et al., 2004b; Horvath, 2005). Within the hypothalamus it is 
possible that the anorectic effect may be mediated by an increase in release of a-MSH 
(Dakin et al., 2004) or by a decrease in the orexigenic NPY/AgRP neuropeptides. It has 
been hypothesised that a positive effect of oxyntomodulin on energy expenditure in 
rodents may occur by stimulating TRH release in the hypothalamus, preventing the 
normal suppression observed in plasma TSH during fasting (Dakin et al., 2002). 
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7.2 Aims 
Use analogues of oxyntomodulin with an increased potency and resistance to proteolytic 
degradation to: 
1) Examine the affect of chronic administration of these peptides on food intake 
and body weight change in rats and obese mice; 
2) Investigate if administration of analogue 6421 causes a change in energy 
expenditure; 
3) Investigate the potential mechanism of increased energy expenditure caused 
by administration of analogue 6421. 
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7.3 Materials and methods 
7.3.1 Custom designed analogues of oxyntomodulin 
Peptide analogues of oxyntomodulin used in this chapter (table 7.1) were manufactured 
using the protocols described in section 2.1. 
7.3.1.1 Animals 
Animal work was completed as described in section 2.2, unless otherwise stated. 
7.3.2 Chronic treatment of diet induced obesity mice with analogues 6421 and 
6407 
A physiologically relevant model of obesity, the diet induced obese (DIO) mouse was 
used to investigate weight loss. Obesity was induced by feeding mice high fat diet 
(energy content 60% fat. Research Diets Inc) for 16 weeks prior to study. Mice were 
group-housed (8 per cage) during the first 12 weeks of high fat diet treatment and then 
singly housed for 4 weeks prior to study, allowing mice to acclimatise to the housing 
conditions used during the study period. Immediately prior to commencing the study, 
the average mouse body weight was 42.3 ±2.26 g. Mice were randomised into 
treatment groups by body weight (n=8-9). 
Mice were fasted from 16:00 on the night preceding the study. On days 0 and 2 to 21, 
mice received SC injection of peptide (6407 or 6421, 20 nmol/kg) or vehicle between 
0900-1000, and their body weight and food intake measured. The last injection was on 
study day 21. From study day 22-37 mouse body weight and food intake was 
monitored daily between 0900-1000. Continuous data was statistically analysed by 
GEE and Mann-Whitney two-sample rank sum test. All other data sets were analysed 
by one-way ANOVA with a Bonferroni post-hoc test. 
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Peptide Residue number 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 
oxyntomotlulin H S Q G T F T S D Y S K Y L D S R R A Q D F V Q W L M N T K R N R N N 1 A 
exen(iin4 H G E G T F T S D L S K Q M E E E A V R L F 1 E W L K N G G P S S G A P P P S 
6407 dH S Q G T F T s D Y s K Y L E E E L V K Y F 1 Q w L K N G G P S K N N 1 A 
6421 dH A Q G T F T s D Y s K Y L E Q E L V K Y F 1 Q w L K N G G P S K N N 1 A 
Q Unique amino acid changes 
Q Position of exendin-4 residues that differ to those found in oxyntomodulin, and denotes position of exendin-4 residues in 
analogues 
dH = DHis stereoisomer of histadine 
Table 7.1 Peptides used in the studies described in chapter 7 
w 
7.3.3 Chronic administration of analogues 6407 and 6421 to rats 
To ensure the effects of analogues 6407 and 6421 observed in study 7.3.2 were not 
specific to mice, further studies were completed in rats. In a similar study design to 
7.3.2, rats received a daily SC injection of 6407 or 6421 (peptides tested at 5 and 20 
nmol/kg) for 13 days, and their food intake and body weight were monitored for a 
further 20 days post-treatment. Prior to the start of the study, rats had a body weight 
between 264.3-292.1 g (mean body weight 274.38 ± 1.48 g)., and were randomised into 
groups by body weight (n=8-9). Rats were fasted 24 hours prior to the start of the study 
and received a reduced dose of peptide (3 or 10 imiol/kg) on day zero, their first 
treatment day. From day 1 to day 12 rats were injected with 6407, 6421 (5 or 20 
nmol/kg) or vehicle between 0900-1000 and their food and body weight recorded. 
Between days 13 and 32 rats' body weight and food intake was monitored and recorded. 
Continuous data was statistically analysed by GEE and Mann-Whitney two-sample rank 
sum test. All other data sets were analysed by one-way ANOVA with a Bonferroni 
post-hoc test. 
7.3.4 Continuous administration of peptide analogue 6421 to DIO mice 
Studies described in 7.3.2 and 7.3.3 demonstrated that analogue 6421 was more potent 
than analogue 6407 at reducing body weight and body weight gain. It was therefore 
selected for use in further studies. 
DIO mice (obesity induced as described in section 7.3.2), body weight between 54.3-
36.1 g (mean body weight 44.8 ± 1.78 g). Mice received continuous administration of 
oxyntomodulin (2000 pmol/kg/min, equivalent to 2880 nmol/kg over a 24 hour period), 
6421 (10 and 30 pmol/kg/min, equivalent to 14.4 and 43.2 nmol/kg over a 24 hour 
period) or vehicle (saline) from an equilibrated subcutaneous osmotic pump (n=8-9) 
(see section 2.2.5.1). Mice underwent surgery in the morning of day. A 7 day Alzet® 
osmotic pump (model 1007D) was implanted and their food intake and body weight 
monitored for a further 7 days. Measurements were taken between 0900-1000. After 
body weight and food intake measurements on day 7 the animals were culled and 
pumps removed. Remaining contents was removed from the pump and stored at -20°C 
until analysis. Continuous data was statistically analysed by GEE and Mann-Whitney 
two-sample rank sum test. All other data sets were analysed by one-way ANOVA with 
a Bonferroni post-hoc test. 
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7.3.5 HPLC analysis of recovered pump content 
Samples collected from study 7.3.4 were analysed by HPLC, using a 2-45% 
acetonitrile/water gradient (both containing 0.05% TFA) over 50 minutes (Jasco HPLC 
system, solvent delivery system PU-2080 plus, autosampler AS-2057 plus, degasser 
DG2080-53, dynamic mixer 2080-32 UV detector uv-2075, using a Phenomenex 
Gemini Cig (5-|im particles) 250 mm x 4.6 mm column). All samples were stored at -
20°C prior to analysis. Samples were loaded onto the column in 5 nmol 
(oxyntomodulin) and 15 nmol (6421) quantities. 
7.3.6 Continuous administration of analogue 6421 to rats and pair-feeding study 
The experiment described in section 7.3.4 demonstrated a reduction in weight gain of 
rats treated with analogue 6421 compared to saline controls. To further investigate the 
mechanisms by which this could occur, in particular through a reduction in food intake 
and/or change in energy expenditure, the following study was completed. 
As this was a pair-fed study, surgery of rats took place on two consecutive days where 
all rats had an Alzet® osmotic pump model 2001 implanted. On day 1 of surgery, rats 
treated with 6421 (30 pmol/kg/min) (n=12) and half of the vehicle control group (n=6) 
had pumps implanted. On surgery day 2, the pair-fed group (n=12) and 6 saline 
controls had pumps containing saline implanted. Pair-fed animals had daily food 
restricted to the median quantity consumed by the analogue 6421 group (pair-fed to 
same study day). Body weight of rats and their food intake was measured at 0900 on 
days 1 to 7 post-surgery. On the animals' seventh study day, they were transferred to 
the metabolic cages (see section 2.2.6.1) and their food removed. Over a six hour light-
phase period their metabolic parameters were measured. Throughout the study, no 
significant difference was observed between the control animals which had undergone 
surgery on day 1 and those on day 2, and the data was thus merged for statistical and 
graphical analysis. Continuous data was statistically analysed by GEE and Mann-
Whitney two-sample rank sum test. All other data sets were analysed by one-way 
ANOVA with a Bonferroni post-hoc test. 
7.3.7 Static incubation of hypothalamic explants and pituitary quarters 
Studies were completed as described in section 2.8. Briefly, oxyntomodulin (10, 100 
and 1000 nM), exendin-4 (10, 100 and 1000 nM) and analogue 6421 (1, 10, 100 and 
1000 nM) were tested for their ability to stimulate a-MSH release from hypothalamic 
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explants. Release of TRH was measured following stimulation of hypothalamic 
explants with oxyntomodulin (10, 100, and 1000 nM) and analogue 6421 (10, 100, 1000 
nM). Release of TSH was measured following stimulation of pituitary quarters with 
oxyntomodulin (10, 100 and 1000 nM) and analogue 6421 (1, 10, 100 and 1000 nM). 
Hormone levels from aCSF were measured by RIA (appendix C). 
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7.4 Results 
7.4.1 Chronic treatment of obese mice (diet induced) with oxyntomodulin 
analogues 6421 and 6407 
7.4.1.1 Body weight change 
Fasting on the day preceding the study (study day -1) caused a reduction in body weight 
to a similar degree in all groups (saline -2.75 ± 0.22 g; 6407 -2.75 ± 0.19 g; 6421 -2.40 
± 0.40 g) (figure 7.1). Saline control animals returned to pre-fasted body weight on day 
11, while treatment groups did not return to pre-fasting body weight during the 
treatment period (change in body weight from day -1 to day 22 (last injection on day 
21): saline 0.27 ± 0.25 g; 6407 -2.26 ± 0.74 g; 6421 -3.89 ± 0.56 g) (figure 7.1). 
Longitudinal analysis of differences between groups confirmed that chronic 
administration of oxyntomodulin analogues caused significant changes in the animals' 
body weight (GEE p=0.001). Further analysis of the results demonstrated both peptides 
caused a significant reduction in body weight during the treatment period, except 
treatment group 6407 on day 2, (no injection on day 1) and these effects were 
maintained into the post-treatment period (figure 7.1). Whilst a trend was observed for 
analogue 6421 to cause a greater reduction in body weight than analogue 6407, there 
were no significant differences between groups on any day. 
During the 15 day monitored post-treatment period, body weight of all groups increased 
(figure 7.1). Average body weight of the group treated with analogue 6407 returned to 
pre-fasting levels by study day 37, whilst body weight of those treated with analogue 
6421 remained lower than pre-fasting levels at the end of the study (saline 1.60 ± 0.34 
g; 6407 0.163 ± 0.67 g, 6421 -1.43 ± 0.68 g) (figure 7.1). 
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Figure 7.1 Body weight change from baseline (pre-fasting levels). Bodyweight 
was measured daily at 09:00, change from day -1 values calculated daily (n=8-9). 
*p<0.05, **p<0.01 6407 compared to saline, ^p<0.05, ^^p<0.01 6421 compared to 
saline. 
7.4.1.2 Food intake 
Analogues 6407 and 6421 caused a significant reduction in cumulative food intake 
during the treatment period, compared to saline controls. Cumulative food intake of 
mice treated with analogue 6421 was significantly less than the saline control group at 
all points in the treatment period (figure 7.2a). Cumulative food intake of mice treated 
with analogue 6407 was significantly less than that consumed by saline controls up to 
day 12 of the treatment period (figure 7.2a). Longitudinal analysis of cumulative food 
intake confirmed a significant difference between treatment groups (GEE, p-0.020). 
Total food intake of mice treated with oxyntomodulin analogues was less than those 
receiving a saline control during the treatment period (total food intake and % of saline 
at day 22: saline 62.62 ± 3.66 g, 6407 56.73 ± 2.72 g (90.59 ± 4.42%) and 6421 52.98 ± 
1.98 g (84.61 ± 3.16% ) (figure 7.2a, 7.2b). Analyses of cumulative food intake as a 
percentage of saline shows analogues were most potent at reducing food intake at the 
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start of the treatment period (figure 7.2b). This trend is further exemplified when food 
intake is analysed in weekly intervals. Analogues of oxyntomodulin caused a 
significant reduction in food intake in days 1-7 (total food intake and percentage of food 
intake compared to saline: saline 21.25 ± 1.23 g, 6407 17.25 ± 0.56 g (15.96 ± 3.61%), 
6421 16.31 ± 0.96 g (23.26 ± 4.53%)) (figure 7.4a). A non-significant reduction in food 
intake was observed in mice treated with oxyntomodulin analogues in weeks 2 and 3 of 
the treatment period (week 2 total food intake: saline 19.43 ± 1.26 g; 6407 18.02 ± 1.05 
g, 6421 16.94 ± 0.70 g, week 3 total food intake: saline 19.38 ± 1.05 g; 6407 18.31 ± 
0.93 g, 6421 17.42 ± 0.61 g) (figure 7.4b,c). A trend for analogue 6421 to cause a 
greater reduction in food intake than 6407 was observed when daily food intake was 
analysed, with 6421 reducing food intake significantly on 5 of the treatment days, 
whereas 6407 did so on only 3 days (figure 7.3). 
Daily food intake of the treatment groups during the monitored post-treatment period 
was similar to the saline control groups (figure 7.3). Analysis of cumulative food intake 
during the post-treatment period showed a trend of a small increase in the food intake in 
mice which had received oxyntomodulin analogues during the treatment period 
(percentage of cumulative food intake compared to saline on study day 37: 6407 94.25 
± 3.74%, 6421 89.90 ± 2.72%) (figure 7.2b). However, no significant differences in 
food intake were present when food intake in the post-treatment period was analysed in 
weekly intervals (figure 7.5a, b). 
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7.4.2 Daily subcutaneous administration of 6407 and 6421 to rats 
7.4.2.1 Effect of administration of 6407 and 6421 on rat body weight 
Between days 1-12 (period of full compound dosage) body weight increase of the 
treatment groups was less than that of the saline control group (body weight change 
between days 1-12: saline 71.89 ± 4.89 g; 6407 5 nmol/kg 65.89 ± 2.98 g; 6407 20 
nmol/kg 56.33 ± 3.13 g; 6421 5 rmiol/kg 66.13 ± 4.97 g; 6421 20 rmiol/kg 42.75 ± 4.02 
g) (figure 7.6a). Generalised estimating equation analysis confirms a significant 
difference between groups (p=0.024), and a dose dependent effect on body weight was 
observed for analogue 6421. Further analysis identified that rats treated with 20 
nmol/kg gained significantly less weight than saline controls during parts of the 
treatment and post-treatment period (7.6a). 
Analysis of body weight change by day highlights that both analogues were most 
effective at preventing body weight gain at the start of the treatment period (figure 
7.6b). Body weight for all treatment groups except 20 nmol/kg 6421 was initially 
reduced and then maintained at a fixed lower level during the treatment period (figure 
7.6b). Analogue 6421 at 20 nmol/kg was the only treatment to cause a significant 
difference in body weight change on any specific day, with body weight on days 3 and 
5-20 significantly lower than saline controls (figure 7.6b). 
During the monitored post-treatment period, the increase in body weight was greater for 
all treatment groups than the control group (change in body weight between days 13-32: 
saline 63.89 ± 3.77 g; 6407 5 nmol/kg 65.89 ± 2.98 g; 6407 20 nmol/kg 80.57 ± 4.99 g; 
6421 5 nmol/kg 65.00 ± 5.01 g; 6421 20 nmol/kg 72.25 ± 6.13 g) (figure 7.6a). 
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Figure 7.6 a) Cumulative b) daily (percentage of saline control) body weight 
change of rats treated with 6407, 6421 (5 and 20 nmol/kg) or vehicle (n=8-9). Rats 
received daily SC injections of peptide on days 0-12, bodyweight was measured 
daily at 09:00 on days 0-32. "p^ O.OS, '^p<0.01 20 nmol kg 6421 compared to saline. 
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7.4.2.2 Effect of administration of oxyntomodulin analogues 6407 and 6421 on food 
intake in rats 
Cumulative food intake during the study was significantly different amongst groups 
(p=0.04, GEE test). Further analysis confirmed both 6421 and 6407 at 20 nmol/kg 
caused a significant reduction in food intake compared to saline controls during parts of 
the treatment and post-treatment phases (figure 7.7a). The overall trend observed was 
of analogues at 20 nmol/kg causing a reduction in food intake during the treatment 
period and analogue 6421 causing a greater reduction than analogue 6407. 
At 5 nmol/kg analogues 6421 and 6407 caused a small non-significant reduction in 
daily food intake during the treatment period (figure 7.7b). Cumulatively this decrease 
was insufficient to result in a significant difference in total food intake (figure 7.8a). 
Statistical analysis of daily food intake during the treatment period shows no significant 
difference between groups (GEE p=0.419). However, analysis of daily food intake 
showed a significant reduction in food intake on several days of the treatment period in 
the group receiving 20 nmol/kg analogue compared to saline controls (figure 7.7b). 
Total food intake during the treatment period was significantly lower in groups 
receiving 20 nmol/kg 6407 and 6421 compared to saline controls (total food intake days 
1-13: saline 428.45 ± 10.23 g; 6407 5 nmol/kg 414.20 ± 12.18 g; 6407 20 nmol/kg 
383.28 ±11.20 g; 6421 5 nmol/kg 416.56 ± 16.03 g; 6421 20 nmol/kg 358.56 ± 8.47 g) 
(figure 7.8a). 
No significant reduction in daily food intake was observed in the post-treatment period, 
except for 20 nmol/kg 6421 on day 13 (peptide administered on day 12 and its affects 
on food intake measured on day 13) (figure 7.7b). During the monitored post-treatment 
period a significant increase in daily food intake compared to saline was observed on 
several occasions in the 20 nmol/kg 6407 group (figure 7.7b). No sigmficant difference 
in total food intake was observed between groups during the monitored post-treatment 
phase (figure 7.8b). 
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Figure 7.7 a) Cumulative, b) daily (as a percentage of saline control), food 
intake. Rats received daily injections of 6407, 6421 (5 and 20 nmol/kg) or vehicle 
on days 1-12 and food intake measured daily at 09:00 on days 0-32 (n=8-9). 
*p<0.05, **p<0.01, ***p<0.001 20 nmol/kg 6407 compared to saline, "p^O.OS, 
''^ pSO.Ol, ''''*p<0.001 20 nmol/kg 6421 compared to saline. 
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7.4.3 Continuous administration of oxyntomodulin analogue 6421 to DIO mice 
7.4.3.1 Effect of continuous administration of oxyntomodulin and analogue 6421 on 
body weight of DIO mice 
Mice were organised into groups with equal median body weight prior to surgery. All 
groups, including saline controls, lost weight during the 7 day post-implant period 
(weight loss over 7 day treatment period: saline -0.78 ± 0.42 g, 2000 pmol/kg/min 
oxyntomodulin -1.33 ± 0.16 g, 6421 10 pmol/kg/min -1.51 ± 0.38 g, 6421 30 
pmol/kg/min -4.18 ± 0.53 g (figure 7.9a). Generalised estimate equation confirmed that 
overall the treatment groups were significantly different (p=0.001). Cumulative weight 
change for all groups was significantly different to the saline control group up to day 3. 
Cumulative body weight gain of animals receiving 30 pmol/kg/min 6421 was 
significantly reduced compared to saline controls throughout the study period (figure 
7.9.a). Analysis of total weight loss over the seven day study period demonstrates that 
30 pmol/kg/min caused a significantly greater percentage weight loss than saline or 
2000 nmol/kg/min oxyntomodulin (figure 7.9b). 
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Figure 7.9 Body weight change a) cumulative body weight change, b) % weight 
loss on day 7 of starting weight. Body weight measured daily at 09:00 (n=8-10). a) 
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7.4.3.2 Effect of continuous administration of oxyntomodulin and analogue 6421 on 
food intake in DIO mice 
All treatment groups consumed less food than the saline control group during the 
treatment period (total food intake on day seven post-implantation: saline 18.24 ± 0.52 
g; oxyntomodulin 15.47 ± 0.83 g; 6421 10 pmol/kg/min 15.94 ± 0.60 g; 6421 30 
pmol/kg/min 11.98 ± 0.70 g (figure 7.11). Analysis by GEE confirmed significant 
differences were present between treatment groups' cumulative food intake (p=0.001) 
and daily food intake (p=0.001). Food intake of animals treated with 30 pmol/kg/min 
analogue 6421 was significantly less than that consumed by saline treated animals 
throughout the study period (figure 7.10a, b). Mice treated with 2000 pmol/kg/min 
oxyntomodulin consumed significantly less food than saline controls on days 1 and 7 
post-implantation (figure 7.10b). Total food intake over the seven day period for 
animals treated with 30 pmol/kg/min was significantly lower than that observed for 
animals treated with 2000 pmol/kg/min oxyntomodulin and saline (figure 7.11). 
7.4.3.3 Analysis of peptides used in continuous administration study 
Sample of peptide used to fill the osmotic minipumps on day 0 was compared to the 
recovered content extracted from the pump on day 7, by HPLC analysis. Samples of 
oxyntomodulin recovered from osmotic pumps on day 7 showed a change in peptide 
retention properties compared to the oxyntomodulin sample of day 0 (figure 7.13 a), 
while all samples of analogue 6421 showed only trace amounts of novel peaks (figure 
7.13b). 
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Figure 7.10 Effect of continuous administration of 6421 and oxyntomodulin on a) 
cumulative b) daily food intake in DIO mice. Oxyntomodulin was administered at 
2000 pmol/kg/min, 6421 administered at 10 and 30 pmol/kg/min via a 
subcutaneous Alzet® osmotic pump (n=8-10). Food intake was measured daily at 
09:00. **p<0.01 oxyntomodulin compared to saline, ^p<0.05, '"'p<0.01 6421 10 
pmol/kg/min compared to saline, ®p<0.05 ^^p<0.01, ®® p^<0.001 6421 30 pmol/kg/min 
compared to saline. 
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Figure 7.11 Total food intake during 7 day treatment period (n=8-10). Food 
intake measured daily at 09:00. * p<0.05, *** p<0.001, compared to saline, 
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7.4.4 SC mini-pump infusion of oxyntomodulin analogue 6421 (30 pmol/kg/min); 
effect on food intake, body weight and metabolic parameters compared to pair-fed 
male Wistar rats 
7.4.4.1 Effect of continuous administration of oxyntomodulin analogue 6421 on 
food intake 
As previously demonstrated in DIO mice, continuous subcutaneous administration of 
6421 caused a significant reduction in food intake in rats compared to saline controls 
(total food intake over test period: saline 215.92 ± 6.87 g, 30 pmol/kg/min 6421 137.94 
± 3.77 g (figure 7.13a). Analogue 6421 effect on food intake appeared most potent at 
reducing daily food intake during the first 3 days of the study, and continued to reduce 
daily food intake compared to saline up to day 6 of the study (figure 7.13b). A third 
group of animals used in this study were pair-fed to the median daily food intake of 
6421 30 pmol/kg/min (day 1: 15.5 g, day 2: 0.00 g, day 3: 10.95 g, day 4: 26.1 g, day 
5: 25.73 g, day 6: 27.59 g, day 7: 26.99 g). The pair fed animals ate all food given to 
them on each day (data not shown). 
7.4.4.2 Effect of continuous administration of analogue 6421 and pair-feeding on 
body weight 
Oxyntomodulin analogue 6421 and the pair-fed group had a significant reduction in 
cumulative body weight change compared to saline controls on all days of the study 
(study 7.14a). A trend for analogue 6421 to cause a greater reduction in body weight 
than pair-feeding was observed, and cumulative weight change was significantly 
different on days 1, 2, 6 and 7 (figure 7.14a). The group receiving 30 pmol/kg/min had 
a significantly greater reduction in total body weight over the 7 day period compared to 
saline controls and the pair-fed group (body weight change after 7 days post-
implantation: saline 27.67 ± 2.47 g, 6421 30 pmol/kg/min -14.70 ± 1.94 g, pair-fed -
6.91 ± 1.73 g) (figure7.14b). The difference in body weight change between the saline 
control and pair-fed groups was also sigmficant, with pair-fed animals losing more 
weight than the controls. 
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Figure 7.14 Effect of continuous administration of 6421 and pair-feeding on a) 
cumulative b) total body weight change in rats. 6421 was administered at 30 
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7.4.4.3 Effect of continuous administration of analogue 6421 and pair feeding on 
metabolic parameters 
Metabolic parameters of animals were investigated 7 days after SC pump implantation. 
Animals were transferred to metabolic cages and access to food removed. 
Oxyntomodulin analogue 6421 caused a significant increase in VO2 production at 
several time points throughout the investigation (figure 7.15a). Longitudinal analysis of 
the data showed no significant difference between groups (GEE p=0.586), however total 
VO2 production over the 6 hour period was significantly higher for the 6421 group 
compared to control animals and the pair-fed group (figure 7.15b). 
No significant differences were detected between groups in rats' locomotor activity, in 
either the X or Z axis (figure 7.16 & b). A trend of the pair-fed group having increased 
activity compared to saline and 6421 group, and of the 6421 group having increased 
activity compared to the saline group, was observed. 
Respiratory exchange ratio (RER; VCO2/VO2 = RER) was significantly reduced by 
continuous administration of analogue 6421 and pair-feeding compared to saline 
controls (figure 7.17). Analysis using GEE demonstrated that the data sets were 
significantly different (p=0.01). Further analysis highlighted a trend for 6421 to cause a 
reduced RER compared to pair-feeding, which reached significance at 0.5, 1.5 and 6 
hours. 
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Figure 7.15 Effect of continuous administration of 6421 and pair-feeding on a) 
interval b) total VO2 production (n=12). Animals were tested over a 6 hour light 
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7.4.5 Static incubation of hypothalamic explants and pituitary quarters 
Incubation of hypothalamic explants with oxyntomodulin showed a trend for increased 
a-MSH release at all doses of oxyntomodulin tested (10 nM oxyntomodulin 1.94 ± 0.21 
fold increase, 100 nM oxyntomodulin 1.46 ± 0.29 fold increase, 1000 nM 
oxyntomodulin 1.53 ± 0.58 fold increase) (figure 7.18a), whereas incubation with the 
same concentrations of exendin-4 did not alter a-MSH release levels (10 nM exendin-4 
0.71 ± 0.18 fold increase, 100 nM exendin-4 1.01 ± 0.23 fold increase, 1000 nM 
oxyntomodulin 1.01 ± 0.24 fold increase) (figure 7.18a). Incubation of hypothalamic 
explants with oxyntomodulin analogue 6421 at 10 nM and above caused a significant 
increase in a-MSH release (1 nM 6421 1.26 ± 0.11 fold increase, 10 nM 6421 1.71 ± 
0.18 fold increase, 100 nM 6421 1.52 ± 0.15 fold increase and 1000 nM 6421 1.62 ± 
0.17 fold increase) (figure 7.18b). 
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Incubation of hypothalamic explants with oxyntomodulin at 100 and 1000 nM 
significantly increased release of TRH (10 nM oxyntomodulin 1.38 ± 0.31 fold increase, 
100 nM oxyntomodulin 3.06 ± 0.55 fold increase and 1000 nM oxyntomodulin 2.74 ± 
0.29 fold increase) (figure 7.19a). Incubation of hypothalamic explants with peptide 
6421 showed a trend of increased TRH release (10 nM 6421 1.67 ± 0.38 fold increase, 
100 riM 6421 1.91 ± 0.52 fold increase and 1000 nM 6421 2.42 ± 0.43 fold increase) 
(figure 7.19b). 
Incubation of pituitary quadrants with oxyntomodulin significantly increased TSH 
release at all doses tested (10 nM oxyntomodulin 2.27 ± 0.29 fold increase, 100 nM 
oxyntomodulin 2.18 ± 0.30 fold increase, 1000 nM oxyntomodulin 2.17 ± 0.27 fold 
increase) (figure 7.20a). A non-significant trend of increased TSH release with 
increasing concentration of analogue 6421 was observed when pituitary quarters were 
incubated with peptide (1 nM 6421 1.17 ± 0.21 fold increase, 10 nM 6421 1.31 ± 0.15 
fold increase, 100 nM 6421 1.40 ± 0.21 fold increase and 1000 nM 6421 1.58 ± 0.17 
fold increase) (figure 7.20b). 
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Figure 7.18 Release of a-MSH from hypothalamic explants in response to 
incubation with a) oxyntomodulin at a concentration of 10 nM (n=8), 100 nM (n=9) 
and 1000 (n=8); exendin-4 at a concentration of 10 nM (n=8), 100 nM (n=10) and 
1000 nM (n=8). Percentage increase calculated from release of a-MSH caused by 
treatment with aCSF (n=13). b) 6421 at a concentration of 1 nM (n=10), 10 nM 
(n=15), 100 nM (n=15) and 1000 nM (n=12). Percentage increase calculated from 
release of a-MSH caused by treatment with aCSF (n=30). Significance shown 
graphically refers to comparison of the peptide-stimulated period with the basal 
period, **p<0.01, ***p<0.001. 
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(n=10) and 1000 (n=9). Percentage increase calculated from release of TRH 
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Figure 7.20 Release of TSH from pituitary explants in response to incubation 
with a) oxyntomodulin at a concentration of 10 nM (n=14), 100 nM (n=35) and 
1000 (n=15). b) aCSF (n=39). Percentage increase calculated from release of TSH 
caused by treatment with aCSF (n=39). b) 6421 at a concentration of 1 nM 
(n=22), 10 nM (n=25) and 100 nM (n=24) and 1000 nM (n=17). Percentage 
increase calculated from release of TSH caused by treatment with aCSF (n=19). 
Significance shown graphically refers to comparison of the peptide-stimulated 
period with the basal period, **p<0.01. 
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7.5 Discussion 
Oxyntomodulin is thought to be a satiety signal. Administration of oxyntomodulin to 
rats (Dakin et al., 2002; Dakin et al., 2004) and humans (Cohen et al., 2003; Wynne et 
al., 2006) caused a decrease in food intake. Repeated IP or ICV injections of 
oxyntomodulin over a seven day period has been shown to reduce body weight gain in 
rats (Dakin et al., 2002; Dakin et al., 2004). Conflicting data exist concerning the 
mechanisms by which oxyntomodulin causes a reduction in body weight gain. It is 
widely accepted that part of the change in body weight is caused by reduction in food 
intake. However, the effect of oxyntomodulin on energy expenditure remains unclear 
and the contribution of change in energy expenditure, if any, to weight loss is unknown. 
Data by Dakin et al (2002) demonstrated that rats pair-fed to the median food intake of 
oxyntomodulin treated animals gained more weight than the oxyntomodulin treated 
animals, suggesting that oxyntomodulin increases energy expenditure. These findings 
were supported by data from a human study (Wynne et al., 2006). However, research 
by Baggio et al (2004b) failed to identify any change in energy expenditure in mice 
treated with oxyntomodulin compared to saline controls. Whilst factors such as species 
variation and different methodology may contribute to the observed differences in 
energy expenditure, an underlying factor hindering this work is the peptide's short 
circulating half-life of 6-7 minutes in rat (Kervran et al., 1990) and 11-13 minute in 
humans (Schjoldager et al., 1988). 
A common tool to measure energy expenditure directly in rodent studies is the CLAMS 
system (described in 2.2.5). However, this system only allows 1 reading of gas 
composition every 30 minutes. Therefore, if the time between injection and the first 
reading is significantly greater than the half-life of the peptide's effect on energy 
expenditure, the effect may be missed. To avoid this problem, one could administer the 
peptide at regular intervals to try and maintain an adequate circulatory level of peptide. 
However, this is not a completely satisfactory approach as it results in highly variable 
levels of circulating peptides, with peaks after injections and troughs immediately prior 
to injection. Also, stress associated with repeated injection has been shown to influence 
effect of peptide on satiety (Halatchev et al., 2004; Abbott et al., 2005). A further 
problem of repeated injections in conjunction with the CLAMS system is that an 
equilibrium period is required each time the sealed cage is opened. 
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Continuous infusion of peptide by methods such as osmotic minipumps is an attractive 
alternative to repeated injections, as an elevated steady level of circulating peptide can 
be achieved. However, as oxyntomodulin has a low potency on reducing food intake, a 
high dose is required to cause a measurable effect. The lowest dose found to cause a 
reduction in food intake was 2000 pmol/kg/min (data from dose finding studies not 
shown) and administration of peptide at such a high dose by osmotic pump was 
problematic (figure 7.12). 
An alternative approach to investigating energy expenditure was to develop a more 
potent, longer lasting form of oxyntomodulin to use in such studies. This approach also 
has substantial drawbacks, since by making even minor changes to the peptide, direct 
conclusions about the parent peptide are not possible. As other approaches to study 
energy expenditure were limited, an analogue of oxyntomodulin for use in such studies 
was developed. The start of this chapter describes studies in which two of the most 
promising analogues, based on their potency, length of action, smooth onset of action 
(not completely inhibiting food intake in the first hour - an indicator of a nauseant) and 
minimal sequence changes needed to achieve this, were tested to establish if they were 
suitable for energy expenditure studies. Later work in the chapter describes the use of 
one analogue for energy expenditure studies and for investigating the mechanism by 
which this may occur. 
Peptides 6407 and 6421 (see table 7.1) had previously been shown to be potent long-
lasting anorexigenic agents in acute feeding studies using fasted mice. In this chapter, 
peptides were tested for their ability to cause reduction in body weight in an obese 
model, DIO mice. Over a treatment period of three weeks, both peptides caused a 
significant reduction in body weight compared to saline controls. Sixteen days after the 
last administration of compounds, the body weight of mice treated with peptides 
remained lower than those of saline controls, suggesting that the weight loss caused by 
peptides may be sustained for a prolonged period of time. To investigate whether the 
anorexigenic properties were specific to mice, a chronic study of the affects of 
analogues 6421 and 6407 on rat body weight and food intake was completed. 
Administration of 20 nmol/kg 6421 and 6407 for 13 days caused a significant reduction 
in food intake and a trend of inhibition of body weight gain compared to saline controls. 
In the same study, analogues at 5 nmol/kg were insufficient to inhibit food intake 
significantly and did not alter body weight. Data from the monitored post-treatment 
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period indicate a rebound effect, most notable for analogue 6407 at 20 nmol/kg. A 
rebound in food intake and weight gain following termination of treatment suggests the 
analogues have not lost their efficacy but, rather, that an orexigenic mechanism had 
been activated to counteract the inhibitory effects. 
In conclusion, the studies described above provide evidence that daily subcutaneous 
administration of oxyntomodulin analogues was sufficient to cause weight loss or 
inhibition of weight gain in freely feeding rodents. This effect was at least partially due 
to reduction in food intake. Analogue 6421 caused a greater inhibition of food intake 
and a larger reduction of body weight, or greater inhibition of body weight gain, than 
analogue 6407. The actions of analogue 6421 on inhibiting food intake were 
maintained throughout the treatment period, suggesting that tachyphylaxis was not 
occurring. The above observations were the reasons for selection of 6421 for energy 
expenditure studies. 
In both of the chronic studies, peptides were administered via subcutaneous injections, 
as this route of peptide administration represents a feasible route for peptide delivery to 
humans. Precedents for using subcutaneous oxyntomodulin for the treatment of human 
obesity are provided by the subcutaneous administration of GLP-1 (Naslund et al., 
2004), oxyntomodulin (Wynne et al, 2006) and the long acting analogue exenatide 
(exendin-4) (Buse et al., 2004; Kendall et al., 2005), which have demonstrated a 
reduction in body weight in diabetic patients following chronic therapy. 
Comparison of continuous administration of oxyntomodulin and analogue 6421 showed 
an approximate 200-fold difference in their ability to inhibit food intake. Daily food 
intake of animals receiving continuous administration of 2000 pmol/kg/min 
oxyntomodulin or 10 pmol/kg/min 6421 was significantly reduced compared to saline 
controls for a short period at the start of the study, before returning to the same level as 
controls. Continuous administration of 6421 at 30 pmol/kg/min, equivalent to a single 
daily injection of 43 nmol/kg, was sufficient to cause a significant reduction of food 
intake on each of the study days, compared to saline controls. Results of this study 
demonstrated that continuous administration of analogue 6421 by osmotic minipump is 
an effective method of delivering the peptide, and as such this was the method used for 
further studies. Analysis of the oxyntomodulin arm of the study is complicated by the 
observation that the pump content of oxyntomodulin was degraded after 7 days in the 
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osmotic pump (figure 7.12). MALDI-ToF mass spectrometry analysis of the 
breakdown products would be beneficial in determining the likely cause of peptide 
instability. A precedent for similar peptides losing bioactivity is GLP-1, which, if 
stored on ice whilst in solution, irreversibly forms a non-bioactive structure. It appears 
likely that peptide degradation in the pump may be at least partly responsible for 
oxyntomodulin's apparent loss of activity after day 1. An alternative reason for the 
transient anorectic effect of oxyntomodulin and 10 pmol/kg/min 6421 is the 
development of a counter-regulatory mechanism in response to weight loss, which is 
present in order to prevent starvation. For example, as the animal loses body weight, 
leptin levels will fall, signalling a negative energy balance and resulting in a drive to 
eat, thereby counteracting the effect of the oxyntomodulin and low dose 6421 
administration. It appears that ongoing treatment with the higher dose of analogue 
6421 was sufficient to overcome this counter-regulatory drive to over-eat, resulting in a 
stable, but reduced body weight. This counter-regulatory phenomenon has also been 
observed with chromic administration of other weight-reducing agents. For example, 
chronic PYY(3-36) infusion administered to rodents using osmotic minipumps results in 
a transient reduction of food intake accompanied by a sustained reduction in body 
weight (Pittner et al , 2004). 
Results from a pair-feeding study, designed to measure changes in energy expenditure 
caused by administration of analogue 6421, demonstrated an increase in energy 
expenditure of animals receiving analogue 6421 compared to controls. An indirect 
measurement of energy expenditure was obtained by comparing body weight change of 
rats receiving analogue 6421 to the body weight change observed in animals pair-fed to 
the median food intake of rats receiving analogue 6421. Design of the metabolic cages 
does not allow for accurate pair-feeding, therefore the initial part of the study took place 
in open cages. A direct measurement of energy expenditure was made by monitoring 
VO2 levels of animals treated with analogue 6421 and saline controls during the light 
phase of study day 7, using the CLAMS system. This arm of the study was designed to 
monitor resting metabolic rate and was therefore completed in the light phase, when rats 
are normally at rest. Whilst animals were in the metabolic cages, access to food was 
removed, as differences in food intake would influence the energy expenditure data. 
Rats receiving continuous administration of analogue 6421 had a significantly raised 
VO2 (a marker of increased energy expenditure) compared to the saline control and 
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pair-fed groups. An increase in energy expenditure is a consequence of an increase in 
resting energy expenditure and/or activity-related energy expenditure. Whilst no 
significant differences were observed between groups in either the total amount of 
horizontal or vertical movement, the pair-fed group showed a trend for increased 
movement, possibly as a resuh of stress due to hunger. A trend for a small increase in 
physical movement was also observed for rats treated with 6421 compared to saline; 
therefore the influence of increased physical activity carmot be dismissed when 
interpreting any change in energy expenditure. Indeed, a limitation of the CLAMS 
system is that only movements which break two consecutive laser beams are detected. 
Therefore, 'fidgeting' type movements, which are classified as part of the non-exercise 
activity thermogenesis and are known to be an important process in preserving leanness 
(Levine et al., 1999), may not be accurately recorded in the CLAMS system. To further 
investigate the importance of physical activity, a visual behavioural study would help to 
confirm if any differences exist between groups. However, with only small differences 
in recorded physical activity, the results of the metabolic cage study suggest that the 
observed increase in energy expenditure is caused by an increase in resting metabolic 
rate rather than activity-related energy expenditure. A study completed by Wynne et al 
reported an increase in activity-related energy expenditure in humans treated with 
oxyntomodulin (Wynne et al , 2006). Several factors, such as study design and species 
difference, may explain the difference in energy expenditure between rats and humans. 
Both studies were completed in the light phase of the day, when humans are active but 
rats are at rest. Humans and rats have similar appetite regulating systems, but their 
systems of thermal regulation are divergent, with rats using BAT metabolism as a key 
mechanism to generate heat, a system not used by adult humans. Differences in study 
design limit comparisons which can be made between oxyntomodulin and analogue 
6421 on their effect on energy expenditure. 
Respiratory exchange was also calculated for periods during which that rats were in 
metabolic cages. Pair-fed rats and rats receiving analogue 6421 had reduced RER 
values compared to saline controls, indicating a greater reliance on adipose stores as 
their source of energy. The observed resuh is consistent with the expected one, as rats 
treated with 6421 and those in the pair-fed group have reduced food intake and therefore 
less glycogen available as a source of energy. A trend of RER values being lower in the 
group treated with 6421 compared to pair-fed animals was also observed. Such an 
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observation implies a consequence of treatment with analogue 6421 is to switch the 
preference of energy utilisation to fat. 
Alpha-MSH, the main product of the appetite inhibitory POMC neurones, has 
previously been shown by Dakin et al (2002) to be released from hypothalamic slices 
following treatment with oxyntomodulin. In addition to its actions on feeding, central 
administration of a-MSH is known to increase oxygen consumption (Pierroz et al., 
2002) and to stimulate sympathetic nervous activity in BAT (Yasuda et al., 2004). An 
ex vivo approach was used to establish if analogue 6421 also stimulated a-MSH release 
from the hypothalamus. Results from my studies showed oxyntomodulin caused a non-
significant increase in release of a-MSH at all doses tested, a dose dependent significant 
increase of a-MSH with treatment of analogue 6421 and no change in a-MSH levels 
following treatment with exendin-4. Comparison of a-MSH release caused by exendin-
4 and oxyntomodulin suggests that, whilst the peptides can bind to and activate the 
same receptor, their downstream effects are different. This supports the finding by 
Baggio et al., who demonstrated differences in energy expenditure following peripheral 
administration of oxyntomodulin and exendin-4 to mice (Baggio et al., 2004b). A 
comparison to exendin-4 was also made as several of the changes in analogue 6421 
came from exendin-4 and the difference in a-MSH release provides evidence that the 
peptide is biologically more oxyntomodulin-like than exendin-4-like . 
An alternative mechanism by which oxyntomodulin may cause changes in energy 
expenditure is by stimulating TRH release (Dakin et al., 2002). TRH regulates 
circulating levels of thyroid hormones, which are of particular importance in controlling 
resting energy expenditure (Silva, 1995). This mechanism may be independent of a-
MSH, or could be a downstream effect of a-MSH stimulation, as melanocortin cells in 
the ARC have projections which terminate on TRH-producing cell bodies in the PVN to 
induce release of hypothalamic TRH (Fekete et al., 2000; Fekete et al., 2002; Kim et al., 
2000). The physiological importance of this connection was demonstrated by in vivo 
administration of a stable a-MSH analogue, resuking in an increase of plasma TSH in 
fasted rats (Kim et al., 2000). Thus, oxyntomodulin and analogue 6421 could both 
decrease food intake and increase energy expenditure via stimulation of a-MSH release 
in combination with secondary stimulation of the thyroid gland. To test if TRH and 
TSH release was stimulated by treatment with oxyntomodulin or analogue 6421, their 
levels were measured following treatment of explants. Oxyntomodulin significantly 
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increased both TRH and TSH release, whereas, treatment with analogue 6421 caused a 
significant increase in TRH, at a higher dose than that required for oxyntomodulin, and 
a non-significant, dose-dependent trend for increased TSH release. This demonstrating 
of an increase in TRH and TSH release in ex vivo tissue, after treatment with 
oxyntomodulin or analogue 6421, suggests a potential role of thyroid hormones in 
causing the observed changes in energy expenditure. 
In conclusion it appears that oxyntomodulin and analogue 6421, albeit in a weaker 
fashion, cause an increase in a-MSH levels, which could cause the observed increase in 
TSH release. However, a direct effect of the peptides on TRH release, such as that seen 
by leptin (Nillni et al., 2000), cannot be ruled out. This may be the mechanism by 
which food intake is reduced and energy expenditure increases, since TSH has central 
effects which reduce food intake in fed, fasting and stressed animals, as well as having 
effects on the thyroid axis, thermogenesis, locomotor activity and autonomic regulation 
(Lechan and Fekete, 2004). To try and fiirther elucidate the mechanism by which 6421 
caused an increase in energy expenditure, TSH and thyroid hormones will be measured 
in plasma samples collected from the continuous administration study. 
Due to oxyntomodulin's short half-life it has not been possible to demonstrate the above 
findings in vivo. However, studies using analogue 6421 have clearly shovm that chronic 
administration does cause a reduction in food intake and an increase in energy 
expenditure. 
286 
Chapter 8 
Discussion 
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Oxyntomodulin is a gut hormone encoded by the preproglucagon gene. In the work 
described in this thesis, I have demonstrated that oxyntomodulin is degraded by 
peptidases DPP IV and NEP. By the use of peptide analogues of oxyntomodulin I 
demonstrated that the degradation by peptidases is an important factor in determining 
analogues duration of food intake inhibition. In the design of an analogue with an 
extended duration of food intake inhibition resistance to DPP IV and NEP mediated 
degradation was more crucial than affinity for the GLP-1. Studies using an analogue 
with an extended duration of food intake inhibition demonstrated analogue 6421 caused 
a decreases in food intake and an increase in basal metabolic in rat. These two actions 
may be mediated by stimulation of the thyroid axis at the level of the hypothalamus and 
pituitary and/or by an increase in a-melanocortin stimulating hormone release in the 
hypothalamus. 
Though the inhibitory effects of oxyntomodulin on food intake are well characterised, 
its effect on energy expenditure remains contentious (Baggio et al., 2004b; Dakin et al., 
2002; Wynne et al., 2006). A recent study demonstrated significant weight loss in 
humans undergoing chronic treatment on oxyntomodulin (Wynne et al., 2005), 
highlighting the potential use of oxyntomodulin as a therapy for obesity, and increasing 
scientific interest in the oxyntomodulin and its mechanism of action. A better 
understanding of the mechanisms by which oxyntomodulin regulates food intake and 
energy expenditure is important to gain fiirther insight into its effects on body weight. 
A key question is whether any actions of oxyntomodulin can be attributed to pathways 
other than via the GLP-1 receptor. In characterising the properties of oxyntomodulin, I 
demonstrated that the peptide had affinity for both the GCG and GLP-1 receptor. This 
feature distinguishes oxyntomodulin from related peptides; GLP-1, glucagon and 
exendin-4 have affinity exclusively for only one of these receptors. Experiments by 
Baggio et al (2004b) suggest that an intact GLP-1 receptor is required for 
oxyntomodulin to inhibit food intake. However, several fLinctions of oxyntomodulin 
such as development of the eye (Vessey et al., 2005), the control of intrinsic heart rate 
(Sowden et al., 2007) and gastric acid secretion (Carles-Bonnet et al., 1996) have been 
reported to occur via a GLP-1 receptor independent mechanism. At present the receptor 
which mediates these actions remains unknown. 
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There is also evidence that oxyntomodulin activates different neuronal pathways to 
GLP-1. Peripheral administration of oxyntomodulin and GLP-1 has been reported to 
invoke different patterns of early gene activation. Administration of GLP-1 caused 
increased c-Fos expression in the ARC and brainstem whereas c-Fos expression in rats 
treated with oxyntomodulin was increased in the ARC but not the brainstem (Baggio et 
al., 2004b; Dakin et al., 2004). In addition, differences in the pattern of neuronal 
activation due to administration of these peptides have been demonstrated using the 
technique of manganese-enhanced magnetic resonance imaging (Chaudhri et al., 2006). 
Together these results suggest that GLP-1 and oxyntomodulin may act via different 
neuronal pathways. 
It is possible that the effects of oxyntomodulin are all mediated via the GLP-1 receptor, 
but that oxyntomodulin and GLP-1 have different effects due to differences in receptor 
milieu or downstream signalling (Baggio et al., 2004b). There is growing evidence of 
other factors playing important roles in receptor-ligand activity. Factors such as 
caveolin-1 (Syme CA et al., 2006), or receptor-activity-modifying proteins (Bom et al., 
2002) may contribute to the observed differences between these peptides. Alternatively, 
several actions of oxyntomodulin may be mediated via an unknown receptor. However, 
given the potential therapeutic and commercial value of novel receptors and the 
increasing power of genome screening and homology searches, it seems likely that 
efforts have been made to identify unknown receptors and to screen these against a 
library of potentially therapeutic natural ligands. However, to date oxyntomodulin has 
not been reported to have affinity for any receptors besides the GCG and the GLP-1 
receptor. It thus seems unlikely that oxyntomodulin has actions via an as yet 
unidentified receptor. My rational design of novel oxyntomodulin analogues thus 
focused on their affinity for the GLP-1 receptor, as at present the majority of data 
supports the hypothesis that the actions of oxyntomodulin on food intake are mediated 
by this receptor. However, to ftirther investigate the receptors by which actions of 
oxyntomodulin are mediated, one could use post-embryonic knockout or knockdown 
models to investigate, for example, whether a post-embryonic reduction in GLP-1 
receptor signalling attenuates the anorectic effects of oxyntomodulin. If this was found 
to be the case it would suggest that it is not just the indirect developmental effects 
following the embryonic loss of the GLP-1 receptor that are responsible for the lack of 
the anorectic effects of oxyntomodulin in the GLP-1 receptor knockout mouse. 
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The results described in Chapter 3 demonstrated that oxyntomodulin bound to GLP-1 
receptor prepared from a variety of tissues and cell lines with an affinity two orders of 
magnitude lower than either GLP-1 or exendin-4. The GLP-1 receptors used in binding 
assays for human oxyntomodulin, human GLP-1 and exendin-4 were sourced from two 
different species, but receptor affinities were found to be consistent between species. 
The subtle changes to the amino acid sequence of human oxyntomodulin demonstrated 
by the porcine homologue had no effect on rGLP-1 receptor affinity. However, the 
multiple changes to the oxyntomodulin sequence evidenced in the eel homologue 
reduced affinity of the peptide to the rGLP-1 receptor, demonstrating sensitivity of the 
ligand to amino acid changes. As previously described, oxyntomodulin differs fi-om 
GLP-1 and exendin-4 in binding to the GCG receptor. Depending on the source of 
GCG receptor, oxyntomodulin bound with either 6 or 20-fold lower affinity than 
glucagon. The difference in binding affinities between the two sources of receptor, a 
membrane preparation of liver cells and a cell line overexpressing the human receptor, 
may be caused by presence of receptors other than the GCG receptor, such as the GLP-1 
receptor, in the liver membrane preparation. 
Differences in the affinity of peptides for the GLP-1 receptor were reflected in their 
bioactivity at the receptor. Oxyntomodulin was approximately 100-fold less potent at 
stimulating intracellular levels of cAMP than GLP-1 and exendin-4 in cells 
overexpressing either the human or rat GLP-1 receptor. Bioactivity of oxyntomodulin 
at the GCG was also measured. Oxyntomodulin was 50 times weaker than glucagon at 
stimulating intracellular cAMP. The relatively high affinity and bioactivity of 
oxyntomodulin at the GCG receptor compared to the GLP-1 receptor is intriguing as 
many of the actions of oxyntomodulin, including its effect on food intake, are thought to 
be mediated by the GLP-1 receptor (Baggio et al , 2004b; Scrocchi et al., 1996; Turton 
et al., 1996) and no specific actions have been attributed to activation of the GCG 
receptor. 
Whilst exendin-4 and GLP-1 had similar affinity for the GLP-1 receptor and their in 
vitro bioactivity at the GLP-1 was approximately equal, their effectiveness at inhibiting 
food intake in mice was different. In the series of feeding studies completed in Chapter 
3 the minimal dose of GLP-1 resulting in an acute reduction of food intake in mice was 
30 nmol/kg, 30 times higher than the dose of exendin-4 required (1 nmol//kg). Thus the 
in vivo potencies of GLP-1 and exendin-4 are different whereas their affinities and in 
290 
vitro b i o a c t i v i t i e s f o r t h e G L P - 1 r e c e p t o r a r e s i m i l a r . T h i s d i f f e r e n c e i s l i k e l y d u e t o t h e 
l a r g e v a r i a t i o n i n t h e p l a s m a h a l f - l i v e s o f t h e s e p e p t i d e s ( D e a c o n e t a l . , 1 9 9 5 ; E d w a r d s 
e t a l . , 2 0 0 1 ) . P u b h s h e d l i t e r a t u r e s u g g e s t s t h e s e n s i t i v i t y o f G L P - 1 t o D P P I V i s a n 
i m p o r t a n t f a c t o r i n d e t e r m i n i n g t h e in vivo e f f e c t s o f t h e p e p t i d e . S e v e r a l o t h e r 
h o r m o n e s d e r i v e d f r o m t h e p r o g l u c a g o n g e n e , i n c l u d i n g G L P - 2 a n d o x y n t o m o d u l i n 
h a v e a l s o b e e n i d e n t i f i e d a s in vitro s u b s t r a t e s o f D P P I V ( D e M e e s t e r e t a l . , 1 9 9 9 ; Z h u 
e t a l . , 2 0 0 3 ) . A t p r e s e n t , t h e r e h a v e b e e n n o r e p o r t e d f i n d i n g s c o n f i r m i n g w h e t h e r 
o x y n t o m o d u l i n i s d e g r a d e d b y D P P I V in vivo. T h e r e s u h s d e s c r i b e d i n C h a p t e r 4 
c o n f i r m o x y n t o m o d u l i n i s a n in vitro s u b s t r a t e o f D P P I V . A c o - a d m i n i s t r a t i o n s t u d y , 
w h e r e o x y n t o m o d u l i n w a s a d m i n i s t e r e d w i t h V P , a D P P I V i n h i b i t o r , d e m o n s t r a t e d t h a t 
t h e b i o l o g i c a l a c t i o n s o f o x y n t o m o d u l i n c o u l d b e e n h a n c e d b y b l o c k i n g D P P I V 
m e d i a t e d d e g r a d a t i o n . T h i s r e s u l t s t r o n g l y s u g g e s t s t h a t o x y n t o m o d u l i n i s a n in vivo 
s u b s t r a t e f o r D P P I V a n d i t s e e m s l i k e l y t h a t t h i s e n z y m e p l a y s a r o l e i n r e g u l a t i n g t h e 
b i o l o g i c a l a c t i o n s o f o x y n t o m o d u l i n . 
O x y n t o m o d u l i n w a s s h o w n t o b e l e s s s u s c e p t i b l e t o D P P I V m e d i a t e d d e g r a d a t i o n t h a n 
G L P - 1 i n a n in vitro a s s a y o f p e p t i d e s u s c e p t i b i l i t y t o d e g r a d a t i o n . E x e n d i n - 4 w a s 
r e s i s t a n t t o D P P I V m e d i a t e d b r e a k d o w n u n d e r t h e s a m e a s s a y c o n d i t i o n s . I n a s e r i e s o f 
d e g r a d a t i o n a s s a y s u s i n g a n a l o g u e s o f o x y n t o m o d u l i n w i t h m o d i f i c a t i o n s o f t h e N -
t e r m i n u s s e q u e n c e , I d e m o n s t r a t e d t h a t p e p t i d e s u s c e p t i b i l i t y t o D P P I V d e g r a d a t i o n 
w a s p a r t l y d e p e n d e n t o n t h e f i r s t 3 N t e r m i n a l a m i n o a c i d s . H o w e v e r , a n a l o g u e s o f 
o x y n t o m o d u l i n i n c o r p o r a t i n g t h e f i r s t t h r e e a m i n o a c i d s o f G L P - 1 w e r e m o r e 
s u s c e p t i b l e t o D P P I V m e d i a t e d d e g r a d a t i o n t h a n o x y n t o m o d u l i n b u t l e s s s u s c e p t i b l e 
t h a n G L P - 1 , s u g g e s t i n g o t h e r s e q u e n c e e l e m e n t s a l s o i n f l u e n c e p e p t i d e s s u s c e p t i b i l i t y 
t o p r o t e o l y s i s . V a r i o u s a m i n o a c i d s u b s t i t u t i o n s o f t h e N - t e r m i n u s w e r e t e s t e d , b u t a l l 
f a i l e d t o c o m p l e t e l y b l o c k D P P I V m e d i a t e d d e g r a d a t i o n . T h e r e s u l t s a r e i n a g r e e m e n t 
w i t h t h e g r o w i n g l i s t o f p a p e r s r e p o r t i n g D P P I V s u b s t r a t e s p e c i f i c i t y i s m u c h w i d e r 
t h a n t h o s e i n i t i a l l y i d e n t i f i e d ( B o n g e r s e t a l . , 1 9 9 2 ) . R e m o v i n g , a c e t y l a t i n g , o r 
r e p l a c i n g t h e f i r s t a m i n o a c i d w i t h a D H i s s t e r e o i s o m e r g e n e r a t e d p e p t i d e s r e s i s t a n t t o 
D P P I V m e d i a t e d d e g r a d a t i o n . H o w e v e r , a l l t e s t e d m o d i f i c a t i o n s o f p o s i t i o n 1 a l s o 
r e d u c e d a f f i n i t y f o r t h e G L P - 1 r e c e p t o r b y a t l e a s t 1 0 - f o l d . I t w o u l d b e o f i n t e r e s t t o 
f u r t h e r i n v e s t i g a t e t h e N - t e r m i n u s o f o x y n t o m o d u l i n a n d d e t e r m i n e i f H i s a t p o s i t i o n 1 
i s a b s o l u t e l y c r i t i c a l f o r t h e a f f i n i t y o f o x y n t o m o d u l i n f o r t h e G L P - 1 r e c e p t o r o r 
w h e t h e r o t h e r r e s i d u e s c o u l d b e s u b s t i t u t e d . 
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I n v e s t i g a t i o n o f t h e in vivo e f f i c a c y o f o x y n t o m o d u h n a n a l o g u e s r e s i s t a n t t o D P P I V 
m e d i a t e d d e g r a d a t i o n d e m o n s t r a t e d t h e i m p o r t a n c e o f d e g r a d a t i o n r e s i s t a n c e i n 
d e t e r m i n i n g t h e d u r a t i o n o f f o o d i n t a k e i n h i b i t i o n . I n d e e d , a s t u d y c o m p a r i n g a p e p t i d e 
w i t h g r e a t e r a f f i n i t y t o t h e G L P - 1 r e c e p t o r b u t s u s c e p t i b l e t o D P P I V , t o o n e w i t h 
r e d u c e d a f f i n i t y t o t h e G L P - 1 r e c e p t o r b u t f u l l y r e s i s t a n t t o D P P I V , s h o w e d t h e 
r e s i s t a n t p e p t i d e i n h i b i t e d f o o d i n t a k e t o a g r e a t e r d e g r e e a n d f o r a l o n g e r d u r a t i o n o f 
t i m e . H o w e v e r , t h e r e d u c t i o n o f a f f i n i t y f o r t h e G L P - 1 r e c e p t o r o f a n a l o g u e s o f 
o x y n t o m o d u l i n w i t h m o d i f i c a t i o n s a t t h e N - t e r m i n a l o n l y , w a s s o g r e a t t h e a n a l o g u e s 
c o u l d n o t b e u s e d i n e n e r g y e x p e n d i t u r e s t u d i e s . 
T h e s e n s i t i v i t y o f o x y n t o m o d u l i n t o N E P w a s a l s o i n v e s t i g a t e d a s i t i s b e l i e v e d t o b e 
i m p o r t a n t i n r e g u l a t i n g t h e a c t i v i t y o f g l u c a g o n a n d G L P - 1 ( P l a m b o e c k e t a l . , 2 0 0 5 ; 
T r e b b i e n e t a l . , 2 0 0 4 ) . A n in vitro s c r e e n t e s t i n g p e p t i d e r e s i s t a n c e t o N E P m e d i a t e d 
p r o t e o l y s i s f o u n d t h a t b o t h G L P - 1 a n d o x y n t o m o d u l i n w e r e s e n s i t i v e t o N E P , w h i l s t 
e x e n d i n - 4 w a s r e s i s t a n t . S t u d i e s u s i n g c h i m e r i c p e p t i d e s c o n t a i n i n g s t r u c t u r a l e l e m e n t s 
o f e i t h e r o x y n t o m o d u l i n a n d G L P - 1 a n d o x y n t o m o d u l i n a n d e x e n d i n - 4 p r o v i d e d 
e v i d e n c e t h a t N E P m a y b e a n i m p o r t a n t i n t h e r e g u l a t i o n o f t h e b i o l o g i c a l a c t i o n s o f 
o x y n t o m o d u l i n . C h i m e r i c p e p t i d e s b o u n d w i t h h i g h e r a f f i n i t y t h a n n a t i v e 
o x y n t o m o d u l i n t o t h e G L P - 1 r e c e p t o r , b u t o n l y p e p t i d e s w i t h e x e n d i n - 4 s e q u e n c e 
i n s e r t s c a u s e d g r e a t e r i n h i b i t i o n o f f o o d i n t a k e t h a n o x y n t o m o d u l i n . C h i m e r i c p e p t i d e s 
c o n t a i n i n g G L P - 1 i n s e r t s w e r e m o r e s e n s i t i v e t o N E P m e d i a t e d d e g r a d a t i o n t h a n n a t i v e 
o x y n t o m o d u l i n , w h i l s t t h o s e c o n t a i n i n g e x e n d i n - 4 i n s e r t s w e r e l e s s s e n s i t i v e , 
s u g g e s t i n g t h a t t h e i m p r o v e d a c t i o n o f o x m / e x e n d i n - 4 c h i m e r i c p e p t i d e s o n f o o d i n t a k e 
m a y b e a c o n s e q u e n c e o f i n c r e a s e d r e s i s t a n c e t o N E P m e d i a t e d b r e a k d o w n . 
H a v i n g m o d i f i e d t h e N - t e r m i n u s o f t h e p e p t i d e I n e x t i n v e s t i g a t e d t h e p u t a t i v e h i n g e 
r e g i o n o f t h e m o l e c u l e . B o t h e x e n d i n - 4 a n d G L P - 1 c o n t a i n c o n s e r v e d s e q u e n c e 
e l e m e n t s i n t h i s r e g i o n w h i c h a r e b e l i e v e d t o f o r m a n i d e a l i s e d a - h e l i x ( A l - S a b a h & 
D o n n e l l y , 2 0 0 3 ) . I t h a s a l s o b e e n r e p o r t e d t h a t c e n t r a l h e l i c a l r e g i o n o f G L P - 1 i s l e s s 
h e l i c a l t h a n t h a t o f e x e n d i n - 4 d u e t o t h e s u b s t i t u t i o n o f G l u - 1 6 f o r G l y i n G L P - 1 
( N e i d i g h e t a l . , 2 0 0 1 ) . B a s e d o n t h e i n i t i a l d a t a o f r e s i s t a n c e t o N E P m e d i a t e d 
d e g r a d a t i o n I i n v e s t i g a t e d t h e e f f e c t o f e x e n d i n - 4 s e q u e n c e s u b s t i t u t i o n s i n t o t h e 
o x y n t o m o d u l i n s e q u e n c e . I n s e r t s o f 6 a m i n o a c i d s o r l o n g e r i n c r e a s e d a f f i n i t y f o r t h e 
G L P - 1 r e c e p t o r , r e s i s t a n c e t o N E P m e d i a t e d d e g r a d a t i o n a n d d u r a t i o n o f a n o r e c t i c 
a c t i o n s . H o w e v e r , s o m e s h o r t s e q u e n c e s u b s t i t u t i o n s o f 3 - 4 a m i n o a c i d s r e s u h e d i n 
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a n a l o g u e s w i t h a r e d u c t i o n o f r e c e p t o r b i n d i n g a f f i n i t y a n d a s h o r t e r d u r a t i o n o f f o o d 
i n t a k e i n h i b i t i o n . A s i m i l a r t r e n d o f r e d u c e d b i n d i n g a f f i n i t y w a s o b s e r v e d w i t h s h o r t 
s e q u e n c e i n s e r t s o f e x e n d i n - 4 a t t h e C - t e r m i n u s . I t w a s a l s o s h o w n t h a t m o d i f y i n g t h e 
C - t e r m i n a l r e g i o n a f f e c t e d p e p t i d e s e n s i t i v i t y t o N E P m e d i a t e d b r e a k d o w n . C l o s e r 
a n a l y s i s o f t h e s p e c i f i c s e q u e n c e c h a n g e s i n t h e a n a l o g u e s w i t h g r e a t e r r e s i s t a n c e t o 
N E P m e d i a t e d d e g r a d a t i o n s h o w e d t h a t t h i s r e s i s t a n c e w a s n o t c a u s e d b y r e d u c i n g t h e 
n u m b e r o f p r e d i c t e d c l e a v a g e s i t e s . T h i s s u g g e s t s t h a t o t h e r f a c t o r s s u c h a s s e c o n d a r y 
a n d t e r t i a r y s t r u c t u r e m a y a l s o d e t e r m i n e t h e r e s i s t a n c e o f a p e p t i d e t o N E P r e s i s t a n c e , 
b y b l o c k i n g a c c e s s o f t h e e n z y m e t o h y d r o p h o b i c a m i n o a c i d s . A c u t e f e e d i n g s t u d i e s i n 
m i c e d e m o n s t r a t e d t h a t a n a l o g u e s w i t h g r e a t e r r e s i s t a n c e t o N E P i n h i b i t e d f o o d i n t a k e 
f o r a l o n g e r d u r a t i o n t h a n t h o s e m o r e s e n s i t i v e t o N E P m e d i a t e d d e g r a d a t i o n . A s w i t h 
r e s i s t a n c e t o D P P I V , r e s i s t a n c e t o N E P m e d i a t e d d e g r a d a t i o n w a s m o r e i m p o r t a n t t h a n 
r e c e p t o r b i n d i n g a f f i n i t y i n d e t e r m i n i n g t h e d u r a t i o n o f t h e a n o r e c t i c e f f e c t s o f a n 
a n a l o g u e . 
F u r t h e r a n a l o g u e s w e r e d e s i g n e d i n o r d e r t o d e t e r m i n e a n o x y n t o m o d u l i n a n a l o g u e w i t h 
a g r e a t l y e x t e n d e d d u r a t i o n o f f o o d i n t a k e i n h i b i t i o n . A D P P I V r e s i s t a n t N - t e r m i n u s 
m o d i f i c a t i o n w a s c o m b i n e d w i t h s e q u e n c e c h a n g e s w h i c h i m p r o v e d a f f i n i t y o f t h e 
p e p t i d e t o t h e r e c e p t o r . T h e r e s u l t i n g a n a l o g u e s h a d b i n d i n g a f f i n i t i e s s i m i l a r t o t h o s e 
a n a l o g u e s w i t h a n u n m o d i f i e d N - t e r m i n a l , s u g g e s t i n g t h e i m p r o v e d b i n d i n g a f f i n i t y o f 
t h e m i d - s e c t i o n w a s s u f f i c i e n t t o c o m p e n s a t e f o r t h e n e g a t i v e e f f e c t o f N - t e r m i n a l 
m o d i f i c a t i o n s o n b i n d i n g a f f i n i t y . F u r t h e r a t t e m p t s t o i n c r e a s e t h e p e p t i d e ' s d u r a t i o n o f 
a c t i o n w e r e u n s u c c e s s f u l . T h e a d d i t i o n o f f a t t y a c i d s i d e c h a i n s , d e s i g n e d t o b i n d t h e 
p e p t i d e t o a l b u m i n a n d t h e r e f o r e r e d u c e p e p t i d e ' s s u s c e p t i b i l i t y t o p r o t e o l y t i c 
d e g r a d a t i o n a n d r e d u c e t h e r a t e o f r e n a l c l e a r a n c e , i m p r o v e d t h e a b i l i t y o f n a t i v e 
o x y n t o m o d u l i n t o r e d u c e f o o d i n t a k e . H o w e v e r , t h e s e b e n e f i t s w e r e n o t o b s e r v e d 
f o l l o w i n g s i m i l a r m o d i f i c a t i o n o f D P P I V a n d N E P r e s i s t a n t a n a l o g u e s . O t h e r 
s t r a t e g i e s u s e d i n a n a t t e m p t t o i n c r e a s e t h e d u r a t i o n o f a c t i o n o f o x y n t o m o d u l i n , 
i n c l u d i n g c o n j u g a t i o n t o m o u s e a l b u m i n a n d P E G y l a t i o n , w e r e a l s o u n s u c c e s s f u l w h e n 
a p p l i e d t o a D P P I V a n d N E P r e s i s t a n t a n a l o g u e . A t t a c h m e n t o f a l a r g e s i d e c h a i n c a n 
a l t e r t h e p r o p e r t i e s o f a p e p t i d e , r e s u l t i n g i n l o w e r b i o a c t i v i t y a n d r e d u c e d a f f i n i t y t o i t s 
r e c e p t o r . I t i s a l s o p o s s i b l e t h a t a t t a c h i n g a l a r g e s i d e c h a i n c a n i n t e r f e r e w i t h t h e a b i l i t y 
o f a p e p t i d e t o c r o s s t h e b l o o d b r a i n b a r r i e r . 
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B a s e d u p o n t h e f i n d i n g s I s e l e c t e d a n a n a l o g u e o f o x y n t o m o d u l i n ( 6 4 2 1 ) w i t h s e q u e n c e 
c h a n g e s r e s u l t i n g i n D P P T V r e s i s t a n c e , a n d a p u t a t i v e l y i m p r o v e d a - h e l i x i n t h e h i n g e 
r e g i o n a n d C - t e r m i n u s ( w h i c h i m p r o v e d t h e p e p t i d e s a f f i n i t y t o t h e G L P - 1 r e c e p t o r a n d 
i n c r e a s e d r e s i s t a n c e t o N E P ) f o r u s e i n e n e r g y e x p e n d i t u r e s t u d i e s . 
O x y n t o m o d u l i n , a p e p t i d e w h i c h h a s b e e n r e p o r t e d t o i n c r e a s e e n e r g y e x p e n d i t u r e w h e n 
a d m i n i s t e r e d t o r a t s a n d h u m a n s ( D a k i n e t a l . , 2 0 0 0 2 ; W y n n e e t a l , 2 0 0 5 ) , h a s a s h o r t 
c i r c u l a t i n g h a l f - l i f e o f 1 2 m i n u t e s i n m a n ( S c h j o l d a g e r e t a l , 1 9 8 8 ) . I n v e s t i g a t i o n o f t h e 
m e c h a n i s m b y w h i c h o x y n t o m o d u l i n m a y i n c r e a s e e n e r g y e x p e n d i t u r e h a s b e e n 
h a m p e r e d b y t h e m o l e c u l e s s h o r t h a l f - l i f e . T h e r e f o r e , t o i n v e s t i g a t e t h e e f f e c t s o f 
o x y n t o m o d u l i n s i g n a l l i n g o n e n e r g y e x p e n d i t u r e , a n d t h e m e c h a n i s m b y w h i c h t h e s e 
m a y b e m e d i a t e d , I u s e d a n a n a l o g u e o f o x y n t o m o d u l i n w i t h a n e x t e n d e d d u r a t i o n o f 
a c t i o n . 
C h r o n i c s u b c u t a n e o u s a d m i n i s t r a t i o n o f a n a l o g u e 6 4 2 1 t o D I O m i c e a n d r a t s r e s u l t e d i n 
s i g n i f i c a n t r e d u c t i o n i n b o d y w e i g h t o r b o d y w e i g h t g a i n , a n d r e d u c e d f o o d i n t a k e . 
F o o d i n t a k e c o n t i n u e d t o b e s i g n i f i c a n t l y r e d u c e d t h r o u g h o u t t h e t r e a t m e n t p e r i o d a n d 
b o d y w e i g h t r e m a i n e d l o w e r i n t h e m o n i t o r e d p o s t - a d m i n i s t r a t i o n p e r i o d . C o n t i n u o u s 
a d m i n i s t r a t i o n o f a n a l o g u e 6 4 2 1 b y s u b c u t a n e o u s o s m o t i c m i n i p u m p s w a s a n e f f e c t i v e 
m e t h o d t o a d m i n i s t e r t h e p e p t i d e t o r o d e n t s , r e s u l t i n g i n c o n t i n u o u s w e i g h t l o s s . R a t s 
r e c e i v i n g a c o n t i n u o u s d o s e o f a n a l o g u e 6 4 2 1 l o s t m o r e b o d y w e i g h t t h a n p a i r - f e d 
c o n t r o l s a n d s h o w e d i n c r e a s e d o x y g e n c o n s u m p t i o n l e v e l s c o m p a r e d t o a p a i r - f e d g r o u p 
a n d s a l i n e c o n t r o l s , c o n f i r m i n g t h a t t h e p e p t i d e c a u s e d a n i n c r e a s e i n e n e r g y 
e x p e n d i t u r e w h i c h c o n t r i b u t e s t o t h e o b s e r v e d w e i g h t l o s s . A s n o s i g n i f i c a n t c h a n g e i n 
l o c o m o t o r a c t i v i t y w a s o b s e r v e d i n t h e a n i m a l s t r e a t e d w i t h a n a l o g u e 6 4 2 1 , t h e d a t a 
s u g g e s t s t h a t t h e i n c r e a s e i n e n e r g y e x p e n d i t u r e m a y b e c a u s e d b y i n c r e a s i n g t h e b a s a l 
m e t a b o l i c r a t e . T h i s i s i n c o n t r a s t t o r e s u l t s p u b l i s h e d f r o m a h u m a n s t u d y w h e r e a n 
i n c r e a s e i n a c t i v i t y - r e l a t e d e n e r g y e x p e n d i t u r e w a s o b s e r v e d ( W y n n e e t a l . , 2 0 0 6 ) . 
P r e v i o u s l y i t h a s b e e n r e p o r t e d t h a t o x y n t o m o d u l i n m a y i n c r e a s e e n e r g y e x p e n d i t u r e b y 
a c t i v a t i n g t h e h y p o t h a l a m i c a - M S H T R H p a t h w a y ( D a k i n e t a l . , 2 0 0 2 ) . T o i n v e s t i g a t e 
w h e t h e r a n a l o g u e 6 4 2 1 m i g h t a l s o a c t i v a t e t h e s a m e p a t h w a y , t h e e f f e c t s o f 6 4 2 1 o n t h e 
r e l e a s e o f h y p o t h a l a m o - p i t u i t a r y - t h y r o i d a x i s h o r m o n e s f r o m h y p o t h a l a m i c a n d 
p i t u i t a r y e x p l a n t s w a s e x a m i n e d . 
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I d e m o n s t r a t e d t h a t t r e a t m e n t w i t h o x y n t o m o d u U n a n d a n a l o g u e 6 4 2 1 c a u s e d a n 
i n c r e a s e o f a - M S H r e l e a s e f r o m h y p o t h a l a m i c e x p l a n t s . C e n t r a l a d m i n i s t r a t i o n o f a -
M S H i s k n o w n t o p o t e n t l y r e d u c e f o o d i n t a k e ( B a r s h e t a l . , 1 9 9 9 ) . A l p h a - M S H i s also 
k n o w n t o p l a y a r o l e i n e n e r g y e x p e n d i t u r e : c e n t r a l a d m i n i s t r a t i o n o f a - M S H i n c r e a s e s 
o x y g e n c o n s u m p t i o n ( a m a r k e r o f e n e r g y e x p e n d i t u r e ) ( H w a e t a l . , 2 0 0 1 ) . A n a l o g u e 
6 4 2 1 m a y t h e r e f o r e m e d i a t e i t s e f f e c t s o n f o o d i n t a k e a n d e n e r g y e x p e n d i t u r e v i a a -
M S H r e l e a s e . 
T R H h a s a r o l e i n r e g u l a t i n g b o t h e n e r g y e x p e n d i t u r e a n d f o o d i n t a k e ( L e c h a n a n d 
F e k e t e , 2 0 0 6 ; S u z u k i e t a l . , 1 9 8 2 ; V i j a y a n a n d M c C a n n , 1 9 7 7 ) . I d e m o n s t r a t e d a d i r e c t 
s t i m u l a t o r y e f f e c t o f o x y n t o m o d u l i n a n d a n a l o g u e 6 4 2 1 o n T R H r e l e a s e f r o m 
h y p o t h a l a m i c e x p l a n t s . T h u s a n a l o g u e 6 4 2 1 m a y a f f e c t f o o d i n t a k e a n d e n e r g y 
e x p e n d i t u r e v i a t h e r e l e a s e o f T R H , w h i c h m a y p r e v e n t t h e s u p p r e s s i o n o f T S H r e l e a s e 
i n t h e f a s t e d s t a t e ( D a k i n e t a l . , 2 0 0 2 ) . T R H m a y a l s o h a v e d i r e c t e f f e c t s o n 
t h e r m o r e g u l a t i o n , a s I C V a n d i n t r a - h y p o t h a l a m i c a d m i n i s t r a t i o n o f T R H i n c r e a s e s 
r e c t a l t e m p e r a t u r e a n d t h e t e m p e r a t u r e o f b r o w n a d i p o s e i s s u e , w i t h o u t a n y a l t e r a t i o n i n 
c i r c u l a t i n g T 3 l e v e l s ( S h i n t a n i e t a l . , 2 0 0 5 ) . T h i s i s a p o s s i b l e m e c h a n i s m b y w h i c h 
o x y n t o m o d u l i n a n d o x y n t o m o d u l i n a n a l o g u e s m a y i n c r e a s e i n e n e r g y e x p e n d i t u r e , a n d 
i t w o u l d t h e r e f o r e b e o f i n t e r e s t t o m o n i t o r b o d y t e m p e r a t u r e i n f u t u r e o x y n t o m o d u l i n 
s t u d i e s . 
H y p o p h y s i o t r o p i c a n d n o n - h y p o p h y s i o t r o p i c T R H n e u r o n e s w i t h i n t h e P V N ( K a w a n o 
e t a l . , 1 9 9 1 ) a r e i n t e g r a t e d w i t h n e u r o n e s c o n t a i n i n g a p p e t i t e - r e g u l a t o r y n e u r o p e p t i d e s 
e x t e n d i n g from t h e A R C . T h e m a j o r i t y o f p a r v o c e l l u l a r T R H n e u r o n e s a r e i n n e r v a t e d 
b y s t i m u l a t o r y a x o n t e r m i n a l s c o n t a i n i n g a - M S H ( F e k e t e e t a l . , 2 0 0 0 ; F e k e t e e t a l . , 
2 0 0 2 ) . T h e c e n t r a l a d m i n i s t r a t i o n o f a - M S H i n d u c e s t h e p h o s p h o r y l a t i o n o f c A M P 
r e s p o n s e e l e m e n t b i n d i n g ( C R E B ) p r o t e i n s i n t h e n u c l e u s o f a n t e r i o r p a r v o c e l l u l a r T R H 
n e u r o n e s ( S a r k a r a n d L e c h a n , 2 0 0 3 ) a n d I C V a d m i n i s t r a t i o n o f a s t a b l e a - M S H 
a n a l o g u e i n c r e a s e s p l a s m a T S H i n f a s t e d r a t s ( K i m e t a l . , 2 0 0 0 ) . T h u s , t h e r e i s 
f u n c t i o n a l i n t e g r a t i o n b e t w e e n T R H a n d a - M S H r e l e a s i n g n e u r o n e s w i t h i n t h e 
h y p o t h a l a m u s a n d t h e o b s e r v e d i n c r e a s e i n T R H m a y b e a s e c o n d a r y r e s p o n s e t o t h e 
o b s e r v e d i n c r e a s e i n a - M S H r e l e a s e . T h i s p a t h w a y m a y i n c r e a s e c i r c u l a t i n g T S H a n d 
t h y r o i d h o r m o n e l e v e l s , c a u s i n g a n i n c r e a s e i n e n e r g y e x p e n d i t u r e . A l t e r n a t i v e l y , o r i n 
a d d i t i o n t o t h i s e f f e c t , t h e T R H a n d a - M S H m a y a c t d i r e c t l y t o r e d u c e f o o d i n t a k e a n d 
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i n c r e a s e e n e r g y e x p e n d i t u r e r e s u l t i n g i n n e g a t i v e e n e r g y b a l a n c e a n d s u b s e q u e n t w e i g h t 
l o s s . 
O x y n t o m o d u l i n c a u s e d a d i r e c t e f f e c t o n T S H r e l e a s e from ex vivo p i t u i t a r y g l a n d , 
w h i l s t 6 4 2 1 c a u s e d a n o n - s i g n i f i c a n t d o s e d e p e n d e n t i n c r e a s e i n t h e s a m e s e t t i n g . A n 
i n c r e a s e i n T S H l e v e l s i s a n o t h e r p o s s i b l e m e c h a n i s m f o r t h e o b s e r v e d i n c r e a s e i n 
e n e r g y e x p e n d i t u r e . A n i n c r e a s e i n T S H r e s u h s i n r a i s e d l e v e l s o f t h e t h y r o i d h o r m o n e s 
T 3 a n d T 4 . T h e s e t h y r o i d h o r m o n e s i n c r e a s e t w o c o m p o n e n t s o f t h e b a s a l m e t a b o l i c 
r a t e : o b l i g a t o r y t h e r m o g e n e s i s a n d a d a p t i v e t h e r m o g e n e s i s ( S i l v a , 1 9 9 5 ) . I n t h e 
a b s e n c e o f t h y r o i d h o r m o n e s , b a s a l m e t a b o l i c r a t e i s r e d u c e d b y u p t o 3 0 % a n d a d a p t i v e 
t h e r m o g e n e s i s i n c o l d - e x p o s e d a n i m a l s i s m a r k e d l y i m p a i r e d ( S i l v a , 2 0 0 3 ) . 
H y p e r t h y r o i d i s m , i n c o n t r a s t , i n c r e a s e s b a s a l m e t a b o l i c r a t e ( S i l v a , 2 0 0 3 ) . I t w o u l d b e 
o f i n t e r e s t t o m e a s u r e h y p o t h a l a m i c m R N A a n d p r o t e i n l e v e l s o f a - M S H , T R H a n d 
c i r c u l a t i n g l e v e l s o f T S H a n d t h y r o i d h o r m o n e s f o l l o w i n g c e n t r a l a n d p e r i p h e r a l 
a d m i n i s t r a t i o n o f 6 4 2 1 a n d o x y n t o m o d u l i n t o g a i n f u r t h e r i n f o r m a t i o n o n t h e 
m e c h a n i s m b y w h i c h t h e o x y n t o m o d u l i n - i n d u c e d i n c r e a s e i n e n e r g y e x p e n d i t u r e i s 
m e d i a t e d . P l a s m a s a m p l e s from t h e m o u s e a n d r a t s t u d i e s o f c h r o n i c a d m i n i s f r a t i o n o f 
6 4 2 1 a n d from t h e c o n t i n u o u s a d m i n i s t r a t i o n o f 6 4 2 1 . S a m p l e s w i l l b e a n a l y s e d f o r 
c h a n g e s i n T S H a n d t h y r o i d h o r m o n e s . 
T h e r a p i d l y i n c r e a s i n g p r e v a l e n c e o f o b e s i t y ( H e d l e y e t a l . , 2 0 0 4 ) r e s u l t s from a n 
i n t e r a c t i o n b e t w e e n e n v i r o n m e n t a l f a c t o r s ( s u c h a s w i d e l y a v a i l a b l e , c a l o r i e - d e n s e 
f o o d s a n d a r e d u c t i o n i n p h y s i c a l a c t i v i t y ) a n d g e n e t i c f a c t o r s w h i c h p r e d i s p o s e t o 
w e i g h t g a i n ( R a v u s s i n a n d B o g a r d u s , 2 0 0 0 ) . T h e u n d e r s t a n d i n g a n d m a n i p u l a t i o n o f 
s y s t e m s w h i c h r e g u l a t e e n e r g y h o m e o s t a s i s m a y l e a d t o t h e d e v e l o p m e n t o f n o v e l a n t i -
o b e s i t y t h e r a p i e s . A r e c e n t s t u d y s u g g e s t s t h a t s u b c u t a n e o u s p r e p r a n d i a l i n j e c t i o n o f 
o x y n t o m o d u l i n c a n r e d u c e f o o d i n t a k e a n d b o d y w e i g h t ( W y n n e e t a l . , 2 0 0 5 ) . H o w e v e r 
t h i s e f f e c t r e q u i r e d frequent i n j e c t i o n s w h i c h i m p a i r t h e u t i l i t y o f t h i s p u t a t i v e 
t h e r a p e u t i c o p t i o n . U s i n g t h e d a t a c o n t a i n e d i n t h i s t h e s i s , w h i c h g i v e s a g r e a t e r 
u n d e r s t a n d i n g o f t h e s t r u c t u r e - Z f r m c t i o n r e l a t i o n s h i p o f o x y n t o m o d u l i n a n d t h e 
m e c h a n i s m b y w h i c h i t c a u s e s a n e g a t i v e e n e r g y b a l a n c e , m a y h e l p i n t h e d e s i g n o f a 
n o v e l a n t i - o b e s i t y a g e n t b a s e d o n a m o d i f i e d f o r m o f o x y n t o m o d u l i n s u c h a s a n a l o g u e 
6 4 2 1 . 
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C u r r e n t l y , l i c e n s e d n o n - s u r g i c a l i n t e r v e n t i o n s f o r o b e s i t y a r e o f l i m i t e d e f f i c a c y 
( K a p l a n , 2 0 0 5 ; Y a n o v s k i a n d Y a n o v s k i J A , 2 0 0 2 ) . T h e m e c h a n i s m s o f p o s t p r a n d i a l 
s a t i e t y a r e s t i l l b e i n g c h a r a c t e r i z e d . H o w e v e r , s a t i e t y f a c t o r s s e c r e t e d b y t h e G I t r a c t 
a p p e a r t o p l a y a n i m p o r t a n t r o l e i n m e a l t e r m i n a t i o n a n d t h e l i m i t a t i o n o f m e a l s i z e . 
A l t e r a t i o n s i n l e v e l s o f g u t h o r m o n e s a f t e r b a r i a t r i c s u r g e r y a r e t h o u g h t t o c o n t r i b u t e t o 
t h e a p p e t i t e s u p p r e s s i o n a n d s u s t a i n e d w e i g h t l o s s s e e n i n p a t i e n t s u n d e r g o i n g t h i s 
p r o c e d u r e , s u p p o r t i n g t h e p u r s u i t o f t h e s e h o r m o n a l s y s t e m s a s t h e r a p e u t i c t a r g e t s ( L e 
R o u x e t a l . , 2 0 0 6 ) . I n d e e d , t h e t a r g e t i n g t h e b o d y ' s o w n s a t i e t y s i g n a l s a s t h e r a p e u t i c 
t a r g e t s m a y p e r m i t e f f e c t i v e r e d u c t i o n s i n b o d y w e i g h t w i t h minimum d i s r u p t i o n t o 
o t h e r s y s t e m s , a v o i d i n g t h e s i d e e f f e c t s t h a t o c c u r a s a n u n w a n t e d c o n s e q u e n c e o f 
t h e r a p i e s t a r g e t i n g u b i q u i t o u s n e u r o t r a n s m i t t e r a n d r e c e p t o r c o m p l e x e s ( C h a u d h r i , e t 
al,2008). 
H o w e v e r , d e v e l o p m e n t o f g u t p e p t i d e s a s t h e r a p e u t i c s i s n o t w i t h o u t i t s d i f f i c u l t i e s . 
M a n y g u t - h o r m o n e s h a v e a s h o r t h a l f - l i f e a n d w o u l d t h u s r e q u i r e frequent ( a n d c o s t l y ) 
r e p e a t e d a d m i n i s t r a t i o n r e g i m e n s . I n a d d i t i o n , t h e r e g u l a t i o n o f f o o d i n t a k e i s c o m p l e x 
a n d t h e g u t - b r a i n a x i s o p e r a t e s i n c o n j u n c t i o n w i t h o t h e r c o m p o n e n t s i n c l u d i n g C N S 
r e w a r d p a t h w a y s , i n p u t f r o m h i g h e r c e n t r e s , a n d s o c i e t a l a n d e n v i r o n m e n t a l i n f l u e n c e s , 
a l l o f w h i c h m a y f e e d b a c k t o l i m i t g u t - h o r m o n e i n d u c e d c h a n g e s i n b o d y w e i g h t . 
A n i m p o r t a n t p a r t o f a n y p o t e n t i a l g u t h o r m o n e b a s e d t h e r a p y i s t h e d e v e l o p m e n t o f 
a n a l o g u e s w i t h a n e x t e n d e d p l a s m a h a l f - l i f e . A k e y s t e p i n t h e d e v e l o p m e n t o f s u c h 
a n a l o g u e s i s d e t e r m i n i n g t h e s t r u c t u r e / a c t i v i t y r e l a t i o n s h i p s o f t h e m o l e c u l e . T h e 
u n d e r t a k i n g o f t h e w o r k d e s c r i b e d i n t h i s t h e s i s i l l u s t r a t e s t h e d i f f i c u h i e s i n h e r e n t i n 
s t u d y i n g t h e s t r u c t u r e / a c t i v i t y r e l a t i o n s h i p s o f s u c h p e p t i d e h o r m o n e s . W h i l s t t h e 
s e c o n d a r y s t r u c t u r e o f a p e p t i d e m a y h y p o t h e t i c a l l y d i v i d e i t i n t o d i s c r e t e r e g i o n s , 
m o d i f i c a t i o n a t d i s t a n t p o s i t i o n s c a n a l t e r t h e p r o p e r t i e s o f s u c h r e g i o n s a n d o f t h e 
w h o l e m o l e c u l e . T h e t h e r a p e u t i c p o t e n t i a l o f p e p t i d e s s t r u c t u r a l l y s i m i l a r t o 
o x y n t o m o d u l i n h a s e n s u r e d t h a t d e t a i l e d i n f o r m a t i o n r e g a r d i n g t h e i r s t r u c t u r e a n d 
f u n c t i o n i s a v a i l a b l e . T h e s e p r e v i o u s s t u d i e s p r o v i d e v a l u a b l e c l u e s t o t h e 
s t r u c t u r e / f u n c t i o n r e l a t i o n s h i p o f o x y n t o m o d u l i n . T h e c o n t r a s t i n g p r o p e r t i e s o f G L P - 1 
a n d e x e n d i n - 4 a l s o p r o v i d e v a l u a b l e i n f o r m a t i o n t o a s s i s t t h e d e s i g n o f o x y n t o m o d u l i n 
a n a l o g u e s w i t h a l o n g e r p l a s m a h a l f - l i f e . 
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I n s u m m a r y , m y e x p e r i m e n t s h a v e d e t e r m i n e d s o m e o f t h e s t r u c t u r e / f u n c t i o n 
r e l a t i o n s h i p s o f t h e o x y n t o m o d u l i n m o l e c u l e a n d h i g h l i g h t e d t h e c o m p l e x i t i e s o f 
p e p t i d e s t r u c t u r e u n d e r l y i n g b i o l o g i c a l a c t i v i t y . F u r t h e r s t u d i e s a r e n o w r e q u i r e d t o 
f u r t h e r e l u c i d a t e t h e c h a n g e s t h a t c a n b e m a d e t o t h e o x y n t o m o d u l i n m o l e c u l e t o 
o p t i m i s e i t s t h e r a p e u t i c p o t e n t i a l . 
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9.1 Appendix A: Amino acids 
Ala ( A ) A l a n i n e 
Cys(C) C y s t e i n e 
Asp (D) A s p a r t i c a c i d 
Glu ( E ) G l u t a m i c a c i d 
Phe ( F ) P h e n y l a l a n i n e 
Gly(G) G l y c i n e 
His ( H ) H i s t i d i n e 
He ( I ) I s o l e u c i n e 
Lys(K) L y s i n e 
Leu ( L ) L e u c i n e 
Met ( M ) M e t h i o n i n e 
Asn ( N ) A s p a r a g i n e 
Pro (?) P r o l i n e 
Gin ( Q ) G l u t a m i n e 
Arg (R) A r g i n i n e 
Ser(S) S e r i n e 
Thr ( T ) T h r e o n i n e 
Val ( V ) V a l i n e 
Trp ( W ) T r y p t o p h a n 
T y r ( Y ) T y r o s i n e 
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9.2 Appendix B: Solutions used in this thesis 
A l l w a t e r u s e d f o r p r o d u c t i o n o f s o l u t i o n s w a s p u r i f i e d b y r e v e r s e o s m o s i s u s i n g t h e 
E L G A S T A T p r i m a p u r i f i c a t i o n s y s t e m a n d s u b s e q u e n t l y a u t o c l a v e d u n l e s s o t h e r w i s e 
s t a t e d . 
aCSF: 
2 0 m M N a H C O s , 1 2 6 m M N a C l , 0 . 0 9 m M N a 2 H P 0 4 . 2 H 2 0 , 6 m M K C l , 
1 . 4 m M C a C l 2 . 2 H 2 0 , 0 . 0 9 m M M g S 0 4 . 7 H 2 0 , 5 m M D g l u c o s e , 0 . 1 8 
m g / m l a s c o r b i c a c i d a n d 1 0 0 n g / m l a p r o t i n i n . 
A l k a l i n e S D S ( 0 . 2 M N a O H / 1 % S D S ) : 
m i x 2 m l 1 0 M N a O H , 5 m l 2 0 % S D S a n d 9 3 m l w a t e r . 
B i u r e t r e a g e n t : 
d i s s o l v e 1 . 5 0 g C U S O 4 , 6 g K N a C 4 H 4 0 6 . 4 H 2 0 , 3 0 . 0 g N a O H , 1 . 0 0 g K I 
a n d 1 5 . 0 g d e o x y c h o l a t e i n 9 0 0 m l w a t e r . W a r m t o d i s s o l v e s a l t s . M a k e 
u p t o 1 L w i t h w a t e r . 
2 M C a l c i u m c h l o r i d e : 
d i s s o l v e 5 . 8 8 g C a C l 2 . 2 H 2 0 i n 2 0 m l w a t e r a n d s t e r i l i s e b y p a s s i n g 
t h r o u g h a 0 . 2 2 p - m f i l t e r . S t o r e i n 1 . 0 m l a l i q u o t s a t - 2 0 ° C . 
C a e s i u m c h l o r i d e s a t u r a t e d p r o p a n - 2 - o l : 
m i x 1 0 0 g C S C I 2 w i t h 1 0 0 m l w a t e r a n d 1 L p r o p a n - 2 - o l . L e a v e t o s e t t l e 
b e f o r e u s e . 
D e x t r a n c o a t e d c h a r c o a l : 
d i s s o l v e 2 . 4 0 g c h a r c o a l a n d 0 . 2 4 g d e x t r a n i n 1 0 0 m l p h o s p h a t e b u f f e r 
( R I A b u f f e r ) w i t h g e l a t i n e ( 0 . 0 0 2 5 % w / v ) . M i x f o r 2 0 m i n u t e a t 4 ° C . 
0 . 5 M E D T A p H 8 . 0 : 
d i s s o l v e 1 4 6 . 1 g ( H 0 2 C C H 2 ) 2 N C H 2 C H 2 N ( C H 2 C 0 2 H ) 2 i n 8 0 0 m l w a t e r 
a n d a d j u s t t o p H 8 . 0 w i t h 1 M N a O H . M a k e u p t o 1 L w i t h w a t e r . 
3 0 1 
1 0 m g / m l E t h i d i u m b r o m i d e : 
d i s s o l v e 2 0 0 m g e t h i d i u m b r o m i d e i n 2 0 m l w a t e r . 
G e l l o a d i n g b u f f e r : 
3 . 1 3 m l 8 0 % g l y c e r o l , 5 0 p i 0 . 5 M E D T A a n d 6 . 1 0 m l w a t e r . A d d 1 0 
m g o r a n g e G . 
G T E : 
m i x 2 . 5 m l 1 M T r i s - H C l , p H 8 . 0 , 2 . 0 m l 0 . 5 M E D T A a n d 5 . 0 m l 1 8 % 
g l u c o s e . M a k e u p t o 1 0 0 m l w i t h w a t e r . S t e r i l i s e b y p a s s i n g t h r o u g h a 
0 . 2 n m f i l t e r . 
2 0 m M H E P E S p H 1 1 : 
d i s s o l v e 4 . 7 6 g H E P E S i n 9 0 0 m l w a t e r . A d j u s t t o p H 1 1 w i t h 0 . 5 M 
N a O H a n d m a k e u p t o 1 L w i t h w a t e r . 
K e m t e c b u f f e r : 
d i s s o l v e i n 4 L o f w a t e r , 2 2 . 4 g N a H 2 P 0 4 , 9 . 9 6 g N a 2 H P 0 4 , 1 4 . 8 g 
( H 0 2 C C H 2 ) 2 N C H 2 C H 2 N ( C H 2 C 0 2 H ) 2 , 1 . 0 0 g T h i m e r s a l a n d p H a d j u s t t o 
7 . 4 w i t h H C l . A d d 1 . 0 m l B S A ( 3 0 % ) . 
L B : 
L B a g a r : 
m i x 1 0 . 0 g N a C l , 1 0 . 0 g t r y p t o n e a n d 5 . 0 g y e a s t e x t r a c t m i x e d i n 4 5 0 m l 
w a t e r . A d j u s t t o p H 7 . 5 w i t h N a O H a n d m a k e u p t o 5 0 0 m l w i t h 
w a t e r . S t e r i l i s e d i m m e d i a t e l y b y a u t o c l a v i n g . 
a d d 7 . 0 g a g a r t o 5 0 0 m l L B t h e n a u t o c l a v e . 
1 M M a g n e s i u m c h l o r i d e : 
d i s s o l v e 2 0 3 . 3 g M g C l 2 . 6 H 2 0 i n 1 L w a t e r . 
0 . 1 M P E I p H 7 . 0 : 
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d i s s o l v e 4 5 0 m g P E I i n 8 0 m l w a t e r . A d j u s t t o p H 7 . 0 w i t h H C l . M a k e 
u p t o 1 0 0 m l w i t h w a t e r . F i l t e r s o l u t i o n . 
3 M P o t a s s i u m a c e t a t e p H 4 . 6 : 
d i s s o l v e 2 9 4 . 4 g CH3COOK i n w a t e r , a d j u s t e d t o p H 4 . 6 w i t h g l a c i a l 
a c e t i c a c i d a n d m a k e u p t o 1 L w i t h w a t e r . 
P h o s p h a t e b u f f e r ( R I A b u f f e r ) ; 
d i s s o l v e 4 8 g o f N a 2 H P 0 4 . 2 H 2 0 , 4 . 1 3 g K H 2 P O 4 , 1 8 . 6 g 
(H02CCH2)2NCH2CH2N(CH2C02H)2,2.5 g NaNs in 5 L of water. 
C o n f i r m p H i s 7 . 6 ± 0 . 1 a n d s t o r e b u f f e r a t 4 ° C . 
P h o s p h a t e b u f f e r w i t h g e l a t i n e : 
B u f f e r i s p r o d u c e d a s a b o v e w i t h 1 2 . 5 g o f g e l a t i n e d i s s o l v e d i n 5 L 
w a r m e d w a t e r . Cool s o l u t i o n b e f o r e a d d i t i o n o f o t h e r i n g r e d i e n t s . 
0 . 1 M P h o s p h a t e b u f f e r e d s a l i n e ( P B S ) : 
d i s s o l v e 8 g N a C l , 0 . 2 g K C l , 1 . 4 4 g N a 2 H P 0 4 a n d 0 . 2 4 g KH2PO4 i n 
8 0 0 m l o f w a t e r . A d j u s t t o p H 7 . 6 w i t h H C l a n d m a k e u p t o 1 L w i t h 
w a t e r . 
1 M P o t a s s i u m c h l o r i d e : 
d i s s o l v e 7 4 . 5 g K C l i n w a t e r a n d m a k e u p t o I L . 
S e p h a d e x G 5 0 s u p e r f i n e : 
a d d 8 . 0 g s u p e r f i n e g r a d e S e p h a d e x G 5 0 b e a d s ( d i a m e t e r : 2 0 - 8 0 | i m ) t o 
2 . 0 m l 1 0 0 X T E , 0 . 1 m l 2 0 % S D S a n d m a k e u p t o 2 0 0 m l v w t h w a t e r . 
A u t o c l a v e . 
2 M S o d i u m a c e t a t e p H 5 . 2 : 
d i s s o l v e 1 6 4 . 1 g C H g C O O N a i n 8 0 0 m l w a t e r . A d j u s t t o p H 5 . 2 w i t h 
g l a c i a l a c e t i c a c i d a n d m a k e u p t o 1 L w i t h w a t e r . 
3 M S o d i u m a c e t a t e p H 4 . 6 : 
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d i s s o l v e 2 4 6 . 2 g C H s C O O N a i n 8 0 0 m l w a t e r . A d j u s t t o p H 4 . 6 w i t h 
g l a c i a l a c e t i c a c i d a n d m a k e u p t o 1 L w i t h w a t e r . 
0 . 1 4 M S o d i u m b o r a t e b u f f e r p H 8 . 3 : 
d i s s o l v e 5 . 3 2 g N a 2 B 4 0 7 i n 8 0 0 m l w a t e r . A d j u s t t o p H 8 . 3 b y a d d i t i o n 
o f H C l a n d m a k e u p t o 1 L w i t h w a t e r . 
0 . 3 M S o d i u m c h l o r i d e : 
d i s s o l v e 1 7 . 5 5 g N a C l i n 8 0 0 m l w a t e r . M a k e u p t o 1 L w i t h w a t e r . 
5 M S o d i u m c h l o r i d e : 
d i s s o l v e 2 9 2 . 2 g N a C l i n 8 0 0 m l w a t e r . M a k e u p t o 1 L w i t h w a t e r . 
1 0 M S o d i u m h y d r o x i d e : 
d i s s o l v e 4 0 0 . 0 g N a O H i n 8 0 0 m l w a t e r . M a k e u p t o 1 L w i t h w a t e r . 
5 0 X T A E : 
d i s s o l v e 2 4 2 . 0 g t r i z m a b a s e i n 8 4 3 m l w a t e r a n d 5 7 m l o f g l a c i a l a c e t i c 
a c i d a n d 1 0 0 m l 0 . 5 M E D T A . 
T E S : 
T F B I : 
T F B I I : 
m i x 2 5 m l 1 M T r i s - H C l p H 8 . 0 , 5 m l 5 M N a C l a n d 5 m l 
C i o H i 4 H 2 0 g N a 2 . 2 H 2 0 . M a k e u p t o 5 0 0 m l w i t h w a t e r . 
dissolve 589 g CH3COOK, 2.42 g RbCl, 1.98 g CaClz.lHzO and 438 
m g M n C l 2 . 4 H 2 0 i n 1 0 0 m l w a t e r . A d d 3 7 . 5 m l 8 0 % g l y c e r o l a n d m a k e 
u p t o 2 0 0 m l w i t h w a t e r . S t e r i l i s e b y p a s s i n g t h r o u g h 0 . 2 p m f i l t e r . 
d i s s o l v e 4 1 8 m g C7H15NO4S, 3 . 2 8 g C a C l 2 . 2 H 2 0 a n d 2 4 2 m g R b C l i n 
1 0 0 m l w a t e r . A d d 3 7 . 5 m l 8 0 % g l y c e r o l a n d m a k e u p t o 2 0 0 m l w i t h 
w a t e r . S t e r i l i s e b y p a s s i n g t h r o u g h 0 . 2 p . m f i l t e r . 
1 M T r i s - H C l , p H 7 . 5 : 
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d i s s o l v e 1 2 1 . 1 g t r i z m a b a s e i n 8 0 0 m l w a t e r . A d j u s t t o p H 7 . 5 w i t h H C l 
a n d m a k e u p t o 1 L w i t h w a t e r . 
2 M T r i s - H C l , p H 8 . 0 : 
d i s s o l v e 1 2 1 . 1 g t r i z m a b a s e i n 4 5 0 m l w a t e r . A d j u s t t o p H 8 . 0 w i t h 
H C l a n d m a k e u p t o 5 0 0 m l w i t h w a t e r . 
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9.3 Appendix C: Radioimmunoassay Methods 
9.3.1 General Principle of a Radioimmunoassay 
A l l r a d i o i m m u n o a s s a y s u s e d w e r e d e r i v e d a n d m a i n t a i n e d b y P r o f e s s o r M A G h a t e i 
( P r o f e s s o r o f R e g u l a t o r y P e p t i d e s , M e t a b o l i c M e d i c i n e , F a c u l t y o f M e d i c i n e , I m p e r i a l 
C o l l e g e ) u n l e s s o t h e r w i s e s t a t e d . A l l r e a g e n t s a n d m a t e r i a l s o t h e r t h a n p e p t i d e s w e r e 
s u p p l i e d b y S i g m a . 
T h e p r i n c i p l e o f r a d i o i m m u n o a s s a y i s t h e c o m p e t i t i o n b e t w e e n a r a d i o a c t i v e a n d n o n -
r a d i o a c t i v e a n t i g e n f o r a f i x e d n u m b e r o f a n t i b o d y b i n d i n g s i t e s . W h e n i m l a b e l l e d 
a n t i g e n from s t a n d a r d s o f s a m p l e s a n d a f i x e d a m o u n t o f l a b e l l e d a n t i g e n a r e a l l o w e d t o 
r e a c t w i t h a c o n s t a n t a n d l i m i t i n g a m o u n t o f a n t i b o d y , d e c r e a s i n g a m o u n t s o f l a b e l l e d 
a n t i g e n a r e b o u n d t o t h e a n t i b o d y a s t h e a m o u n t o f u n l a b e l l e d a n t i g e n i s i n c r e a s e d . T h e 
r a d i o i m m u n o a s s a y i s i n c u b a t e d a n d a l l o w e d t o r e a c h e q u i l i b r i u m , a c c o r d i n g t o t h e 
e q u a t i o n : 
*Ag + Ab + Ag *AgAb + AgAb 
A g = u n l a b e l l e d a n t i g e n 
* A g = r a d i o l a b e l l e d a n t i g e n 
A b = a n t i b o d y 
S e p a r a t i o n o f t h e b o u n d from t h e free a n t i g e n i s a c h i e v e d b y a d d i t i o n o f e i t h e r d e x t r a n -
c o a t e d c h a r c o a l ( f r e e l a b e l i s c o n t a i n e d i n t h e c h a r c o a l p e l l e t f o l l o w i n g c e n t r i f r i g a t i o n ) 
o r u s i n g a p r i m a r y - s e c o n d a r y a n t i b o d y c o m p l e x ( f r e e l a b e l i s c o n t a i n e d i n t h e 
s u p e r n a t a n t f o l l o w i n g c e n t r i f r i g a t i o n ) . T h e s e c o n d a r y a n t i b o d y i s d e r i v e d from a n 
a n i m a l s p e c i e s d i f f e r e n t from t h a t u s e d t o g e n e r a t e t h e p r i m a r y a n t i b o d y . A f t e r 
i n c u b a t i o n a n d s e p a r a t i o n , t h e b o u n d a n d free l a b e l a r e c o u n t e d i n a y - c o u n t e r . T h e d a t a 
a r e u s e d t o c o n s t r u c t a s t a n d a r d c u r v e from w h i c h t h e v a l u e s o f t h e u n k n o w n s c a n b e 
o b t a i n e d b y i n t e r p o l a t i o n . 
I n t e r - a s s a y v a r i a t i o n c a n b e c a l c u l a t e d b y a s s a y i n g a l i q u o t s o f t h e s a m e s a m p l e i n e a c h 
a s s a y p e r f o r m e d a n d c o m p a r i n g t h e c o n c e n t r a t i o n s o b t a i n e d i n e a c h . T o m e a s u r e a n d 
c o r r e c t f o r b a s e l i n e d r i f t , t u b e s w i t h n o s a m p l e ( ' z e r o ' t u b e s ) a r e p l a c e d a t r e g u l a r 
i n t e r v a l s t h r o u g h o u t t h e a s s a y a n d s t a n d a r d c u r v e s a r e p e r f o r m e d a t t h e b e g i n n i n g a n d 
306 
e n d o f e a c h a s s a y . T h e g e n e r a l s t r u c t u r e o f t h e R I A i s o u t l i n e d i n t a b l e 9 . 1 , w h i c h 
s h o w s t h e c o n t e n t o f t h e t u b e s a c c o r d i n g t o t h e i r d e s i g n a t i o n . 
T h e f o l l o w i n g t u b e s a r e i m p o r t a n t f o r t h e a s s e s s m e n t a n d p e r f o r m a n c e o f t h e a s s a y : 
Non-specific binding; l o w b i n d i n g i n d i c a t e s a d e q u a t e l a b e l i n t e g r i t y . 
V z X : a s s e s s e s i f g r e a t e r s e n s i t i v i t y c o u l d b e a c h i e v e d b y a d d i n g h a l f t h e v o l u m e o f 
l a b e l . 
2 X : a s s e s s e s i f g r e a t e r s e n s i t i v i t y c o u l d b e a c h i e v e d b y a d d i n g d o u b l e t h e v o l u m e o f 
l a b e l . 
Zero tubes: a l l o w s a s s e s s m e n t o f a s s a y d r i f t . 
Excess antibody: a s s e s s e s t h e i m m u n o l o g i c a l i n t e g r i t y o f t h e l a b e l l e d p e p t i d e . 
Quality Controls: i n c l u d e s p r e v i o u s l y a l i q u o t e d s a m p l e s c o n t a i n i n g h i g h a n d l o w 
l e v e l s o f t h e a n t i g e n . T h e s e t u b e s a l l o w t h e a s s a y s t o b e s t a n d a r d i s e d . 
Tube number Designation 
1-2 Non-specific binding 
3-4 1/2 X 
5-6 2X 
7-8 Zero 
9-10 Zero 
11-12 Standard 1 
13-14 Standard 2 
15-16 Standard 3 
17-18 Standard 4 
19-20 Standard 5 
21-22 Standard 6 
23-24 Standard 7 
25-26 Standard 8 
27-28 Standard 9 
29-30 Standard 10 
31-34 Zero 
35- .... Samples 
Zeros Two zeros every 50 samples 
Standard curve 
Final two tubes Excess 
Table 9.1 The general structure of the radioimmunoassay 
9.3.2 Insulin radioimmunoassay 
P o r c i n e i n s u l i n , u s e d f o r t h e i n s u l i n l a b e l w a s p u r c h a s e d f r o m P h o e n i x P h a r m a c e u t i c a l s . 
T h e l a b e l e d i n s u l i n w a s p r e p a r e d b y P r o f e s s o r M . G h a t e i w h o i o d i n a t e d t h e p e p t i d e 
u s i n g t h e i o d o g e n m e t h o d p u r i f i e d i t b y H P L C ( 2 . 4 . 4 . 2 ) . 
3 0 7 
A s s a y s w e r e p e r f o r m e d i n 0 . 0 6 M p h o s p h a t e E D T A b u f f e r ( 0 . 0 5 M N a ^ H P O i . Z H z O , 0 . 6 
m M KH2PO4, 0 . 0 1 M d i s o d i u m - E D T A . 2 H 2 0 , 0 . 0 0 8 M N a N s ) , a t p H 7 . 4 w i t h 0 . 3 % 
B S A . A l l s a m p l e s w e r e a s s a y e d i n d u p l i c a t e . S t a n d a r d c u r v e s p r e p a r e d f o r e a c h a s s a y 
u s e d p o r c i n e i n s u l i n ( P h o e n i x P h a r m a c e u t i c a l s ) a n d w e r e p r e p a r e d i n a s s a y b u f f e r a t 2 
p m o l / m l a n d a d d e d i n d u p l i c a t e a t v o l u m e s o f 1 , 2 , 3 , 5 , 1 0 , 1 5 , 2 0 , 3 0 , 5 0 a n d 1 0 0 | a l . 
T h e i n s u l i n a n t i b o d y w a s r a i s e d i n g u i n e a p i g s a g a i n s t h u m a n i n s u l i n c o n j u g a t e d t o 
B S A b y g l u t a r a l d e h y d e . T h e a n t i b o d y c r o s s - r e a c t s w i t h a l l m a m m a l i a n f o r m s o f i n s u l i n 
a n d i n t h i s a s s a y t h e a n t i b o d y w a s u s e d a t a d i l u t i o n o f 1 : 2 5 0 0 0 0 . A s a m p l e v o l u m e o f 
2 0 | j , l o f c e l l m e d i a w a s u s e d a n d a l l t u b e s w e r e b u f f e r e d t o a t o t a l v o l u m e o f 7 0 0 | u . l 
w i t h a s s a y b u f f e r . T h e a s s a y s w e r e i n c u b a t e d f o r 7 2 h o u r s a t 4 ° C . F r e e p e p t i d e w a s 
s e p a r a t e d from b o u n d u s i n g c h a r c o a l a d s o r p t i o n . T o e a c h t u b e 4 m g o f c h a r c o a l , 
s u s p e n d e d i n 0 . 0 6 M p h o s p h a t e E D T A b u f f e r w i t h g e l a t i n e w a s a d d e d i m m e d i a t e l y 
p r i o r t o c e n t r i f u g a t i o n . T h e s a m p l e s w e r e t h e n c e n t r i f a g e d a t 1 5 0 0 g , 4 ° C , f o r 2 0 
m i n u t e s . B o u n d a n d free l a b e l w e r e s e p a r a t e d a n d b o t h t h e p e l l e t a n d s u p e r n a t a n t 
c o u n t e d f o r 1 8 0 s e c o n d s i n a y - c o u n t e r ( N E 1 6 0 0 , N E T e c h n o l o g y L t d . ) . I n s u l i n 
c o n c e n t r a t i o n s i n t h e s a m p l e s w e r e c a l c u l a t e d u s i n g a n o n - l i n e a r p l o t ( R I A S o f t w a r e , 
N E T e c h n o l o g y L t d ) a n d r e s u l t s c a l c u l a t e d i n t e r m s o f t h e s t a n d a r d . 
9.3.3 Alpha-MSH radioimmunoassay 
A l p h a - M S H f r o m a C S F w a s m e a s u r e d b y a n i n - h o u s e r a d i o i m m u n o a s s a y . I t i s 
p e r f o r m e d u s i n g t h e s a m e p r i n c i p l e a n d a s i m i l a r p r o t o c o l t o t h a t o f i n s u l i n ( 9 . 3 . 2 ) 
e x c e p t f o r t h e f o l l o w i n g c h a n g e s . A s a m p l e v o l u m e o f 2 0 0 ^ 1 w e r e a s s a y e d i n d u p l i c a t e 
i n a t o t a l v o l u m e o f 4 0 0 | a l c o n t a i n i n g r a b b i t a n t i - r a t a - M S H ( f i n a l d i l u t i o n 1 : 2 0 0 0 0 ) 
a n d 1 5 0 0 c p m / t u b e o f i o d i n a t e d a - M S H . T h e c o n c e n t r a t i o n o f t h e h i g h e s t s t a n d a r d i s 
0 . 0 5 p m o l / m l a n d t h e l o w e s t 0 . 5 frnol/ml. T h e a s s a y w a s i n c u b a t e d f o r 3 d a y s a t 4 ° C . 
T h e s e p a r a t i o n o f b o u n d from free l a b e l w a s a c h i e v e d u s i n g t h e c h a r c o a l s e p a r a t i o n 
m e t h o d ( a s d e s c r i b e d i n 9 . 3 . 2 ) . 
9.3.4 TRH radioimmunoassay 
T h y r o t r o p h i n r e l e a s i n g h o r m o n e ( T R H ) w a s o b t a i n e d from P e n n i n s u l a L a b o r a t o r i e s a n d 
w a s i o d i n a t e d b y P r o f e s s o r M . G h a t e i u s i n g t h e d i r e c t i o d o g e n m e t h o d ( O w j i e t a l . , 
1 9 9 5 ) a n d p u r i f i e d b y H P L C ( 2 . 4 . 4 . 2 ) . T h e T R H a s s a y w a s c o m p l e t e d u s i n g t h e s a m e 
p r o t o c o l a s f o r i n s u l i n ( 9 . 3 . 2 ) e x c e p t f o r t h e f o l l o w i n g m o d i f i c a t i o n s . A s s a y w a s 
c o m p l e t e d i n 0 . 0 6 M p h o s p h a t e E D T A b u f f e r ( p H 7 . 4 ) 0 . 3 % B S A . S a m p l e v o l u m e o f 
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2 0 0 ( J . 1 w e r e a s s a y e d i n d u p l i c a t e i n a t o t a l v o l u m e o f 3 5 0 | j , l , c o n t a i n i n g a n t i b o d y 
( 1 : 1 2 0 0 0 0 ) a n d 1 5 0 0 c p m / t u b e o f A s t a n d a r d c u r v e w a s p r e p a r e d u s i n g 
s y n t h e t i c T R H m a d e u p i n a s s a y b u f f e r a n d a d d e d i n d u p l i c a t e a t v o l u m e s o f 1 , 2 , 3 , 5 , 
1 0 , 1 5 , 2 0 , 3 0 , 5 0 a n d 1 0 0 p , l . T h e a s s a y w a s i n c u b a t e d f o r 7 2 h o u r s a t 4 ° C t h e n f r e e 
a n d a n t i b o d y - b o u n d p e p t i d e w a s s e p a r a t e d b y c h a r c o a l a d s o r p t i o n ( a s d e s c r i b e d i n 
9.3.2). 
9.3.5 TSH radioimmunoassay 
T S H from a C S F w a s m e a s u r e d b y r a d i o i m m u n o a s s a y u s i n g t h e r e a g e n t s a n d m e t h o d s 
g e n e r o u s l y p r o v i d e d b y t h e N I D D K a n d N a t i o n a l H o r m o n e a n d P i t u i t a r y P r o g r a m ( D r 
A . P a r l o w , H a r b o r U n i v e r s i t y o f C a l i f o r n i a , L o s A n g e l e s M e d i c a l C e n t r e ) . 
P u r i f i e d T S H w a s a l i q u o t e d ( 2 | j , g ) i n 0 . 5 M p h o s p h a t e b u f f e r , p H 7 . 6 a n d s t o r e d a t -
7 0 ° C . 2 n g o f h o r m o n e i n 2 0 p . ! o f 0 . 5 M p h o s p h a t e b u f f e r w a s i o d i n a t e d w i t h 0 . 5 m C i 
( A m e r s h a m - P h a r m a c i a B i o t e c h ) o f N a ^ ^ ^ I u s i n g C h l o r a m i n e T ( 1 . 4 ) j , g / 1 0 : 1 ) a n d 
s o d i u m m e t a b i s u l p h a t e ( 4 . 8 [ i g / 1 0 : 1 ) . T h e i o d i n a t e d p e p t i d e w a s s e p a r a t e d from free 
i o d i n e a n d u n l a b e l l e d p e p t i d e b y s i z e e x c l u s i o n c h r o m a t o g r a p h y u s i n g a 1 2 c m 
s e p h a d e x G 5 0 c o l u m n ( P h a r m a c i a ) . T h e c o l u m n w a s e q u i l i b r a t e d w i t h 0 . 5 M 
p h o s p h a t e b u f f e r c o n t a i n i n g 0 . 5 % B S A . 0 . 5 m l f r a c t i o n s w e r e c o l l e c t e d . T h e i o d i n a t e d 
p e p t i d e e l u t e d i n t h e first 1 0 fractions, f o l l o w e d b y t h e free i o d i n e . T h e first 3 fractions 
c o n t a i n i n g t h e h i g h e s t c o u n t s w e r e t e s t e d i n t h e r a d i o i m m u n o a s s a y . 
T h e T S H a s s a y w a s c a r r i e d o u t i n k e m t e c k b u f f e r ( p H 7 . 4 ) . S a m p l e s w e r e a s s a y e d i n a 
t o t a l v o l u m e o f 4 0 0 p i w i t h 1 5 0 0 c p m / t u b e o f i o d i n a t e d h o r m o n e . S t a n d a r d s w e r e 
s e r i a l l y d i l u t e d w i t h t h e c o n c e n t r a t i o n o f t h e h i g h e s t s t a n d a r d a t 1 0 0 n g / m l a n d t h e 
a n t i b o d y w a s u s e d a t a final v o l u m e o f 1 : 2 4 0 0 0 0 . A s a m p l e v o l u m e o f 1 0 p , l from 
p i t u i t a r y q u a d r a n t m e d i u m w a s u s e d . F r e e a n d a n t i b o d y - b o u n d p e p t i d e w a s s e p a r a t e d 
u s i n g s e c o n d a r y a n t i b o d y . T h e s a m p l e s w e r e p r e - i n c u b a t e d f o r 3 0 m i n u t e s w i t h 1 0 0 | j . 1 
o f g o a t a n t i - r a b b i t s e c o n d a r y a n t i b o d y ( P h a r m a c i a D i a g n o s t i c s ) . I m m e d i a t e l y p r i o r t o 
c e n t r i f u g a t i o n , 5 0 0 p i o f 0 . 0 1 % T r i t o n - X - 1 0 0 s o l u t i o n w a s a d d e d t o e a c h t u b e . T h e 
s a m p l e s w e r e t h e n i m m e d i a t e l y c e n t r i f u g e d a t 1 5 0 0 g , 4 ° C , f o r 2 0 m i n u t e s . B o u n d a n d 
free l a b e l w e r e s e p a r a t e d a n d b o t h p e l l e t a n d s u p e r n a t a n t c o u n t e d f o r 1 8 0 s e c o n d s i n a 
y - c o u n t e r ( N E 1 6 0 0 , N E T e c h n o l o g y L t d . ) . P e p t i d e c o n c e n t r a t i o n s i n t h e s a m p l e s w e r e 
c a l c u l a t e d u s i n g a n o n - l i n e a r p l o t ( R I A S o f t w a r e , N E 1 6 0 0 , N E T e c h n o l o g y L t d . ) a n d 
r e s u l t s c a l c u l a t e d i n t e r m s o f t h e N I D D K s t a n d a r d p r e p a r a t i o n ( N I D D K r a t T S H R P - 3 ) . 
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9.4 Appendix D; Generation of stable transfected GPCR 
overexpressing cell lines 
P l a s m i d s c o n t a i n i n g t h e c D N A s e q u e n c e o f t h e G L P - 1 a n d G C G r e c e p t o r s w e r e 
p u r c h a s e d f r o m O r i g e n e , a n d s u p p l i e d i n t h e p C M V 6 - X L 5 p l a s m i d ( F i g u r e 9 . 4 1 ) . 
O v e r e x p r e s s i n g c e l l l i n e s w e r e p r o d u c e d u s i n g t h e p r o t o c o l s o u t l i n e d i n s e c t i o n 2 , a n d 
f u r t h e r d e s c r i b e d b e l o w . 
T7 promoter 
resistant 
pC MV6-XL5 
4482 bp 
M13 reverse 
Sma 
PolyA sign 
ColEI SV40 orj 
Not I 
EcoR I # 
Bgl II 
Kpnl 
EcoRV 
Hind III 
Sal I # ' 
Xba I 
Not I 
Sma I 
# cloning sites: 
lost upon cloning 
M13 
Figure 9.4.1 Plasmid map of supplied clones 
P l a s m i d s w e r e t r a n s f o r m e d i n t o c o m p e t e n t E.coli ( X L 1 - B l u e ) b y h e a t s h o c k t r e a t m e n t 
a n d t h o s e b a c t e r i a w h i c h h a d s u c c e s s f u l l y i n c o r p o r a t e d t h e p l a s m i d w e r e s e l e c t e d f o r b y 
a m p i c i l i n . S m a l l s c a l e D N A p r e p a r a t i o n s w e r e m a d e f r o m a s a m p l e o f p o s i t i v e c o l o n i e s 
a n d a r e s t r i c t i o n e n d o n u c l e a s e d i g e s t s t r a t e r g y u s e d t o e n s u r e t h e c o r r e c t p l a s m i d D N A 
w a s p r e s e n t . D N A w a s i n c u b a t e d w i t h e n z y m e s E c o R I a n d X h o I a n d a 1 7 0 0 b a s e p a i r 
fragment i n d i c a t e d p r e s e n c e o f a n i n t a c t G L P - 1 r e c e p t o r c o d i n g s e q u e n c e ( f i g u r e 9 . 4 . 2 a ) 
a n d a 2 3 0 0 b a s e p a i r fragment i n d i c a t i n g p r e s e n c e o f a n i n t a c t G C G r e c e p t o r c o d i n g 
s e q u e n c e ( f i g u r e 9 . 4 . 2 b ) . 
C o l o n y 1 o f t h e t e s t e d G L P - 1 r e c e p t o r c o n t a i n i n g b a c t e r i a a n d c o l o n y 3 o f t h e G C G 
r e c e p t o r c o n t a i n i n g b a c t e r i a w a s s e l e c t e d f o r l a r g e s c a l e D N A p r e p a r a t i o n a n d u s e d t o 
g e n e r a t e o v e r e x p r e s s i n g c e l l l i n e s . 
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Figure 9.4.2 Restriction endonucleas digestions of plasmid DNA extracted from 
E.coli transformed with plasmid containing a) GLP-1 receptor cDNA, b) GCG 
receptor cDNA. DNA incubared with enzymes EcoR I and Xho I for 60 minutes 
at 37°iC and separated by gel electrophorysis. 1700 base pair fragment indicated 
presence of an intact GLP-1 receptor coding sequence. 2300 base pair fragment 
indicating presence of an intact GCG receptor coding sequence. 
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9.5 Appendix E Mouse behaviour studies 
P r e v i o u s , u n p u b l i s h d w o r k b y m e m b e r s o f t h e g r o u p i n v e s t i g a t e d m o u s e b e h a v i o u r 
f o l l o w i n g a d m n i s t r a t i o n o f o x y n t o m o d u l i n , G L P - 1 a n d e x e n d i n - 4 . A b r i e f s u m m a r y o f 
t h e e x p e r m e n t a l d e s i g n a n d r e s u l t s a r e i n c l u d e d b e l o w . 
9.5.1 Observational analysis of mouse behaviour 
A l l m i c e w e r e s i n g l y h o u s e d a n d t h e a c c l i m a t i s a t i o n p r o c e s s a n d p r e p a r a t i o n f o r s t u d i e s 
w a s t h e s a m e a s t h a t f o r m i c e t a k i n g p a r t i n f e e d i n g s t u d i e s . L i t h i u m c h l o r i d e w a s u s e d 
a s a p o s i t i v e c o n t r o l f o r i l l n e s s / a v e r s i v e b e h a v i o u r . T h i s w a s g i v e n a t a d o s e o f 1 2 7 
m g / k g b y I P i n j e c t i o n ( a d o s e s h o w n i n s e v e r a l s t u d i e s t o p r o d u c e a s e n s a t i o n o f v i s c e r a l 
i l l n e s s ( C a n n o n e t a l . , 2 0 0 5 ; L a c h e y e t a l . , 2 0 0 5 ) . 
M i c e w e r e f a s t e d f r o m 1 6 : 0 0 t h e p r e c e d i n g d a y a n d f o l l o w i n g I P i n j e c t i o n s , m i c e w e r e 
r e t u r n e d a s u s u a l t o t h e i r h o m e c a g e s . A c o l l e a g u e w h o w a s b l i n d e d t o t h e t r e a t m e n t 
t h e y h a d r e c e i v e d a s s e s s e d t h e i r b e h a v i o u r o v e r t h e s u b s e q u e n t 6 0 m i n u t e s u s i n g a 
p r e v i o u s l y - e s t a b l i s h e d p r o t o c o l f o r r o d e n t b e h a v i o u r a n a l y s i s ( N e a r y e t a l . , 2 0 0 5 ) . T h e 
o b s e r v e r a s s e s s e d b e h a v i o u r i n e a c h m o u s e f o r 1 5 s e c o n d s e v e r y 5 m i n u t e s . T h e s e 1 5 -
s e c o n d p e r i o d s w e r e s u b d i v i d e d i n t o t h r e e 5 - s e c o n d p e r i o d s . I n e a c h o f t h e s e p e r i o d s 
t h e o b s e r v e r s e l e c t e d t h e b e h a v i o u r w h i c h m o s t c l o s e l y r e p r e s e n t e d t h a t o f t h e a n i m a l 
u n d e r o b s e r v a t i o n . T h e b e h a v i o u r a l o p t i o n s w e r e f e e d i n g , d r i n k i n g , l o c o m o t i o n , 
g r o o m i n g , h e a d d o w n , s l e e p i n g , b e d - m a k i n g a n d r e a r i n g . 
T h e e f f e c t s o f o x y n t o m o d u l i n G L P - 1 a n d e x e n d i n - 4 o n b e h a v i o u r w e r e e x a m i n e d u s i n g 
d o s e s w h i c h h a v e e q u i v a l e n t e f f e c t s o n f o o d i n t a k e u n d e r t h e s a m e e x p e r i m e n t a l 
c o n d i t i o n s . L i t h i u m c h l o r i d e w a s u s e d a s a p o s i t i v e c o n t r o l i n t h i s e x p e r i m e n t a s i t i s a 
k n o w n c a u s e o f v i s c e r a l i l l n e s s b e h a v i o u r . A d m i n i s t r a t i o n o f p e p t i d e s r e s u l t e d i n a 
m a r k e d r e d u c t i o n i n t h e a m o u n t o f t i m e s p e n t e n g a g e d i n f e e d i n g b e h a v i o u r a n d a 
i n c r e a s e i n a l l o t h e r b e h a v i o u r t y p e s ( a c o n s e q u e n c e o f r e s u l t s b e i n g e x p r e s s e d a s 
p e r c e n t a g e s ) . I n c r e a s e i n ' h e a d d o w n ' b e h a v i o u r ( w h i c h i s t h o u g h t t o b e a m a r k e r f o r 
t h e s e n s a t i o n o f v i s c e r a l i l l n e s s ) o f p e p t i d e t r e a t m e n t g r o u p s w a s n o t i n c r e a s e s t o t h e 
s a m e d e g r e e a s t h e l i t h i u m c h l o r i d e g r o u p . B e t w e e n t h e g r o u p s , t h e r e w e r e n o 
s t a t i s t i c a l l y s i g n i f i c a n t d i f f e r e n c e s i n t h e K r u s k a l - W a l l i s t e s t ( f i g u r e 9 . 5 . 1 ) . 
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Saline LiCI 0.15M 
oxm 1400nmol/kg GLP1 100 nmol/kg 
Feeding 
Climbing 
Head Down 
Bedmal<ing 
Grooming 
Locomotion 
Rearing 
Drinl<ing 
Sleeping 
Exendin-4 1 nmol/kg 
Figure 9.5.1 Behavioural effects in mice of doses of LiCl, oxyntomodulin,GLP-l 
and exendin-4 with equivalent effects on food-intake inhibition, at 0-60 minutes 
after IP injection (LiCl 127 ^g per kg, oxyntomodulin 1400 nmol/kg, GLP-1 100 
nmol/kg and exendin-4 1 nmol/kg). Key to colours shown above. 
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9.5.2 Conditioned taste avoidance 
A n i m a l s , d i e t , p e p t i d e s a n d c h e m i c a l s w e r e a l l a s d e s c r i b e d i n s e c t i o n 9 . 5 . 1 . 1 a b o v e . 
L i t h i u m c h l o r i d e w a s u s e d a s a p o s i t i v e c o n t r o l a s d e s c r i b e d i n s e c t i o n 9 . 5 . 1 . 1 . F l u i d 
p r o v i d e d d u r i n g t h e t r a i n i n g a n d t e s t w e e k s w a s g i v e n i n s p e c i a l l y - d e s i g n e d b o t t l e s t o 
a l l o w v i s u a l r e a d i n g o f f l u i d v o l u m e a c c u r a t e t o 0 . 1 m l . E a c h b o t t l e c o m p r i s e d a 1 0 m l 
p i p e t t e s a w n o f f a t b o t h e n d s a n d a t t a c h e d t o a s t a i n l e s s s t e e l b a l l - b e a r i n g n o n - d r i p 
s i p p e r s p o u t r e m o v e d f r o m a 5 0 m l m o u s e f e e d e r b o t t l e t h r o u g h a p o l y t h e n e c a p . 
P a r a f i l m w a s s t r e t c h e d u n t i l a i r t i g h t a c r o s s t h e o p e n t o p o f p i p e t t e a f t e r f i l l i n g . T w o s e t s 
o f b o t t l e s w e r e p r e p a r e d , o n e f o r w a t e r a n d t h e o t h e r f o r t h e n o v e l f l a v o u r t o p r e v e n t 
' t a i n t i n g ' o f t h e w a t e r b o t t l e s . N o v e l f l a v o u r w a s p r o v i d e d d u r i n g t h e t r a i n i n g w e e k 
u s i n g s w e e t e n e d K o o l - A i d d i l u t e d a c c o r d i n g t o t h e p a c k e t i n s t r u c t i o n s ( 1 t u b g r a p e 
f l a v o u r K o o l - A i d , 7 6 0 0 m l d i s t i l l e d w a t e r , 2 t a b l e t s S w e e t e x s a c c h a r i n ) . 
T h e e x p e r i m e n t a l p r o t o c o l w a s b a s e d o n a m o d i f i c a t i o n o f a n e s t a b l i s h e d m e t h o d f o r 
a n a l y s i s o f c o n d i t i o n e d t a s t e a v o i d a n c e b y s i n g l e - b o t t l e m e t h o d ( L a c h e y e t a l . , 2 0 0 5 ) . 
D u r i n g t h e f i r s t w e e k o f t h e p r o t o c o l , m i c e w e r e g i v e n f o o d a n d w a t e r ad libitum a n d 
h a n d l e d d a i l y t o a c c l i m a t i s e t h e m t o s i n g l e h o u s i n g . T h e f o l l o w i n g w e e k ( ' t r a i n i n g 
w e e k ' ) f o o d w a s p r o v i d e d ad libitum w h i l e a c c e s s t o w a t e r w a s p r o v i d e d i n t h e 
m e a s u r i n g b o t t l e d e s c r i b e d a b o v e a n d w a s t i m e d t o o c c u r f o r 1 h o u r d u r i n g e v e r y 2 4 
h o u r s , a t t h e s a m e t i m e e v e r y d a y ( 1 0 : 0 0 - 1 1 : 0 0 ) . T h e p u r p o s e o f t h i s w a s n o t t o 
r e s t r i c t f l u i d b u t t o t r a i n t h e m i c e t o d r i n k t h e i r f u l l f l u i d r e q u i r e m e n t d u r i n g t h a t p e r i o d . 
I P i n j e c t i o n s o f s a l i n e w e r e a d m i n i s t e r e d a t t h e e n d o f t h e w a t e r a c c e s s p e r i o d o n d a y s 2 
a n d 4 o f t h a t w e e k t o a c c l i m a t i s e t h e m i c e t o t h e p r o c e d u r e a n d m i n i m i s e s t r e s s d u r i n g 
t h e s t u d y . W a t e r a n d f o o d i n t a k e a n d b o d y w e i g h t w e r e m e a s u r e d d a i l y f o r e a c h m o u s e . 
A t t h e s t a r t o f t h e t h i r d w e e k ( ' t e s t w e e k ' ) b y w h i c h t i m e w a t e r i n t a k e h a d s t a b i l i s e d f o r 
a l l t h e m i c e , t h e m i c e w e r e r a n d o m i s e d i n t o t r e a t m e n t g r o u p s , e n s u r i n g t h a t a l l g r o u p s 
h a d e q u i v a l e n t m e a n b o d y w e i g h t a n d m e a n d a i l y f l u i d i n t a k e . D u r i n g t h e t e s t w e e k , 
f l u i d a n d f o o d i n t a k e a n d b o d y w e i g h t w e r e m e a s u r e d d a i l y f o r e a c h m o u s e . O n d a y 1 
o f t h e t e s t w e e k , m i c e h a d a c c e s s t o K o o l - A i d i n s t e a d o f w a t e r f o r 1 h o u r . T h i s w a s 
f o l l o w e d b y a n I P i n j e c t i o n o f s a l i n e o r p e p t i d e . O n d a y 2 a l l m i c e r e c e i v e d w a t e r f o r 1 
h o u r . O n d a y 3 , m i c e h a d a c c e s s t o K o o l - A i d f o r 1 h o u r f o l l o w e d b y a n i n j e c t i o n o f t h e 
s a m e s u b s t a n c e t h e y h a d r e c e i v e d o n d a y 1 . v O n d a y 4 a l l m i c e r e c e i v e d w a t e r f o r 1 
h o u r . O n d a y 5 ( t e s t d a y ) t h e m i c e r e c e i v e d K o o l - A i d f o r 1 h o u r a n d fluid i n t a k e w a s 
m e a s u r e d . 
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T h e e f f e c t s o f o x y n t o m o d u h n ( 1 4 0 0 m n o l / k g ) a n d G L P - 1 ( 1 0 0 n m o l / k g ) a t d o s e s w h i c h 
p r o d u c e e q u i v a l e n t e f f e c t s o n f o o d i n t a k e w e r e i n v e s t i g a t e d w i t h r e s p e c t t o t h e 
p r o d u c t i o n o f C T A . L i t h i u m c h l o r i d e 1 2 7 m g / k g w a s a d m i n i s t e r e d a s a p o s i t i v e 
c o n t r o l . A n a d d i t i o n a l g r o u p r e c e i v e d e x e n d i n - 4 a t a h i g h e r d o s e t h a n t h a t r e q u i r e d t o 
p r o d u c e a n e q u i v a l e n t r e d u c t i o n i n f o o d i n t a k e ( 3 n m o l / k g ) . L i t h i u m c h l o r i d e r e s u l t e d 
i n a s i g n i f i c a n t r e d u c t i o n i n K o o l - A i d i n t a k e o n t h e t e s t d a y - t h e r e f o r e i t d i d p r o d u c e 
C T A . O x y n t o m o d u l i n a n d G L P - 1 d i d n o t p r o d u c e s i g n i f i c a n t C T A i n t h i s p a r a d i g m . 
T h r e e t i m e s t h e s t a n d a r d f o o d i n t a k e i n h i b i t i o n d o s e o f e x e n d i n - 4 w a s a d m i n i s t e r e d t o 
t e s t w h e t h e r t h e s e r e l a t e d p e p t i d e s a r e c a p a b l e o f i n d u c i n g C T A a t h i g h e r d o s e s a n d 
i n d e e d t h i s d i d r e s u l t i n a r e d u c t i o n i n K o o l - A i d i n t a k e ( f i g u r e 9 . 5 . 2 a ) . 
I n a s e c o n d s t u d y , e x e n d i n - 4 ( 3 n m o l / k g ) , a d o s e 3 - f o l d h i g h e r t h a n t h e m i n i m a l d o s e 
r e q u i r e d t o i n h i b i t f o o d i n t a k e w a s t e s t e d . E x e n d i n - 4 ( 3 n m o l / k g ) p r o d u c e d a t r e n d 
t o w a r d s C T A b u t d i d n o t r e a c h s t a t i s t i c a l s i g n i f i c a n c e ( f i g u r e 9 . 5 . 2 b ) . 
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Figure 9.5.2 Conditioned taste avoidance following IP injection of oxyntomodulin 
and related peptides to mice. Graphs show Kool-Aid intake in the hour of access 
to fluid on test day. This followed two training days in which access to Kool-Aid 
was paired with an IP injection of substances shown a) LiCl (127 mg/kg) GLP-1 
(100 nmol/kg) and oxyntomodulin (1400 nmol/kg). b) LiCl (127 mg/kg), exendin-4 
(3nmol/kg). *p<0.05, **p<0.01, vs. saline. 
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9.6 Appendix F: Suppliers 
A b b o t t L a b o r a t o r i e s L i m i t e d , B e r k s h i r e , U K 
A d v a n c e d B i o t e c h n o l o g y C e n t r e , I m p e r i a l C o l l e g e , L o n d o n , U K 
A l d r i c h C h e m i c a l C o m p a n y , P o o l , D o r s e t U K 
A m e r s h a m - P h a r m a c i a B i o t e c h , B u c k s , U K 
B a c h e m L t d , M e r s e y s i d e , U K 
B a y e r , H a y w a r d s H e a t h , U K 
B D H , P o o l e , D o r s e t , U K 
B e c k m a n C o u l t e r , H i g h W y c o m b e , B u c k i n g h a m s h i r e , U K 
B I O M O L I n t e r n a t i o n a l L . P . , E x e t e r , U K 
C a m p d e n I n s t r u m e n t s , L o u g h b o r o u g h , U K 
C o l u m b u s I n s t r u m e n t s , C o l u m b u s , O H , U S A 
C r y s t a l C h e m I n c . , I L , U S A 
D u P o n t L t d . , C a m b r i d g e s h i r e , U K 
D u r e c t C o r p o r a t i o n , C u p e r t i n o , C A , U S A 
G r a p h P a d S o f t w a r e I n c . , S a n D i e g o , U S A 
H a r l a n , O x o n , U K 
I C E H e a l t h c a r e , B e r k s h i r e , U K 
I K A L a b o r t e c h n i k , S t a u f e n , G e r m a n y 
I n v i t r o g e n , P a i s e l y , S c o t o l a n d 
J e n c o n s , E a s t G r i n s t e a d , W e s t S u s s e x , U K 
J a s c o , E s s e x , U K 
L a b s y s t e m s a n d L i f e S c i e n c e I n t e r n a t i o n a l L t d . , U K 
L G C P r o c m o c h e m , M i d d l e s e x , U K 
M i l l i p o r e , M i l f o r d , M A , U S A 
M P B i o m e d i c a l s , C a m b r i d g e , U K 
N E T e c h n o l o g y L t d . , R e a d i n g , B e r k s h i r e , U K 
N e w E n g l a n d B i o l a b s , H i t c h i n , H e r t f o r d s h i r e , U K 
N u n c I n t e r n a t i o n a l , D e n m a r k 
O r i g e n e , R o c k v i l l e , M D , U S A 
P e r k i n E l m e r , B e a c o n s f i e l d , U K 
P h e n o m e n e x , M a c c l e s f i e l d , C h e s h i r e , U K 
P h o e n i x P h a r m a c e u t i c a l s , B e l m o n t , C A , U S A 
P i e r c e C h e m i c a l s C o , P e r b i o S c i e n c e U K L t d . , C r a m l i n g t o n , U K 
R & D S y s t e m s E u r o p e L t d . , A b i n g d o n , U K 
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R a t h b u m C h e m i c a l s L t d . , W a l k e r b u m , S c o t l a n d 
R e s e a r c h D i e t s I n c . N e w B r u n s w i c k , U S A 
S i g m a , P o o l e , D o r s e t , U K 
S p e c i a l D i e t S e r v i c e s L t d , W i t h a m , E s s e x , U K . 
S h i m a d z u , K y o t o , J a p a n 
S t r a t a g e n e L t d . , A m s t e r d a m , T h e N e t h e r l a n d s 
V W R I n t e r n a t i o n a l , L e i c e s t e r s h i r e , U K 
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